An investigation of heterologous expression of human steroidogenic cytochromes P450 in yeasts by Kolar, Norbert Wilhelm
An investigation of heterologous expression
of
human steroidogenic cytochromes P450
in
yeasts
Norbert Wilhelm Kolar
Dissertation
presented for the
Degree of Doctor of Philosophy
(Biochemistry)
in the
Faculty of Science
at the
University of Stellenbosch
Promoter: Prof. P. Swart
Co-promoter: Dr. A. C. Swart
Department of Biochemistry, University of Stellenbosch, Stellenbosch, South Africa.
April2005
Declaration ii
Declaration:
I, the undersigned, hereby declare that the work contained in this dissertation is my own
original work and that I have not previously in its entirety or in part submitted it at any
university for a degree.
Signature:
Date:
Stellenbosch Univ rsity http://scholar.sun.ac.za
Summary 111
SUMMARY
This study:
1. Compares various heterologous expression systems for high-level expression of
cytochromes P450. Limitations of the existing cytochromes P450 expression
systems are discussed and possibilities to improve the expression yields of
human steroidogenic enzymes, are suggested. In addition the potential
applications of human steroidogenic cytochromes P450 expressed in Pichia
pastoris are illustrated.
2. Describes the cloning and extracellular expression of a recombinant full-length
human cytochrome P450 17a-hydroxylase (p45017a) enzyme in Saccharomyces
cerevisiae. After the optimisation of expression conditions, it was shown that this
system is not suitable for the expression of full-length human P45017a.
3. Describes the cloning and extracellular expression of the full-length human
cytochromes P45017a, aromatase, bs and truncated human cytochrome P45017a
in P. pastoris. The limitations using P. pastoris as an export system for expressed
P450 enzymes were pointed out.
4. Describes the cloning and intracellular expression of the full-length human
cytochrome P45017a in P. pastoris as well as the functional expression of
human P45017a in P. pastoris, showing progesterone conversion to 17a-
hydroxyprogesterone and 16a-hydroxyprogesterone in vivo, for the first time.
5. Evaluates developed methods for the preparation of mierosomes from P. pastoris
expressing human P45017a and the spectral characterisation of detergent
solubilised human P45017a.
6. Describes the development of protocols for the purification of human P45017a
from P. pastoris microsomes.
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Opsomming iv
OPSOMMING
Hierdie ondersoek:
1. Vergelyk verskillende heterologiese proteïen uitdrukkings-sisteme vir die
preperatiewe produksie van sitochrome P450. Die tekortkomings van bestaande
sitochroom P450-uitdrukkings-sisteme word bespreek en moontlikhede om die
opbrengs van menslike steroïedogeniese ensieme te verbeter word voorgestel.
Die potensiële aanwendings van menslike steroïedogeniese sitochrome P450, wat
in Pichia pas/oris uitgedruk word, word ook geïllustreer.
2. Beskryf die klonering en ekstrasellulêre uitdrukking van die rekombinante
vollengte menslike sitochroom P45017a-hidroksilase (P45017a) ensiem in
Saccharomyces cerevisiae. Na optimisering van die kondisies vir die uitdrukking
kon aangetoon word dat hierdie sisteem nie geskik is vir die uitdruk en sekresie
van vollengte menslike P45017a nie.
3. Beskryf die klonering en ekstrasellulêre uitdrukking van die vollengte menslike
sitochrome P45017a, aromatase, b5 en verkorte menslike sitochroom P45017a
in P. pas/oris. Die beperkinge van P. pas/oris as 'n uitvoersisteem vir die
uitdrukking van P450 ensieme word bespreek.
4. Besryf die klonering en intrasellulêre ekspressie van die vollengte menslike
sitochroom P450 17a. Die funksionele ekspressie van menslike sitochroom P450
17a in P. pas/oris is vir die eerste keer gekarakteriseer.
5. Evalueer die ontwikkelde metodes vir die voorbereiding van mikrosome van P.
pas/oris wat menslike P45017a uitdruk en karakteriseer die detergent
opgelosbare menslike P45017a t.o.v. spektroskopiese eienskappe.
6. Beskryf die ontwikkelling van protokolle vir die suiwering van die uitgedrukte
menslike P45017a vanuit P. pas/oris mikrosome.
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Zusammenfassung v
ZUSAMMENFASSUNG
Diese Studie:
1. Vergleicht verschiedene heterologe Expressionssystemen fUr die Ïlberproduktion
von Cytochrom P450. Die Begrenzungen von den existierenden Cytochrom
P450-Expressionssystemen wurden besproehen und Mëglichkeiten urn die
Produktion von menschlichen Steroid-Enzyme zu verbessem wurden
vorgeschlagen. Die potenzialen Anwendungen von menschlichen Cytochrom
P450 Steroid-Enzymen, welche vom Hefe Pichia pastoris produziert werden,
wurden illustriert.
2. Beschreibt das Klonieren und extrazellulare Expression von dem rekominanten
menschlichen Cytochrom 17a-hydroxylase (P45017a) Enzym in Saccharomyces
cerevisiae. Nachdem der Optimierung der Expressionskonditionen konnte
gezeigt werden, daB das Expressionssystem fUr die Produktion von dem
menschlichen P45017a nicht geeignet ist.
3. Beschreibt das Klonieren und extrazellulare Expression von dem rekominanten
menschlichen Cytochromen P45017a, aromatase, b, und ein verkilrztes
menschliches Cytochrom P450 in P. pastoris. Das Benutzen von P. pastoris als
ein extrazellulëres Expressionssystem hat Begrenzungen die besproehen werden.
4. Beschreibt das Klonieren und intrazellulare Expression von dem rekominanten
menschlichen Cytochrom P45017a. Die funktionelle Expression von dem
menschlichen Cytochrom P45017a in P. pastoris wurde fUr das erste Mal
karakterisiert.
5. Evaluiert entwiekelte Metoden fur die Vorbereitung von Mikrosomen von P.
pastoris die das menschliche P45017a heterolog exprimieren und die
spektroskopischen Eigenschaften von dem detergens auflosbare menschliche
P45017a karakterisiert.
6. Beschreibt die Entwicklung von Protokollen fUr die Sëuberung von dem
P45017a Enzym das in den Mikrosomen von P. pastoris vorkommt.
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CHAPTER 1: INTRODUCTION
The cytochrome P450 dependent enzymes, a diverse group of heme-containing enzymes
found in all prokaryotic and eukaryotic species, were discovered in the 1940s, during a
series of experimental reactions involving molecular oxygen. These hemoproteins are
defined as monooxygenases, because they catalyse the incorporation of a single oxygen
atom from molecular oxygen into a large variety of endogenous and foreign lipophilic
compounds. These reactions proved to be important in the metabolism of numerous
groups of xenobiotics', including pesticides, drugs and hydrocarbons (1, 2). Not only are
the P450-dependent enzymes essential in detoxification systems, but they also play an
important role in the metabolism of endogenous substances produced within the body
(3). These substances can be fat-soluble vitamins, fatty acids, eicosanoids, alkaloids and
most importantly steroids.
Steroids are a uruque group of hormones responsible for stress management, the
maintenance of water and mineral balance and control of male and female sex
characteristics in mammals. These steroids are synthesised by a unique set of enzymes,
the steroidogenic cytochromes, which are localised in tissue-specific environments such
as placenta, adrenals and gonads. Three of these essential enzymes, cytochrome P450
17a-hydroxylase (P45017a), cytochrome b, (bs) and cytochrome P450arom (arornatase)
are the main focus of this study and an overview of their structure, function and role in
steroidogenesis is given in Part I Section 2.1.
Pure proteins are required to better understand the mechanism and structure/function
relationship of the steroidogenic P450 enzymes. The low concentrations and legal
implications involved in obtaining the P450 enzymes from human tissue for the direct
isolation and purification lead to the development of heterologous expression systems.
The heterologous expression systems for cytochrome P450-dependent enzymes,
reviewed in Part I Section 2.2, has become an attractive tool in P450 biotechnology for
the expression of cDNA encoding specific P450 enzymes and also offers several
advantages in the research fields, pharmacology and toxicology. An ultrapure protein
I Chemical substances that are foreign to the biological system. They include naturally occurring compounds, drugs, environmental
agents, carcinogens, insecticides, etc.
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can, for instance, be produced to raise specific antibodies, which could serve as a
diagnostic tool (i.e. immunohistochemistry) or for immunoinhibition studies. The
potential to acquire large quantities of the native enzyme via heterologous expression,
will facilitate the crystallisation of these extremely labile membrane proteins. In
addition, heterologous expression systems can also help to investigate the functional
relevance of genetic polymorphisms of P450 enzymes. By altering certain residues with
site-directed mutagenesis, followed by heterologous expression, the structure/function
relationship associated with cytochromes P450 can be elucidated.
A comprehensive updated study of heterologous expression systems for cytochromes
P450, used in the past 20 years, is tabulated in Part I, Section 2.2. This compilation
shows that most of the expression systems did not produce large quantities of P450
enzymes. In section 2.2 the limitations of the existing cytochrome P450 expression
systems are discussed and possibilities to improve the expression yields of steroidogenic
P450 enzymes are suggested.
The first strategy was to export the expressed P45017a protein into the expression media
using the yeast Saccharomyces cerevisiae. Two major reasons for this decision was that
secreted proteins are more readily available for further manipulations (antibody
production) and by passing through the secretory pathway the chances of proper folding
and modifications are increased. An insight of the yeasts' secretory pathway is given in
Part I, Section 2.3. The experimental work, cloning and expression of a full-length
human P45017a in S. cerevisiae is described in Part II. Optimisation of expression
conditions, determined by P45017a mRNA levels, were performed and on the basis of
the results some disadvantages concerning this system have been formulated.
In Part III, the extracellular expression of the full-length P45017a, b, and aromatase in
an industrial yeast, Pichia pastoris, was investigated. Various peR strategies were
employed to amplify the different cDNAs followed by cloning in reading frame into
suitable expression vectors. The plasmids, harbouring the P45017a, b, and aromatase
cDNAs, were subsequently integrated into the genomic DNA of two P. pastoris strains.
Growth of different recombinant strains was monitored and expression levels of P450
enzymes were determined, using immunoblotting, in the intracellular and extracellular
Stellenbosch University http://scholar.sun.ac.za
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fractions. The results of the studies are discussed and shortcomings, using P. pastoris as
an export system for expressed P450 enzymes, are pointed out.
In order to investigate the intracellular expression of a full-length human P45017a. in P.
pastoris, cloning, integration and culturing of a suitable strain are carried out. Methods
are developed and evaluated for the preparation of mierosomes from P. pastoris
expressing human P45017a.. In addition, protocols are developed and evaluated for the
purification of P45017a. from the P. pastoris microsomes. These experiments are
described in Part IV.
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CHAPTER 2: LITERATURE REVIEWS
SECTION 2.1: An insight in structure, function and role of two key
steroidogenic enzymes P45017a and aromatase
2.1.1 Cytochromes P450
The absorbance spectra of all heme proteins reveal a characteristic peak at - 420 nm
called the Soret peak. Factors that cause this specific absorbance are the chemistry of the
heme and its attachment to the protein. The conjugated bond system of heme can be
influenced by changes in the nearby protein, resulting in a change of electron
distribution in the heme which, in turn, will cause a shift in the Soret peak. A common
method used to demonstrate this phenomenon is when carbon monoxide (CO) is bubbled
through a solution of reduced P450. The CO competes with oxygen for binding to the
iron and causes a peak to appear at 450 nm instead of 420 nm, hence the name
"cytochrome P450". This spectral shift provides the most useful method for detecting
and measuring cytochrome P450 in biological samples (4, 5).
Cytochrome P450 consists of an apoprotein of 30.000-60.000 Daltons (Da) together with
a protoheme. The heme iron, which is attached to the protein by hydrophobic and
Coulombic forces, can exist in either of the two-valence states - pentacoordinate or
hexacoordinate. Four of the valencies are associated with the four pyrrole nitro gens of
the heme. The fifth bond involves a sulphur atom in the protein taking the form of a
thiolate bond with cysteine as seen in Figure 2.1.
~ /N\-""""""'N
Cys- S---I-...,Ftf-f-- O<H~ N~\j H
Figure 2.1: Conformational representation of heme binding in cytochromes P450.
Stellenbosch University ttp://scholar.sun.ac.za
Part I Overview of cytochromes P450 9
It is suggested that the active site of these enzymes, which must include the heme group
to .which the substrate oxygen binds, take the form of hydrophobic crevices. The four
bonds to the pyrrole nitrogen are lying in the same plane as the heme ring, hence planar
and the fifth and sixth bonds are at a right angle to this plane, hence axial and distal. It is
still uncertain as to what function the sixth ligand has.
2.1.1.1 The mechanism of cytochromes P450
The major role of the cytochrome P450 family of enzymes is to convert a lipophilic
substrate to a hydrophilic substance by adding a new hydroxyl group, thereby removing
the harmful substrate from the body. Such a reaction is accomplished by means of a
monooxygenation, which can be represented as follows:
RH + NADPH + H+ + O2,....----+
The P450-dependent enzymes, which are reduced by electrons from reduced pyridine
nucleotides (NADPH), activate molecular oxygen. One atom of the oxygen is inserted
into the substrate to form a hydroxyl group while the other is incorporated into water (6).
The electron donors, involved in the reduction of cytochrome P450-dependent enzymes,
differ between the endoplasmic reticulum (ER) and the mitochondria. In the ER
electrons from NADPH are transferred to cytochromes P450 via a membrane-bound
NADPH-P450 reductase (OR), containing both Flavin adenine dinucleotide (FAD) and
Flavin mononucleotide (FMN), whereas in mitochondria this transfer is mediated by a
FAD-containing reductase and a ferrodoxin-type iron-sulphur protein that is loosely
bound to the inner membrane (7).
Like other enzymes the P450 enzyme releases the product so that it can bind to the next
substrate. The reduced P450 enzyme then is restored to its original state (i.e. the ferric
state) in order to oxygenate the next substrate. A schematic representation of the
catalytic cycle of the cytochromes P450, which consists of eight reactions, is given in
Figure 2.2. During the first step the substrate binds to P450 to form a substrate-enzyme
complex. The binding elicits a conformational change in the P450 protein, i.e. a
perturbation of heme iron spin-state equilibrium (from low spin to high spin) (8), thereby
UNMRsrrrn MU..EIIBOSCH
:lItlLlOTEEK
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lowering the P450 redox potential which facilitates the next step where the first electron
(donated by NADPH) reduces the iron (ferrous state) of the substrate-enzyme complex
(9). In step three the reduced heme of the complex binds oxygen returning the iron to its
low-spin state. A more reactive form of substrate-enzyme complex (i.e. a superoxide
attached to the ferric iron) is subsequently formed in step four followed by a second
electron transfer process in step five thereby reducing the ferric iron back to the ferrous
state. Steps five to eight, involving the mechanism of oxygen insertion into substrates, is
still under investigation and up to date three possible mechanisms of oxygen insertion to
produce oxy-iron intermediates have been proposed (10, 11, 12) and are summarised by
Lewis (13). The substrate is subsequently hydroxylated in step eight. The last step of the
cycle is the release of the hydroxylated product from the enzyme. A reaction enhanced
by the hydroxyl group that creates repulsive forces in the hydrophobic crevice of the
enzyme that houses the heme group and the substrate. The free oxidised P450 is ready to
start the cycle.
2W
OH
k
Figure 2.2 Schematic representation of the cytochrome P450 catalytic cycle showing the oxygenation
of a substrate (yellow) by a cytochrome P450-dependent enzyme (purple). LS: low-spin, HS: high
spin. Adapted from (13).
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2.1.1.2 Membrane topology of cytochromes P450 together with their electron
donors
Cytochrome P450-dependentmonooxygenase systems of mammals are found associated
with the mitochondria and ER. In order to understand the full regulation of biosynthetic
reactions involving P450 in these membranes, the arrangement of the different P450
proteins, located in the membrane and their interaction with other membrane proteins,
have to be understood. Up to date, we can distinguish between three different
cytochrome P450-dependent monooxygenase systems, which are shown in Figure 2.3.
ONE· PROTEIN SYSTEM
P480_ monooxygen ••• from Bacil/u. mt{llttrlum
CD O,+RH
NADPH+H'- Reductase-CytochromeP450protein-!
! FAO- FMN- hem. I H,O + ROH
TWO· PROTEIN SYSTEM
Mlcl'OIom.1 P480monooxyg.na •••
CD @ O,+RH
NAD(P)H+ H'- Reductase - CytochromeP450-!
!FAO_FMNI !hemel H,O+ROH
THREE· PROTEIN SYSTEM
Mitochondrlal.nd mOlt bactert.1 P480monooxyg.n .. n
CD @ @ O,+RH
NAD(P)H+H'- Reductase- Redoxln-Cytochrome P450-!
! FAO0( FMN I [!!!] 8 H,O + ROH
Figure 2.3 Comparison of three different P450 monooxygenase systems. The bacterial P450BM-3
monooxygenase from Bacil/us megaterium uses one protein to reconstitute the monooxygenase activity,
whereas mierosomes use two and the mitochondria three proteins. Adapted from (14).
The first system, a single protein P450-dependent monooxygenase system that was
isolated from Bacil/us megaterium, consists of a single soluble polypeptide complex
containing FAD, FMN and a P450 heme moiety. The mechanism of electron transfer has
been discussed in (14). The second system is the two-protein P450-dependent
monooxygenase system found in the ER of higher animal cells as well as in most other
eukaryotes, including yeast and is by far the largest class of cytochromes P450. Since
P45017a and aromatase are part of this microsomal P450 system, it will be a point of
focus further on in this section. The third monooxygenase system is the three-protein
component type that occurs in the mitochondria of mammalian cells (normally those
involved in steroid metabolism) and in those bacteria shown to contain P450-dependent
monooxygenase systems. Here the transfer of electrons is mediated by two proteins
before reduction of the P450 enzyme. One protein is a reductase (containing FAD)
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which interacts directly with NADPH and the second protein, a small ferrodoxin-like
protein (adrenodoxin). After transfer of one electron to adrenodoxin, which associates
with the reductase, it dissociates from the reductase and binds to the P450 in a
mechanism known as the "shuttle mechanism" (15). The mitochondrial cytochromes
P450 are intrinsic membrane proteins while the associated electron-transfer components
can be isolated in soluble form. On the other hand the bacterial proteins, including the
P450 components, are generally soluble (16).
2.1.1.2.1 Microsomal P450 monooxygenases
2.1.1.2.1.1 Mechanism of action of cytochromes P450 and their electron carriers
The microsomal P450 system has only one electron-transfer protein that interacts with
NADPH and transfers electrons directly to the various cytochrome P450 species. This
protein, OR, contains both FAD and FMN. FAD receives the first electron from NADPH
whereas FMN serves as the analogue to the redoxin (used in the mitochondrial three-
protein system shown in Figure 2.3) by interacting with the P450 enzyme and reducing
it. Numerous studies have been carried out to evaluate those factors that influence the
interaction of the OR with the P450 since protein-protein interaction is essential for
electron transfer [207]. The ratio between these two proteins must be 1:1 to ensure
electron transfer (17). It has been proposed that the docking is affected between the
positively charged amino acids on the P450 and the negatively charged amino acids on
the reductase. This was confirmed by Shen and Kasper who showed unique clusters of
acidic amino acids on the surface of the reductase near the FMN -binding domain, that
might serve as binding site for interaction with cytochrome P450 (18).
2.1.1.2.1.2 Mechanism of membrane insertion and protein retention
Sequences of the microsomal cytochromes begin with a highly hydrophobic segment of
about 20 amino acid residues that is followed by a short polycationic segment. The
microsomal cytochromes P450 fall in the integral membranous proteins class that may
be inserted into the ER by an amino-terminal signal peptide, but one that is not cleaved
and also serves as an anchor. The signal-anchor sequence is followed by a stop-transfer
signal, which is a short segment of light cationic amino acid contents that halts the
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translocation of the rest of the protein across the membrane (19, 20). To note is also the
absence of N-linked glycosylation or any Lys-Asp-Glu-Leu (KDEL)- like sequence at
the carboxyl terminus, which is a characteristic of the ER retention signal of soluble ER
proteins.
The mechanism of the cytochromes P450 ER translocation machinery is complex and
was illustrated well by Roux et al. (21). There is a signal recognition particle (SRP), an
SRP-receptor/docking protein, a chaperone protein and a ribosome receptor. The
molecular determinants for the insertion of the signal and the mechanism of insertion
have not yet been determined. There are possible mechanisms of how the mammalian
cytochromes P450 are inserted into the ER, which are well reviewed (22, 23). Two of
these postulations were recently shown to be correct (Figure 2.4). The P450 is located in
the ER either bitopic (i.e. touching both leaflets of the membrane) or polytopic (multiple
membrane crossing). The former is also called type I signal-anchor (SA-I) and the latter
type II signal-anchor (SA-II). Inboth of these suggestions the carboxyl terminus is in the
cytosol. Nelson and Strobel (24) concluded that at the amino terminus was a helical
hairpin and a large, globular heme domain with the plane of the prosthetic group parallel
to the membrane. Therefore the amino-terminus together with the heme domain would
be situated on the cytosol side of the ER. This would comply with the polytopic
postulation.
A B
cytoplasm
lumen
Figure 2.4 Two possibilities of the integral membrane topology for the mammalian cytochromes
P450 of the ER. (A) shows the scenarios where one membrane anchor is used type I signal-anchor (SA-I)
and (B) P450 uses the two membrane anchor inserted as a "hairpin" or SA-II.
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The b, is anchored to the membrane by a carboxyl-terminal hydrophobic segment, which
penetrates the membrane ER exposing its carboxyl-terminus in the lumen (25, 26).
2.1.2 Enzymes in the steroidogenic pathways and steroid hydroxylases
Steroidogenesis from precursor cholesterol involves several complex enzymatic
reactions, most of which are mediated by specific cytochromes P450 located primarily in
the adrenal cortex, gonads and placenta. The first step of steroidogenesis, illustrated in
Figure 2.5, is the conversion of cholesterol to pregnenolone by the mitochondrial
cholesterol side-chain cleavage enzyme, cytochrome P450scc, located on the matrix side
of the inner mitochondrial membrane (27). This conversion is accomplished using a
three-step process involving the hydroxylation of C20 and C22 followed by cleavage of
the C-C bond yielding the C21 steroid pregnenolone. The availability of cholesterol for
this reaction is the determining step to initiate steroidogenesis and is regulated at the
level of cholesterol flow from the outer mitochondrial membrane to the inner
mitochondrial membrane mediated by the steroidogenic acute regulatory protein (StAR)
(28). The mechanism and site of action of StAR is still under investigation (29).
The next step in steroid biosynthesis is the metabolism of the intermediate hormone
pregnenolone, which is the key substrate of androgen and oestrogen synthesis in the
gonads and mineralocorticoids and glucocorticoids in the adrenal cortex. Two different
enzymes, 3J3-HSD (3J3-hydroxysteroiddehydrogenase ~s-isomerase) and P45017a can
metabolise pregnenolone and their competition for pregnenolone will determine the flow
of steroids through the different pathways. In addition, P45017a can carry out both
hydroxylase and lyase reactions, which makes this enzyme a centre player in the branch
point in steroid hormone synthesis. P45017a can direct pregnenolone to
mineralocorticoids (neither activity), to glucocorticoids (17a-hydroxylation but not
CI7,20cleavage) or to sex steroids (after both 17a-hydroxylation and C17,20 cleavage), as
seen in Figure 2.5.
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Figure 2.5 Pathway of initial steps of human steroid hormone biosynthesis in the adrenal cortex and
the gonadal cells. The arrows indicate substrate conversion to product by the enzyme listed next to the
arrow. The enzymes boxed in are located in the mitochondria whereas the rest are found in the ER. The
physiological function of each steroid end product is indicated by the dotted arrows. Pregnenolone, the
precursor for progesterone, androgen and oestrogen synthesis, is used by P45017a or 3p-HSD in a
competing reaction. If pregnenolone is first used by P45017a, it is oxidised to 17-hydroxypregnenolone
(l7a-hydroxylase activity) and then to a A5 steroid, dehydroepiandrosterone, by subsequent cleavage of
the side chain (l7,20-lyase activity). It is referred to as the A5 pathway. If, however, pregnenolone is fust
used by 3p-HSD, the A4 steroid, progesterone, is formed and subsequently metabolised to 17-
hydroxyprogesterone (l7a-hydroxylase activity) and then to the androgen precursor androstenedione by
P45017a (l7,20-lyase activity), hence the A4 pathway. This latter 17,20-lyase activity, indicated by a thin
dotted arrow, is extremely low in humans, primates, sheep and cattle and therefore androstenedione is
synthesised via the A5 pathway. P450scc: (cytochrome P450 side chain cleavage enzyme), P45017a:
(17a-hydroxylase), P450c21: (21-hydroxylase), P450c11: (11 P-hydroxylase), P450aldo: (aldosterone
synthase), 3p-HSD: (3P-hydroxysteroid dehydrogenase), 17p-HSD: (l7p-hydroxysteroid dehydrogenase),
17-KSR: (17 -ketosteroid reductase).
The use of the pathways to produce these different steroidal hormones are determined by
the different steroidogenic tissues which express specific steroidal enzymes in particular
zones as swnmarised in Table 2.1 .
The gonads are involved primarily in production of sex hormones including oestrogens
and androgens. This is achieved by the two sequential reactions catalysed by P45017a..
The first reaction is the 17a.-hydroxylation of pregnenolone to 17-hydroxypregnenolone
and the second reaction is the 17,20-lyase activity, wherein the C21 steroid 17a.-
hydroxypregnenolone is converted to the C19 androgen, dehydroandrostenedione
(DHEA) and subsequently androstenedione. In the testis, androstenedione is converted
to testosterone and 5a.-dihydrotestosterone by a series of non-P450-dependent enzymatic
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reactions, whereas in the ovary it may be converted to oestrone catalysed by aromatase,
located only in the ovary (30). A second oestrogen, oestradiol, can be synthesised either
from testosterone or oestrone, mediated by aromatase and 1713-hydroxysteroid
dehydrogenase (1713-HSD), respectively. The cytochrome P450-dependent 21-
hydroxylase (P450c21) is not expressed in gonads (excluding many fish species),
therefore intermediates are not channelled to the mineralocorticoids and glucocorticoids.
The adrenal cortex produces mineralocorticoids and glucocorticoids within a single
gland, due to the broadest spectrum of steroid hydroxylases, including P450c 11 and
P450c21, which are solely available in adrenal tissue (Table 2.1 ). Progesterone, an
intermediate ill corticosterone and aldosterone biosynthesis and 17a-
hydroxyprogesterone, an intermediate in cortisol biosynthesis, are both metabolised by
P450c21 to deoxycorticosterone and deoxycortisol, respectively (Figure 2.5).
Table 2.1 Steroidogenic enzymes expressed specifically in different mammalian cell types. P450cll
and P450c21 are expressed solely in the adrenals and aromatase solely in the ovary.
Luteioized Gniuulosa
Cytochrome fasciculatal Zona gnuiUIo!a ~ SertoIi I TropbooI..
retiadari. gJomeru lose iutema (corpus fuDicle)
1uImm)
+ + + + + + + +
+1 + + + +2
+ + + + + + + +
+ 3
+ +
.+
+4 + + +
+ ? + +
M.jor Ghaco- MiDera1o- AIooIrepoo o..ar.,.. Pt'6jtltlti.. PJ g I lW ,,__. A..t._ ~ ~
Steroid Corticoid corticoid
products Androgen Androgm Oestrogen Proge.temne l'rogestaooe
1Not expressed in rat and rabbit adrenaIs, but found in hamster.
2 Significant activity found in certain species including sheep, but human only P450scc and aromatase (30).
3 Present in rat.
4 Expression dependent on species.
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The deoxycorticosterone and deoxycortisol moves from the ER to the mitochondria
where the cytochrome P450 aldosterone synthase (P450aldo) and cytochrome P450 11p-
hydroxylase (P450cll) catalyses the production of aldosterone and cortisol,
respectively.
Apart from producing mineralocorticoids and glucocorticoids, the adrenal tissue of
higher mammals is capable of extra-gonadal CI9 steroid synthesis. DHEA and its
sulphate conjugate, DHEA-S, are the most abundant steroids produced by the human
adrenal, but their role and function has not been established other than as precursors for
sex steroid biosynthesis.
2.1.2.1 Role and mechanism of P45017a. in gonadal and adrenal steroidogenesis
2.1.2.1.1 Role of the l Za-hydroxylase and C17,20-lyase reaction
One of the important abilities of P45017a. is that it can metabolise more than one
substrate. Hence P45017a. can act on both pregnenolone and progesterone (Figure 2.5).
3pHSD can act also on pregnenolone, 17-0H pregnenolone and DHEA. Therefore there
are two alternative ways by which C19 steroids may be derived, which are known as the
115and 114pathways, respectively. In the 115pathway, pregnenolone is primarily utilised
by P45017a. followed by 3pHSD, resulting in the synthesis of 17-0H pregnenolone,
DHEA via CI7,20-lyase and finally androstenedione. In the 114pathway, the initial
metabolism is the conversion of pregnenolone to progesterone by 3pHSD, which can be
further converted by P45017a. to 17-0H-progesterone and then to androstenedione. As
was mentioned before, the steroid flux through each pathway is determined by 1) the
competition between P45017a. and 3pHSD for pregnenolone and the intermediates of
114/115 metabolism and 2) the relative efficiency (substrate specificity) of the hydroxylase
and lyase metabolism of the 114and 115steroids (31). In reproductive biology, however,
the 17,20-lyase activity is more important since there are significant differences between
species and tissue, based on the specificity of the P450 17a. towards its substrate. Porcine
P45017a. has 17,20-lyase activity for both 115(17a.-hydroxypregnenolone to DHEA) and
114(l7a.-hydroxyprogesterone to androstenedione) pathways (32, 33), as do the rat (34),
hamster (35), trout (36) and shark enzymes (37). But in guinea pig the P45017a. enzyme
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seems to be incapable of metabolising 17-0H pregnenolone to DHEA (38). In human,
bovine and baboon adrenals, it appears that P45017a selectively produces DHEA in
greater quantities than androstenedione (39, 40, 41), In hamster adrenals, P45017a
expression favours androstene production, based on experimental results obtained with
adrenal cell suspensions and microsomal preparations (42, 43, 44). However, P45017a
is not expressed in the adrenal glands of rats (34) and mice (45), although in the gonads
of these species P45017a has 17,20-lyase activity preferentially producing
androstenedione (34). It is, however, possible for human and baboon P45017a to
convert progesterone to 16a-hydroxyprogesterone (46, 41).
2.1.2.1.2 Mechanism of 17a-hydroxylase
The reaction mechanism of 17a-hydroxylation of pregnenolone, catalysed by P45017a,
is well understood and documented in (47). An iron-bound peroxy intermediate is
heterolytically cleaved to form activated oxygen, known as "oxene". The oxene then
takes away a hydrogen atom from the substrate which results in the formation of the
equivalent of an iron-bound hydroxy radical as well as a substrate-based radical
2.1.2.1.3 Mechanism and regulation of 17,20-lyase activity
The studies of Akhtar et al. as well as Swinney (48, 47) support the hypothesis that
P45017a catalyses carbon-carbon bond cleavage resulting in the formation
androstenedione from 17a-hydroxyprogesterone via a ferric-peroxy-dependent pathway.
The ferric peroxy intermediate could then rearrange heterolytically, via the Baeyer-
Villiger rearrangement, to form a hemiacetal or homolytically gem-diol form (47).
The 17a-hydroxylase and 17,20-lyase activities of human P45017a can be regulated
independently (49) and the latter is influenced by three factors - (i) by the binding and
interaction of redox the partner OR (50, 51); (ii) by serine/threonine phosphorylation of
P45017a (52) and (iii) by the presence of b, (53). The exact role of bs in human
P45017a is, however, controversial.
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To date it is not clear how or if bs regulates human P45017a activities in vivo. The
augmentation of the 17,20-lyase activity of P45017a by b, has been observed in vitro,
but could not be seen in COS-l cells. Similar effects can be seen in the guinea pig
adrenal mierosomes (54). In human adrenals the addition of b, promoted hydroxylase
and ~S-lyase activities (48) On the other hand no effect of b, was observed in the studies
on sheep adrenal P45017a (55). The conclusion of these findings is that the
hydroxylase/lyase activities are species-specific and that the ratio of 17,20-lyase to 17a-
hydroxylase activity of P450 17a is regulated by the availability of reducing equivalents
flowing to the enzyme. This can be increased by increasing the molar concentration of
electron-donating redox partners, such as OR or possibly bs.
Auchus et al. (56) proposed the function of bs which is illustrated in Figure 2.6 and
concludes that the 17,20-lyase activity is not mediated by electron transfer from b, and
that bs exerts an allosteric effect on the P45017a-OR complex. This suggests that bs
interacts primarily with the P45017a-OR complex and not with P45017a alone. This
was confirmed by three other independent laboratories (54, 57, 58). The structure of the
interaction of P45017a with OR is still uncertain. Some clues are, however, provided
from the structural interaction between the rat OR and P450-BMP.
A crevasse that extends down to the face of the P450-heme opposite the substrate-
binding pocket (59), is lined on the one side with positively charged residues from the J'
and K helices which participate in electrostatic pairing with negatively charged residues
in OR. Geller et al. (50) showed with molecular modelling that the P45017a also has
this similarly located crevasse of positively charged residues which interact with OR.
The FMN protein of rat OR is also situated at the base of the concave cleft which is
connected to the FAD domain via a flexible hinge. When the OR approaches the
concave binding site of the P45017a, the FMN moiety must move 90° to ensure binding
(50). Geller also believes that since the oxidative scission of the C17-C20 bond of 17a-
hydroxypregnenolone appears to require stronger constraints on the active-site topology
ofP45017a than 17a-hydroxylase reaction, the b, plays a role in the optimisation of the
geometry of P45017a-OR complex (Figure 2.6). This postulation of b, being an
allosteric effector has been strengthened by the observation that serine phosphorylation
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Figure 2.6 Proposed mechanism of the electron transfer and conformational arrangement of the
microsomal NADPH-reductase with P45017a.. (A) Two electrons from NADPH are donated to the
flavin adenine dinucleotide (FAD) domain ofNADPH-oxidoreductase (OR) in the microsomal membrane.
The electron passes on to flavin mononucleotide (FMN). (B) In order for the translocation of the electrons
to the P450 17a. the OR with its two moieties (connected together by a connecting domain or hinge region
(H» has to dock onto the P45017a. binding site. This is achieved by a 90 0 rotation of the FMN domain.
The P45017a.-OR complex is adequate to support 17a.-hydroxylation, but rarely catalyses the 17,20-lyase
reaction. Therefore b, is needed. (C) The presence of b, facilitates the orientation ofP45017a. and OR in a
way that is required for the more stringent 17,20-lyase reaction. This results in an electron transfer from
OR to P45017a. and subsequent catalysis. The precise binding site for the b, is still not known. This
mechanism has been modified from (56).
ofP45017a selectively increases 17,20-lyase activity (52) by increasing electron transfer
and coupling efficiency.
2.1.2.2 Role and mechanism of aromatase in gonadal steroidogenesis
Aromatase is the cytochrome P450 responsible for the conversion of androgens to
oestrogens, shown in Figure 2.5. Oestrogen synthesis is critical for normal physiological
processes such as expression of secondary sexual characteristic, establishment and
maintenance of pregnancy and maintaining bone mineral homeostasis (60). In humans,
aromatase is expressed in steroidogenic tissues, e.g. ovary (granulosa cells), placenta and
testis (Table 2.1 , Sertoli and Leydig cells) and in a number of extragonadal tissues
including, breast, muscles, adipocytes, skin and in various sites in the brain and (61,62).
Recent evidence suggests that aromatase may also be capable of xenobiotic metabolism
(63).
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2.1.2.2.1 Reaction mechanism of aromatase
Aromatase converts androstenedione to oestrone and testosterone to oestradiol. The
aromatase mechanism involves a unique 3-step process, which is shown in Figure 2.7.
The first two oxidative steps are thought to be typical cytochrome P450 hydroxylations.
A theory originally proposed by Akhtar et al., suggests the third step to be a ferric
peroxide attack to remove the aldehyde, followed by the aromatisation of the A ring.
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Figure 2.7 Overview of the reaction mechanism of aromatase showing the conversion of
androstenedione to oestrone. Adapted from (64).
2.1.3 Sequence and structural similarities of P45017a and aromatase
genes
During the past decade, cDNAs for all the major steroidogenic enzymes have been
isolated and it has been shown that almost every steroidogenic enzyme is encoded by
only one gene (65). The single P45017a gene (CYP17) has been characterised in
humans and it contains eight exons located on human chromosome 10 (65). The human
and bovine P45017a amino acid sequence consists between 508-509 amino acids in
contrast with rat P45017a, which contains 507 amino acids.
Evolutionarily, the oldest of the steroid hydroxylase genes is CYP19 which encodes
aromatase. The derived coding region of aromatase clearly indicates that this
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polypeptide belongs to a member of the cytochrome P450 superfamily of genes.
Generally, no greater than 30% sequence homology was found between aromatase and
other forms of cytochromes P450, indicating that aromatase, in common with other
steroidogenic P450 species, belongs to a separate gene family within the overall
superfamily, designated cytochrome P450XIX (66). The length of 503 residues and the
calculated exact molecular weight for equine aromatase is 57800 Da.
Cytochrome P45017a and aromatase have similar structural features, which are common
to all cytochromes P450, sharing the most highly conserved regions in the 200 residue
carboxyl terminus shown in Figure 2.8. There is a heme-binding region which has a
cysteine that is believed to be the fifth coordinating ligand of the heme iron. Upstream is
the second most conserved region in all P450 species, the l-helix, which has been
suggested to be involved in substrate binding by forming the substrate-binding pocket
proximal to the heme prosthetic group (67, 68) that contain Ozols (residues 349-371 in
K-helix) and aromatic (residues 407-418) (69, 70). In addition, near the amino-terminal
end a highly hydrophobic region (residues 1-20), present in all microsomal P450 species
and believed to be the membrane-spanning domain, is found. However, it is the amino-
terminal side of the aromatase that differs from most microsomal membrane
cytochromes P450. The membrane-anchoring domain, comprising highly hydrophobic
amino acid residues at the amino-terminus, as seen with P45017a, is not located at the
amino-terminus in aromatase, but is situated 20 amino acids downstream from the
methionine start codon, shown in Figure 2.8. Interestingly, the first 20 amino acids of the
aromatase sequence have been identified as an N-linked glycosylation consensus
sequence with asparagine at position 12 the site of glycosylation. Aromatase of human
placenta has been shown to have attached sugar residues (71, 72, 73). It is believed that
the first 20 amino acid sequence with the sugar residues is protruding into the luminal
space of the ER membrane with the hydrophobic region (residue 20 to 40) acting as the
membrane-spanning domain (64).
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Figure 2.8 Sequence alignment of human P45017a and aromatase with the structural alignments of
P450BMP, P450cam and P450terp. Residues that comprise the a-helices (alphabetically identified) and 13-
sheets (numbered) are underlined and the most conserved residues (the C-helix tryptophane, catalytic
threonine in the l-helix, the ExxR sequence in the K-helix and the absolutely conserved cysteine in the
heme-binding region) are in colour. The amino-terminal sequence of P450 17a and aromatase are shown
with symbols above to indicate hydrophobic (~), positively charged (+) and negatively charged residues
(-). The putative membrane-spanning domain of P450 17a is indicated by the lined sequence (S 1 and S2).
Aromatase has a glycosylation site at position 12.
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This overview clearly shows that these steroidogenic cytochromes P450 (P45017a.,
aromatase and bs) play an essential role in the biosynthesis of the mineralo-and
glucocorticoids as well as the sex hormones. It is, however, obvious that a large amount
of research, concerning these P450 enzymes, still needs to be conducted in order to
obtain a precise insight into their role, localisation and function in their physiological
environment. In addition, these cytochromes P450 have been implicated in various
diseases, such as polycystic ovarian syndrome (74, 75), congenital adrenal hyperplasia
(76) and various cancers (77), although a detailed description falls outside the scope of
this thesis. In order to resolve these issues, pure P450 enzymes need to be produced via
heterologous expression systems, which are discussed in the next section.
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SECTION 2.2: Comparative study of heterologous expression
systems for high-level expression of cytochromes
P450 Potential Applications of human
steroidogenic cytochromes P450 expressed in Pichia
pastoris
2.2.1 Introduction
Heterologous expression of recombinant cytochromes P450 provides unparalleled
versatility for investigating different aspects of these mixed-function oxidases. One can
examine, for example, the enzymatic properties of individual forms of P450 in the
absence of significant background enzymatic activities (78) and reconstruct enzymatic
pathways involving specific forms of P450 in cells that do not normally contain these
pathways (79). One can carry out site-directed mutagenesis studies that will facilitate
investigations into the catalytic role of specific amino acids (80). Furthermore, metabolic
reactions of P450 enzymes can be assessed even when these enzymes are expressed at
low levels in human tissue.
An important application for the heterologous expression of cytochromes P450 is to
achieve large-scale production of recombinant enzymes, which is the main focus of this
chapter. Once sufficient amounts of a specific form of P450 can be produced,
downstream applications such as antibody production and crystallisation studies can be
carried out. The crystallisation of mammalian P450 enzymes is vitally important since
the basic structures of these intrinsic membrane proteins have not been resolved. The
overexpression of unmodified' full-length P450 enzymes remains an enormous
challenge in the field of biotechnology and successes have been limited. The main
contributing factors to this shortcoming are the hosts and the type of expression systems,
which will be discussed in this chapter.
I The modifications are in the context of truncation or alteration (e.g. nucleotide substitution or deletion) of the P450 encoding
sequence at the amino terminus. Epitope tags such as FLAG and histidine are fused to the protein and do not alter the native P450
encoding sequence.
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Although COS cells and vaccinia viruses are widely used to study recombinant P450
enzymes and their activities, they are not suitable for large-scale expression and
production. The transfection efficiency of COS cells can be as low as 10%, and this
system is therefore not capable of producing sufficient quantities of P450 enzymes for
biophysical studies. Vaccinia viruses has been used extensively for drug metabolism
studies with regard to the hepatic P450 enzymes, since they harbour a fair amount of ER,
OR, bs and microsomal epoxide hydrolase (81). However, the expression levels are also
inefficient for large-scale production of P450 enzymes.
Heterologous expression systems such as Escherichia coli, baculovirus and
Saccharomyces cerevisiae which are capable of high expression levels, focus on
xenobiotic-metabolising P450 enzymes, because of their substrate specificity in drug
metabolism. The application of these expression systems has shifted from protein
production to toxicology studies which are of vital importance in drug development (82,
83). Bacterial mutagenicity assays have been developed for screening newly developed
drugs for genotoxicity and human P450 expression vectors used in E. coli are now being
transformed into Salmonella typhimurium, the classical Ames tester strain (84, 85, 86).
A baculoviral system has been developed to ascertain the function of various enzymes
by modulating the toxic effects of chemicals in an eukaryotic environment (87). The
worldwide focus has thus shifted to drug-metabolising enzymes and their potential
applications in drug development.
Although some success has been achieved with regards to the functional expression of
steroidogenic human cytochromes P450, the expression levels and yields are relatively
low. However, high-level expression is critical in the large-scale production of these
proteins for biophysical studies, such as the protein-membrane interactions, site-directed
mutagenesis and crystallisation to be accomplished. E. coli expression systems were
found to produce the highest yield of P450 enzymes followed by baculoviral cells and S.
cerevisiae cells. Studies done by Barnes et al. indicated that the yield of expressed
bovine P45017a between E. coli, baculovirus and S. cerevisiae was 412, 88 and 2.5
nmol/ml culture, respectively (88). However, every system has its limitations, and will
be discussed in this chapter.
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It seems that in the P450 research arena the abovementioned expression systems have
reached limitations and many strategies which have the potential of increasing
expression levels via co-expression and using multiple-copy clones, were unsatisfactory.
However, leading the way into the new millennium, novel expression systems are
becoming available and showing great success in producing high yields of various
proteins (89, 90). The methylotrophic yeast, P. pastoris, has been employed successfully
in the production of high levels of a broad range of heterologous proteins (91). Factors,
which have contributed towards the success of this system, include high cell density
cultures, vector stability, strong and tightly regulated promoters and the ease with which
applications can be scaled up for fermentor production.
The aims of this review are to present the advantages and limitations of expression
systems - conventional bacterial, baculoviral and yeast systems and non-conventional
P. pastoris yeast systems with respect to high-level expression and yields of P450
enzymes. Factors, which may increase expression levels and affect overexpression, will
be discussed. These include the host strain, specific strategies for co-expression systems,
the influence of promoters on transcriptional control, formatting the initiation site of the
cDNA creating a strong initiation context and removing potential secondary structures,
adapting fermentation procedures with different organisms with regard to copy-number
and vector stability thus increasing cell density and the use of signal peptides to direct
extracellular secretion thereby facilitating purification. Finally, we will show the
potential applications in the use of P. pastoris cells expressing full-length steroidogenic
human P45017a, aromatase and bs.
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2.2.2 Factors influencing high P450 expression levels in heterologous
expression systems
2.2.2.1 The host
The most striking advantages of using bacteria as a heterologous expression system are
that bacteria are genetically well defined, grow rapidly, DNA manipulations are easy,
fermentation technology is well developed and, most importantly, bacteria are a proven
host for may heterologous proteins. Many results have shown that bacteria are
generating large quantities of enzymatically active proteins. However, in P450 research,
heterologous expression of an active P450 enzyme was not achieved unless NADPH-
reductase and b, were present. These enzymes do not occur in bacteria and although they
have an alternative electron transfer system (92, 93), it was found desirable to co-express
OR and b, with the P450 enzyme (94, 95, 96). Numerous attempts to enhance the
electron transport to P450 enzymes using various co-expression methods have been
investigated and the P450 enzymes expressed to date, in bacteria have been summarised
in Table 2.2 A. It clearly shows that, although the activities of expressed P450 enzymes
increased, the overall yield was not improved unless the amino terminal of the P450
enzyme was modified significantly.
Protein expression in baculovirus can produce high levels of cytochromes P450 as
shown in Table 2.2 B, although relatively labour intensive and time consuming. Using
insect cells, the system is an attractive candidate for expressing large functional amounts
of recombinant P450, including bovine P45017a (88). Insect cells contain both ER and
mitochondria, but are deficient in all electron-transport components and hemin (97),
required for the expression of catalytically active P450. Therefore these must be added
to the cell extracts, making it a costly procedure. Another shortcoming of baculoviral
cells is that the enzymes are produced transiently in the host cells, thereby increasing
variability between different batches of preparations (98).
The yeast S. cerevisiae has several advantageous features establishing it as an important
tool in the expression of foreign proteins for research, industrial or medical applications.
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As a. GRAS (Generally Regarded As Safe) food organism, it is highly acceptable for the
production of pharmaceutical proteins. S. cerevisiae can be grown rapidly to a high cell
density on simple media resulting in the high-level production of soluble cytosolic as
well as secreted proteins (99). Yeasts are free of lipopolysaccharides and associated
problems of pyrogenicity, which are problems encountered with bacteria. Furthermore,
S. cerevisiae is a useful host for the expression of mammalian genes, especially
cytochromes P450, as yeast cells contain microsomal membranes, OR and b5 resulting in
membrane integration and catalytic stability. It was the first system used successfully by
Oeda et al. (100, 101) to express a mammalian P450. Novel strains of S. cerevisiae,
integrating the genes encoding either human OR or hamster OR have been designed and
many more P450 enzymes have since been produced in yeast as listed in Table 2.2 C.
The methylotrophic yeast, Pichia pastoris, has become the yeast of choice since S.
cerevisiae has major drawbacks - the absence of strong, tightly-regulated promoters,
the need for a fed-batch fermentor to reach high cell densities and the occurrence of
hyperglycosylation (99). The P. pastoris heterologous expression system has become
one of the most popular systems used in the production of recombinant proteins,
including enzymes, proteases, protease inhibitors, receptors, single-chain antibodies, and
regulatory proteins. Several general reviews of this system have been published giving a
broad insight into P. pastoris (102, 103, 104, 105). The application of P. pastoris in the
P450 research field has gained popularity, as reports show that this expression host is
well suited in producing unmodified P450 enzymes at moderate to high yields, as listed
in Table 2.2 D. GSl15 (his4) and the wild-type X-33 P. pastoris strains, which have a
higher growth rate using methanol as the sole carbon source, are the most commonly
used P. pastoris strains (106). KM71 (his4, aoxl::arg4), is a slower growing strain
utilising methanol at a lower rate, has been shown to be advantageous if overexpressed
proteins are detrimental to the heterologous host (107). In addition, protease deficient
strains such as SMDll68 are also available (105).
2.2.2.2 Co-expression of cytochromes P450 with OR
In bacteria co-expression of P450 enzymes and OR as a fusion protein has become a
common approach to express active P450 enzymes and was first introduced by Fisher et
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al. when expressing bovine P450l7a or rat P450 4Al fused to rat OR (400-700
nmollL)(108). However, expressing P450 enzymes as a fusion protein with rat OR in the
E. coli showed little or no metabolic activity (109, 7, 110), although moderate
expression levels (50-250 nmollL) were obtained, as shown in Table 2.2 A. In an
attempt to increase catalytic activity and expression levels of a human P450 enzymes in
bacteria, a bicistronic system was developed by Dong et al. (111), which overcame the
problem of the insufficient electron transport from NADPH to heterologously expressed
P450. A bicistronic vector was designed by cloning a bicistronic construct downstream
of a single promoter (tac). This construct consisted of a microsomal P450 cDNA
encoded by the first cistron (first ribosome binding site) and the auxiliary protein OR
cDNA encoded by the second cistron (second ribosome binding site). The vector was
used for independent co-expression of P450 and NADPH-P450 reductase (bicistronic
construct) and was shown by Shet et al. to produce levels up to 200 nmollL culture when
co-expressing the steroidogenic bovine P450l7a and rat OR. (112). However, for most
P450 enzymes co-expressed with the bicistronic vector, an increase in activity was
achieved, but the yields of the recombinant P450 proteins decreased significantly, seen
in Table 2.2 A.
There is strong evidence that to increase the turnover of some substrates the bicistronic
vector is unsatisfactory and the addition of b, essential. Voice et al. co-expressed P450
3A4, OR and bs, in an E. coli system (113) and showed that the turnover of the
substrates increased in the presence of b, in the whole cell and bacterial membrane
fraction. Although the stability of a spectrally active enzyme was also prolonged, the
expression levels of P450 3A4 was reduced by - 50%.
Another attempt to increase expression levels in bacteria is to use double promoter
constructs as described by Blake et al. (114). The modified human P450 3A4 cDNA and
human OR cDNA, each independently under control of the tac promoters, produced
P450 3A4 expression levels of approximately 200 nmol/L culture. This level was lower
than when P450 3A4 was expressed alone or as a fusion protein with OR which yielded
370 and 230 nmol/L culture, respectively (115, 116). Many microsomal human liver
P450 enzymes have since been expressed in E. coli and in S. typhimurium and are listed
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in Table 2.2 A. However, the data show that the expression levels of P450 without OR
are higher that P450 expression with double promoter constructs.
A fmal approach to increase expression levels of P450 enzymes in bacteria was to
introduce two different plasmids carrying respective human P450 cDNA and human OR
cDNA into E. coli (JM109) cells simultaneously, first shown by Pritchard et al. (117).
Expression levels of P450 2D6 in E. coli whole cells determined by CO-difference
spectra were 381 nmoI/L culture.
Baculovirus expression offers high-level expression (300-1000 pmoI/mg total cell
lysate) of both P450 and OR, using a single transfer vector. However, in a co-expression
system, using a dual expression plasmid (i.e. P450 cDNA and OR cDNA located in one
plasmid controlled by two independent promoters), the catalytic activity of expressed
P450 enzymes can be increased although the yields of spectral P450 decreased around
10 fold when compared to the expression of P450 cDNA without OR cDNA (118).
Wang et al. have shown that although an imbalance of the molar ratio between the
human P450 2E1 and the OR of 1:5 occurs when using a dual expression virus, 170
pmoI/mg membrane protein was produced (119). Another approach to increase
expression levels was to co-infect Sf9 cells with two baculoviruses, one containing
human P450 2E1 cDNA and the other containing human OR cDNA, which yielded
expression levels of human P450 2E1 at 400-800 pmoI/mg cell proteins. (119).
s. cerevisiae cells contain endogenous OR and bs activity, although low levels and
availability can impact negatively on the specific activity of expressed P450 enzymes
(120, 121). Co-expression of OR with P450 enhances the P450-dependent
monooxygenase activity in yeast as was shown by Murakami et al. when expressing rat
P450 with OR as a fusion protein in S. cerevisiae (122). Although the focus was not on
increasing the yield of recombinant P450, the expression of bovine P45017a, rat P450
lAl and bovine P450c21 fused to yeast OR (123, 124, 125, 126), led not only to the
gaining of knowledge in applications of the fusion expression systems but also to
invaluable insight into the interaction between cytochrome P450 and OR (1-200
pmoI/mgmicrosomal protein).
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Alternative strategies for co-expressing OR with P450 enzymes in S. cerevisiae is to
either use a single plasmid containing multiple expression cassettes, i.e. each
recombinant cDNA has its own promoter (127, 128, 129), or transforming yeast cells
with multiple vectors (130). However, these yeast expression systems are mitotically
unstable, due to the large plasmids burdening the cells resulting in low cell growth.
Pompon et al. therefore developed a yeast expression system to optimise the redox
environment, since earlier yeast expression systems showed interference from
endogenous OR and b, (131). The gene encoding endogenous OR located on the yeast
chromosomal DNA, under the control of the GALIO-CYCI promoter, was disrupted by
site-directed integration of the human OR gene. In another strain the OR gene was
substituted with the expression cassette containing human bs. Co-expression of the
associated electron-transfer proteins by integration of galactose-inducible expression
cassettes into the yeast genome under the control of an efficient and externally
controllable promoter, enhanced specific P450 3A4 activity 73-fold in comparison with
the activity observed in a wild-type strain (132, 133). However, the production level of
P450 lAl in the microsomal fraction did not improve and the level of P450 3A4
decreased (134, 135). Ohgiya et al. followed the same principal of integration of the
expression unit into the yeast genome, inserting hamster OR at multiple-copy sites into
the yeast retrotransposon Ty, resulting in a 20-times increase of P450 reductase activity
compared to the parent yeast (136).
To date co-expression of OR with P450 enzymes in P. pastoris has not been
investigated. Preliminary results from our research group (not published) show high
P45017a. hydroxylase and lyase activity in whole cells, indicating that the endogenous
yeast OR and b, electron transport to the P45017a. enzyme is adequate.
In summary, different strategies employed in the co-expression of the electron transport
equivalents, have lead to enhanced efficiency of electron transfer from OR to P450
enzymes, increasing the catalytic activity of the expressed enzymes albeit at lower
yields.
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2.2.2.3 Co-expression of P450 enzymes with chaperones
The heterologous expression of P450 enzymes in E. coli is enhanced by ethanol, which
triggers the heat shock response (associated with protein folding through molecular
chaperones) and some C-group antibiotics, which trigger the cold shock response
(translational regulation by protein synthesis inhibitors (137, 138). Inoue el al. reported
elevated expression levels of P450 3A7 in the presence of molecular chaperone GroEL,
known to assist the correct folding of proteins in E. coli (139). This chaperone, co-
expressed with a modified human aromatase gene, also led to stable expression levels of
400 nmol/L culture in E. coli (140). The use of another heat shock protein, HSP40,
enhanced expression levels and catalytic activity of P450 1A2 in bicistronic format
(141). However, although the co-expression with chaperones increased the production of
several P450 enzymes, the success of this strategy appears to be protein specific (142).
2.2.2.4 Transcriptional control: vectors and promoters
Heterologous expression levels in any organism are dependent on the type of vector and
copy-number used to introduce foreign DNA in the host. Expression levels are
influenced by the type (induced or constitutive) and strength of the promotor as well as
gene stability. In the last decade various promoters have been investigated and their
application in the heterologous expression of cytochrome P450 will be discussed.
One of the first promoters used in E. coli systems to express of large amounts of bovine
P45017a was the powerful T7 phage promoter (143). However, most of the recombinant
proteins were found in inclusion bodies since the expression rate of the recombinant
proteins exceeded the capability of the cell to synthesise these ancillary elements thus
failing to fold correctly and accumulate irreversibly in inclusion bodies (IB). Many
proteins produced in E. coli accumulate in IB as a denatured form or can be present as
dimers and higher-molecular-mass multimers. Tedious isolation protocols, including
denaturation techniques, need to be applied compromising high yields of correctly
folded protein. To date, the most preferred promoter for cytochrome P450 expression is
the lac-lac promoter of the pCWori+ vector (Table 2.2 A.
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In baculoviral systems a conventional strong polyhedrin promoter is commonly used in
the expression of heterologous proteins in Sf9 cells. However, high levels of expression
of recombinant P450, coupled to a strong promoter, can be detrimental to correct folding
and heme incorporation resulting in an inactive and insoluble apoprotein. To overcome
these shortcomings a moderate or weaker promoter was employed by Paine et al. (118).
Initially the alcohol dehydrogenase promoter (ADH1) located in the pAAH5 vector (101,
144, 145, 146) was the promotor of choice in S. cerevisiae systems but many alternative
promoters have since been used. The acid phosphatase (PH05) (147, 148) and
metallothionine (CUP1) promoter in the inducible vector Yep13 (149, 150,151) were
able to express a number of different P450 enzymes at low concentrations in S.
cerevisiae expression systems, as summarised in Table 2.2 C. The use of a medium
strong constitutive phosphoglycerate kinase (PGK) and glyceraldehyde-3-phosphate
dehydrogenase (GAP) promoter produced moderate levels of P450 enzymes (40-100
pmol/mg microsomal proteins) in the yeast strains AH22 (152, 153, 154, 155, 156) and
W303 (56). Urban et al. improved the yield of expressed P450 enzymes in yeast by
developing the GAL 1O-CYC1 hybrid promoter which remains one of the most powerful,
tightly-regulated, inducible promoters of S. cerevisiae (132, 131). This promoter is
induced more than 1000-fold by the addition of galactose but strongly repressed by
glucose. In cultures grown in glucose medium maximal induction can only be achieved
following depletion of glucose at the end of the exponential phase and the addition of
galactose during the stationary phase (99). In yeast, tightly regulated promoters therefore
separate the growth phase from the induction phase minimising stress and avoiding the
selection of variants expressed at low levels often seen during large-scale culture
fermentations.
The improved expression levels of P450 enzymes cannot be attributed to the GAL 10-
CYC 1 hybrid promoter alone since the plasmid copy-number in the yeast cells also plays
a vital role. Pompon et al. used E. coli-yeast shuttle vectors based on the 2Jl
autonomously replicating vectors, pYeDP (which are stably maintained at 50 to 200
copies per cell (133, 157). The successful production of human cytochrome P450 lAl
was achieved in S. cerevisiae YME2 by incorporating the cDNA encoding the enzyme
into the yeast 2f.l episomal plasmid pDP34 (158, 159). Unfortunately yeast cells, which
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harbour episomal vectors need to be grown under selective pressure to ensure high levels
of expression and stability. The cells therefore have to be grown on a selective medium
(selective defined), resulting often in retarded growth, which in turn decreases the yield
of expressed protein considerably.
Integrating vectors (YIp) contain yeast chromosomal DNA which permits the expression
units, selectable marker and bacterial replicon to be stably integrated via a single
crossover integration resulting in the duplication of the chromosomal target sequence.
Yeast cells can therefore be grown for sixty generations without selective pressure in a
rich medium (160). The copy number remains constant in S. cerevisiae and independent
of culture conditions, it is very low (1 copy per cell) and expression levels therefore
depend only upon promoter efficiency.
The compromise between high, stable integration and low copy number can be
circumvented in the P. pastoris multi-copy expression system. Cleavage of the P.
pastoris vector within a sequence, shared by the host genome, stimulates homologous
recombination events, which target integration of the vector to either the his4 or the aoxl
loci efficiently. The latter is shown in Figure 2. 2.9. Alternatively, single-copy
integration may also be achieved replacing the AOXl gene (transplacement) via double
homologous recombination, depicted in Figure 2.10. However, during these single
homologous recombinations, multi-copy integration can arise (1-10% frequency) and
multi-copy transformants containing over 20 tandem repeats can be generated (161). In
most cases, multi-copy integrants are more likely to express higher levels of the
recombinant protein in comparison to the single-copy strains (162).
P450 proteins can be expressed in P. pastoris controlled by the strong and highly
regulated alcohol oxidase (AOX1) promoter, which can maintain P450 genes in a
suppressed expression mode on a non-methanolie carbon source minimising selection
for non-expressing mutant strains during cell growth. The promoter is switched on by
shifting to methanol feeds. The AOXI promoter therefore tightly regulates expression at
transcriptional level. RNA is undetectable in cells cultured on carbon sources such as
glucose, glycerol or ethanol, but in methanol-grown cultures the AOXI message
represents ~ 5% of total poly.A" RNA producing 30% of the total soluble protein (163).
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The AOXI promoter produced moderate levels of a plant P450 (128 pmol/mg
microsomal proteins) in yeast strain X-33 (164) and higher levels of the human P45017a
(300 pmol/mg microsomal proteins) inyeast strain OS115 (165) .
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Figure 2. 2.9 Schematic representation of a gene insert event at AOXI. In GS 115 cells, gene insertion
events at the aoxl locus arise from a single crossover event between the aoxl locus in the chromosome
and the AOXI gene on the vector. One or more copies of the vector are inserted at the aoxl locus. By
linearising the recombinant vector at a restriction enzyme site located in AOXI gene, Mut+ recombinants
can be conveniently generated depending on the host strain used. (From Ref. 166)
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Figure 2.10 Schematic representation of a gene replacement event at AOXI. In a his4 strain such as
GSl15, a gene replacement (omega insertion) event arises from a double crossover event between the
AOXI promoter and 3' AOXI regions of the vector and genome. This results in the complete removal of
the AOXI coding region (i.e. gene replacement) and the gain of an expression cassette containing PAOXh
the gene of interest, and HlS4. (From Ref. 166)
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2.2.2.5 Translational efficiency: strong initiation sites, secondary structures and
codon usage
Factors, such as codon usage, GC content, secondary structure formation, potential
splice sites and favourable translation initiation codon context in a given mRNA, can
influence the efficiency of translation, often resulting in low levels of heterologously
expressed proteins. The parameters of these factors differ between host organisms and
studies, conducted in COS (167), S. cerevisiae (168, 169) and E. coli cells (170), have
shown that certain codons and consensus sequences around the initiation site are
recognised most efficiently by the most abundantly available tRNA species (171, 172,
173). Based on this knowledge, P450 researchers have modified the amino terminal of
the P450 cDNA which, in many cases, lead to increased levels of heterologous protein
expression. These strategies are summarised below.
The expression levels of full-length P450 enzymes are very low in bacterial expression
systems and efficient expression was achieved with modifications of the lipophilic
amino-terminal sequence. In E. coli, parameters such as codon usage preferable to
bacteria and the minimisation of secondary structure of mRNA ensure good translational
initiation context (174, 175). Since the expression of the native form of bovine CYP17
cDNA failed in E coli, Barnes et al. increased the expression levels by modifying the 5'-
end, illustrated in Figure 2.11 (176). The second codon was changed from TGG (Trp) to
GCT (Ala) to ensure a preferred second codon for expression of the LacZ gene (177).
Furthermore, modifying codons 4 and 5 to TTA created an AT rich sequence which is a
more favourable initiation sequence, since most mRNA expressed in E. coli has been
shown to be adenosine and uridine nucleotides (178). In addition, the last nucIeotides of
codons 6 and 7 were changed to A and T respectively, which ensured a decrease in the
synthesis of the secondary structures around the ribosome binding-site which resulting
an inhibition of translation (174, 175).
When the modified bovine amino-terminal sequence (MALL LAVF) replaced the amino-
terminus of human P45017a (Figure 2.11 B modified), expression of human P45017a
increased by 40% (179). Numerous cytochromes P450 have since been expressed in E.
coli by generating chimeric enzymes utilising the modified bovine sequence.
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A
native bovine CYPI7: ATGTGG CTG CTC CTG OCT GTC TIT CTG .
Met Trp Leu Leu Leu Aln Val Pile Leu .
modified ATG GCT CTG 1TA TTA OCA GIT TIT CTG .
Met Ala Leu Leu Leu Ala Val Pile Leu ...
B .
native human CVPl7: ATG TGG GAG CTC GTG OCT CTC TIG CTG .
Met Trp Glu Leu Vnl Aln Val Pile Leu .
modified ATG GCT CTG TTA TTA GCA GIT TIT CTG .
Met Ala Leu Leu Leu Ala Val Pile Leu .
Figure 2.11 Modifications of the amino-terminus for the efficient expression of bovine P45017a. (A)
and human P450l7a. (B) in E. coil. The red indicates the nucleotide changes introduced via peR
mutagenesis.
Other studies have attempted to reduce the number of amino acid changes, replacing
only the second codon with alanine, and found different levels of expression, suggesting
that additional factors influencing translational initiation are required for high-level
expression in E. coli. (180, 181, 182). However, Shimada et al. observed no consistent
correlation between expression levels of human P450 1B1 with the potential for
secondary structure formation in the mRNA transcripts or with the presence of Ala/GCT
in the second codon position (183).
Another strategy to increase expression levels in conjunction with the solubility of P450
enzymes was to truncate the highly hydrophobic amino-terminal region of the P450
(184). The first report from Li et al. demonstrated that deleting the amino-terminal
hydrophobic sequence of amino acids 2-24 (P450c7~-24) increased the expression
level by 10% and, in addition, the protein was mainly cytosolic (185). Sagara et al.
expressed a truncated bovine P45017a (d2-17) in E. coli, and although not able to
integrate into the membrane, remained functional in E. coli (186). It was therefore
concluded that the hydrophobic amino terminus was not essential for the folding
pathway. In contrast, in mammalian cells the folding pathway leading to functional
P45017a appears to require a signal anchor sequence since the same truncated P45017a
is found to be inactive (187). Larson et al. found that the removal of amino acid residues
3-29 did not prevent a functional P450 2El binding to the membrane (188). It seems,
that the latest trend in attempting to overexpress cytochromes P450 successfully in
bacteria is to delete the hydrophobic amino-terminal sequence and replacing it with
either the 5'-MALLLAVF sequence or various favourable translation initiation codon
Stellenbosch University http://scholar.sun.ac.za
Part I Comparison of heterologous expression systems 39
contexts such as 5'-MARQVHSSWN and 5'-MAKKTSSK. Additional altered
modifications are summarised in Table 2.2 A.
Unlike E. coli based expression of P450 enzymes, it is unnecessary to modify
mammalian cDNAs extensively for their heterologous expression in baculoviral
systems.
Few reports dealing with amino-terminal modifications of P450 cDNA in order to
increase the expression levels of P450 enzymes in S. cerevisiae have been published. A
more recent study by Batard et al. investigated the adjustment of the amino-terminal of
the coding sequence of a monocot P450 gene (P450 73A17) to a more favourable codon
usage characteristic of the expression host S. cerevisiae (189). The data suggests that
certain rare codons, including repetitive CTC triplets nearer the translation initiation site,
is more critical than unfavourable codons distal to the ATG start site. Recoding the first
111 base pairs yielded P450 73A17 expression levels of 300 pmol P450/mg proteins.
However, upstream of the ATG initiation site, certain consensus sequences have shown
to increase initiation and promote efficient translation in S. cerevisiae (190, 191). Sakaki
et al. employed a short (AT)-rich sequence upstream of the ATG codon, increasing the
yield of bovine P45017a twofold in S. cerevisiae (123). Hayes et al. inserted two
nucleotide fragments upstream of the initiation site (192) - AACA found in several
abundantly expressed yeast genes (193), while GATC was previously shown to increase
the expression ofP450 1A2 in yeast (194).
The criteria ensuring translational efficiency in S. cerevisiae also apply in P. pastoris.
The mRNA secondary structure around the AUG start codon may be adjusted so that
AUG is relatively free of secondary structure as predicted by the RNA-fold analysis
computer program.
2.2.2.6 Fermentation conditions of high cell density growth in fermentor cultures
In recent years, medium optimisation and high cell density culture techniques have been
employed in an endeavour to enhance productivity of proteins in fermentation processes
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utilising recombinant orgamsms. Scale-up procedures of heterologous expression
systems, from a shake-flask environment to fermentors, are a complex process. Not only
are fermentors ideal for the efficient production of expressed proteins, but they can be
used as chemostats maintaining constant cell cultures growth, important for enzyme
kinetics. Controlled conditions will contribute to reproducibility which many P450
expression systems lack. The expression of recombinant P450 enzymes has been
optimised primarily for in vivo activity studies and the plasmids and promoters are
therefore unsuitable for high cell density fermentations.
Protein production in E. coli can be increased significantly through the use of high-cell-
density culture systems, but most expression plasmids used to date are unstable in long
fermentation periods. In addition, expression of P450 enzymes in E. coli can be
increased with the supplementation of cofactors, such as a heme precursor, i)-
aminolevulinic acid (i)-ALA) and flavins (195, (196, 197, 198,199). This would,
however, lead to an increase in the costs of large-scale fermentations.
Baculovirus expression system also requires the addition of hemin to the culture
medium for the production of functional P450 enzymes. The baculoviral system can be
scaled up to larger volumes for the use in fermenter systems. However, since the
consequence of infection is cell death, it is not possible for relevant protein production to
be maintained in continuous cultures.
In S. cerevisiae, heme is the prosthetic group of different hemoproteins or enzymes
involved in important physiological functions of yeast cells, such as respiration
(cytochromes of the mitochondrial respiratory chain), detoxification (peroxidase and
catalases), sterol and unsaturated fatty acid metabolism (b, and cytochromes P450) and
sporulation. It was shown that yeast expressing bovine P45017a is capable of acquiring
heme, even under heme-limiting conditions. However, competition for heme between
hemoproteins incorporating heme and the cells' own vital ergosterol biosynthesis, was
reported (200). The hierarchy of fulfilment of heme requirements may however be
avoided by the supplementation of the medium with hemin.
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Scaling-up into production fermentor systems (l l C-liter), utilising S. cerevisiae strains
D12 and AH22 transformed with the vector pAAH5 harbouring P450 3A4 or P450 2ClO
cDNA, was described by Guengerich et al. (201). Results indicated that the
transformants could only be maintained at low cell density culture due to plasmid loss,
producing low P450 2C9 and P450 3A4 levels of at 2.25 nmol/L and 2.0 nmol/L cell
cultures, respectively. Nishihara et al. subsequently showed high-level production of the
bovine P450l7a protein in S. cerevisiae (GRF18) under the control of the GALlO
promoter (202). In a 30-L fermentor P450l7a, determined by CO-difference spectra on
whole cell assay, was increased 4.7-fold (37 mg/L) compared to small-scale shake-flask
cultures.
The industrial yeast P. pastoris, together with the AOXI promoter, is a unique system in
large-volume high-density fermentor cultures. The promoter is efficiently transcribed in -
cells exposed to methanol as sole carbon source but is strongly repressed under most
other growth conditions. This aspect is important since the selection for non-expressing
mutant strains is minimised during the growth phase, ensuring high cell densities
without induction. Unlike most regulated promoters described in S. cerevisiae systems,
the AOXI promoter is regulated or "switched on" by methanol alone and remains
"switched off' even under limiting growth conditions (e.g. carbon starvation) which
normally results in the derepression of other promoters relying on the carbon levels. P.
pastoris is therefore grown on glycerol containing media, a repressing carbon source
which will not, even at very low levels of glycerol, lead to expression of the AOXI
promoter. Once the glycerol has been depleted, methanol must be added to ensure
induction of AOXI expression, allowing the cells in a fermentor environment to grow in
a high cell density prior to the addition of the inducer. Large-volume continuous cultures
therefore can be maintained at cell densities in excess of 100 grams/litre. Our research
group is currently investigating the optimisation of heterologously expressed human
P450 enzymes in fermentors, monitoring various fed-batch and continuous culture
schemes (203, 204, 205).
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2.2.2.7 Fusion of cytochromes P450 to signal peptides and secretion
Expressing proteins in the periplasmie space or culture media via a signal sequence can
ensure simple, cost-effective downstream purification processes which ultimately
increases protein production. The oxidising environment of the periplasm and secretory
organelles facilitates proper protein folding and, in addition, the signal peptide is
removed and degraded during translocation of the polypeptide across the inner
membrane, leaving the authentic amino-terminus of the target protein intact (206).
This strategy was first used by Prichard et al., whereby high levels of unmodified P450
enzymes were expressed in E. coli, by fusing translational amino-terminals to bacterial
leader sequence, pelB and ompA (207). The omp-3A4 fusion resulted in higher levels of
expression and improved recoveries of active P450 enzyme in bacterial membrane
fractions in comparison to yields obtained with the modified amino-terminal bovine
P45017a cDNA
The P. pastoris expression system is becoming more popular due to its ability to secrete
heterologous proteins (208). In an attempt to increase human P450 production we have
expressed various steroidogenic P450 enzymes extracellularly in P. pastoris.
Preliminary results indicate low expression levels in the medium necessitating further
investigation (165).
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2.2.3 Genetically-engineered human steroidogenic cytochromes P450 from
P. pastoris - potential applications
P. pastoris, is an industrial yeast which has been optimised for large-scale production of
heterologous proteins in fermentors (209). Preliminary investigations into the expression
of human steroidogenic P450 enzymes in P. pastoris in shake-flask experiments suggest
that these enzymes can be overexpressed and scaled-up into fermentors, leading to major
applications indicated in Figure 2.12. The P. pastoris expression system can be
employed to produce high yields of human steroidogenic P450 proteins which may, after
successful purification and downstream processes, aid in biophysical studies. The
purified proteins can also be used in processes such as raising poly- and monoclonal
antibodies. Whole P. pastoris cells can be harvested, producing a cell line mimicking
metabolic profiles specific to individual tissue types permitting in vivo investigations.
These two products, e.g. proteins and whole cells, can generate further potential
applications, which will be discussed in this section. These applications can be divided
into two categories - Primary fundamental applications are defined as applications
wherein the expressed protein or the expression host are utilised for basic cytochrome
P450 research. Many primary applications that arise from the basic cytochrome P450
research are important to various commercial industries, especially the pharmaceutical
industry. Secondary applications are defined as the transfer of knowledge obtained
during ongoing P450 research at academic level to the industrial level for commercial
exploitation of these enzymes.
2.2.3.1 Potential applications using pure proteins
2.2.3.1.1 Analysing structures
Steroidogenic P450 proteins, produced from genetically engineered P. pastoris are
suitable for crystallographic structural experiments. X-ray crystallography is one of the
most powerful tools available for determining the structure of proteins, since the x-ray
crystal structure represents the three-dimensional conformation of a protein in a solid
state.
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Figure 2.12 Diagrammatic representation of potential applications of human steroidogenic
cytochromes P450 expressed in P. pastaris.
The first successful x-ray crystallography was achieved with a soluble prokaryotic
P450cam(P450 101) (210), and subsequently with various bacterial P450 enzymes, viz.
P450SM3(P450 102) (211, 212), P450terp (P450 108) (213), P450eryF(P450 107A1) (214),
P450sca2(215), P450 119 (216) and P450cin (P450 176) (217), including a fungal P450nor
(p450 55A1) (218). Until recently, eukaryotic cytochromes P450 could not be
crystallised due to two factors. Firstly, their hydrophobic amino-terminal domain
prevented the P450 proteins from being overexpressed in bacteria resulting in low yields
failing to meet the requirement for crystallisation. Secondly, the microsomal P450
proteins need to be in a lipophilic environment to prevent aggregation. However, the use
of nonionic surfactants such as Emulgens interfere with the crystallisation processes.
Various attempts to produce a more soluble form of P450 have been made. Some
research groups have removed the hydrophobic sequences (219, 198, 220) while others
expressed P450 enzymes with a cleavable membrane segment removing it with specific
proteases (221). Sueyoshi et al. replaced the amino terminus of a mouse P450 2A4 with
an amphipathic 24 residue sequence (222).
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The tertiary structures of four mammalian cytochromes P450 have been solved by X-ray
analysis using these and new novel strategies to produce soluble proteins. These include
rabbit P450 2e5 (223, 224), rabbit P450 2B4 (225, 226), human P450 2e8 (227) and
human P450 2e9 (228). The P450 2e8 cDNA was modified by replacing the sequence
encoding the first 27 amino acids with one encoding a short hydrophilic, positively
charged amino-terminus (MAKKTSSKG) identical to that employed for the expression
and crystallisation of P450 2e5 (220, 229). This modification of the amino-terminus of
P450 2e8 converts the integral membrane protein to one that binds peripherally to
membranes and that can be separated from the membrane by elevating the ionic strength
of the medium. A similar modification and mutagenesis strategy was employed for
human P450 2e9 protein expression (228). However, no human steroidogenic P450
protein has, to date, been crystallised. The P. pastoris expression system potentially
allows the production of large quantities of pure P45017a proteins for x-ray
crystallography.
2.2.3.1.2 Determination of substrate specificity
Human steroidogenic P450 proteins isolated from recombinant P. pastoris cells will
contribute towards the determination of the structure/function relationships. The
predicted structure of the active site, which plays a role in the substrate specificity of
P450 enzymes, is as yet not fully understood and may be resolved from reconstituted
systems in conjunction with site-directed mutagenesis studies. Important residues
proximal to the active site can be altered, expressed in P. pastoris and activity of the
mutated protein compared to that of the wild-type.
2.2.3.1.3 Elucidating electron transfer of redox partner
There is intense interest in the involvement of b, in the regulation ofNADPH-supported
cytochrome P450 mono oxygenase reaction (230), specifically regarding the catalytic
activity of human P45017a. Although it was shown that bs donates the second electron
to the oxyferrous form of P450 during catalysis (231), Auchus et al. subsequently
showed, using microsomal yeast preparations, that both holo- and apo-b, acts principally
as an allosteric effector interacting primarily with the P45017a-OR complex stimulating
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the 17,20-lyase, but not the 17a.-hydroxylase activity (56). Similar effects have been
shown for P450 3A4 (232, 57) and P450 4A7 (233), suggesting that the electron transfer
to the P45017a. protein is not via bs. However, recent publication by Guryev et al.
challenges the allosteric effector hypothesis (234). Purified human P45017a. together
with human b, expressed in P. pastoris cells may contribute towards the characterisation
of the binding site and elucidate the mechanism of action as the precise site of action of
b, remains unknown.
Pharmaceutical drug design will be enhanced once the three-dimensional structure of the
steroidogenic P450 enzymes has been determined. A detailed knowledge of the active
site will permit the synthesis of specific compounds which will bind specifically to the
active site of these P450 enzymes, inhibiting their activity (235, 236, 237). P45017a. and
aromatase have been identified as crucial pharmacological targets for the treatment of
prostatic androgen dependent diseases (benign hypertrophy and carcinoma) (238, 239)
and breast cancer (240, 241), respectively. Although potent therapeutic inhibitors
targeting P45017a. and aromatase have been suggested (242, 243, 244) and
physiochemical requirements for their inhibitory activity have been shown (245, 246),
their exact interaction with the appropriate P450 enzymes are, however, predictive
mathematical algorithms based on theoretical three-dimensional models.
2.2.3.1.4 Production of antibodies
Polyclonal and monoclonal antibodies (mAbs) can be raised with the successful
production of human P45017a. and aromatase proteins expressed by P. pastoris.
Monoclonal antibodies, which are highly specific and often a limitless source, can be
used in an array of applications for P450 research and has been reviewed by Gelboin et
al. (247, 248). MAbs play an important role in the field of immunohistochemistry and
have made possible not only the identification and localisation of specific steroidogenic
proteins in selected tissue but also the quantification of these proteins. mAbs can be used
in immunological detection assays such as ELISA, radioimmunoassay (RIA) and
Western blotting. Furthermore, mAbs are directed to conformational or sequential
epitopes on the surface of the P450 protein. Based on this principle, it was found that
P450 reactions can be inhibited by mAbs binding to the epitope-specific P450 protein,
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thus determining the location of the substrate binding site (regio-and stereospecificity) as
well as the protein content.
Evidence to date indicates that oestrogens, especially 17p-oestradiol, functions as a
mitogenic factor in human endometrial, ovarian and breast cancers and could potentially
regulate cellular proliferation and development of these neoplasms (77). Human
aromatase catalyses the final step of oestrogen biosynthesis (249) and the ideal anti-
cancer strategy would be to block the terminal step in oestradiol biosynthesis without
inhibiting production of other important steroids. Therefore, the application of mAbs,
raised against aromatase, as a therapeutic inhibitor in oestrogen dependent cancers is an
attractive alternative to synthetic chemical inhibitors (250) due to the high specificity
with which mAbs recognise and bind their target antigen.
Immunoaffmity chromatography is one of the most powerful fractionation steps
available in protein purification and mAbs has an application in this field of
biotechnology (251). A highly selective purification and concentration method is
ensured by applying a protein mixture to a specific antibody immobilised on a resin or
membranous support, washing off nonspecific contaminating proteins and eluting the
absorbed antigenic protein with appropriate elution agents. The use of mAbs against
human aromatase and their use in purification procedures have been previously
described (252, 253). Immunoaffmity chromatography has been optimised for various
proteins and is another proteomics tool (254).
2.2.3.2 Potential applications using whole cells
2.2.3.2.1 Regulation of steroid metabolism
In vivo investigations using bacteria, baculoviral and yeast models represent rapid and
simple methods for assessing the role of cytochromes P450 in drug metabolism under
physiologically relevant conditions (255). Although whole cell assays are very useful for
predictive studies, they may not reflect the true cellular complex environment where
drug disposition, transport, adsorption and secretion are factors to be considered. In
addition, external factors such as cell densities, pH and growth media can differ
considerably from one experiment to another resulting in discrepancies. However,
Stellenbosch University http://scholar.sun.ac.za
Part I Potential Applications 48
recombinant P. pastoris cells can be grow under highly controlled constant conditions in
an chemostat, thereby ensuring reproducibility from batch to batch. Furthermore, the
characterisation of the steroidogenic enzymes with respect to kinetic parameters and
optimal reaction conditions can result in superior yields by using enzyme variants that
exhibit optimal activity under thermodynamically favourable conditions (256). P.
pastoris may therefore, become a model system for steroidogenic and drug metabolism
research.
2.2.3.2.2 Testing mutagenicity and carcinogenicity
The P. pastoris model system may be used to test the mutagenicity of chemicals once
the system has been evaluated and standardised based on the enzyme kinetic levels.
2.2.3.2.3 Manufacturing of metabolite in bioreactors
At the level of the organism, knowledge pertaining to sequence and structure may be
combined with metabolic pathway analysis allowing the engineering of P. pastoris
strains that direct their carbon flow towards specific compounds. This principal of
biotransformation is very useful in [me-chemical and pharmaceutical industries and
certain steroids and enzymes can be manufactured at lower costs instead of using tedious
and costly chemical synthesis processes (257). Hydrocortisone, an anti-inflammatory
used in the treatment for rheumatoid arthritis, was recently successfully biosynthesised
in recombinant S. cerevisiae grown on a simple carbon source (258). Based on this
principal, genetically engineered P. pastoris whole cells, immobilised in a fixed-bed
reactor or grown in stirred fermentors, would be able to produce significant
steroidogenic metabolites from the complete bioconversion of substrate. Therefore,
clinically marketable steroids such as oestrogens synthesised from androgens in
recombinant P. pastoris cells, is likely possibility in the near future.
2.2.4 Conclusion
The choice of heterologous expression system for cytochrome P450 production depends
on the type of investigation. If one wants, for example, to determine the enzyme activity
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of a heterologously expressed P450 in whole cells, then the use of a yeast system would
be the most likely candidate since the endogenous or co-expressed electron transfer
machinery is available under most conditions to maintain activity. On the otherhand, if
one wants to determine the enzyme activity in isolated microsomal environment or in a
reconstituted system, baculoviral and bacterial systems are the preferred systems of
choice.
We are however, interested in a suitable expression system that can a) overexpress a
full-length P450 protein, b) correctly fold the translated protein, c) produce high yields
and d) grow in high cell density fermentations. The most common organisms, E. coli,
baculovirus, S. cerevisiae and P. pastoris were investigated to see which one could fulfil
all these four criteria. Few reports have compared the first three expression systems
based on P45017a (88) and P450 3A4 (259) expression levels and yields, but these are
not truly comparable, since the cDNA of the expressed proteins were modified and
optimised for each particular organism.
Although E. coli produces the highest levels of P450 enzymes, the cDNA of eukaryotic
P450 enzymes have to be modified extensively before they can be expressed
successfully. In addition, the protein folding pathway in E. coli differs from that in
mammalian cells, leading to improper conformation, often leading to the accumulation
of an inactive protein form in IB (260). Therefore, bacteria are not the ideal organisms
for expressing a full-length P450 protein at high yields.
The baculovirus expression system offers high expression levels of an active P450
protein, therefore meeting three of the four criteria. However, engineering cDNA-
carrying viruses is very laborious and time-consuming. Once high-level expressing cells
have been identified, P450 expression levels are very difficult to maintain since the cells
are transiently infected. The baculoviral system's shortcoming therefore lies in high cell
density fermentations as small changes in growth conditions from batch to batch
increase variability thus hampering reproducibility (98).
S. cerevisiae expression systems are preferred in the P450 field of research, since the
ancillary enzymes needed for the correct functioning of the P450 enzymes are present. In
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some cases however, the activity of the yeast OR and the availability of internal
membranes in which they are anchored, limits the expression of human cytochromes
P450 in yeast (261). Earlier studies using yeast expression systems were able to produce
low to moderate levels of expression. However, with stable integration of plasmid DNA,
several milligrams of active protein could be readily expressed and purified.
While much work has been done to modify and improve S. cerevisiae as an expression
system, several laboratories have investigated alternative yeast hosts for the high-level
production of active proteins, resulting in the identification and development of a non-
Saccharomyces yeast. P. pastoris is a powerful tool for the production of foreign
proteins since its AOXl promoter is strongly regulated and well-developed methods for
classical- and molecular-genetic manipulation of the organism exist. Furthermore, the
technology for P. pastoris growth in large high-density fermentor is well understood and
the up-scaling process for commercial use can be readily achieved. Therefore the
flexibility of the P. pastoris expression system makes it an ideal tool for P450 research
in primarily fundamental applications as well as for secondary industrial applications.
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Table 2.2 A
Summary of heterologous expression of cytochromes P450 in bacteria.
cw· Modification 2 e-h Vector Promoter Strain4 Expression Ref.ut'S leve~0."'lOIS
"'
Replace 2'"' codon wit§ Ala pCWori+ lac OH5a 25 nmoVL 262Max. AT content
Replace 2'"' codon with Ala f pCWori+ lae OH5a 150 nmoVL 263
Replace 2'"' codon with Ala 27
nmoVL
b pCWori+ lac OH5a 16 nmoVL •
116
Replace 2'"' codon with Ala 2x pCWori+ toe OH5a 310 nmoVL 264
N/A 2x pCWori+ lac YG71087 N/A 265
N-term. MALLLA VF 2x pCWori+ toe TAI5387 54 nmoVL 266
N term. truncation
pET8, lac, BL2I. mlO 260
pGEX
9 toe JMIOI
N-term. MALLLA VFII 12 pCWori+ toe OH5a 520 nmoVL 141••••••••••••••••••••••• '13' ••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••
N-term. A 1-20 aa pCWori+ toe OH5a 700 nmoVL 267
N-term. MALLLA VFL
N-term. MALLLA VFL pCWori+ toe OH5a 245 nmoVL 268
N/A pCWori+ toe MXIOO N/A 269
N-term. MALLLA VF f pCWori+ toe OH5a 150-250 nmoVL 110
N-term. A 3-13 aa, b pCWori+ OH5a 350 nmoVL 116N-term. MALLLA VF toe 190 nmoVL'
N-term. A 3-13 aa, 2x pCWori+ toe OH5a 520 nmoVL 264N-tenn. MALLLA VF
N/A 2x pCWori+ toe TAl 5387 N/A 270
N/A 2x pCWori+ toe YG7108 N/A 265..............................................................................................................................
N-term. A 2-4 aa, pCWori+ lac OH5a 800 nmoVL 197
N-term. A 2-4 aa, b pCWori+ toe OH5a 200 nmoVL 183N-tenn. MALSPNOPWPL
N/A 2x pCWori+ tac YG7108 N/A 265..........................................................................................................................
N-term. MALLLA VF pCWori+ tac JMI09 455 nmoVL 207
OmpA_14• pCWori+ tac JMI09 193 nmoVL 207C-tenn. 6 x histidine tag
I Cytochrome P450 gene nomenclature.
2 Genetic modifications of the P450 encoding sequence at amino terminus (N-term) or carboxyl terminus (Csterm.)
3 Expression of P450 enzymes without OR (-) or with OR in certain constructs. f = fusion, b = bicistronic, t = tricistronic, 2 x = 2
~enes under the control of two independent promoters, 2 p = two plasmids.
All E. coli strains, except where indicated.
5 nmol/L = expression level of nmol P450 enzyme per liter of culture; pmol/mg = expression level of P450 content per mg of cell
protein.
6 Maximising the AT content at the amino terminus.
• The yield of OR.
7 S. typhimurium.
8 Six histidine tag at carboxy-terminal.
9 GST (glutathione demethylase) tag at the carboxyl terminus.
10 The expressed proteins were in inclusion bodies.
II Replacement of the hydrophobic sequence at the amino-terminal with the modified bovine P45017a coding sequence
(MALLLA VFL).
12C .. h ho-expression Wit c aperone Hsp40.
13 deletion (~) of20 amino acids (aa) at amino-terminus.
14 Bacterial leader signal (OmpA arPelB) fused to the amino terminal of the full-length P450 coding sequence.
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N-term. '" 3-27 aa.,
N-term. MAKKTSSKG,
C-term. 4 x histidine tag
N-term. '" 3·20 aa.,
Replace 2nd codon with Ala,
N·term. MARQVHSSWNL
N/A 2 x pCWori+ lac YG7108 N/A 265..." , .
N-term. MALLLA VF
N-term. '" 3·29 aa.,
N-term. MAKKTSSKGR,
C·term. 4 x histidine tag
N-term. '" 3-19 aa.,
Replace 2nd codon with Ala
N-term. '" 3-20 aa.,
Replace 2nd codon with Ala
N-term. MARQSSGRGK
N/A 2 x pCWori+...., " , .
N-term. '" 3-24 aa.,
Replace 2nd codon with Ala,
N-term. MARQVHSSWNL
N/A 2 x pCWori+ lac YG7108 N/A 265
Replace 2"" codon with Ala pCWori+ lac OH5a 210 nmol/l.. 271............................................................................................................
N-term. MALLLA VF,
C-term. 6 x histidine tag
N-tenn. MALLLAVF 2 x pCWori+ lac OH5a N/A 273...........................................................................................................
N-term. MALLLA VF
N-term. '" 3-20 aa.,
Replace 2"" codon with Ala
N-tenn. MARQSSGR
Partial sequence
VF
2x pCWori+ /ac
lac
lac
/ac
lac
lac
lac
lae, toe
/ac
lac
lac
lac
lac
OH5a
MVI304
CJ236
XL-I blne
OH5a
OH5a
OH5a
OH5a
BL2I,
JMIOI
XL-I blne
OH5a
OH5a
YG7108
XL-I blne
XL-I blue
OH5a
YG7108
25-80
870 nmol/l.. 264
272
274
196
227
264
275
275
260
196
228
116
264
265
196
pCWori+
N-tenn. MALLLA VF 2 x pCWori+
N/A 2 x pCWori+...., ' .
196
264
265
N-term. MALLLA VF
N-term. '" 25 aa., replaced,
with 6 x histidine tag
N-tenn. '" 18 aa., aligned,
with P450 2EI
OmpA,
N-term. MALLLA VF
N-term. '" 3-25 aa.,
Replace 2nd codon with Ala,
N-term. MARQVHSSWNL
N-term. '" 3-24 aa.,
Replace 2"" codon with Ala,
N-term. MARQVHSSWN
N/A
N-tenn. MALLLA VF
pCWori+
Pc2A
pCWori+
pCWori+
2 x pCWori+
pCWori+
pCWori+
pET,pGEX
pCWori+
b pCWori+
2 x pCWori+
pCWori+
pCWori+
pOS
pCWori+
f YPD2b
b pCWori+
2 x pCWori+
2 x pCWori+
2p
PCWori+,
pACYCI84
lac
lac
/ac
lac
T5-lac
lac
lac
lac
lac
lae
lac
OH5a
JMI09
OH5a
OH5a
OH5a
OH5a
YG7108
JMI09
60-100
nmol/l..
17 nmol/l..
198
199
198
276
116
264
265
117
OmpA, 2 p PCWorl+, lac JMI09 365 nmol/l.. 117
pACYCI84
··R;i~·:i.:;~~·~ili·~··············································O·H··5·:··············N··/·A······················2··7·7···
Silent mutations 3-7 aa6 pKK233-1 Trp-lac ~
N-term. '" 3-21 aa,
Replace 2nd codon with Ala
Partial seqnence
N-term. MALLLA VF
OmpA,
C-tenn. 6 x histidine tag
Replace 2nd codon with Ala
N-term. '" 3-21 aa.,
Replace 2nd codon with Ala
N-tenn. '" 3-24 aa.,
Replace 2"" codon with Ala,
N-tenn. MARQVSSWNCP
pCWori+
PET;pGEX
pCWori+
pCWori+
b P1L2
b pCWori+
2 x pCWori+
lac
Lac; lac
lac
lac
lac
/ac
lac
OH5a
BL21
JMIOI
JMI09
JMI09
XL-I blne
OH5a
OH5a
1500 nmol/l..
N/A
1620 nmol/l..
5-11 nmol/l..
9-19 nmol/l..
500 nmol/l..
170
170
nmol/L
nmol/l..·
1210 nmol/l..
N/A
450 nmol/L
700
750
N/A
nmol/l..
nmol/L
600 nmol/L
14.7 nmol/l..
90 nmol/l..
nmol/l..
130
34
nmol/L
nmol/l..·
580 nmol/l..
N/A
381 nmol/l..
40 nmol/L
68
175
0.8
4.7
160
59
nmol/L
nmol/L
nmol/l..
nmol/l..·
nmol/L
nmol/L"
1250 nmol/L
278
260
207
207
III
116
264
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pCWori+ 370 nmol/L 115lac DH5a
Partial sequence
OmpA}',
C-tenn. 6 x histidine tag
PelB -'\
C-tenn. 6 x histidine tag
N-term. !;. 1-20 aa,
N-tenn. MALLLA VFL
N-tenn. !;. 3-12 aa,
N-tenn. MALLLA VF
N-tenn. !;. 3-12 aa,
N-tenn. MALLLA VF
N-tenn. !;. 3-12 aa,
N-tenn. MALLLA VF
BL2I,
JMIOI
JMI09 504
PET,pGEX lac. lac NlA 260
nmollL 207pCWori+ lac
nmol/L 207pCWori+ toe JMI09 143
nmol/L 109f lac DH5a 200pCWori+
nmollL
nmol/L'
230
200
82
116b pCWori+ laC DH5a
nmol/l, 113PB216 toe JMI09
nmol/l. 1142 x pCWori+ JMI09 200lac
N-tenn. !;. 3-24 aa,
N-tenn. MALLLA VF
..........., ,..~!~ ~.~ P!:.Vf.~~.~ u:.~ ~~:!?~ ~~~ ~~?..
2x pCWori+ 410 omollL 264lac DH5a
N-tenn. !;. 18 aa
N-tenn. MALLLA VF
........, ~!~ ~.~ P!:.Vf.~ !r;.~•••••••••••• ~~:!?~ ~~~ ~~?..
nmol/L 139
139
pCWori+ 260 279lac DH5a nmollL
N-tenn. MALLLA VF
N-tenn. MALLLA VF
b
15
pCWori+
pCWori+ toe
50
78
lac DH5a
DH5a nmol/L......':: .
N-tenn. MALLLA VF, PSE380 N/A TOPP3 4-28 nmol/L
C-tenn. 6.~.~~!?~.~~~ •••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••
N-term. MALLLA VF pCWori+ lac DH5a 400 nmollL
......~;!~~.:.~~~~~~ P!:.v:.~~.~ Ir;.~•••••••••••• ?~~~ !~ !'.'!'~.~...•.••••
N-tenn. !;. 1-38 aa
N and C-tenn. 6 x histidine pET3b 17;10 BL21 N/A 281
tag
N-term. !;. 3-37 aa, " pCWori+ lae DH5a 240 nmollL 140N-tenn. MARQSFGRGKL
N-term. !;. 3-37 aa,
N-tenn. MARQSFGRGKL, _IS pCWori+ lac DH5a 350-400 nmol/L 138
....~:~e:!?!.~.~."!!~:.~~ .
pET BL21lac
··R;i~;ï.:.·~~~:;iliAi;:········· ·············D·H .. 5·~ ·1·60.. •••• .. ·n·m··o·l/L• •
Silent mutations 3-7" pCWori+ lac ~
N-tenn. IJ. 3-27 aa
pCWori+ DH5a 390-650 omollLlac
..~;!:?!..~.~.~~~.'.:!~.............................................................................................
N-tenn. 4 x histidine tag PT7-7 17 BL21 1300 omol/L
Replace 2nd codon with Ala,
PTrc99A NIA JMI09 10-35 omol/L 286Silent mutations 3-7"
N-tenn. MALLLA VF pKK233-J Trp-lac XL-I blue 35 nmol/L 287..." " " " .
500-
1500pCWori+ omol/Llac DH5a
pCWori+
........ " " ••• " -1
N-tenn. IJ. 1-23 aa,
N-tenn. MALLLAVF, pCWori+ toe DH5a
C-term. 6 x histidine tag... " " ••• " " ~ -1
Replace 2nd codon with Ala
f lae DH5a 400-500 omol/L
N/A 289
0.2 %16 185
2.0 % 185
3000-
omol/L 290
6000
191
pKK233-1 Trp-lac XLI-blue
N-term. IJ. 2-24 aa pKK233-1 Trp-lac XLI-blue... " " " " ' -1
Full-length f pCWori+ lac JMI09
N-tenn. MALL LA VF f
15 Co-expression with chaperone GroES/GroEL
16 This value is probably based on apoprotein determination and does not reflect the level of expression of holoenzyme.
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N-tenn. I:;. 2-17 aa,
Replace with amphipathic pCWori+ lac DH5a N/A 222
peptide
N-term. I:;. 1-20 aa,
N-tenn. MALLLA VF, pET23b TI BL219D3 25-60 nmollL 292
C-term. 6 x histidine
C-term. 4 x histidine tag pCWori+
JMI09,
DH5a.,
BL21
300 nmollL 293
N-term. 1:;.2-17 aa
N-term. MALLLA VF
N-tenn. MALLLA VF,
C-term. 4 x histidine tag
N-term. MALLLA VF,
C-term. 6 x histidine tag
N-term. MALLLA VF
N-tenn. MALLLA VF
N-term. I:;. 2-27 aa,
Replace 2"" codon with Ala
N-term. MALLLA V
lac
pCWori+
pCWori+
pCWori+
XLI-blue
JMI-O
JMI09
nmollL
nmollL
I~
176
294
7
108
112
184
295
N-term. I:;. 3-21 aa, 800-
N-term. MAKKTSSKK, pKK233-3 Trp-lac Topp3 1000 nmol/L 225
C-tenn. 4 x histi<l"!~.t.:!.~••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••
N-term. MALL LAVLL pKK233-1 Trp-lac Topp3 100 nmol/L 295
...." " " " ~~~~:! ~!'!'; ~!.~!!'!' ? •••.•~.!!~ •••.•••.~~7.
lae 600
412lae
lae 450 nmol/L
f
f
b
600-700 nmol/LpCWori+
pCWori+
pCWori+
lae DH5a
GM48
DH5a
700
150-200
nmol/L
nmol/L
lac
lac
pGEx"
pKK233-1
300-400
100
nmollLlac MV1304
Topp3 nmol/LTrp-lae
pCWori+ lac nmol/LXL-I blue 180
pCWori+ lac nmol/LXL-I blue 300
pCWori+ lae XL-I blue 400 nmol/L 196
pCWori+ lac XL-I blue 500 nmol/L 196
N-tenn. MALLLAVF,
Replace IO,14,15""codon pCWori+ lae XL-I blue 400 nmollL 296
with Gly, Leu and Leu
N-term. I:;. 3-20,
4 x His C-term
NH2 I:;. 3-20,
N-term. MALLLA VF, pCWori+ lac XL-I blue N/A 220
4 x His C-tenn
N-term. MALLLA VF pCWori+ lac XL-I blue 350 nmol/L 196............
%17Noue pKKHC /re MV1304 0.3 188
N-tenn. I:;. 3-29 pKKHC trc MV1304 0.1 %11 188
N-tenn. MALLLA VF pKK233-1 Trp-lac XL-I blue 100 nmol/L 287
N-term. MALLLAVF, pET2l 17-lae BL21 37C-tenn. 6 x histidine
N-tenn. I:;. 3-31 aa,
max. AT content pCWori+ lac JMI09 200 nmol/L 297
C-term. 4 x histidine
pCWori+ lac JMI09 265 nmollL 298.............................................
196
196
17 The figure is the percentage expressed P450 of the total E.coli protein, measured via immunoassay and does not reflect the level of
expression of holoenzyme.
Stellenbosch University http:// cholar. un.ac.za
Part I Table 2.2A: Bacterial expression systems 55
N-tenn. MALLLA VF pCWori+ lac JMI09 500 nmol/L 298
N-tenn. MALLLA VF pCWori+ /ac JMI09 350 nmol/L
300
N-tenn. MALLLA VF f PQE-ó DS4lO
/ac JMI09
NlA
500 nmol/L
182
NH2A 1-25
N-tenn. MALLLA VF pSPI9gl0L
tre PI-J3e 340 nmoVL
301,
210
302,
217
303
N-tenn. 2 aa changes pSE380
PGK300
None pCWori+
None pETlla
lac JM83
tac DH5a
17
BL2I,
2000 nmoVL
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Table 2.2 B
Summary of heterologous expression of cytochromes P450 in baculovirus.
Cells!
virus
Expression
lever
CYP Modification
...........................................................................................................................................
...........................................................................................................................................
Full-length.............................................................................................................................................SI9 N/A
....................................................... ....'._..~'._.."'._.."'..."'._.."'.~."'._. ..,._...,....,._.."'..."'._.._.,._.."' ..."'....,..."'..."'._.._.~.~."'...
Full-length
Full-length 2 x............................................................ ,.._."'._.."' .._."' ..."'.._.~,.~."'._.._.,._.._.._.._.,._.._.,._.."'._..~,~._._., ..."'..~~,..."'..."'._.._.~~~._.,...
Full-length
Full-length
Full-length
PVLI393
Bacêak
306
1500 pmol/mg 308
500 pmoVmg 309
170 pmoVml 119
400-800 pmoVmg' 119
107 pmoVmg 312
2 x P2&c
SI9
TN5/
SI9/Full-length
Full-length
'"'._.._..·._.·. '"'.. _..·.·... .'"'....F._..~..~_~=,..ngth........_.•• :::::::::::::::::::::::.! ~~!:~~~~!~~:::::::::::::~~~::::::::::::::::::::::::I:I~~~~~:::·::~~~~:::::::::~~~::::l
Full-length 2 x PAcUW51 T_ni
... ._.._. ,._. ._.~.~_.~._.._.~... .._.._.._.._.._.. ._.._.._. :..~".~ .'.. ._.."' :.•.!.•.'~"'._. "._. ._.~,•.~~"'.. ._..,._.._.._.."' ::! ..
Full-length
Full-length
Full-length
NH2!J. 1-41,
C-tenn_ 6 x histidine tag
2 x4 PlucGRhac I
pBluehac I
PVLI392
St9/
AcMNPV
TN5/AcMNPV 105 pmol/mg
N/A
SI9 N/A
Full-length 88 nmol/L
6PVL1393 St9
SI9/
AcMNPV 44 97
.................~~:!~?~ ~.t? ~~ P~?~~~ ._.3..06"._. ..
Full-length PAC373 pmoVmg
1 Expression of P450s without OR (-) or with OR in certain constructs. 2 x = Dual expression system. The P450 and OR cDNAs in a
single plasmid are controlled by two independent promoters., i = co-infection of two baculoviruses, one with the P450 cDNA and the
other with OR cDNA
2 pmol/mg = expression level ofP450 content per mg of total cellular protein. nrnol/L = expression level ofnmol P450 enzyme per
liter of culture
3 pmol/mg of membrane protein
4 Aromatase co-expressed with luciferase
5 Specific content of P450 per mg protein in crude cell lysate.
6 P450 content in membranes
56
ReC.
304
316
317
318
88
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Table 2.2 C
Summary of heterologous expression of cytochromes P450 in S. cerevlsiae.
CVP Modification
g-.- 'g
~~.a Vutor Promoter Strain
V ~ ...
lo< EI..
2x pHEIO GAPDH YHE2
pYeDP GALJO-CYCI W303.JB
pHEIOIlI GAPFL. YHE2POH5
pCK-I PGK AH22
2x pSB229 GAPDH YHE2
pAAH5N ADHl AH22
f pNW255, GAPDH YHE2.......................P~~:.~~. .............................
2x pHE36 GAPDH YHE2
PDP34 GAPDH YHE2
2x pCS316 GAPDH YHE2
Expression
lever Ref.
Full-length
Full-length
Full-length
Full-length
Full-length
Full-length
3 mglml 127,128
43 pmol/mg 132,134
156 pmol/mg 159
43 pmol/mg 152
17.2 mglml 128
19 pmol/mg 146
321
7 rnglml
191
8.4
Full-length
liiiiiiiiiiPiiïiii~ ·• ,,·~!!~:~~~~:'!..,..·········.···~···.····PX~.r:.~ ?::!!:!.q-sr.c;.!.•••••••••••••••••••••••••• !"!~ " ·-,;;·~·..i
PYES2 GAPDH JL20I!!!!!!!~~!!!!!!!!!! " .-" .- " •..ot
pAAH5N ADH I AH22..................... ;; .
pAAH5N ADH I AH22.................... :; , " " • • .. ot
pAAH5N ADH I AH22 283
......"....'F~U:I~:~~h....······················PM7··········GAL7·············MTS:i··············ïoo···
pAAH5 ADHI DI2 60
......" ~.'!J~:~e;~~~ ~~;~ ~~; rif-~ :.~ O;;;;;~~;:' ,~-:;=.. i
......" ,~~I!:I.~!!~~ P~.~~ 1R!!! ~~ .IR~ o;;;;;;;,;.:' ,;;".;.. 'ot
............~~::;;:;:: ~~ ~~~·············~i··..······..·..··;J·····.-..,..~,~·.-·.. ".. ··'!!,,·ot
pMA91 PGK AH22 98
...... ".-.;;;;;;;;·.;-.;.;.~.;; pX~.r:!. ?Af:!.q-E!E!. •••••~~!!~ .I.r:!•••••• · " ,.. ot
pAAH5 ADHI AH22 32........................................................................................
~!!!lI!!~~!!!lI!!l .......... ,,·;~:i:~;~~~·..······················~~~·······::~;·············:ii···············7:IT·····..,;.;;~UL~~.-·.. " .. ~·~~,,·ot
pAAH5 ADH/ AH22 156 pmol/mg 146
f pAAH5N ADHI AH22 52 pmol/mg 129
2 x pAAH5N ADHl AH22 131 pmol/mg 129
Full-length f,2x3 pAAH5N ADHI AH22 85 pmol/mg 129
Full-length pAAH5 ADH/ DI2, AH22 N/A 325
Full-length pYeDPI/8 GALJO-CYCI lAl-3 90 pmol/mg 326
Full-length pAAH5 GALJO-CYCI W303.1B 2-3 nmol/l, 327
Full-length pAAH5 GALIO-CYCI W303.1B 85 nmol/L 132
.........." pX~p.~ ~~~p.!: ~ ~'!!.'!-: ..•••• !!!~..
::::::::::j~j~~~;. pGYRI GAP AH22 10.6 nmol/mg 156·················j········py~DP60······GAL'jó:cyëï·····;;;(R)'············NiA············:·········'iis··.::::::::::::::::::::::::::i?yE(::::::::?:~::::::::::::::~~:::::::::::::!:?:::::::::~?v.~~:::::X~~::
1 Expression ofP450s without OR (-) or with OR in certain constructs. f= fusion; 2 x = dual expression system. The P450 and OR
cDNAs in a single plasmid are controlled by two independent promoters., i = yeast genomic integration of various expression
cassettes habouring the human OR eDNA or human b5 eDNA (132)
2 pmollmg = expression level of P450 content per mg of microsomal protein; nmol/L = expression level of nmol P450 enzyme per
liter of culture, mgfml = protein content of microsomes.
3 Dual expression system of (p450 3A4 eDNA and yeast OR eDNA fused) and human b5 eDNA in one plasmid controlled by two
independent promoters.
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N-term.l!. 1-18 aa,
C-term. 5 x histidine tag
.................................................................................................... ,....
pPRL2 N/A VPH259 N/A 329
pYE8 GAPDH. ADH 20B-12 0.8
pAAH5 Q 334 250
F-.:li:i;~gïh··························j,AAii5···························sËY6ii,o·········rS····
Full-length pAAH5 ADHI AH22 N/A
Varous lengths pAAH5 ADHI AH22 N/A
............................................. ~.~~ ' ········· ············.·····1
Full-length
323
88
123
130
f
Full-length pYeDP60 GAL/O-CYCI W(R) N/A 332
Full-length
Full-length f
pAAH5 ADHI 1.4 %4 101
pAAH5 ADHI AH22 N/A 124
pAFCR! ADHI AH22
110 pmoVmg
122
lO pmoVmg •
pAMR2 ADHI AH22
pmoVmg
pAM82 PH05 AH22
Full-length f
Full-length f
Full-length
Full-length pAAH5 ADHI 50JA N/A
Full-length pYe GALIO-CYCI. W303.1B 0.6 %4DPl,IO PGK
pYe
W303.IB
DPl,1O
.7 pRS404 ADHI VPH500 38.8 pmoVmgI
335
191
120
136
pAAH5 ADHI AH22 N/A 339
.....................................................................................................................................
pAAH5 w
.....................................................................................................................................
Full-length pAAH5, CUPI 50.lA 30-60 pmoVmg 149
•••••••••••••••••••••••••••••••••••••••••••••••~.l.~ •••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••
Full-length YEpl3 CUPI 50.lA 70 pmol/mg 150.....................................................................................................................................
4 Expression level given in % (w/w) of the protein relative to the total proteins in yeast microsomal fractions.
• the content ofNADPH-P450 reductase in mierosomes
5 estimated percentage of expressed P450 of the total yeast protein
6 Co-expression ofP450c27 with bovine adrenodoxin and NADPH-adrenodoxin reductase
7 i = yeast genomic Ty transposon integration of multi-integration (six copies) expression cassettes with the hamster OR cDNA
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...................................................................................................................................
Full-length pAAHS ADHI AH22 60-180 pmoUmg.....................................................................................................................................
pYe GALIO-CYCI W303.IB 337DPI,IO
YEpSI GALlO 334 338
N-tenn. YEpSI GALlO GRFI8 N/A 341truncated 47 or 97aa
Full-length,
insert Xa-factor recognition YEpSI GALlO GRFI8 620 pmoUmg 221
site at 62-66 aa
YEpSI GALlO GRFI8 340- pmoUmg 3427S0
Full-length PYeDP60 GALlO-CYCl N/A 343.............................................................................
pGY2 PGK...............................................................................
Full-length PYeDP60 GALIO-CYCI.............................................................................
Full-length PYeDP60 GALlO-CYCI 80 pmoUmg 298
...............................................................................
Full-length PYeDP60 GALIO-CYCI SO pmoUmg 298................................................................................
Full-length PYeDP60 GAL I O-CYCI 527 pmoUmg 298...............................................................................
Full-length PYeDP60 GALIO-CYCI W303.1B 200 pmoUmg 344345................................................................................
N-term. PYeDP60 GALIO-CYCI W303.IB 300 pmoUmg 189modification 36 aa.............................................................................
Full-length PYeDP60 GALlO-CYCI...............................................................................
Full-length PYeDP60 GALIO-CYCI........................................................................
Full-length PYeDP60 GALIO-CYCI...................................................
...................................................
PYeDP60 GALlO-CYCI...................................................
PYeDP60 GALlO-CYCI..............................
PYeDP60 GALlO-CYCl....................................................
PYeDP60 GALlO-CYCI
PYeD60 GALIO-CYCI WATlI, 346WAT21
pYES2 GALIO-CYCI 0.18 nmoUmg 347
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Table 2.2 D
Summary of beterologous expression of cytocbromes P450 in P. pastorls,
Full-length pPHIL.................................................................. ,.... ,.... '.... '.... ,.... '.. ..,.... '.... '.... ,.... ,.... ,.... ,.... ,.... ,.... '·····1AOXI OS1l5 N/a 349
CYP Modification Vector Promoter Strain ExpressionleveII ReC.
Full-length pPIC3.5K AOXI OS1l5 300 pmoVmg 165
,••••••••,•••C••-.t~...?~~~?~?!~.~ .
...............:~I!;!~~ p.:!~~ ~~!.~ ~~.~!? ~£ ~~~~~.~ !~~..
Full-length
Two silent mutaions at codon 2 and 6 pPICZc AOXI X-33 128 pmol/mg 164
I pmol/mg =Expression level of P450 content per mg of microsomal protein.
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SECTION 2.3: Heterologous protein secretion by yeasts' secretory
pathway
2.3.1 Introduction
The eukaryotic secretory pathway plays an essential role in maintaining the cellular
requirements for biochemical compartmentation and it is mediated by biochemically and
morphologically distinct membrane enclosed organelles (350), shown in Figure 2.13. In
these organelles activities such as protein transport, sorting of proteins from the
cytoplasm to various intracellular organelles and cell surface transport takes place.
Newly expressed proteins have to pass through this multi-component secretory
apparatus, within which disulphide bond formation, proteolytic maturation of
prohormones, N- and O-linked glycosylation and other post-translational modifications
occur (351). The synthesised proteins in the cytoplasmic ribosomes are inserted into the
lumen of the ER and are subsequently transported to the Golgi complex. From there, the
protein is delivered to the cell surface via the Golgi complex-derived secretory vesicle
and the plasma membrane.
In the field of biotechnology, the potential of exploiting this secretory pathway to
produce recombinant proteins was soon realised and many proteins were successfully
secreted (352). The secretion of heterologous proteins from yeast has many advantages
over intracellular expression. Intracellular expressed proteins are mostly insoluble and
may not adopt their correct conformation (e.g. disulfide bonding) in the cytosol. This can
be prevented with extracellular expression, since the secretion of foreign proteins
undergo proper posttranslational processes within the secretory compartments ensuring
correctly folded proteins (353). Secretion is highly advantageous because of the initial
purity of the product in the substantially protein-free culture medium leading to a
minimal purification from the culture medium. The choice between intracellular or
extracellular expression also lies in the type of protein that needs to be expressed. Some
protein products are toxic or unstable when produced cytoplasmically, which can be
avoided when they are secreted into the medium (354).
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In this Chapter we look at each of the individual secretory compartments of S. cerevisiae
and describe their role and function. Secretion of proteins in yeasts is a very complex
process and the exact detail of this is beyond the scope of this thesis. Therefore, a basic
outline of the secretory pathway is described in this chapter and excellent comprehensive
reviews are to be found in (350,355,356,357,358,359). This section discusses some of
the factors involved in secretion of heterologous proteins from S. cerevisiae.
Additionally, we outline the potential limitations of secreting expressed cytochrome
P450 proteins with regards to hydrophobicity, glycosylation and size.
Galgi
CompIIll
Figure 2.13 An illustration of the yeast secretory pathway. Yeast secretory glycoproteins synthesised in
the cytoplasm are transported over the ER membrane to the ER lumen where they undergo N-linked core
glycosylation and correct folding. After passage through the Golgi complex, where the outer chain
glycosylation modifies the secretory protein, the glycosylated proteins are delivered either to the vacuole
or the cell surface via secretory vesicles.
2.3.1.1 Passage of protein from the cytoplasm to ER and processing in the ER
There are four distinct events that occur during the protein passage from the cytoplasm
to the ER and in the lumen of the ER - (a) the initial sorting event, where proteins
destined for export are recognised by their amino-terminal signal peptides, which
consists of a precursor form, (b) the delivery of the protein with its secretory precursor
polypeptide to the target membrane of the ER, where translocation of the protein through
the proteinaceous pores of the membrane occurs, (c) the proteolytic processing of the
signal peptide and (d) the correct folding and N-glycosylation of the secreted protein.
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2.3.1.1.1 Leader sequences for initiation of secretion
For a protein to enter the S. cerevisiae secretory pathway, it requires an amino-terminal
hydrophobic signal peptide. There are two classes of signal sequences - one uses a
heterologous signal peptide, often derived from the protein being secreted, and the other
uses a homologous yeast signal peptide. It was found that the majority of heterologous
signal peptides will not direct efficient secretion of a protein from S. cerevisiae (360),
and subsequent research endeavours concentrated on the more reliable homologous S.
cerevisiae signal sequences. The most frequently used homologous signal sequences are
the yeast invertase (SUC2) (361, 362, 353), acid phosphatase (PR02) and prepro-u-
factor (MFa1) (363, 364). Only the latter will further be discussed, as it is the most
successfully used signal sequence and it was used in our expression experiments.
The yeast pheromone a-factor is a tridecapeptide mating factor, 12-13 L-amino acid
residues in length, produced and secreted by haploid cells of the a-mating type and is
required for efficient mating of haploid a and a cells to form diploids in the G1 phase of
the cell division cycle. The a-factors are derived by proteolytic processing from a larger
precursor, the prepro-u-factor, which is encoded by the MFa1 gene. The prepro-a-factor
protein consists of the pre region, a hydrophobic signal sequence of 22 amino acids, a
pro region of approximately 61 amino acids and the mature a-factor (mating factor and
pheromone) sequence of four tandem repeats of 13 amino acids seen in Figure 2.14. The
repeats are flanked by short peptides consisting of Lys-Arg-(Glu/ Asp-Alajj., (365). The
pre region of the prepro-c- factor is the actual signal peptide that acts as the specific
target signal and has three distinct domains which is common in most signal peptides: (i)
a positively charged amino-terminus (n-region, 1-5 residues), (ii) a central, hydrophobic
part (h-region, 7-15 residues) and (iii) a more polar carboxyl-terminus (c-region, 3-7
residues) (366, 367).
Signal sequences can direct proteins to a membrane through different targeting pathways
and select different translocation systems such as the signal recognition
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N-term
Proteolytic processing during 1
translocation across ER I
Modifications in ER lumen
Pro
~ - signal peptidase cleavage
I -N-Ilnked glycosylatlont -Correct refolding
M~dificatlons -;;-GOIQll
~ - Q-Unked glycosylatlon
J~~
Jl
Figure 2.14 The processing of the prepro-a-factor in the secretory pathway. Signal peptidase in the
ER cleaves the signal peptide, Kex2p endoprotease in the Golgi cleaves at carboxyl terminal of Lys-Arg,
Ste13 diaminopeptidase removes the Glu-Ala pairs, Kexlp protease removes Lys and Arg at carboxyl
terminus. N-and O-linked glycosylation of the pro-region at three sites is shown as N and 0, respectively.
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discriminating between SRP-dependent and SRP-independent pathways (369). The
prepro-a-factor precursor uses the SRP-dependent pathway.
2.3.1.1.2 The translocation of the protein from the cytoplasm to the ER
The signal peptide, usually located at the amino-terminus of nascent polypeptides,
initiates the cotranslational export of the secretory protein from the cytoplasm into the
ER by binding to the SRP. The SRP is a ribonucleoprotein particle consisting of a 300-
nucleotide RNA component (7SL RNA) which is complexed with six unique
polypeptides of 9, 14, 19, 54, 68 and 72 kDa (370). It serves as a cytoplasmic adapter
between nascent secretory polypeptide chains and the protein translocation apparatus of
the ER membrane, shown in Figure 2.15. After the SRP binds to the ribosome carrying
the nascent polypeptide chain with the signal sequence, the complex is targeted to the
ER membrane. The targeting process is regulated by a nascent-polypeptide-associated
complex (NAC) (371), which has been implicated in modulating the interaction between
the ribosome and SRP (372). At the ER membrane the complex binds to the SRP
receptor, a heterodimeric integral membrane protein, located in the ER membrane.
Cyto,ol
Figure 2.15 A schematic illustration of the export ofa secretory protein from the cytoplasm into the
ER (signal hypothesis). Nascent polypeptide chains are bound by a signal-recognition particle (SRP) to
form a soluble SRP-nascent chain-ribosome complex. This is directed to the ER membrane through the
interaction of the SRP with a heterodimeric membrane-bound SRP receptor (docking protein). The signal
sequence receptor is engaged by the signal peptide resulting in a release of the SRP into the cytosol ready
for another round ofER targeting. The mechanism of translocation of the nascent polypeptide is unknown,
the signal-peptide cleavage occurs either during or immediately after the translocation step.
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The nascent chain-ribosome complex associates with the protein translocation channel
after the targeting step. This channel provides an aqueous environment in which the
hydrophilic nascent secretory peptide chain can be translocated (373).
2.3.1.1.3 The processing of the prepro-a-factor during translocation
The translocation of the secretory protein into the ER is initiated by the hydrophobicity
of the pre region, directed by the signal sequence. The pre region is cotranslationally
cleaved by a highly specific signal peptidase (Figure 2.14) resulting in a pro-a-factor.
2.3.1.1.4 Correct folding of heterologous proteins and N- glycosylation
After the heterologous protein with its modified a-factor secretion signal peptide has
been translocated into the lumen of the ER, it needs to undergo correct folding and N-
glycosylation prior to its continuation through the secretory pathway.
Correct folding of the secretory protein is facilitated by a number of lumenal proteins.
They include the Kar2p/BiP (a chaperone) and the protein disulfide isomerase (PDI),
which mediates the formation of disulfide bonds (374). The efficiency and accuracy of
the yeast's folding mechanism, which uses similar components and machinery as the
mammalian ER, produces authentic refolded mammalian heterologous proteins (375).
Efficient secretion of the heterologous protein will only be achieved once the protein is
correctly folded.
Nascent polypeptides, translocating across the ER membrane, are cotranslational (i.e.
membrane translocation is obligatorily coupled with protein synthesis) or
posttranslationally (i.e. membrane translocation follows after protein synthesis) N-
glycosylated by an oligosaccharyltransferase complex (OST) at the potential
glycosylation motif (Asn-X-Thr/Ser) (376), as seen in Figure 2.16. Residue X can be any
amino acid except proline. The inner core of the glycosylated chain consists of three
glucose (Glc), nine mannose (M) and two N-acetylglucosamine (GlcNAc) residues,
which are linked to the N-amide group of Asn, hence N-linked glycosylation. The pro
region of the MFa1 factor is also glysosylated at three potential glycosylation sites
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(377). Investigations into the glycosylation of the precursor structure showed that N
glycosylation of pro-a- factor is important, but not essential for the transport of the ER to
the Golgi. Mutations of any of the three glycosylation sites in the pro region resulted in a
slight reduction in a-factor secretion and intracellular accumulation of the pro-a-factor
(378). Therefore it was concluded N-linked oligosaccharides increase the solubility and
stability of many proteins, ensuring correct folding of secretory proteins.
A
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Figure 2.16 Typical structure of yeast N-and O-Iinked oligosaccharides. Asparagine-linked core
oligosaccharides (A) are assembled and added in the ER. N-linked core oligosaccharides are usually
modified during transit through the Golgi complex by the addition of an outer chain carbohydrate. (B) M:
mannose, P: phosphate; GlcNAc: N-acetylglucosamine; Glc: glucose. a-l,6; a-l,3; a-I,2 and ~-1,4
linkages are designated,
2.3.1.2 Transport from the ER to the Goigi complex
There are three steps involved in the transport from the ER to the Golgi complex - a)
budding of transport vesicles, COPI-, COPII- and clathrin-coated vesicles, from the cell
surface; b) targeting of the ER-derived vesicle to the Golgi complex and c) fusion of the
transport vesicle to the acceptor membrane. A detailed biochemical dissection of these
processes has been well documented and models have been postulated (357, 379, 380).
Three G'I'P-binding proteins Arrlp, Arflp and Yptlp have been implicated in transport
from the ER to the Golgi complex in S. cerevisiae (356, 381,).
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2.3.1.3 Golgi processing and passage from Golgi to secretory vesicles
The Golgi complex plays an important role in regulating several aspects of protein and
membrane movement throughout the cell. This organelle is the compartment for sorting
proteins from the constitutive secretory pathway to the lysosomal and regulated
secretory pathways. Additional functions are the regulation of membrane recycling from
the cell surface and involvement with the endocytic pathway (382). Although the
complex functions of this organelle remain unclear, two functions executed by the Golgi
apparatus, namely outer chain glycosylation and proteolytic processing of the a-factor,
are of interest for our investigations into the extracellular heterologous protein
expression and will therefore be addressed.
2.3.1.3.1 Outer chain glycosylation
In the Cis-Golgi phase, the ER-secreted protein or pro-a- factor with its inner core is
elongated by the addition of an outer chain containing 50 or more mannose units (Figure
2.16). The outer-chain carbohydrates consists of a-D-mannose residues in a-(1 ~6), a-
(1~2) and a-(l ~3) linkages together with a limited number of mannobiosylphosphate
groups in diester linkage. The order of glycosylation from the core oligosaccharide to the
matured N-linked glycans and the compartmentalisation of mannosyltransferase
activities are well documented (383, 384).
This elongation by the addition ofmannose residues of the pro-a-factor outer chain in S.
cerevisiae (hyperglycosylation) does not occur in higher eukaryotes. In mammalian
Golgi cells, mannosidases trim back core oligosaccharides to three mannose residues and
substitute the residues with sialic acid, galactose and N-acetylglucosamine (385). These
significant differences in the mechanism of glycosylation between the yeast-derived and
native glycoproteins consequently limit the use of S. cerevisiae as a secretory expression
host. The addition of large numbers of non-native sugar residues to heterologous
proteins, can also act as immunogenic determinants (386).
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2.3.1.3.2 Proteolyticprocessing step
In the trans-Golgi phase an endoprotease, Kex2p, cleaves the dibasic residues, Lys-Arg,
at the carboxyl-terminus, separating the pro-region from the a-factor. During the
formation of the secretory vesicle, destined for the plasma membrane, dipeptidyl
aminopeptidase A, Ste13p, remove the dipeptides Glu-Ala, Asp-Ala or Val-Ala from the
amino-terminus of the a-factor. Carboxypeptidase B (Kexlp) removes Lys-Arg from the
carboxyl-termini of the first three excised units to generate mature a-factor peptides
(Figure 2.14).
2.3.1.4 Passage of the Golgi complex-derived vesicles and fusion to the plasma
membrane
At least two different classes of secretory vesicles, which bud from the trans-Golgi and
fuse to the plasma membrane, have been identified (387). Fusion to the plasma
membrane requires vesicle- and target membrane specific factors, such as the SNARE
(soluble N-ethylmaleinide sensitive factor attachment protein receptor) complex (388)
and the GTPase protein complex, called Sec4p (389).
The accepted model for the function and interaction of the Sec4p protein in the fusion of
secretory vesicles is illustrated in Figure 2.17. The soluble Sec4p exchanges GDP for
GTP. The Sec4p-GTP complex attaches to a newly formed secretory vesicle and moves
towards the plasma membrane. The docking and fusion onto the plasma membrane is
facilitated by a membrane bound effector protein which recognise the Sec4p protein.
After the release of the proteins from the vesicle into the periplasmie space, the Sec4p-
GTP vesicle complex dissociates from the membrane due to a conformational chance
induced by GTP hydrolysis. The Sec4p-GDP complex is then ready for another cycle of
secretory vesicle docking and fusion.
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Figure 2.17 Schematic illustration of the passage and fusion of the secretory vesicle to the plasma
membrane. Soluble Sec4p exchanges GDP for GTP and binds to a newly formed secretory vesicle,
resulting in the interaction with a plasma membrane effector protein. Engagement of the vesicle with the
effector protein induces the fusion event and the recombinant proteins inside the secretory vesicle moves
into the periplasm. Sec4p-GDP disengages from the effector protein by guanine nucleotide hydrolysis so
that both proteins can then be reutilised for another round of secretory targeting and fusion. Adapted from
(390).
2.3.1.5 Passage of proteins through eeUwall
Whether a secreted protein is retained in the periplasmie space or cell wall, or diffuses
into the culture medium depends on the characteristics of the secreted protein (e.g.
molecular size, shape, electric charge and glycosylation (391, 392) and is also highly
dependable on the cell wall permeability which is influenced by the following factors.
Firstly, the permeability varies depending on the physiological condition the yeast cells
were subjected to. Fast growing cells have higher cell wall porosity than slow-growing
cells due to stretching of the cell wall (393), thereby increasing permeability. Secondly,
the permeability of the cell wall is also dependent on the constituency of the
mannoproteins in the cell wall which limit the porosity due to disulphide bonds, ionic
interactions and large mannan side-chains (394, 395). The mannoproteins in the cell wall
differ from strain to strain (396). Finally, the composition of the medium also affects the
cell wall porosity (394).
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2.3.2 Discussion
The secretory pathway in eukaryotes is a highly complex system that can be summarised
as follows - (i) proteins which enter the secretory pathway are specified by short
peptide sequences within the protein which determine specific interactions with
particular components of the secretory machinery; (ii) proteins are transported between
organelles in vesicles, which bud from a donor organelle upon assembly of cytosolic
protein complexes and which subsequently fuse with an acceptor organelle upon
assembly of complexes composed of proteins from both vesicle and acceptor membranes
and (iii) the macromolecular assembly along the secretory pathway is coupled to
nucleotide hydrolysis by the action of either ATPases or GTPases. New genes that
encode specific proteins involved in the secretory pathway are discovered daily and new
insight will lead to improved systems for the heterologous expression and production of
extracellular proteins.
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CHAPTER 3: GOALS OF THE STUDY
• To update and compare heterologous expression systems used for the expression
of P450 enzymes.
• To find suitable expression systems that produce full-length steroidogenic P450
enzymes at large-scale.
• To determine and suggest cloning strategies that increase expression levels.
• To overexpress unmodified human P45017a, b, and aromatase in a heterologous
expression system that will secrete the protein into the medium.
• To overexpress unmodified human P45017a intracellularly.
• To develop methods for preparation of yeast micro somes containing expressed
P450 enzymes.
• To develop a purification protocol that will be rapid and cost efficient.
• To develop purification steps that will yield ultrapure recombinant P450 enzymes
for future antibody production and crystallisation.
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INTRODUCTION
Due to the low level of expression and instability outside the lipid environment of the
membrane, human P45017a has not been previously purified from human tissue. The
limited availability of human tissue and the genetic variability between human samples
has also complicated matters in this regard. To overcome these problems researchers
have been using several heterologous expression systems, such as COS cells (1, 2, 3,4,
5,6, 7), baculovirus (8), yeast (9, 10, 11, 12) and E. coli (13, 14, 15, 16), to produce an
active human P45017a protein (17). Of these expression systems only the bacterial
system was capable of producing high yields of P45017a protein (18). However, in E.
coli expression systems most P450 cDNA, including the human CYP17 cDNA,
sequence had to be modified at the amino terminus to achieve adequate levels of
expression (13). The most frequently used modification was the replacement of the
native P450 amino-terminus with the sequence (MALLLAVF) derived from bovine
P45017a coding sequence (13), which created a preferred translational initiation context
in E. coli and minimised the potential for unwanted secondary structure formation.
Although, these small changes in the membrane binding domain were shown to have no
significant effect on the catalytic properties of cytochromes P450 (19), the alterations
might influence the secondary refolding of the membrane protein and therefore
crystallisation might not reflect the true secondary and tertiary structures when
compared to an unmodified protein. Secondly, the antibodies raised against an altered or
truncated form of human P45017a might be slightly different since the immunogenicity
will differ.
The aim of this study was to express an unmodified human P45017a protein, fused at
the amino-terminus to a yeast secretory signal peptide, thereby producing high yields of
a pure full-length human P45017a protein. The initial aim was to obtain sufficient
protein for antibody production alone and preservation of activity was therefore not a
priority. The use of signal peptides to express the human cytochromes P450 proteins
(P450 2A6, P450 2E1 and P450 3A4) in E. coli, without changes to the amino-terminus
of the P450 coding sequence, was demonstrated by Pritchard et al. (20). Although this
procedure resulted in a three times more spectrally active P450 enzymes in bacterial
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cells, the membrane P450 content was not higher compared to traditional amino-terminal
modified bovine P45017a P450 2E1 and P450 2A6 (21, 22). This system, in addition,
did not remove the signal peptide successfully during its translocation across the
bacterial inner membrane, producing an unprocessed protein.
It was envisaged that the yeast expression system initially chosen for this study would
export the expressed protein directly into the culture media. This approach could provide
several advantages over the E. coli systems traditionally used. Firstly, the CYP17 cDNA
sequence would not have to be modified. In S. cerevisiae the CYP17 cDNA is fused to
the a-factor secretory signal sequence which, during its direction through the yeast's
secretory pathway (23, 24), should be translationally cleaved thereby producing a full-
length, unmodified P45017a protein. Secondly, there would be no requirement for the
optimisation of a preferred translational initiation context at the amino-terminal of the
MFa-P45017a fusion protein, as the ATG site of a-factor is in context. Thirdly, the
formation of an unwanted secondary structure around the ribosome binding site and
initiation site would be reduced, which could lead to increased translation (25). Finally,
exporting the expressed P45017a protein directly into the culture media may improve
the recovery and yield, since no cell disruption and isolation of P450 enzymes from
bacterial membrane fractions would be necessary.
For this study the commercially available yeast amino-terminal FLAG expression
system was used. The FLAG octapeptide epitope, linked to the P45017a coding
sequence as a fusion protein, it is useful for the rapid affinity purification and facile
immunological detection with the anti-FLAG Ml affinity gel and anti-FLAG M2
monoclonal antibodies, respectively. The FLAG tag also contains a five amino acid
recognition sequence for enterokinase, thus facilitating the recovery of an intact protein
following its proteolytic removal.
We have constructed a novel recombinant FLAG-P45017a fusion protein. The CYP17
cDNA with a nucleotide sequence encoding six histidine residues at the carboxyl-
terminus was incorporated into the YEpFLAG-1 expression vector. This construct was
inserted downstream from a-factor secretory signal sequence and the FLAG marker
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octapeptide. Sequencing (results not shown), restriction digests, PCR amplification and
Southern blot analyses confirmed the correct cloning of the CYP 17 into pFLAG-1 to
yield pFLAG-CYP17. The cloned expression vector pFLAG-CYP17 was subsequently
transformed into a protease deficient S. cerevisiae host strain and screened by means of
tryptophane selectivity and PCR.
To optimize extracellular excretion from the yeast under the control of the alcohol
dehydrogenase promoter (ADH2), six different expression media were investigated.
Although Northern analyses confirmed transcription of CYP17, immunological
investigation of the extracellular, intracellular and periplasmie fractions did not indicate
any P45017a protein.
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CHAPTER 1: CLONING AND CONSTRUCTION OF THE
FULL-LENGTH HUMAN CYP17 INTO YEpFLAG
EXPRESSION VECTOR AND
TRANSFORMATION IN S. CEREVISlAE
1.1 Materials and Methods
The E. coli strain HBIOI (Promega) was used in all DNA manipulations. For routine
growth in E. coli, sterile Luria-Bertani (LB) medium (l% Bacto- Tryptone, 0.5% Bacto
Yeast Extract, 1% NaCl, pH 7.0) was used. All media components were purchased from
Difco. Selection of bacteria transformants was carried out on LB-agar (15 gIL)
containing ampicillin (100 ug/ml). For blue /white selection X-Gal (5-bromo-4-chloro-
3-indolyl-j3-D-galactoside), 20 mg/ml, was added to LB-agar.
S. cerevisiae strain BJ3505 (a pep4::HIS3 prb-é l.ëk HIS3 lys2-208 trp l-ó lOl ura3-52
gal2 canI) (Sigma, St. Louis, USA), used for the expression of human cytochrome
P45017a, were grown, transformed and analysed according to the manufacturer's
instructions. For the routine growth of yeast, YPD media (1% yeast extract, 2% peptone,
and 2% glucose) was used. Selection of yeast transformants was carried out in synthetic
complete medium containing 0.67% yeast nitrogen base without amino acids, 0.072%
amino acids without tryptophane and 2% glucose (Sc-TRP). For heterologous expression,
S. cerevisiae was grown in buffered YPHSM medium (0.1 M potassium phosphate pH
6.0, 1% glucose, 3% glycerol, 1% yeast extract, 2% peptone and 20 mM calcium
chloride) or in YPEM medium (0.1 M potassium phosphate pH 6.0, 1% glucose, 3%
glycerol, 1% yeast extract, 8% peptone). For the optimisation of expression YEPM
media was used, replacing glucose and glycerol with either 2% raffinose and 2% ethanol
or 0.8% galactose and 3% glycerol.
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1.1.1 Cloning and construction of the pFLAG-CYP17 expression vector
1.1.1.1 Polymerase chain reaction (peR)
All DNA manipulations were carried out using standard procedures (26). The full-length
CYPI7, located in the pCDI7 vector' was used as the template to amplify a full-length
CYPI7 cDNA. The upstream primer STEl (5'-ATGCGAATTCATGTGGGAGCTC
GTGGCTCTC-3') and the downstream primer 574 (5'-TAGAAGCTTATGGTGATG
GTGATGGGTGCTACCCTCAGCCTG-3') were used. The STEl primer introduced an
EcoRI site (underlined) and the latter primer a nucleotide sequence encoding five
histidine residues (bold).
Each PCR amplification mixture (100 ul) contained pCDI7 vector DNA (400 ng), 200
).lM each of dGTP, dATP, dTTP and dCTP, 0.6 ).lM each of the sense and antisense
primers and 2.5 U proof-reading enzyme Pwo-polymerase (Roche) in Pwo buffer
containing MgS04 (20 mM). The following procedure was carried out in a PCR-Sprint
thermo cycler (Hybaid): (1) denaturation of the template at 94°C for 3 min; (2) 35 cycles
of denaturing at 94°C for 30 s, annealing at 60°C for 30 s and extension at 72°C for 3
min; (3) and a final extension at 72°C for 15 min. The amplified DNA fragment was
purified using an 0.8% low-melting agarose gel in TAE buffer (40 mM) (Tris-HCI pH
8.0, glacial acetic acid and 5 mM EDTA). The DNA samples (1 ug), diluted in 0.2%
loading buffer (0.1% Orange G (w/v), 20% Ficoll (w/v), 10 mM EDTA, pH 7.0), were
electropheresed (EC Minicell® EC370M), at 55 V for 90 min, stained in ethidium
bromide (10 ).lg/).ll)and visualised under a UV lamp (Vilber Lourmat). The CYPl7
fragment was excised and purified using the Wizard™ PCR Preps DNA Purification
system (Promega, Madison, USA), according to the manufacturer's instructions. The
DNA was eluted with deionised water, 50 ul, and stored at -20°C.
1.1.1.2 Restriction digestion
The PCR product was digested with EcoRI yielding CYPl7 cDNA fragments containing
EcoRI compatible 5'-termini and blunt-end 3'-termini (Figure LI) which was
I The pCD 17 vector was a kind gift from Prof RW Estabrook, UT Southwestern Medical Centre, Dallas
Texas, USA.
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subsequently cloned into the YEpFLAG-I expression vector', linearised with EcoRI and
Smal (Promega, Madison, USA) (Figure 1.2).
(A) Tbe PeR prodUfl .ner u.lnl Pwo polymer."
S' - ATGCG' AATTC
EtoRI
Blunt end
GTAGTGGTAGTGGTA TTCGAAGAT •• 3'
(Hia) ,
(B) Tbe Insert .ner reall'ltllon Indonuclellt re.etlon
5'_1. A:rrC~-"l
£CoRI
overbana
Blunt end
GTAGTGGTAG TGGTA TTCGAAGATI·3'
(Hil)'
Figure 1.1 peR amplification (A) and restriction digestion (B) products. The peR method amplified
eYP17 together with the nucleotide sequence encoding five histidine residues and the restriction sites.
Pwo proofreading polymerase ensured that a blunt end was created (A). The peR product (A) was
digestedwith EcoRl resulting in a protruding EcoRl 5' end and a blunt 3' end (B).
Two separate restriction digestions, one containing amplified CYP17 cDNA and the
other YEpFLAG-l DNA were carried out. The amplified CYP17 cDNA (2 Jlg) was
digested at 37°C for 90 min, in a final volume of 30 JlI containing 5 JlI restriction buffer
B (supplied), acetylated BSA (5 ug) and EcoRI (10 U)(Promega). The YEpFLAG
expression vector was digested with EcoRI and Smal (Promega) in two consecutive
steps. The plasmid DNA (1 ug) was digested at 25°C for 60 min, in a fmal volume of 20
JlI containing 2 JlI Multicore buffer (supplied), acetylated BSA (2 ug) and Smal (5
U)(Promega). The plasmid DNA was further digested at 37°C for 60 min, in a final
volume of 30 JlI containing 1 JlI Multicore buffer, acetylated BSA (2 ug) and EcoRI (5
U). The digested CYPI7 fragment and linearised vector were electrophoresed on an
0.8% low-melting agarose gel in TAB buffer (40 mM) and purified as described in
1.1.1.1.
1.1.1.3 Ligation
The purified CYP 17 cDNA was subsequently ligated using 1:1 and 1:3 molar ratio of
vector:insert DNA. For a 1:1 molar ratio, DNA insert (11 ng) and vector (50 ng) was
2 Kindly donated by Prof. W. H. van Zyl of the Microbiology Department, University of Stellenbosch,
Stellenbosch, South Africa.
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used in a 10 J.lIligation reaction containing T4 ligase (1.5 U)(Promega), 0.5 ul ligase
buffer (30 mM Tris-HCI, pH 7.8, 10 mM MgCh, 10 mM DTT and 1mM ATP) and ATP
(0.5 mM). The reaction was incubated at 16°C for 18 hours and the construct stored at
-20°C.
Tho '.... 1'1.11... ' d ........ PCR p, ....... ,
.vk. :ca.l ~.I ~II (:1rr.1 ...... ",*1 ~l ItKII NI.o&I,
l ~nJl;npLl C!UININOSITl! .J
························;~7'j........ . .
1217 ~'-:-::"',,___ •••••••••
71~l
IIII
Figure 1.2 Schematic representation of the cloning strategy for the construction of the pFLAG-
CVPt7 expression vector. The PCR amplified CYPl7 was digested with EcaRt and inserted into the
YEpFLAG-l expression vector. The CYP17 was cloned in reading frame of the a-factor secretion signal
and contained nucleotide bases encoding five histidine residues at the 5'-terminal.
1.1.1.4 Transformation
Competent bacteria (HB 101) were prepared and the transformation was carried out as
described in protocol 1 (26). Competent bacterial cell suspension (50 ul) was added to 5
J.lIof the ligation reactions, mixed gently and placed in ice for 30 min. The mixtures
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were subsequently heat shocked at 42°C for 90 s and incubated in ice for 90 s. After the
addition of 800 ~l SOC medium (37°C) (2% tryptone, 0.5% yeast extract and 0.05%
NaCl, 250 mM KCI, pH 7.0, 10 mM MgCh and 20 mM glucose), the cultures were
incubated at 37°C for 45 min in a shaking incubator at 225 rpm. The cell suspension
(100 and 150 ul) was plated out on LB-agar medium containing ampicillin (100 ug/ml)
and incubated at 37°C overnight.
1.1.2 Analyses of E. coli transfonnants
Positive colonies were subsequently incubated overnight in LB medium (5 ml) at 37°C
and the plasmid DNA was isolated using the Wizard™ Plus Minipreps DNA Purification
System (Promega), according to the manufacturer's instructions. The purified
recombinant plasmid DNA was digested with EcoRI and BamHI and analysed by
agarose gel electrophoresis. Plasmids containing the correct insert were subsequently
prepared by a modified alkaline/SDS lysis method using a Nucleobond" AXlOO plasmid
isolation kit (Macherey-Nagel) as described in the manual for high-copy number
plasmids. The purified isolated pFLAG-CYPI7 plasmid DNA was further analysed by
PCR, DNA sequencing and Southern blotting.
1.1.2.1 peR amplification of E. coli transformants
The pFLAG-CYP 17 vector was analysed by PCR using the forward primer YaN -21 (5'-
AGCACAAATAACGGGTTATTG-3') and reverse primer YcC-21 (5-TACAGACGC
GTGTACGCATGT-3'), supplied with the FLAG Expression System kit (Sigma, St.
Louis, USA). Each PCR amplification mixture (50 ~l) contained pFLAG-CYPI7 DNA
(100 ng), 200 ~M each of dATP, dTTP, dCTP and dGTP, 2.5 ~M each of the YaN-21
and YcC-21 primers and DNA Taq polymerase (2.5 U) (Promega, Madison, USA) in
Tris-HCI (lO mM), pH 9.0, containing 50 mM KCI, 0.1% v/v Triton X-WO and 1.5 mM
MgCh. The following procedure was carried out in a MiniCycler™ (MJ Research): (1)
denaturation at 94°C for 3 min; (2) 35 cycles of denaturing at 94°C for 30 s, annealing at
60°C for 30 s and extension at 72°C for 3 min; (3) and a final extension at 72°C for 15
min. The PCR product was analysed by agarose gel electrophoresis.
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1.1.2.2 DNA sequencing strategy of E. coli transform ants
The purified pFLAG-CYP17 plasmid (100 ng/Ill), together with its insertion sites was
analysed by DNA sequencing using eight primers (1.1 pmol/ul) (Figure 1.3). The sense
primers were STEl; 4011 (5'-TGGCAGCTCATCGAAGGCT-3'); 1496 (5'-GAAGC
TCTACGAGGAGATTGACCAG-3') and the antisense primers were 3989 (5'-
AGCCTTCGATGCAGCTGCCAG-3 '); 8982 (5' -CTGGTCAA TCTCCTCGTAGAGCT
TC-3 '); STE2 (5' -AGCT AAGCTTTT AGGTGCTACCCTCAGCCTG-3 '). Upstream
and downstream sequencing primers (YaN-21 and YcC-21) were also used for the
sequencing reaction. Nucleotide sequences were determined using the Bigdye™ Version
2 determinator sequencing kit (model 373A ABI, Applied Biosystems, Foster City, CA).
5'
I-factor III -~CYP17 (H,s) III3'
Figure 1.3 Schematic representation of the DNA sequencing strategy for the full-length human
CYP17 in the pFLAG-CYP17 expression vector. Primers YaN21 and YcC21 sequence from the outside
of the flanking regions of the CVP17 insert confirmed correct insertion.
1.1.2.3 Southern hybridisation of CYPt7 DNA
The recombinant pFLAG-CYPI7 plasmid DNA, previously linearised EcoRI, was
transferred onto a nylon Hybond-N' membrane (Amersham, High Wycombe, UK) as
described by Sambrook et al., Section 10.46 (26). The plasmid DNA was fixed and the
membrane hybridised with DIG-labelled (digoxigenin-labelled) human CYP17 cDNA3
(25 ng/ml), as described in the DIG High Prime DNA Labelling and Detection kit
(Roche, Mannheim, Germany). Immunodetection of the hybrids were carried out with
anti-digoxigenin-AP Fab fragments (1:5000) and subsequently visualised with
colorimetric substrates NBTIBCIP, according to the manufacturer's instructions (Roche,
Mannheim, Germany).
3 The DIG-labelled human CVP17 eDNA was prepared and kindly donated by Dr. A. C. Swart,
Department of Biochemistry, University of Stell enbosch, Stellenbosch, South Africa.
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1.1.3 S. cerevisiae transformation and screening of transform ants
S. cerevisiae strain BJ3505 was transformed with the pFLAG-CYP17 expression vector
using the LiOAc/DMSO method (27). Three controls, viz. the original YEpFLAG-1
plasmid without insert, a negative control without plasmid DNA and a positive control,
YEpFLAG-1 BAP were included. Transformed cells were grown on Sc-TRP• The yeast
DNA was isolated from positive colonies according to the rapid yeast DNA preparation
protocol described by Hoffman and Winston (28) and CYP17 was amplified using the
upstream primer STEl and the downstream primer 574. Each PCR amplification mixture
(50 J.11)contained pFLAG-CYP17 DNA (100 ng) and the reaction was carried out as
described in section 1.1.2.1. The amplified DNA was analysed by agarose gel
electrophoresis.
Single colonies containing verified recombinants in BJ3505 were grown in 10 ml Sc-TRP
overnight at 30°C. The cells were isolated by centrifugation at 3000 x g for 5 min at
room temperature and resuspended in fresh Sc-TRP containing 15% glycerol. Cells were
frozen in liquid nitrogen and stored at -80°C.
1.2 Results
1.2.1 Confirmation of the integrity of the YEpFLAG-l plasmid
The authenticity of the donated YEpFLAG-1 plasmid, was confirmed by restriction
digest analyses with EcoRIlSmaI followed by 1% agarose gel electrophoresis. The
linearised plasmid DNA yielded the expected band corresponding to 7205 bp as
indicated in Figure 1.4, lane 3.
1.2.2 Analyses of E. coli transformants
Transformed bacterial colonies were grown in small-scale cultures. The plasmid DNA
isolated from each culture was digested with EcoRI and BamHI and analysed by 1%
agarose gel electrophoresis. The pFLAG-CYP 17 plasmid (8740 bp), containing the
insert, yielded two 7175 and 1565 bp fragments as shown in Figure 1.5.
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Figure 1.4 Restriction digest analysis of the original YEpFLAG-l plasmid. Lanes 1 and 7: DNA
marker, "'DNA!EeoRI/HindIll. Lane 2: undigested YEpFLAG-l DNA. Lane 3: YEpFLAG-I DNA (0.5
J..lg)digested with EcoRi and Smal. Lane 4: EcoRi digest of YEpFLAG-1 DNA (0.5 ug). Lane 5:
YEpFLAG-l DNA (0.5 ug) with Smal. Lane 6: YEpFLAG-I DNA (0.5 ug) digested with BamHI. Lane
8: YEpFLAG-1 DNA digested with Smal.
• 7175 bp
• 1565 bp
Figure 1.5 Restriction digest analysis of pFLAG-l plasmids containing the CVP17. Lane 1: DNA
marker, "'DNA!HindIII. Lane 2: Undigested pFLAG-CYP17 plasmid (I ug). Lane 3: EeoRi digest of
pFLAG-CYP17 DNA (0.5 ug) containing the CYP17 yielding an 8740 bp fragment. Lane 4: BamHI
digest of pFLAG-CYP17 DNA (0.5 ug), Lane 5: EeoRI/BamHI digest of plasmid DNA (0.5 ug)
containing the CYP17 yielding 7175 and 1565 bp fragments. Lane 6: DNA marker,
",DNA! EeoRI/ HindIII.
Plasmid DNA isolated from each culture was amplified with CYP17 specific primers
and analysed by 1% agarose gel electrophoresis as shown in Figure 1.6. PCR and DNA
sequencing analyses confirmed that the CYP17 fragment had been correctly inserted in
reading frame in the YEpFLAG-1 vector. A 1793 bp fragment was amplified using
primers (YaN-21 and YcC-21) which recognise the sequence flanking the inserted DNA
shown in Figure 1.6. These primers were subsequently used to sequence 300 bp from the
5' and 3' end of the CYP17 eDNA. The integrity ofCYP17 (1193 bp) was confirmed by
further sequencing and showed that no mutations or alterations occurred during the
cloning procedures.
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Figure 1.6 PCR amplification analysis of the recombinant YEpFLAG-CYPI7 plasm ids. Lane 1:
Negative control, PCR amplification without DNA template. Lane 2: DNA marker, ADNA /HindIll.
Lanes 3 and 4: Amplified CYPl7 fragment, 1793 bp, using primers Ya.N-21 and Ya.C-21. Each lane
contained 0.5 ug DNA. Lane 5: DNAmarker, ADNAIEcoRIlHindIll.
Southern blot analysis was carried out usmg a DIG-labelled probe, DIG-CYP17,
complementary to the human CYP17 cDNA sequence. The linearised pFLAG-CYP17
recombinant plasmid was positively identified as shown in Figure 1.7.
A B
8740 bP.
7205 sp-
Figure 1.7 Southern blot analysis. Lanes 1 and 9: DNA marker, ADNA /HindIll. Lanes 2 and 3:
Undigested and EcoRI digest of the recombinant pFLAG-CYPI7 plasmid, respectively. Lanes 4 and 5:
Undigested and EcoRI digest of the original YEpFLAG-1 plasmid, respectively. Lane 6: DNA marker,
ADNA/HindIIll EcoRI II. Lanes 7 and 8: Undigested and EcoRI digested pCD17a. plasmid, respectively
The probe hybridised to the original plasmid (pCD-CYP 17) from which the CVP 17
cDNA was amplified. No hybridisation was detected with the plasmid YEpFLAG-1
containing no CVP 17 insert.
1.2.3 Analyses of S. cerevisiae transformants
Small-scale cultures of the transformed yeast cells were grown and total yeast DNA was
isolated. DNA purified from two cultures was amplified with gene specific primers
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(STEl and 574) and the PCR products analysed by 1% agarose gel electrophoresis. The
cloned pFLAG-CYP17 vector should yield one amplified CYP17 fragment (1549 bp) as
shown in Figure 1.8.
1234587
Figure 1.8 PCR amplification analysis of pFLAG-CYPI7 plasmid DNA isolated from BJ3505 yeast
cells. Lanes 1, 4 and 7: DNA marker, A.DNA /EcoRI/HindIII. Lanes 2 and 3: Negative controls, PCR
amplifications without DNA template. Lanes 5 and 6: Amplified CYP17 fragment, 1549 bp. Each lane
contained 0.5 ug DNA.
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CHAPTER 2: CULTURE OF S. CEREVISIAE EXPRESSING
P45017a AND OPTIMISATION OF PROTEIN
EXPRESSION
2.1 Materials and Methods
2.1.1 Growth and optimisation of S. cerevisiae P45017a expression
The heterologous expression was carried out according to the FLAG Expression System
protocol (Sigma, St. Louis, USA) and is summarised in Table 2.1. Growth media (SC
TR\ 25 ml, were inoculated with colonies containing pFLAG-CYP17 and control
plasmids (strain BJ3505) and incubated at 30°C in a shaking incubator, 175 rpm, for 48
hours. At selected time intervals (24 and 48 hours) 1 ml samples were collected and the
cell density determined spectrophotometrically at 600 nm. After 48 hours different
expression media, 300 ml, (Table 2.1) were inoculated with 20 ml of cell suspension and
incubated at 30°C in a shaking incubator, 175 rpm, for 162 hours. Attempting to
optimise expression, cells from a single culture, flask 5, were harvested after 48 hours by
Table 2.1 Expression media used in the optimisation of CVP17 expression at transcriptional level.
The expression method, according to the manufacturer's protocol, was carried out in flask 3 and 4 while
optimisation was carried out in flask 5 to 8.
Flasks \\ ith different expression media
"1'11\(,-11 \\1' 1 1'11\(,.('1'17
Flask: 1 1 3 4 S 6 7
Growth sc
TRP2 scTRP scTRP scTRP scTRP scTRP scTRP scTRP
media: 2%glucose 2% glucose 2% glucose 2% glucose 8"10glucose 2%glucose 8"loglucose 8"10glucose
YPHSM3 YPHSM YPHSM YPEM' YPEM. YPEM YPEM SCTRP
Expression + + + + + + + +1% glucose 1% glucose 1% glucose 1% glucose 2% raffinose 2% raffinose 0.8"10galactose 0.8% galactosemedia: 3% glycerol 3%glycero' 3% glycerol 3% glycerol 2%ethanol 2%ethanol 3% glycerol
1 WT: wild type strain 813505
2 Sc-TRP: synthetic complete medium minus tryptophane
3 YPHSM: Yeast Peptone High Stability Media (0.1 M potassium phosphate pH 6, 01 % yeast extract, 8 %
peptone and 20 mM calcium chloride)
4 YPEM: Yeast Peptone Expression Media (0.1 M potassium phosphate pH 6, Ol % yeast extract, 2 %
peptone)
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centrifugation at 2000 x g for 5 mm at room temperature. The cell pellet was
resuspended in 10 ml of ddH20 and centrifuged at 2000 x g for 5 min at room
temperature. The washed cells were resuspended in expression medium and added to the
fresh expression medium.
The growth rate was determined at 4, 18, 24, 72 and 164 hr time intervals by monitoring
yeast cell density spectrophotometrically at 600 nm in 1 ml samples. At the stipulated
time intervals, 50 ml of the expression culture was harvested by centrifugation at 5000 x
g for 5 min at 4°C. The supernatant (medium) was stored at -20°C and the cells were
immediately used to determine RNA expression levels and intracellular and periplasmie
protein expression. The supernatant was used to analyse extracellular protein expression
levels
2.1.2 Evaluation ofP45017a expression at transcriptional level
2.1.2.1 RNA isolation
Total RNA was isolated using the phenol/chloroform/isoamyl alcohol isolation reagent
according to the methods described by Hoffman et al. in Current Protocols, section
13.2.2 (29).
The harvested yeast cells were thawed on ice and resuspended in 300 III cold STE buffer
(100 mM NaCI, 10 mM Tris-HCI pH 8.0 and 1 mM EDTA pH 8.0). The resuspended
cells were transferred to ice-cold 2 ml microcentrifuge tubes and 300 III of phenol, 1
volume of acid washed glass beads and 3 III of SDS (20% w/v) was added. The
suspension was vortexed for 50 s, 300 III of a chloroform: isoamyl alcohol (24: 1 v/v)
mixture was added and vortexed for a further 20 s. The broken yeast cells were
centrifuged (Hettich Microliter Type 2021) in the same 2 ml microcentrifuge tubes at
13000 x g for 10 min at 4°C. The upper clear layers (200-250 Ill) were carefully pipetted
into sterile, ice-cold 2 ml microcentrifuge tubes. The tubes were briefly vortexed after
adding 1 volume of PCI solution (phenol: chloroform: isoamyl alcohol at 25: 24: 1
(v/v/v)) to each tube, and centrifuged at 13000 x g for 5 min at 4°C. The upper clear
layers were removed and transferred into new 2 ml microcentrifuge tubes. The
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extraction procedure was repeated once more with one volume of PCI solution and the
upper clear layers removed and transferred to new ice-cold 2 ml microcentrifuge tubes.
RNA was precipitated with 0.1 volume NaCI (5M NaCI, vortexed twice) and two
volumes of 100% ethanol. The tubes were placed at -80°C for 4 hours and the RNA was
subsequently collected by centrifugation at 13000 x g for 10 min at 4°C. The RNA
pellets were dried slightly at 65°C for 10min and resuspended in 50 ,.ilof distilled water.
The concentration of the RNA was determined spectrophotometrically at 260 nm RNA
samples were stored at -80°C and dot blot and Northern blot analyses were subsequently
carried out.
2.1.2.2 Northern hybridisation of CYPt7 mRNA
The RNA preparations (10 ug) were denatured, electrophoresed on a 0.8% agarose gel,
containing 37% (v/v) formaldehyde, and transferred onto a Hybond" nylon membrane
(Amersham) by capillary transfer as described by Sambrook et al., section 10.46 (26).
The nylon membrane was pre-hybridised in 30 ml high SDS hybridisation buffer (7%
SDS, 50% formamide, 5 x SSC, 2% blocking reagent, 50 mM sodium-phosphate, pH 7.0
and 0.1% N-Iauroylsarcosine) at 50°C for 6 hours. The pre-hybridisation buffer was
discarded and the DIG-labelled CYP17 DNA probe (120 ng/ul), diluted in the
hybridisation buffer and heat-denatured by boiling in a waterbath for 10 min, was added.
After hybridising overnight in a shaking hybridisation bath, the membrane was washed
twice in 2 x wash solution (2 x SSC, 0.1% SDS) for 15 min at room temperature and
twice in 0.5 x wash solution (0.5 x SSC, 0.1% SDS) for 15 min at 50°C.
The hybrids were imrnunodetected with anti-digoxigenin-Al' Fab fragments (1 :5000)
and then visualised with the colorimetric substrates NBTIBCIP, according to the
manufacturer's instructions (Roche, Mannheim, Germany).
2.1.2.3 RNA dot blot
Equal concentrations of isolated total RNA obtained from culture samples at specific
time points, with were spotted onto a dry membrane. The RNA spots were dried for 15
min. at room temperature and cross-linked to the membrane by UV for 6 s. Northern blot
analysis was carried out as described in section 2.1.2.2.
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2.1.3 P45017a protein expression
2.1.3.1 Extracellular protein expression
Yeast cultures (IS ml) obtained at selected time intervals (4, 24, 48, 72, 96 hours) were
harvested by centrifugation at 2000 x g for 5 min at room temperature. Extracellular
protein fractions were prepared by adding PMSF to the supernatant to a fmal
concentration of 1 mM. The fractions were transferred into pre-washed Ultrafree-15
(Biomax ™ High Flow Ultrafiltration membrane, Millipore) ultrafiltration units (MCa of
10000) and centrifuged at 2000 x g for 2 hours at 4°C in a fixed angle rotor. The
fractions (30 x concentrated) were transferred into 1.5 ml eppendorf tubes and stored at
20°C. The expressed proteins in the concentrated fractions were subjected to SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot analyses.
2.1.3.2 Preparation of the intracellular protein fraction
Yeast cells were harvested at 72 hours by centrifugation at 5000 x g for 5 min. at 4°C.
The resulting pellet was resuspended in 5 ml of protein extraction buffer (200 mM Tris-
HCI pH 8.0, 400 mM ammonium sulphate, 10 mM MgCh, 1 mM EDTA, 10% glycerol,
1 mM PMSF and 7 mM p-mercaptoethanol). The resuspended cells were transferred to
50 ml centrifuge tubes and centrifuged at 5500 x g for 10 min. at 4°C. The cells were
resuspended in protein extraction buffer (400 Ill), transferred to ice-cold 2 ml
microcentrifuge tubes containing acid-washed glass beads (300 Ill). The cells were
mechanically disrupted by vortexing 20 times for 30 s with 30 s intervals on ice. The
breakage of the yeast cells was monitored under a microscope. After incubation on ice
for 30 min, the broken cells were centrifuged at 13500 x g for 5 min at 4°C. The
supernatant was transferred to 2 ml microcentrifuge tubes and centrifuged at 13500 x g
for 60 min at 4°C. The proteins in the supernatants were precipitated by the addition of
two volumes of acetone (100% v/v) followed by thorough mixing and incubation for 60
min at -20°C. The contents of the tubes was gently mixed at specific intervals. The
precipitated proteins were collected by centrifugation at 13500 x g for 10 min at 4°C and
the supernatant discarded. The protein pellet was resuspended in ice-cold HEPES buffer
(240 1l1)(I0 x HEPES buffer, 7 mM p-mercaptoethanol, 1.25 mM PMSF) and glycerol
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(80% v/v) (75 JlI). Isolated intracellular proteins were stored at -80°C until and
subsequently subjected to Western blot analysis.
2.1.3.3 Preparation of the periplasmie and intracellular protein fractions
P45017a retained in the periplasmie space were isolated by spheroplasting as described
by La Grange et al. (30). Yeast cells harvested at 72 hours by centrifugation at 5000 x g
for 5 min. at 4°C were washed in ice-cold distilled water and resuspended in 1.5 ml ice-
cold Tris-HCI (50 mM, pH 7.4). The resuspended cells (300 JlI) were added to 1.5 ml
phosphate buffer (6.7 mM K2HP04 pH 7.5, 120 mM p-mercaptoethanol, 1.25 mM
PMSF) and distilled water (1.2 ml) incubated for 30 min at room temperature. The cells
were lysed with Quantazyme (Quantum Biotechnologies) (20 U/JlI), incubated for 90
min at room temperature and centrifuged at 1000 x g for 1 min at 4°C.
The supernatants, representing the proteins in the periplasmie fraction, were precipitated
overnight with two volumes of ice-cold acetone (100% v/v), harvested by centrifugation
and resuspended in 50 JlIHEPES buffer (20 mM HEPES pH 8.0, 5 mM EDTA pH 8.0, 7
mM p-mercaptoethanol, 1.25 mM PMSF). The periplasmie fractions were subjected to
SDS-PAGE and Western blot analyses.
The pellets, representing spheroplasts, were washed twice with ice-cold phosphate buffer
and once with sorbitol solution (1 M sorbitol, 0.2% v/v CaCh). The spheroplasts were
centrifuged at 1000 x g for 1 min at 4°C and the pellet was subsequently resuspended in
distilled water (100 JlI), lysed by adding 10 JlI SDS (20% w/v) and incubated for 10 min
at 65°C. The intracellular proteins were harvested by centrifugation at 1000 x g for 1
min at 4°C and precipitated with two volumes of ice-cold acetone and stored at -20°C.
The intracellular fractions were subsequently analysed by SDS-PAGE and Western blot.
2.1.4 SDS-PAGE and Western blot analyses
SDS-polyacrylamide gel electrophoresis was carried out according to the method of
Laemmli (31) using an acrylamide concentration of 10% (v/v). Fractions to be analysed
were denatured in equal volumes of treatment buffer (0.125 M Tris-HCI pH 6.8, 4%
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SDS, 20% glycerol and 10% l3-mercaptoethanol) and 20 f.llbromophenol blue, boiled for
5 min and immediately placed on ice. Low Range molecular weight markers (Biorad)
and Rainbow coloured protein molecular weight markers (Amersham Pharmacia)
consisting of myosin (220 kDa), phosphorylase b (97.4 kDa), bovine serum albumin
(66.2 kDa), ovalbumin (45 kDa), carbonic anhydrase (30 kDa), trypsin inhibitor (21
kDa) and lysozyme (14.4 kDa) were used.
Electroblotting was carried out in a wet blotting system. Electrophoretically resolved
protein samples were transferred onto a nitrocellulose membrane (Schleicher&Schueller)
and the primary antigen-probe, a monoclonal anti-FLAG M2 mouse antibody (Sigma, St.
Louis, USA) was visualised by peroxidase staining colorimetric method. The probe was
diluted at 1:1000 in casein buffer. A FLAG-BAP (bacterial alkaline phosphatase),
supplied with the kit, was protein used as a positive control.
2.2 Results
2.2.1 Growth of S. cerevisiae
Cell culture samples were taken during the expression phase at 4, 18, 24, 72 and 164
hours time intervals to monitor the cell growth rate. Results shown in Figure 2.1 indicate
that cells grew linearly up to 72 hours where after growth declined due to autolysis of
the yeast cells.
2.2.2 Transcription levels ofCYP17 in yeast during induction phase
The same samples were analysed to ascertain the level of CYP17 transcription and
results showed that the highest level of total RNA synthesis was between 18 to 24 hours
(Figure 2.2). Total RNA isolated from B13505 cells transformed with pFLAG-CYP17
was subsequently analysed by RNA dot blot analysis using the DIG-labelled CYP17
eDNA as the probe. As shown in Figure 2.3, RNA could only be detected at 18-24
hours. Cells grown in raffinose (2% w/v) as the carbon source and ethanol (2% v/v) as
non-fermentable carbon source (flask 5 and 6), produced the highest levels of CYP17
transcripts. Cells grown in the original
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-Is- Flask 1: Control
{J- Flask 2: WT
-+- Flask 3: YP + 3% glycerol + 2% glucose +CaCI
___Flask 4: YP + 3% glycerol + 2% glucose
-0- Flask 5: YP + 2% raffinose + 2% ethanol
-e- Flask 6: YP + 2% raffinose + 2% ethanol
-.- Flask 7: YP + 3% glycerol + 0.8% galactose
-Flask 8: SC·Trp + 0.8% galactose
Figure 2.1 Growth curves of BJ3505 transformants in the expression phase. YP: yeast peptone, SC
TIp: selective minimal medium without tryptophane.
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-e- Flask 6: YP + 2% raffinose + 2% ethanol
-+- Flask 7: YP + 3% glycerol + 0.8% gelactose
--+ Flask 8: SC' Trp + 0.8% galactose
Figure 2.2: Total RNA in yeast cultures assayed at 4 - 72 hours. YP: yeast peptone, WT: wild-type,
SCTIp: synthetic complete medium without tryptophane.
St llenbosch University http://scholar.sun.a .za
Part II Growth and expression of cytochromes P450 in S. cerevisiae 115
TIme (houra)
4 18 24 48 72 182
8
Flask No.2
3
4
5
e
7
Figure 2.3 Dot blot analysis of the CVP17 transcripts expressed in BJ3505 assayed in different
expression media. Total cellular RNA, 35!lg, from flasks 2-8, collected at 4, 18,24,48,72 and 162 hours,
was spotted in each lane. DIG-labelled CYP17 DNA was used as a probe. The intensity of the coloured
blot reflects the concentration of the CYP17 mRNA in the preparations.
expression media with glycerol as the non-fermentable carbon source, did not show
significant amounts of RNA (flasks 3 and 4).
Samples, taken at 24 hours, subjected to Northern blot analyses, previously shown to
have the highest mRNA, confirmed full-length CVP17 transcripts without premature
termination of the transcription (Figure 2.4). The relative position of 18S and 28S
ribosomal RNA fractions indicate the estimated size ofCVP17 synthesised in yeast to be
approximately 2.2 kb. This would be consistent with the predicted DNA fragment size
285+
185+
Figure 2.4: Analyses of CVP17 mRNA from yeast strain BJ3505 transformed with pFLAG-CVP17
grown for 24 hours in specified media. A: Formaldehyde agarose gel and B: Northern blot analysis
Isolates oftotal RNA, 10 ug, were analysed on a agarose gel (1.2%) in formaldehyde/MOPS buffer, in the
presence of 0.5 ug/ml ethidium bromide. The number in each lane represents the flask number. DlG-
labelled CYPl7 cDNA was used as a probe. Yeast ribosomal RNAs are indicated at 18S and 28S.
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obtained if transcription of the CYP17 cDNA in the plasmid construct is initiated and
terminated at the ADH2 promoter and CYCI terminator sites, respectively.
2.2.3 Intra- and extracellular expression ofP45017a
SDS-PAGE analyses of the expressed proteins in the YPHSM medium are shown in
Figure 2.5. Yeast transformed with the parent YEpFLAG-l vector expressed a small
amount of background proteins (lanes 2, 3 and 4). The transformed clones, however,
produced proteins after 48 hours which appear to have molecular masses ranging from
45 to 60 kDa. The expected molecular mass of the P45017a fusion protein was in the
order of 58 kDa.
kOa
220
9766
45
30
20
14
Figure 2.5: SDS-PAGE analysis of the extracellular protein expression in YPSHM medium. Lanes 1
and 5: Low-molecular weight Marker. Lanes 2, 3 and 4: Negative control, BJ3505/YEpFLAG-l cell
culture, total protein (10 ug) assayed at 24, 48 and 72 h. Lanes 6, 7 and 8: BJ3505/pFLAG-CYPI7 cell
culture, total protein (lO f.1g)assayed at 24,48, and 72 hours. The apparent molecular mass of the FLAG-
P450 170. fusion protein is 59 kDa indicated by the arrow.
In an attempt to obtain better resolution preparative SDS-PAGE was performed. The
larger acrylarnide gel (14 x16 cm) yielded greater resolution in the 46 to 66 kDa range
(Figure 2.6).
FLAG-P45017a fusion protein was not detected with Western blot analysis of
intracellular (Figure 2.7) and periplasmie (Figure 2.8) proteins expressed by cells
transformed with pFLAG-CYPI7.
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A B
Figure 2.6: Analyses of extracellular protein expression. A: SDS-PAGE analysis: Lane 1: Low-
molecular weight Marker. Lanes 2 and 3: Negative control, BJ3505/YEpFLAG-l cell culture, total
protein assayed at 24 and 72 h. Lanes 4 and 5: BJ3505/pFLAG-CVP17 cell culture, total protein (100 ug)
assayed at 24 and 72 hours. Two additional proteins at 58 kDa and 66 kDa detected in the induction phase,
are indicated by the arrows. B Western blot analysis: Positive control containing BAP protein expressed
by BJ3505 transformed with pFLAG-BAP. BAP protein detected with an anti-FLAG M2 monoclonal
antibody at 1:1000.
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Figure 2.7: Analyses oCtotal intracellular protein expression by transformed yeast cells in specified
growth media, assayed at 72 hours A: SDS-PAGE analysis and B: Western blot analysis. Lanes 1
and 5: Low-molecular weight Marker. Lanes 2 and 7: Positive control containing BAP protein expressed
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by BJ3505 transformed with pFLAG-BAP. Lanes 3, 4, 5, 8, 9 and 10: Total protein (100 ug) in BJ3505/
pFLAG-CYP17 cell cultures grown in flask 2 (lane 3), flask 3 (lane 4), flask 4 (lane 5), flask 5 (lane 8),
flask 6 (lane 9) and flask 7 (lane 10). Detection was carried out using an anti-FLAG M2 monoclonal
antibody at 1:1000.
Figure 2.8 SDS-PAGE analyses of the intracellular and periplasmie expressed proteins in 8J3505
cells transformed with pFLAG-CYP17, assayed at 72 hours. Lane 1: Low-molecular weight Marker.
Lane 2: Positive control containing BAP protein Lanes 3 and 5: proteins isolated from periplasmie space.
Lane 4: intracellular proteins (20 ug) isolated from the spheroplasts. No bands were detected in the
immunoblot with anti-FLAG antibody in lanes 3, 5 and 6 (results not shown).
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CHAPTER 3: DISCUSSION
In this Chapter, the cloning of an unmodified human cytochrome CYP17 cDNA into as.
cerevisiae expression vector was described. The expression is under the control of the a-
factor secretory signal sequence (MFa-factor), which would facilitate the export of
P45017a protein into the culture medium. RNA blot experiments revealed that the level
of CYP 17 mRNA appeared to be higher in yeast cells grown on raffinose and ethanol
than on the conventional glycerol source. SDS-PAGE experiments showed that two
unidentified proteins were extracellulary expressed and present in the medium, but could
however not be characterised by inmmunoblotting experiments.
Since the first report of the successful expression a recombinant cytochrome P450
enzyme in S. cerevisiae (32), a steady increase of publications on various heterologously
expressed cytochromes P450, originating from a wide range of species from mammals to
plants, have been noted as summarised in Part I Chapter 2 Section 2. The use of yeast-
based systems has become popular in studying the enzymatic properties of cytochromes
P450, as the yeasts contain an endoplasmic reticulum, endogenous NADPH-P450
reductase and cytochrome b5 ensuring a suitable environment for the functional
expression of cytochromes P450 in vivo (12) or in isolated yeast mierosomes (33, 34).
Furthermore, yeast strains have been used to elucidate cytochrome P450 structure-
function relationships by expressing different forms of P450 enzymes altered by site-
directed mutagenesis (35, 36, 37). Although researchers are striving to optimise the
specific activity of cytochromes P450 expressed in yeast, either by co-expression (38,
39) or alteration of the amino terminal (40), not many reports concentrate on the yield of
cytochromes P450. Early reports have shown that the yeast expression system expresses
relatively low levels of 8 nmol/L culture (41), but with newly developed yeast
expression systems such as Pichia pastoris (42, 43) and Schizzosaccharomyces pombe
(44) improvement in expression levels are possible (45, 46).
The aim of this project was the large-scale production of a pure full-length P45017a
protein. Since the ultimate goal was to raise polyclonal and monoclonal antibodies
against human P45017a, a pure recombinant protein rather than a catalytically active
enzyme was required. Therefore, a different approach, the secretion of heterologously
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expressed P45017a into the culture medium, was attempted. Directing the expressed
protein through the secretory pathway of the yeast ensures correct folding of the protein
and protection from cytoplasmic proteases, which could ultimately result in greater
stability and purity of the P45017a, simplifying the purification procedure.
Transformed yeast cells were initially grown on YPHSM and YPEM media. The former
was the preferred expression medium, since YPHSM maintains a pH of 7.3 at 48-72
hours, suitable for high levels of stable protein expression. YPEM media becomes more
acidic at 48 hours, leading to a possible degradation of the fusion protein by acid
induced denaturation (47). It has been reported that some proteins only accumulate
efficiently in rich media or minimal media buffered to near neutral pH (pH 6.0) (48).
The media was therefore buffered at pH 6.0 to optimise the physiological environment
for P45017a. SDS-PAGE analysis of these media revealed two induced protein bands
corresponding to molecular masses in the 45 and 60 kDa range. It is possible that the
latter was the expressed P45017a, as the calculated molecular mass of the FLAG-
P45017a fusion protein is estimated to be -59 kDa. This protein was, however, not
detectable with the anti-FLAG monoclonal antibodies. The inability of the anti-FLAG
monoclonal antibodies to detect the heterologously expressed P45017a could be
ascribed to three factors. Firstly, the concentration of the heterologously expressed
P45017a in the media could be too low for immunological detection. However, this was
unlikely since the media was concentrated prior to immunological analysis. Secondly,
the sensitivity of the detection method could have been too low. The method relies on a
colorimetric detection system with 4-chloronaphtol as a substrate which is less sensitive
than a chemiluminescent substrate such as luminol (49). Thirdly, the hydrophilic FLAG
octapeptide could have been shielded by the large hydrophobic P45017a, hindering the
binding of the FLAG antibody. Western blot analysis of the expression media using a
nickel-HRP probe which recognises the five histidine tag on the carboxyl-terminal of
FLAG-CYPI7 fusion protein was also unsuccessful (results not shown).
The possibility that CYP17 was not transcribed or that a premature splicing of mRNA
could have occurred was also investigated. Northern blot analysis of mRNA from yeast
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cells in the exponential phase, grown in the rich media with glycerol (3% v/v), indicated
that the CYP17 sequence was successfully transcribed and that the mRNA was intact.
It could be speculated that the ADH2 promoter was not efficiently switched on in cells
grown on glycerol, resulting in low initiation of CYP17 translation, leading to low
expression levels in the medium. The ADH2 promoter is one of many yeast genes of
which expression is regulated by glucose repression. The transcription of ADH2 is
undetectable when yeast is grown on glucose and is derepressed to a level representing
~1% of soluble cellular protein when yeast is grown on a non-fermentable carbon
source, e.g. glycerol (50). It has been shown that certain yeast strains harbouring the
ADH2 promoter are induced more efficiently with alternate non-fermentable carbon
sources such as ethanol, raffinose or galactose (48). The physiological conditions and
media were optimised by changing the carbon and non-fermentable carbon sources of
either the expression or of the growth media in an effort to increase mRNA levels
(different promoter induction). Dot blot analyses of CYP17 transcripts from cells grown
in complex expression media supplemented with 2% raffinose and 2% ethanol showed
considerably higher levels of mRNA than cells using glycerol. The highest level of
CYP17 transcription was at 24 hours which can be ascribed to the strong facilitation of
ADH2 promoter induction.
Romanos et al. suggested that yeast harbouring a vector with an ADH2 promoter need to
be grown on plates containing excess glucose (8% w/v) in order to maintain repression
(48). The same expression media, containing 2% raffinose and 2% ethanol, was
therefore used in this investigation and, in addition, comparative analyses were carried
out in cells grown on 8% glucose instead of 2% glucose, prior to induction. Dot blot
analysis showed that the promoter is switched on much sooner as indicated by maximum
transcription levels detected at 18 hours. Although cells grown on 3% glycerol and 0.8%
galactose showed higher transcription levels than cells grown in original medium, 3%
glycerol and 1% glucose, transcription levels were lower than that detected in cells
grown on ethanol and raffinose.
Yeast cells harbouring a multi-copy episomal plasmid, YEp, tend to lose their plasmid
during non-selective growth on complex medium, resulting in low transcription levels
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(51). Cells were therefore also grown in synthetic selective medium supplemented with
0.8% galactose. No increase in expression levels were seen with dot blot analyses
suggesting that plasmid stability was not the cause of low transcription levels. It was
concluded from the dot blot analyses that the cells grown on ethanol and raffinose
induced the ADH2 promoter most efficiently and, in addition, Northern blot analyses
confirmed the formation of full-length CYP17 transcripts of2.2 kb.
It is likely that the B13505 yeast strain is not suitable for high levels of heterologous
protein expression when expression is under the control of the ADH2 promoter. It is
commonly known that some strains are incompatible with certain promoter constructs
and Pluddemann et al. observed low levels of transcription of a hepatitis B gene using
the ADH2 promoter with the B13505 strain. It was shown that by simply changing the
yeast strain (Y294) mRNA levels were increased significantly (52)
Despite being able to increase the transcriptional level of CYP17 by optimising the
media, immunodetection identified no expressed fusion protein in the media. This would
suggest that the fusion protein still remained intracellular, either located in the
periplasmie space or in the endoplasmic reticulum (ER).
S. cerevisiae has often been used as a host for the production and secretion of large
heterologous proteins (> 250 kDa) into the medium (53). Many expressed proteins were,
however, not able to cross the yeast cell wall and were therefore found in the periplasmie
space. Molecular mass, shape and electric charge are characteristics that appear to affect
the movement of the expressed proteins through the cell wall (54). The possibility that
the expressed human P45017a was retained by the cell wall, due to relative high
molecular mass and hydrophobic nature could however not be verified as the
immunoblot of the fractions isolated from the periplasmie space fractions did not detect
FLAG-P45017a fusion protein.
Unsuccessful secretion of the FLAG-P45017a fusion protein could also be due to failure
of translocation across the ER membrane. The protein, with its hydrophobic membrane-
binding domain, is likely to bind to the ER preventing it to be transported through the
secretory pathway. Sakaguchi et al. provided evidence that a short amino terminal of
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microsomal P450 protein serves not only as a signal for the membrane insertion but also
as a "stop-transfer" sequence (55). The intracellular fraction was subsequently
investigated and FLAG-P45017a fusion protein was not detected. In summary, no
immunological detectable FLAG-P45017a protein was present in the intracellular or in
the periplasmic fractions and it was therefore concluded that the secretion of
heterologously expressed human cytochrome P45017a into the medium was
unsuccessful.
A feasible explanation for the absence ofheterologously expressed human P45017a was
sought at the translational level - the encoded mRNA was not translated efficiently.
CYP17 cDNA was correctly inserted in reading frame with the initiation codon of the
MFa-l secretory secretion gene. This AUG codon is the first AUG codon encountered
by the scanning ribosomal complex. Investigation of the 5' untranslated region of the
mRNA did not indicate any translational barriers such as of G residue repeats or the
formation of secondary structures. Both can lead to a significant reduction in translation
efficiency (56, 57). The use of non-preferred codons could also have contributed to the
efficiency of translation of a specific mRNA in S. cerevisiae (58). Furthermore
inadequate or incorrect folding of the expressed protein in the ER could result in the
absence of the heterologously expressed fusion protein. Yeast proteins assisting in
folding and disulphide bond formation differ from their counterparts in higher
eukaryotes (e.g. mammalian cells). Malfolding may result in the retention of expressed
fusion proteins in the ER and subsequent degradation (59).
The heterologous production of significant levels of fusion proteins in a yeast expression
system had major limitations and was clearly unsuitable. Firstly, yeast cells that harbour
episomal vectors, such as YEpFLAG, need to be grown under constant selective
pressure in order to remain stable and ensure good expression levels. These conditions
result in slow growth characterised by low yields. Secondly, glucose-repressible
promoters, such as ADH2, are not suited for industrial fermentation processes since
maintaining controlled glucose-repression under conditions of glucose limitations,
required for high cell density, remains a formidable challenge (60). Thirdly, the
YEpFLAG plasmid is an autonomously replicating vector. It has been shown that
secreted proteins are produced at higher levels when the transcriptional unit is integrated
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in the yeast chromosomes as apposed to an autonomously replicating vector (61). The
former will provide greater vector stability. Fourthly, it is also possible that the ADH2
promoter and the yeast strain used in the expression of P45017a as a fusion protein are
not compatible. Finally, the supplementation of the media with raffmose or galactose in
an attempt to increase protein production would be very costly and is not commercially
viable. Taking into consideration all of the aforementioned factors, a more efficient
expression system for the heterologous expression and production of human P45017a
was subsequently investigated.
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INTRODUCTION
In human adrenal and gonadal steroidogenesis, two key hemeproteins, P45017a and
aromatase are involved in sex steroid biosynthesis. P45017a converts C21 steroids to Cl9
sex steroids in two different reactions. Firstly, pregnenolone and progesterone are
converted to 17-hydroxylated intermediates (17-hydroxypregnenolone and 17-
hydroxyprogesterone) catalysed by a 17a-hydroxylase reaction. Subsequently only 17-
hydroxypregnenolone is further catalysed by a 17,20-lyase reaction to DHEA (1). The
conversion of the second hydroxylated intermediate, 17-hydroxyprogesterone to
androstenedione is found to be insignificant in humans and rodents (2, 3, 4). DHEA is
catalysed to androstenedione by 313-HSD,which is converted to oestadiol by aromatase
(5).
The 17a-hydroxylation reaction that directs pregnenolone and progesterone to the
glucocorticoids has been well characterised, but the subsequent 17,20-lyase reaction that
converts 17-hydroxypregnenolone to the sex steroid precursor, DHEA, is still under
investigation (6). An understanding of the regulation of the 17,20-lyase activity very
important, as it is the sole pathway to the biosynthesis of sex steroids thereby regulating
the onset of DHEA formation during adrenarche and the physiological development of
polycystic ovary syndrome (pcaS) (7). Furthermore, the regulation of the 17,20-lyase
activity seems to be under the control of the rate of flow of electrons to the enzyme and
it has been suggested that b5 may function as an alternative source of electrons specific
for the 17,20-lyase reaction but not the 17a-hydroxylase reaction (8, 9). The conversion
of the androgen, androstenedione, to oestrogens, a reaction known as aromatisation, is a
key regulatory step in oestrogen biosynthesis. Aromatase has been the focus of much
interest since the correlation of oestrogen levels to human disease conditions, such as
breast and endometrial cancer is well established (10, 11, 12). A better understanding of
the relationship of structure to function in P45017a, b, and aromatase, will enable
researchers to gain a better understanding in the involvement of these complex enzymes
in their respective reactions. The availability of purified aromatase will permit the
development of specific inhibitors which could be used in the prevention of human
breast, endometrial and ovarian cancers (13, 14, 15, 16, 17). In addition, poly- and
monoclonal antibodies against these enzymes would assist in diagnostic applications
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such as immunohistochemistry and specific targeting (18). Monoclonal antibodies
against aromatase could also be used to identify the exact location of intratumoral
aromatisation in clinical samples of breast cancer.
Several research groups have attempted to isolate and purify aromatase from human
placenta, encountering the following obstacles. Firstly, the specific content of their
preparations was low (19, 20). Secondly, only a partially purified human placental
microsomal aromatase was obtained (21, 22). Thirdly, although a homogenous
aromatase protein was produced, it was either unstable (23) or the recovery after
substrate affinity chromatography purification was low (24). Kellis and Vickery (25) and
Yoshida and Osawa (26) were able to obtain a pure, catalytically active aromatase in a
stable form from human placenta. The isolation of P45017a from tissue was
unsuccessful, since the concentrations were very low.
To circumvent the experienced difficulties of isolating these eukaryotic cytochromes
P450 directly from their specific tissues, scientists relied on molecular biology to
synthesise specific forms of cytochromes P450 in various heterologous expression
systems. E. coli (27,), S. cerevisiae (28, 29, 4), COS 1 (30) and baculoviral cells (31, 32,
33, ) have been used as hosts for the expression of human P45017a, b, and aromatase.
However, various shortcomings which include inactive enzyme, low concentrations and
improper folding limited their usefulness as systems for large-scale production and
therefore rendered them unsuitable for antibody production.
Extracellular expression systems were considered to overcome the obstacles of
intracellular expression. Secreting expressed cytochromes P450 into the culture medium
via the hosts' secretory pathway has the following advantages: (i) secreted cytochromes
P450 are more readily available in the essentially protein-free culture medium, leading
to minimal purification steps from the expression medium, (ii) the usage of harsh
denaturants and detergents to facilitate breakage of cells and creating an unsuitable
oxidising environment might be avoided, (iii) proper protein folding and translational
modifications of the P450 enzyme will be increased and protection from cytoplasmic
proteases will take place (34) and (iv) the cytoplasmically expressed protein products
may exert a toxic or unstable effect in the host, which can be avoided when they are
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secreted into the medium (34). High yields of stable, intact cytochromes P450 may
therefore be obtained.
These requirements for high-level extracellular expression of recombinant proteins are
met by the methylotrophic yeast Pichia pastoris (35, 36). Recently, P. pastoris has
gained widespread attention as an extracellular expression system which secreted many
different types of proteins, including membrane proteins (37, 38, 39) into the medium.
One of the reasons why P. pastoris could be successful in secreting proteins
extracellulary is that its ultrastructural organisation differs from that observed in S.
cerevisiae. P. pastoris has a similar transitional ER-Golgi system to that of vertebrate
cells (40) and the secretory vesicles of P. pastoris are three times larger than that of S.
cerevisiae (41). Furthermore, P. pastoris offers many additional advantages - (i) the
heterologous genes are integrated into the yeast genome downstream of an alcohol
oxidase 1 (AOX1) gene promoter, which ensures stable integrations for many
generations and tightly regulated methanol-induced expression at very high levels, (ii)
maintenance in large-volume fermenter cultures and at cell densities in excess of 100-
500 gramslL (42) and (iii) P. pastoris secretes very low levels of native proteins.
Therefore, the isolation and purification of the expressed protein from the cellular
proteins is easier and more effective in the P. pastoris system than in S. cerevisiae.
There are three major criteria in secretion of expressed proteins that may interfere or
limit the extracellular expression of cytochromes P450. Hydrophobicity, protein size and
glycosylation, which are the focus of this study.
A hydrophobic sequence in the protein can bind to the ER thereby preventing the
movement to the outside of the cell. Eukaryotic microsomal cytochrome P450 proteins
are integral membrane proteins of the ER and are targeted to the ER via the signal
recognition particle pathway (43). The targeting and the insertion of these cytochromes
P450 are defined by a hydrophobic sequence (signal anchor sequence) which is usually
situated in the amino-terminal of the protein (44, 45). Several cytochromes P450 lacking
the hydrophobic amino-terminal region have been studied in various laboratories and in
most cases the heterologously expressed, modified proteins retained their catalytic
activity and membrane-binding capability, as summarised by Pemecky and Coon (46).
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However, studies have shown that the removal of portions of the putative membrane-
anchor domain from microsomal cytochromes P450 rendered these proteins incapable of
membrane insertion and were primarily located in the soluble fraction in E. coli (47, 48,
49, 50) and S. cerevisiae (51).
We therefore investigated the effect of the hydrophobic domain of P45017a on the
solubility of the protein by comparing the full-length P45017a with a truncated form
(deletion of first 18 amino acids) by expressing the two forms of P45017a
extracellularly. By deleting the hydrophobic membrane-binding domain, the chances of
the expressed truncated P45017a binding to the membranes of the secretory organelles,
while being transported through the Pichias' secretory pathway to the outside of the
cells, could be minimised and higher expression levels could be obtained in the medium.
Protein size has also been documented to influence extracellular expression in yeast
(52). It is not a problem for large secreted proteins to be transported through the yeast's
secretory compartments. The crossing of the yeast cell wall of expressed proteins does,
however, present an obstacle. In earlier studies it was believed that secreted proteins in
S. cerevisiae, in excess of 30 kDa, are retained within the cells or the periplasmie space.
Recent findings, however, show molecules with relative masses as great as 400000 kDa
often diffuse through the yeast cell wall quite easily (52). The reason for this is that
although the average pore sizes of the cell wall are small, the permeability of the cell
walls vary, depending on the yeast strain and its physiological conditions, i.e. growth
conditions. In the exponential growth phase very large proteins are able to passage over
the cell wall compared to non-growing yeasts which retain the large proteins.
Furthermore, the biochemical make-up of the heterologous protein secreted, such as
molecular mass, shape and electric charge appears to affect movement through the cell
wall. The b5, which is a fairly small protein (15199 Da), might be secreted more readily
than the bigger sized P45017a (~57 kDa) or aromatase (~58 kDa)
In P. pastoris the problem of glycosylation is far less than in S. cerevisiae (53). The
reason being that instead of an average oligosaccharide chain length of 40 mannose
residues from S. cerevisiae, glycoproteins from P. pastoris synthesise an average chain
length of 8-12 mannose residues. Therefore P. pastoris, unlike the wild-type S.
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cerevisiae, does not hyperglycosylate (outer chain glycosylation) secreted glycoproteins.
It appears that the glycosylation process of P. pastoris is closer to the mammalian high-
mannose type than to that of S. cerevisiae. Shimozawa et al. found that aromatase
purified from human placenta mierosomes is glycosylated (54) and Gartner et al. also
produced a glycosylated aromatase protein which was heterologously expressed in a
baculovirus expression system (33).
In this study we investigated these abovementioned three criteria, i.e. hydro)'hobicity,
size and glycosylation, by heterologously expressing a full-length P45017a, a truncated
P45017a, b5 and aromatase, which would be secreted into the media by two different P.
pastoris yeast strains. The cDNA of the different steroidogenic enzymes were cloned in
reading frame to the a-factor secretory signal sequence which directs the translated
proteins to the medium under the control of a MFa-factor secretory signal. The fusion
proteins with histidine affinity tags at the carboxyl end of the protein allowed for
immunological detection of the expressed proteins. The culture media were screened for
the presence of secreted cytochromes P450. In addition the cytoplasmic fractions were
analysed for the presence of expressed cytochromes P450. Comparisons between GS 115
and KM71 cells were also investigated.
This is the first report of an attempt to express human P450 enzymes extracellularly in a
yeast system.
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CHAPTER 1: PLASMID PREPARATIONS,
TRANSFORMATION AND SCREENING
OF P. PASTORIS
1.1 Cloning and construction of the full-length human CYP17 into
pPIC9K expression vector and integration in P.pastoris
1.1.1 Materials and Methods
1.1.1.1 Strains and media
The E. coli strain JMI09 (Promega) was used in all DNA manipulations. For routine
growth in E. coli, sterile Luria-Bertani (LB) medium (1% Bacto- Tryptone, 0.5% Bacto
Yeast Extract, 1% NaCl, pH 7.0) was used. All media components were purchased from
Difco. Selection of bacteria transformants was carried out on LB-agar (15g/L)
containing ampicillin (100 ug/ml). For blue /white selection X-Gal (5-bromo-4-chloro-
3-indolyl-f3-D-galactoside), 20 mg/ml, was added to LB-agar.
P. pastoris strains GS115 (his4) and KM71 (arg4 his4 aoxl:: ARG), used for the
expression of human cytochrome P45017a, were grown, transformed and analysed
according to the manufacturer's (Invitrogen) instructions. For the routine growth of
yeast, YPD media (1% yeast extract, 2% peptone, and 2% glucose) was used. Selection
of yeast transformants was carried out in minimal dextrose (MD) medium containing per
liter: 13,4 g yeast nitrogen base without amino acids, 400 ug biotin and 20 g dextrose.
Minimal methanol (MM) medium contained 13.4 g yeast nitrogen base without amino
acids, 400 j..lgbiotin and 5 ml methanol per liter. Regeneration dextrose base (RDB)
plates contained 1 M sorbitol, 2% dextrose, 1.34% yeast nitrogen base without amino
acids, 4 x 10-5% biotin, L-glutamic acid, L-methionine, Ldysine, Ldeucine, L-isoleucine
each at 0.005% and 2% agar. For heterologous expression P. pastoris was grown in
buffered minimal glycerol (BMGY) medium (0.1 M potassium phosphate pH 6.0, 1.34%
w/v yeast nitrogen base without amino acids, 4 x 10-5% biotin, 1% v/v glycerol) or in
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buffered minimal methanol medium without glycerol, containing 0.5% v/v methanol
(BMMY).
1.1.1.2 Subeloning of the CVPt7 eDNA
All DNA manipulations were carried out using standard procedures (55).
1.1.1.2.1 Polymerase chain reaction (peR) amplification
The full-length CYPl7 in the pFLAG-CYPl7 construct, cloned in this laboratory, was
used as the template to amplify a full-length CYPl7 cDNA, depicted in Figure 1.1. The
upstream primer STEl (see Appendix B) and the downstream primer Pl04 (5'-
CCGGAATTCTTATGATGGTGATGGTGATGGGTGCT-3') were used. The STEl
and P104 primers introduced an EcoRI site (underlined) and the latter primer introduced
a nucleotide sequence encoding six histidine residues (bold).
peR product (11183 bpI
EcoRI
5'-ATGCOAATTC
EcoRl
OAATTCCGG-3'
YEpFLAG-1
7205 bp
Figure 1.1 Schematic representation of the cloning strategy for the PCR amplification of CYPI7
cDNA from the YEpFLAG-CVPI7 vector. The upstream primer STEl is complementary to the
unmodified 5'-terminal and includes the start codon. The downstream primer Pl04 is complementary to
the 3' -terminal, including the stop codon and nucleotide bases encoding six histidine residues. Both
primers include a nucleotide sequence encoding an EeoR! site for subeloning into the pUC18 vector,
Each PCR amplification mixture (100 JlI) contained pFLAG-CYPl7 vector DNA (750
ng), 200 JlM each of dGTP, dATP, dTTP and dCTP, 0.6 JlM each of the sense and
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antisense primers and 2.5 U proof-reading enzyme Pwo-polymerase (Roche) in Pwo
buffer containing MgS04 (20 mM). The following procedure was carried out in a PCR-
Sprint thermo cycler (Hybaid): (1) denaturation of the template at 94°C for 3 min; (2) 35
cycles of denaturing at 94°C for 1 min, annealing at 60°C for 1 min and extension at
noc for 3 min; (3) and a final extension at 72°C for IOmin. The amplified DNA
fragment was purified using an 0.8% low-melting agarose gel in 40 mM TAB buffer
(Tris-HCI pH 8.0, glacial acetic acid and 5 mM EDTA). The DNA samples (1 f.lg),
diluted in 0.2% loading buffer (0.1% Orange G (w/v), 20% Ficoll (w/v), 10 mM EDTA,
pH 7.0), were electropheresed (EC Minicell® EC370M), at 55 V for 90 min, stained in
ethidium bromide (10 ug/ul) and visualised under a UV lamp. The CYP 17 fragment was
excised and purified using the Wizard™ PCR Preps DNA Purification system
(Promega), according to the manufacturer's instructions. The DNA was eluted with
deionised water, 50 ul, and stored at -20°C.
1.1.1.2.2 Restriction digestion
The PCR product was digested with EcoRI yielding CYPI7 cDNA fragment containing
EcoRI compatible 5' and 3' termini (Figure 1.2), which was subsequently cloned into
the pUCI8 vector, linearised with EcoRI. Two separate restriction digestions, one
containing amplified CYPI7 DNA (2 ug) and the other pUCI8 DNA (2f.lg)(Promega)
were carried out at 37°C for 90 min, each in a final volume of 30 ul containing 5 ul
restriction buffer B (supplied), acetylated BSA (5 ug) and EcoRI (10 U), (Promega). The
digested DNA fragments were electrophoresed on an 0.8% low-melting agarose gel in
TAB buffer (40 mM), and the digested CYP 17 fragment and linearised vector were
extracted and purified as described in 1.1.1.2.1.
1.1.1.2.3 Dephosphorylation
The linearised pUCI8 vector was dephosphorylated prior to ligation to prevent religation
without insert DNA in downstream reactions. Dephosphorylation mix (50 ul) containing
DNA (1.8 ug), 5 ul reaction buffer (50 mM Tris-HCI, pH 9.3, 1 mM MgCh, 0.1 mM
ZnCh and 1 mM spermidine) and calf intestinal alkaline phosphatase (ClAP) (0.02 U)
(promega) was incubated at 37°C for 30 min. Another 0.02 U calf intestinal alkaline
phosphatase was added to the mixture and incubated for 30 min. The dephosporylation
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reaction was terminated as follows: 2 ul EDTA (0.5M) was added and the resultant
reaction mixture was incubated at 65°C for 20 min. The DNA was purified from the
mixture with the Magic DNA Clean-Up® kit (Promega), according to the
manufacturer's instructions.
pUC18
2686 bp
Figure 1.2 Schematic representation of the subcloning of the full-length CYP17 cDNA into pUC18
vector. The 3' -terminal of CVP17 contains a nucleotide sequence encoding the six histidine tag
incorporated upstream of the stop codon.
1.1.1.2.4 Ligation
The purified CYP17 cDNA was subsequently ligated using 1:1 and 1:3 molar ratio of
vector:insert DNA. For the 1:1 ratio DNA insert (112 ng) and vector (200 ng) was used
in a 10 ul ligation reaction containing T4 ligase (1.5 U)(Promega), 0.5 ul ligase buffer
(30 mM Tris-HCl, pH 7.8, 10 mM MgCh, 10 mM DTT and 1 mM ATP) and ATP (0.5
mM). The reaction was incubated at 16°C for 18 hours. Competent JM109 cells were
transformed with the ligated vectors. In addition to ampicillin selection, the vector
contained the lacZ gene, which allowed for blue/white colony selection.
The following ligation reactions were set up: A) dephosphorylated plasmid DNA (200
ng) without insert (negative control), B) dephosphorylated plasmid DNA (200 ng) with
insert DNA (200 ng) carrying compatible phosphorylated termini and C) linearised
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plasmid DNA (200 ng) not treated with CIAP. A positive control ligation and control
transformations were also included.
1.1.1.2.5 Analyses of correct clones
Positive colonies were subsequently incubated overnight in LB medium (5 ml) at 37°C
and the plasmid DNA was isolated using the Wizard™ Plus Minipreps DNA Purification
System (Prornega), according to the manufacturer's instructions. The purified
recombinant plasmid DNA was digested with XbaI and analysed by agarose gel
electrophoresis. Plasmids containing the correct insert were subsequently prepared by a
modified alkaline/SDS lysis method using a Nucleobond" AXIOO plasmid isolation kit
(Macherey-Nagel) as described in the manual for high-copy number plasmids. The
purified isolated pUCI8-CYPI7 plasmid was further analysed by PCR amplification.
The pUCI8-CYPI7 vector was analysed by PCR using the forward primer STEl and
reverse primer P104. Each PCR amplification mixture (50 Ill) contained pUCI8-CYPI7
DNA (200 ng), 200 IlM each of dATP, dTTP, dCTP and dGTP, 2.5 IlM each of the
STEl and PI04 primers and Supertherm DNA Taq polymerase (2.5 U) (Abgene) in
TAPS (25 mM), pH 9.3, containing 50 mM KCI, I mM p-mercaptoethanol and 2.5 mM
MgCh. The following procedure was carried out in a MiniCycler™ (MJ Research): (I)
denaturation at 94°C for 3 min; (2) 35 cycles of denaturing at 94°C for 30 s, annealing at
60°C for 30 s and extension at 72°C for 3 min; (3) and a final extension at 72°C for 15
min. The PCR product was analysed by agarose gel electrophoresis (result not shown).
1.1.1.3 Construction of the pPIC9K-CYP17 expression vector
The cloned CYPl7 in pUCI8-CYPI7 construct was confirmed by DNA sequence
analyses. CYPl7 was subsequently excised from the vector with EcoRI and ligated into
pPIC9K vector (Invitrogen) previously linearised with EcoRI as shown in Figure 1.3.
Two separate restriction digestions, one containing pUCI8-CYPI7 DNA (2 ug) and the
other containing pPIC9K DNA (2Ilg) were carried at 37°C for 90 min, each in a final
volume of 30 III containing 5.0 III restriction buffer B (supplied), acetylated BSA (5.0
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ug) and EcoRI (lOU). The digested CYP17 fragment and linearised pPIC9K vector
were electrophoresed on an 0.8% low-melting agarose gel in TAE buffer (40 mM),
extracted and purified using the Wizard™ PCR Preps DNA Purification system.
pPIC9K
9276 bp
pPIC9K.CYP17
10827 bp
Figure 1.3 Schematic representation of the cloning strategy for the construction of the pPIC9K-
CVP17 expression vector. The cloned CYP17 in the pUC18 vector was digested with EcoRI and inserted
into the pPIC9K vector at the EcoRI site. The CYP17 was cloned in reading frame of the a-factor
secretion signal and contains a nucleotide sequence encoding the six histidine tag.
The linearised pPIC9K DNA was dephosphorylated prior to ligation as described in
section 1.1.1.2.3. The dephosphorylated linear vector was purified with the Magic DNA
Clean-Up® kit (Promega), according to the manufacturer's instructions and analysed by
agarose gel electrophoresis.
The purified digested CYP17 fragment (32.3 ng) and pPIC9K DNA (200 ng) were
subsequently ligated as described in section 1.1.1.2.4. Competent JM109 cells were
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transformed with the ligated vectors and selected on LB-agar plated containing
ampicillin.
1.1.1.4 Amplification of pPIC9K-CYP17 inE. coli.
1.1.1.4.1 Transformation
Competent bacteria were prepared and the transformation was carried out as described in
protocol 1 (55). Competent bacterial cell suspension (50 JlI) was added to 5 JlI of the
ligation reactions, mixed gently and kept on ice for 30 min. The mixtures were
subsequently heat shocked at 42°C for 90 s and incubated in ice for 90 s. After the
addion of 800 JlI SOC medium (37°C) (2% tryptone, 0.5% yeast extract and 0.05%
NaCl, 250 mM KCI, pH 7.0, 10 mM MgCh and 20 mM glucose), the cultures were
incubated at 37°C for 45 min in a shaking incubator at 225 rpm. The cell suspension
(100 and 150 ul) was plated out on LB-agar medium containing ampicillin (100 ug/ml)
and incubated at 37°C overnight.
1.1.1.4.2 Isolation
Positive colonies were subsequently incubated overnight in LB medium (5 ml) at 37°C
and the plasmid DNA was isolated as described in 1.1.1.2.5. The purified recombinant
plasmid DNA was digested with Xbal and analysed by agarose gel electrophoresis.
Plasmids containing the correct insert were subsequently prepared by a modified
alkaline/SDS lysis method using a Nucleobond" AX100 plasmid isolation kit as
described in section 1.1.1.2.5.
1.1.1.4.3 DNA sequencing analysis of E. coli transformants
The purified pPIC9K-CYP17 plasmid (100 ng/ul), together with its insertion sites was
analysed by DNA sequencing using eight primers (1.1 pmol/ul) (Figure 1.4). The sense
primers were STEl, 4011, 1496 and the antisense primers were 3989, 8982 and STE2.
The upstream and downstream sequencing pnmers 5' (l-factorP (5' -
TACTATTGCCAGCATTGCTGC-3') and 3'AOX1P (5'-GCAAATGGCATTC
TGACATCC-3') were also used for the sequencing reaction. Nucleotide sequences were
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determined using the Bigdye™ Version 2 diterminator sequencing kit (model 373A
ABI, Applied Biosystems, Foster City, CA).
5'
t.u.tor • IT
3'
5 q -tactore. • "AOX1P
Figure 1.4 Schematic representation of the DNA sequencing strategy for the full-length human
CYP17 in the pPIC9K-CYP17 expression vector. Primers a-factor and 3'AOX 1 sequenced from the
outside of the flanking regions of the CVP17 insert confirmed correct insertion. The remaining six primers
sequenced the CVP17.
1.1.1.5 Screening of GS115/pPIC9K-CYP17 and KM71/pPIC9K-CYP17
transformants for integration
The cloned expression vectors, pPIC9K-CYP17 (10 ug) and the parent vector pPIC9K
(10 ug), were linearised with San and transformed into competent P. pastoris strains,
GS115 Mut+ (Methanol ytilisation plus) and KM7l Muf (Methanol ytilisation ~low)
using the spheroplast method as described by Pichia Spheroplast Module (Invitrogen).
Controls (no DNA and parent vector without insert) were included to monitor
contaminants and were used as background controls for expression. Before the linearised
DNA was transformed into P. pastoris cells, spheroplasts were prepared by partially
digesting the cell wall with Zymolyase (supplied with spheroplast kit) according to the
manufacturer's instructions.
Transformants were plated on a selective medium lacking histidine, i.e. on minimal
dextrose RDB plates, and the plates were incubated for 4 days at 30°C to select for His+
recombinants. Transformants were then pooled and plated on YPD-G4l8 plates
containing G4l8 (of 0.25 mg/ml). The level of G4l8 resistancy correlates with the
number of kanamycin genes integrated into the Pichia genome. A single copy of
pPIC9K plasmid integrated confers resistance to G4l8 to a level of 0.25 mg/ml.
Screening for methanol utilisation, the single colonies (His+transformants) were picked
up with a sterile toothpick and patched in a regular pattern on both MM plates and MD
plates. The same procedure was used for the two control strains GSl15/His+ Muf
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Albumin and GS 115/His+ Mut" J3-gal. The plates were incubates at 30°C for 2 days and
scored for Mut and Muf phenotype by comparing the transformed colonies with the
controls.
The presence of cDNA encoding the appropriate cytochrome genes integrated into the
yeast chromosomes was subsequently confirmed by PCR amplification analyses. The
protocol for direct PCR Screening was adapted from a method as described by Linder et
al. (56). A pin-point-sized part of six single colonies from MD plates were selected,
suspended in sterile water (30 Ill) and lyticase (100 U) (crude, from Arthrobacter luteus;
Sigma) added. The mixture was subsequently incubated at 30°C for 12 min. The
digested cells were frozen in liquid nitrogen for 1 min and the lysate (5 Ill) was used for
the PCR amplification.
Each PCR amplification mixture (50 Ill) contained of DNA/cell lysate (5 Ill), 200 IlM
each ofdGTP, dATP, dTTP and dCTP, 2.5 IlM each of the 5'AOX1P and 3'AOX1P
primers and of Taq-polymerase (2.5 U) in reaction buffer containing MgCh (25 mM).
The following procedure was carried out in a PCR-Sprint thermo cycler: (1) denaturation
template at 94°C for 3 min; (2) 35 cycles of denaturing at 94°C for 1 min, annealing at
54°C for 1 min and extension at 72°C for 1 min; (3) and a final prolonged elongation
time at 72°C for 7 min. The amplified DNA fragment was analysed by agarose gel
electrophoreses as described in section 1.1.1.2.5.
Single colonies that contained the verified recombinants in GSl15 or KM71 were grown
in MD (10 ml) overnight at 30°C. The cells were isolated by centrifugation at 3000 x g
for 5 min at room temperature and resuspended in fresh MD containing 15% glycerol.
Cells were frozen in liquid nitrogen and stored at -80°C.
1.1.2 Results
1.1.2.1 Subeloning of the CVPl7 eDNA
The full-length human CYP17, located in the pFLAG-CYP17 expression vector cloned
in this laboratory, was used as the template to amplify a full-length CYP17 cDNA. The
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predicted size of the amplified CVP 17 cDNA product was -1563 bp which included the
nucleotides encoding the restriction enzymes. This was confirmed by 0.8% agarose gel
electrophoresis (Figure 1.5 lanes 3 and 4).
1 2 3 4 5
Figure 1.5 Agarose gel electrophoretic analysis of amplified CYP17. Lane 1: Negative control, PCR
amplification without DNA template. Lane 2: DNA marker A.DNAIEcoRl/HindIII. Lanes 3 and 4:
Amplified CYP17 (1563 bp) fragment (0.8 J.lg)using primers STEl and P104. Lane 5: Undigested
pFLAG-CYP17 plasmid DNA (0.5 ug) used as template for PCR.
The integrity of the newly constructed pUC18-CYPI7 vector was confirmed by
restriction digest analyses with XbaI followed by 1% agarose gel electrophoresis. The
pUCI8-CYPI7 plasmid (4237bp) with the insert yielded two 3902 and 335 bp fragments
as shown in Figure 1.6, lanes 12 and 16. These positive clones were isolated and the
presence of the CYPI7 was subsequently confirmed by PCR amplification with CYPI7
specific primers as shown in Figure 1.7.
1 2 3 4 5 • 7 1 • 10 11 1213 14 15 111711 11 20 21 22
.335 bp
Figure 1.6 Restriction digest analysis of pUC18 plasmids containing the CYP17. Lanes 1, 10, 11 and
22: DNA marker A.DNAIEcoRl/HindIll. Lanes 9,12 and 16:XbaI digest of plasmid DNA containing the
CYP17 in the 5'- 3' orientation yielding 3902 bp and 335 bp fragments. Lanes 3-8,15 and 18-21: XbaI
digest of plasmid DNA containing the 3'- 5' orientated CYP17.
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Figure 1.7 PCR amplification analysis of recombinant pUCI8-CYPI7 plasm ids. The reaction
products (0.5 ug) were analysed by 1% agarose gel electrophoresis Lanes 1 and 8: DNA molecular
weight marker VI (Roche). Lanes 2, 3,4 and 6: CYPl7 fragment (1563bp) amplified from recombinant
vectors using gene specific primers STEl and PI04. Lane 5: DNA marker A.DNAJEeoR!/HindIII. Lane 7:
Negative control, PCR amplification without DNA template.
1.1.2.2 Construction of the pPIC9K-CYP17 expression vector
The EcoRI digested pUC18-CYP17 and pPIC9K plasmids were electrophoresed on an
0.8% low melting agarose gel and the CYP17 fragment and linearised plasmid DNA
were excised and purified. Prior to ligation the cohesive compatible ends of the EcoRI
linearised pPIC9K DNA were dephosphorylated and the CYP17 fragment successfully
ligated. To evaluate the absence of religated plasmid DNA, the dephosphorylated
plasmid (9276 bp) and the CYP17 fragment (1545 bp) were analysed by 1% agarose gel
electrophoresis as shown in Figure 1.8.
1 2 3 4
Figure 1.8 Restriction digest analysis of the CVP17 fragment and pPIC9K plasmid. Lanes 1 and 3:
DNA marker A.DNAJEeoRIlHindIII. Lane 2: CYPl7 fragment (1545 bp) obtained with the EeoR!
digestion at 0.2 ug. Lane 4: The EcoRllinearised, dephosphorylated pPIC9K plasmid (I ug).
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Transformed bacterial colonies, were selected from the LB-ampicillin plates and grown
in small-scale cultures. Plasmid DNA isolated from each culture was digested with XbaI
and analysed by 1% agarose gel electrophoresis. The recombinant pPIC9K-CYP17
vector (10827 bp) with the insert in the correct orientation (5'-3' orientation) should
yield 2053 and 8774 bp fragments of as shown in Figure 1.9.
DNA sequencing analyses, Appendix A.1, of these clones confirmed that the CVP 17 had
been inserted in reading frame for eukaryotic translation initiation and secretion.
12345878
Figure 1.9 Restriction digest analysis of pPIC9K plasmids containing the CYPI7. Lanes 1, 4 and 8:
DNA marker 'ADNNHindIII. Lanes 2, 3 and 7: XbaI digest ofpPIC9K vector (8774 bp) containing the
CYP17 (2053bp) in the 5'-3' orientation. Lanes 5 and 6: XbaI digest ofpPIC9K vector containing no
insert. Each lane contained 0.5 ug DNA.
1.1.2.3 Screening of GS115/pPIC9K-CYP17 and KM71/pPIC9K-CYP17
transformants for integration
The recombinant pPIC9K-CYP17 and the parent vector pPIC9K DNA were linearised
with San and transformed into two different P. pastoris host strains OS 115 and KM71.
The transformants were selected on the requirement of a His+ phenotype for growth and
selected for single copy integration into the Pichia genome by conferring resistancy of
0418 at 0.25 mg/ml.
The OS 115 His+ transformants were screened for their methanol utilisation (Mut)
phenotype, since methanol will be the sole carbon source used for expression and a wild-
type Mut is required. Most of the His+ transformants should be Mut+, because
transformation of OS 115 with San -linearised constructs favor recombination at the H1S4
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locus. However, with the presence of the AOXl gene in the plasmid, there is a chance
that recombination will occur at the AOXl locus, disrupting the wild-type AOXl gene
and creating His+MutS transformants. The deletion of the AOXI results in the loss of the
2100 bp PCR amplified fragment.
PCR amplification followed by 1% agarose gel electrophoretic analyses of lysed His+
transformants could not determine if the CYPI7 was integrated correctly, since the
expected two fragments have similar sizes and could not be separated. One corresponded
to the CYPI7 (2044 bp) and the other to the AOXl gene (2100 bp) as shown in Figure
1.10, lane 3. A gene-specific primer, STEl together with 5' AOXIP primer was used to
confirm the presence ofCYPI7 (1680 bp) as shown Figure 1.10, lane 4. Mut+ integrants
with only the parent vector pPIC9K, produced 492 bp and 2100 bp PCR products as seen
in Figure 1.10, lane 5.
2100 bo.
1680 bo.
.2044 bo
.4Q2bo
Figure 1.10 Direct PCR screening of GSI15/pPIC9K-CYPI7 clones. Lane 1: Amplification of the
wild-type AOXI gene (2100 bp) using AOXIP primers. Lanes 2 and 6: DNA molecular weight marker
VI. Lanes 3 and 4: Contains a clone carrying both the AOXI gene (2100 bp) and CYP17 (2044 bp). In
lane 3, AOXIP primers were used and in lane 4 an insert-specific primer STEl and the 3' AOXIP primer
were used resulting in a 1680 bp PCR product. Lane 5: Contains a clone with the AOXI gene(2100 bp)
carrying the pPIC9K vector without insert (492 bp). AOXIP primers were used. Lane 7: Positive PCR
control containing CYP17 fragment (2044 bp) amplified from pPIC9K-CYPI7 plasmid using AOXIP
primers. Lane 8: Negative control, PCR amplification without DNA template. Each lane contained 20 ul
reaction product.
The successful integration of the CYPI7 and truncCYPI7 into the yeast genomic DNA
was shown by Sac! restriction digestion of the amplified PCR products. The integrated
CYPI7, with two Sac! digestion sites, produced four fragments. Three corresponded to
the CYPI7 (1344, 385 and 315 bp) and the remaining to the AOXl gene (2100 bp) as
shown in Figure 1.11, lane 5. The truncCYP 17 has only one Sac! digestion site since the
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second site was in the 5'-terminal of the full-length CYPI7, which had been excised.
Therefore three bands were produced. Two corresponded to the truncCYPI7 (1675 and
315 bp) and the other to the AOXl gene (2100 bp). This was confirmed by 1% agarose
gel electrophoresis (Figure 1.11, lane 7).
Figure 1.11 Restriction digest analysis of the PCR products from GS115/pPIC9K-CYP17 and
GSl15/pPIC9K-truncCYP17 clones. Lanes 1 and 2: undigested and Sad digested PCR products (0.5
ug) of the wild-type AOXlgene, respectively. Lanes 3 and 6: DNA molecular weight marker VI. Lanes 4
and 5: undigested and Sad digested PCR products (0.5 ug) of the clone carrying both the AOXl gene and
the CYPI7, respectively. Sad digest resulted in four bands. The 1344, 385 and 315 bp fragments
corresponded to the CYPI7 and the 2100 bp band to the AOXl gene. Lanes 7 and 8: Sad digested and
undigested PCR products (0.5 ug) of the clone carrying both the AOXl gene and the truncCYP17,
respectively. Sad digest resulted in three bands. The 1675 and 315 bp fragments corresponded to the
truncCYP17 and the 2100 bp band to the AOXl gene.
The same PCR analysis was carried out on KM71 integrants. The results, analysed by
1% agarose gel electrophoresis, were similar except that the wild-type AOXl gene in
KM71 cells was approximately 4500 bp instead of 2100 bp, because the ARG4 was
inserted into the AOXl gene. Two bands were produced. One corresponded to the
CYPI7 (2044 bp) and the other to the AOXl gene (4500 bp) as shown in Figure 1.12,
lane 1.
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Figure 1.12 Direct PCR screening of KM71/pPIC9K-CYP17 clones. The reaction products (20 Ill)
were analysed by 1% agarose gel electrophoresis. Lanes 1 and 3: Contains a clone carrying both the
wild-type AOXI gene (4500 bp) and the CYP17 insert cloned into the pPIC9K plasmid resulting in a
2044 bp PCR product. In lane 1 AOXIP primers were used and in lane 3 two insert-specific primers
STEl and 3989 were used resulting in a 380 bp PCR product. Lane 2: DNA molecular weight
marker VI. Lane 4: DNA marker A.DNAIEcoRI/HindITI. Lane 5: Positive PCR control containing
CYP17 fragment (2044 bp) amplified from pPIC9K-CYP17 plasmid using AOXIP primers. Lane 6:
Negative control, PCR amplification without DNA template.
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1.2 Cloning and construction of the truncated human CYP17
(truncCYPl7) into the pPIC9K expression vector
1.2.1 Materials and methods
1.2.1.1 Subeloning of the truneCYP17 eDNA
The full-length human CYP17 in the pPIC9K-CYP17 construct was used as the template
DNA to amplify a truncCYP17 eDNA, depicted in Figure 1.13. An upstream primer
Pl03 (5'-ATGCGAATTCAAGAGAAGGTGCCCTGGTGC-3') was designed to delete
the first 18 amino acid residues (membrane binding site) and the downstream primer
Pl04 complementary to the histidine tag including the stop codon. Both primers
introduced EcoRI sites (underlined).
PCRproduct
EcoRI
S'-ATGCGAATTC
EcoRI
GAATTCCGG-3'
hydf'ophoblcm.mbr.n.
binding Iltl I
pPIC9K-CYP17
10827 bp
Figure 1.13 Schematic representation of the cloning strategy for the truncCVP17 amplified from the
pPIC9K-CYP17 expression vector. The nucIeotides encoding the first 18 amino acid residues from the
5' -terminal of the CVP 17 were truncated using the upstream primer PI 03, which is complementary to the
DNA sequence downstream from the nucleotides encoding the first 18 amino acid residues. The
downstream primer PI 04 is complementary to the 3' -terminal including the stop codon and nucleotide
bases encoding six histidine residues. Both primers include a nucleotide sequence encoding an EeaR! site
for subeloning into the pUC 18 vector.
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Each PCR amplification mixture (100 J.lI)contained pPIC9K-CYPI7 vector DNA (750
ng) and the reaction was carried out as described in section 1.1.1.2. The amplified DNA
fragment was electrophoresed on an 0.8% low melting agarose gel, extracted and
purified as described in section 1.1.1.2.
The truncCYP 17 PCR product was digested with EcoRI resulting in a fragment
containing EcoRI digestion sites on the 5' and 3'-termini which subsequently was cloned
into the pUCI8 vector linearised with EcoRI as shown in Figure 1.14. Two separate
restriction digestions, one containing amplified truncCYPI7 DNA (2 ug) and the other
containing pUCI8 DNA (2 ug) were carried out as described in section 1.1.1.2.2. The
digested CYPl7 fragment and linearised vector were electrophoresed on an 0.8% low-
melting agarose gel in TAB buffer (40 mM) and purified as described in section
1.1.1.2.1.
EooRI
S'-ATGCGAATTC
EooRI
GAATTCCGG-3'
pUC18
2686 bp
pUC18-trunc.CYP17
4182 bp
Figure 1.14 Schematic representation of the subcloning of the truncCYP17 into pUC18 vector.
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The linearised pUC18 vector (1.89 ug) was dephosphorylated with CIAP (0.022 U) as
described in section 1.1.1.2.3. The purified digested truncCYP17 fragment (112 ng) and
pUC18 DNA (200 ng) were subsequently ligated as described in section 1.1.1.2.4.
Competent JM 109 cells were transformed with the ligated vectors. In addition to
ampicillin selection, the vector contained the lacZ gene, which allowed for blue/white
colony selection.
Positive colonies were subsequently incubated overnight in LB medium (5 ml) at 37°C
and the plasmid DNA was isolated using the Wizard™ Plus Minipreps DNA Purification
System as described in section 1.1.1.2.5. The purified recombinant plasmid DNA was
digested with XbaI and analysed by agarose gel electrophoresis. Plasmids containing the
correct insert were subsequently prepared by a modified alkaline/SDS lysis method
using a Nucleobond" AXI00 plasmid isolation kit as described in section 1.1.1.2.5. The
purified isolated plasmids were analysed by DNA sequencing and subsequently used in
the construction of the pPIC9K-truncCYPI7 expression vector.
1.2.1.2 Construction of the pPIC9K-truncCVP17 expression vector
The pUCI8-truncCYPI7 construct (4182 bp), was digested with EcoRI and the
truncCYP17 was ligated into pPIC9K DNA linearised with EcoRI as shown in Figure
1.15. Two separate restriction digestions, one containing pUCI8-CYPI7 (2 ug) and the
other pPIC9K DNA (2 ug) were carried out at 37°C for 90 min in a final volume of 30
j..llcontaining 5.0 j..llrestriction buffer B (supplied), acetylated BSA (5.0 ug) and EcoRI
(10 U). The digested truncCYP17 fragment and the linearised vector were
electrophoresed on an 0.8% low-melting agarose gel and extracted from the agarose gel
as described in section 1.1.1.2.1.
The linearised pPIC9K DNA (14j..lg) was dephosphorylated with ClAP (0.05 U) as
described in section 1.1.1.2.3. The purified digested truncCYP17 DNA (32.3 ng) and
pPIC9K plasmid DNA (200 ng) were subsequently ligated as described in section
1.1.1.2.4. Competent JM109 cells were transformed with the ligated vectors and
transformants were selected on LB-agar plated with ampicillin as described in section
1.1.1.4.1.
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Positive colonies were incubated overnight in LB medium (5 ml) at 37°C and the
plasmid DNA was isolated as described in section 1.1.1.2.5. The purified recombinant
plasmids were digested with Xbal and analysed by agarose gel electrophoresis. Plasmids
containing the correct insert were subsequently prepared by a modified alkaline/SDS
lysis method using a Nucleobond" AXI 00 plasmid isolation kit as described in section
1.1.1.2.5.
EcoFU
S'-OAAnc
EcoRI
GAAnC-3'
pPIC9K
9276 bp
!
pPIC9K-CYP17
10773 bp
Figure 1.15 Schematic representation of the cloning strategy for the construction of the pPIC9K-
truncCYP17 expression vector. The cloned truncCYP17 in the pUC18 vector was digested with EeoRl
and inserted into the pPIC9K expression vector at the EeoRl site. The truncCYP17 was cloned in reading
frame of the a-factor secretion signal and contains a nucleotide sequence encoding the six histidine tag.
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The recombinant pPIC9K-truncCYP17 vector was analysed by DNA sequencing as
described in section 1.1.1.4.3. The truncated CYP17 with its insertion sites was
sequenced with seven primers as illustrated in Figure 1.16. The DNA sequencing
analyses was carried out as described in 1.1.1.4.3, confirming correct insertion.
11'1'11 TT
" q ""storP ..
Figure 1.16 Schematic representation of the DNA sequencing strategy for the truncCYP17 in the
pPIC9K-truncCYPI7 recombinant vector.
1.2.1.3 Screening of GS115/pPIC9K-truncCYP17 and KM71/pPIC9K-
truncCYP17 transformants for integration
The cloned expression vectors, pPIC9K-truncCYP17 (10 ug) and the parent vector
pPIC9K (10 ug), were linearised with San and transformed into competent P. pastoris
strains, GS115 Mut (Methanol ytilisation plus) and KM71 Muf (Methanol gtilisation
slow) using the spheroplast method as described in section 1.1.1.5. The presence of
truncCYP17 cDNA integrated into the yeast chromosomes was subsequently confirmed
by PCR amplification analyses as described in section 1.1.1.5.
1.2.2 Results
1.2.2.1 Subeloning of the truncCYP17 cDNA
The full-length human CYP17, located in the pPIC9K-CYP17 expression vector was
used as the template to amplify a truncCYP 17 cDNA, yielding a 1510 bp product. This
amplified product was subsequently subeloned into an intermediate vector, pUC18,
before cloning it into the pPIC9K expression vector.
The integrity of the newly constructed pUC18-truncCYP17 vector was confirmed by
restriction digest analyses with Xbal followed by 1% agarose gel electrophoresis. The
pUC18-truncCYP17 plasmid (4182 bp), containing the insert yielded two 3902 and 280
bp fragments as shown in Figure 1.17, lanes 7, 10 and 11.
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.280 bo
Figure 1.17 Restriction digest analysis of pUC18 plasmids containing the truncCYP17. Lanes 1 and
12: DNA marker A.DNAIEcoRIlHindIII. Lanes 2-6, 8, 9, and 13-15: Xbal digest of plasmid DNA (0.5 ug)
containing the truncCYP17 in the 3'-5' orientation yielding 2912 and 1270 bp fragments. Lanes 7, 10 and
11: Xbal digest of pUC18 plasmid DNA (0.5 !lg) containing the truncCYP17 in the 5'-3' orientation
yielding 3902 and 280 bp fragments.
1.2.2.2 Construction of the pPIC9K-truncCVP17 expression vector
The EcoRI digested pUC18-truncCYP17 and pPIC9K DNA were electrophoresed on an
0.8% low melting agarose gel and the truncCYP17 and linearised plasmid DNA were
excised and purified. Prior to ligation the cohesive compatible ends of the linearised
pPIC9K DNA were dephosphorylated and the truncCYP17 successfully ligated.
Transformed bacterial colonies, were grown in small-scale cultures. Plasmid DNA
isolated from each culture was digested with XbaI and analysed by 1% agarose gel
electrophoresis. The cloned pPIC9K-truncCYP17 vector (10773 bp) with the insert in
the correct orientation (5'-3' orientation) should yield 2053 and 8720 bp fragments as
shown in Figure 1.18, lanes 13 and 16.
Analyses of PCR amplifications, seen in Figure 1.19 and DNA sequencing analyses,
Appendix A.2, confirmed that the truncCYP 17 had been inserted in reading frame for
eukaryotic translation initiation and secretion.
1.2.2.3 Screening of GS115/pPIC9K-truncCYP17 transformants for integration
Results were shown inFigure 1.11.
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Figure 1.18 Restriction digest analysis of pPIC9K plasmids containing the truncCVPl7. Lane 1:
Positive control containing XbaI digest of pPIC9K-CYPI7 plasmid (0.5 ug). Lanes 2,4-11 and 14: XbaI
digest of plasmid DNA (0.5 ug) without the truncCYP17. Lanes 3 and 12: DNA marker
ADNAlEcoRI/HindIII. Lanes 13 and 15: XbaI digest of plasmid DNA (0.5 ug) containing the
truncCYPl7 in the 5'-3' orientation yielding 8720 and 2053 bp fragments.
1 2 3 466 7 8
Figure 1.19 PCR analysis of the recombinant pPIC9K-CVPI7 and pPIC9K-truncCVP17 plasmids.
The reaction products (20 Ill)were analysed by 1% agarose gel electrophoresis. Lanes 1 and 2: Negative
controls, PCR amplifications without DNA template. Lanes 3 and 7: DNA marker ADNAlEcoRIlHindIII.
Lane 4: Amplified CYPl7 (1747 bp). Lane 6: Amplified truncCYPl7 (1693 bp). All amplifications were
carried out with 5'-a-factorP and 3'-AOXIP primers. Lane 8: Positive control containing amplified
pPIC9K-CYP17 plasmid using primers PI05 and PI06.
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1.3 Cloning and construction of the full-length human bs gene
(CYBS) into the pPIC9K expression vector
1.3.1 Materials and Methods
1.3.l.1 Subeloning of the CYB5 eDNA
All DNA manipulations were carried out using standard procedures (55). The full-length
human CYB5, located in the pCMV5-CYB5 vector', was used as the DNA template to
amplify a CYB5 cDNA as depicted in Figure 1.20. The first amplification used the
upstream primer PI07 (5'-AGGCGAATTCATGGCAGAGCAGTCGGAC-3') and the
downstream primer PI08 (5' -GTGATGGTGATGGTGATGGTCCTCTGCCATG
TATAGG-3'). The former introduced an EcoRI site (underlined) and the latter a six
histidine coding region (bold). The PCR 1 product was the template for the second
amplification using the forward primer PI09 (5'-AGGCGAATTCATGGCAGA-3') and
reverse primer PlIO (5'-CCGGAATTCTCAGTGATGGTGATGGTGATGGT-3').
The latter introduced a stop codon (italics) after the nucleotide bases encoding six
histidine residues followed by an EcoRI site.
Each PCR amplification mixture (100 !J.I)contained pCMV5-CYB5 vector DNA (750
ng) and the reaction was carried out as described in section 1.1.1.2. The PCR 1 product
was electrophoresed on an 0.8% low melting agarose gel, extracted and purified as
described in section 1.1.1.2. The same reaction procedure was followed for a second
amplification using the purified PCR 1 product (400 ng) as a template. The PCR 2
product was electrophoresed, extracted and purified as described in section 1.1.1.2.
The CYB5 PCR 2 product was digested with EcoRI and cloned into the pVC 18 vector
linearised with EcoRI, depicted in Figure 1.21. Two separate restriction digestions, one
containing amplified CYB5 DNA (2 !J.g)and the other containing pVC18 DNA (2 ug)
were carried out as described in section 1.1.1.2.2.
1A kind gift from Prof Ronald Estabrook, University of Texas Medical Centre, Dallas, Texas, USA
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Figure 1_20 Schematic representation of the cloning strategy for the CYB5 amplified from the
pCMV5-CYB5 vector. The first peR amplification using the upstream primer PI07 and the downstream
primer Pl08 introduced a EcoRl site and a nucleotide sequence encoding six histidine residues,
respectively. Pl09 and PlIO primers were used in the second amplification. The latter introduced
nucleotide bases encoding a stop site followed by an EcoRl site.
The digested CYB5 fragment and linearised vector were electrophoresed on an 0.8%
low-melting agarose gel in 40 mM TAE buffer and purified as described in section
1.1.1.2.1. The linearised pUC18 vector (3.66 ug) was dephosphorylated with ClAP
(0.042 U) as described in section 1.1.1.2.3. The purified digested CYB5 fragment (62.4
ng) and pUC18 (200 ng) DNA were subsequently ligated as described in section
1.1.1.2.4. Competent JM109 cells were transformed with the ligated vectors. In addition
to ampicillin selection, the vector contained the lacZ gene which allowed for blue/white
colony selection.
Positive colonies were subsequently incubated overnight in LB medium (5 ml) at 37°C
and the plasmid DNA was isolated using the Wizard™ Plus Minipreps DNA Purification
System as described in section 1.1.1.2.5. The purified recombinant plasmid DNA was
digested with PstI / EcoRI and analysed by agarose gel electrophoresis. Plasmids
containing the correct insert were subsequently prepared by a modified alkaline/SDS
lysis method using a Nucleobond" AX100 plasmid isolation kit as described in section
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1.1.1.2.5. The purified isolated plasmids were analysed by DNA sequencing and
subsequently used in the construction of the pPIC9K-CYB5 expression vector.
pUC18
2686 bp
!
pUC18.CYB 5
3115 bp
Figure 1.21 Schematic representation of the subcloning of the CYB5 into pUC18 vector.
1.3.1.2 Construction of the pPIC9K-CYB5 expression vector
The pUC18-CYB5 construct (3115 bp), was digested with EcoRI and the CYB5 was
ligated into pPIC9K vector, linearised with EcoRI as depicted in Figure 1.22. Two
separate restriction digestions, one containing pUC18-CYB5 (2 ug) and the other
pPIC9K DNA (2 Jlg) were carried at 37°C for 2 hours, each in a final volume of 30 JlI
containing 5.0 JlI restriction buffer B (supplied), acetylated BSA (5.0 ug) and EcoRI (10
U). The digested CYB5 fragment and linearised vector were electrophoresed on an 0.8%
low-melting agarose gel, extracted and purified from the agarose as described in section
1.1.1.2.1.
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AATTCCCQG-3'
pPIC9K
9276 bp
pPIC9K-CYB5
9705 bp
Figure 1.22 Schematic representation of the cloning strategy for the construction of the pPIC9K-
CYB5 expression vector. The cloned CYB5 in the pUC18 vector was digested with EcaRi and inserted
into the pPIC9K expression vector at the EcaRi site. The CYB5 was cloned in reading frame of the (X-
factor secretion signal and contains a nucleotide sequence encoding the six histidine tag.
The linearised pPIC9K DNA (4.62 ug) was dephosphorylated with ClAP (0.015 U) and
purified as described in section 1.1.1.2.3. The purified digested CYB5 (8.71 ng) and
pPIC9K DNA (200 ng) were subsequently ligated as described in section 1.1.1.2.4.
Competent JM109 cells were transformed with the ligated vectors and transformants
were selected on LB-agar plates with ampicillin as described in section 1.1.1.4. Positive
colonies were subsequently incubated overnight in LB medium (5 ml) at 37°C and the
plasmid DNA was isolated as described in section 1.1.1.2.5. The purified recombinant
plasmid DNA was digested with Sad and analysed by agarose gel electrophoresis.
Plasmids containing the correct insert were subsequently prepared by a modified
Stellenbosch University http://scholar.sun.ac.za
Part III Construction of pPIC9K-CYBS 163
alkaline/SDS lysis method using a Nucleobond® AXlOO plasmid isolation kit as
described in section 1.1.1.2.5.
The purified recombinant pPIC9K-CYBS vector was analysed by restriction digestion
and DNA sequence analyses as described in 1.1.1.4.3. Primers 5' AOXIP and 3' AOXIP
were used as illustrated in Figure 1.23.
pPIC9K-CYB5
9705 bp
Figure 1.23 Scbematic representation of tbe DNA sequencing strategy for tbe CVBS in tbe pPIC9K-
eVBS expression vector.
1.3.1.3 Screening of GS115/pPIC9K-CYB5 and KM711pPIC9K-CYB5
transformants for integration
The cloned expression vectors, pPIC9K-CYBS (lO ug) and the parent vector pPIC9K
(10 ug), were linearised with San and transformed into competent P. pastoris strains,
GSllS Mut" (Methanol gtilisation plus) and KM71 Mue (Methanol ytilisation §.low)
using the spheroplast method as described in section 1.1.1.5. The presence of CYBS
cDNA integrated into the yeast chromosomes was subsequently confirmed by PCR
amplification analyses as described in section 1.1.1.5.
1.3.2 Results
1.3.2.1 SubcIoning of the CYB5 cDNA
The full-length human CYB5, located in the pCMVS-CYBS expression vector was used
as the template to amplify a CYBS cDNA, yielded a PCR 1 product (427 bp). This
amplified product was subsequently used as a template for the second amplification,
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which yielded the expected PCR 2 product (440 bp) as seen in Figure 1.24. PCR 2
product was subeloned into an intermediate vector, pUCI8, before cloning it into the
pPIC9K expression vector.
Figure 1.24 Agarose gel electrophoretic analysis of amplified CYB5. The reaction products (lO Ill)
were analysed by 1% agarose gel electrophoresis. Lane 1: Negative control, PCR amplification without
DNA template. Lanes 2 and 6: DNA molecular weight marker VI. Lane 3: Amplified CYB5 (PCR I
product, 427 bp using primers PI07 and PI08. Lanes 5 and 7: Amplified CYB5 (PCR 2 product, 440 bp)
using primers PI09 and PlIO. Lanes 4 and 8: Positive PCR controls containing CYF17 fragment
amplified from pPIC9K-CYFI7 using primers PI05 and PI 06.
The integrity of the newly constructed pUCI8-CYB5 vector was confirmed by
restriction digest analyses with either PstIor EcoRI followed by 1% agarose gel
electrophoresis. The pUCI8-CYB5 plasmid (3115 bp) containing the insert yielded the
expected two bands corresponding to 2715 and 400 bp for the PstI digestion and two
bands corresponding to 2689 and 426 bp for the EcoRI digestion as shown in Figure
1.25, lanes 3 and 11.
1.3.2.2 Construction of the pPIC9K-CYB5 expression vector
The EcoRI digested pUCI8-CYB5 and pPIC9K plasmid DNA were electrophoresed on
an 0.8% low melting agarose gel and the CYB5 and linearised plasmid were excised and
purified. Prior to ligation the cohesive compatible ends of the linearised pPIC9K plasmid
DNA were dephosphorylated and the CYB5 successfully ligated.
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Transformed bacterial colonies were grown in small-scale cultures. Plasmid DNA
isolated from each culture was digested with Sad and analysed by 1% agarose gel
electrophoresis. The cloned pPIC9K-CYB5 vector (9705 bp) yielded the correct
1 2 3 4 5 6 7 8 9 10 11 12 13 141516171819 20
Figure 1.25 Restriction digest analysis of pUC18 plasm ids containing the CYB5. Lanes 1 and 12:
DNAmolecular weight marker VI. Lanes 2, 4, 5, 7, 8 and 9: Psti digest of plasmid DNA (0.5 ug) without
insert. Lane 3: Psti digest of plasmid DNA containing the CYB5 yielding 2715 and 400 bp fragments.
Lanes 6 and 18: DNA marker '-DNA/EcoRIlHindIII. Lanes 10, 13-17: EcoRI digest of plasmid DNA
(0.5 ug) without insert. Lane 11: EcoRI digest of plasmid DNA (0.5 ug) containing the CYB5. Lane 19:
undigested plasmid DNA (0.5 ug). Lane 20: Positive control containing EcoRI digested pPIC9K-CYPI7
plasmid DNA (0.5 ug),
8435 and 1270 bp fragments as shown in Figure 1.26,lanes 3, 14 and 19.
1 2 3 4 5 8 7 8 9 10 111213 1415 1817181920
Figure 1.26 Restriction digest analysis of pPIC9K plasmids containing the CYB5. Lane 1: Positive
control containing Sad digested pPIC9K plasmid DNA (0.5 ug). Lane 2: DNA marker '-DNA/HindIII.
Lanes 9 and 15: DNA molecular weight marker VI. Lanes 3, 14 and 19: Sad digest of plasmid DNA
(0.5 ug) containing the CYB5 in the 5'-3' orientation yielding 8435 and 1270 bp fragments. Lanes 4-8,
10-13,16-18 and 20: Sad digest of plasmid DNA (0.5 ug) without an insert.
The 1% agarose gel electrophoresis could not distinguish between the correctly 5'-3'
orientated (8435 and 1270 bp) and incorrectly 3'-5' orientated (8518 and 1187 bp) insert
Stellenbosch University http://scholar.sun.ac.za
Part III Construction of pPIC9K-CYB5 166
in the plasmid. Therefore a 2% agarose gel electrophoresis, separating and resolving the
smaller sized DNA, was used to identify the correct fragments. Out of the three digested
plasmids, shown in Figure 1.26, lanes 3, 14 and 19, the first two clones were in the
correct orientation as shown in Figure 1.27, lanes 2 and 4. DNA sequence analyses,
Appendix A.3, of these clones confirmed that the CYB5 had been inserted in reading
frame for eukaryotic translation initiation and secretion.
Figure 1.27 Restriction digest analysis of pPIC9K plasm ids containing CYB5. The reaction products
(0.5 ug) were analysed by 1% agarose gel electrophoresis. Lane 1: DNA marker )"DNA/HindIll. Lanes 2
and 4: Sad digest of plasmid DNA containing the CYB5 in the 5'-3' orientation yielding 8435 and 1270
bp fragments. Lanes 3 and 6: DNA molecular weight marker VI. Lane 5: Sad digest of plasmid DNA
containing the CYB5 in the incorrect (3'-5') orientation.
1.3.2.3 Screening of GS115/pPIC9K-CYB5 and KM711pPIC9K-CYB5
transformants for integration
PCR followed by 1% agarose gel electrophoretic analyses of lysed His + transformants
showed that the CYB5 was integrated correctly, since two bands were produced. One
corresponded to the CYB5 (429 bp) and the other to AOXI gene (2100 bp) as shown in
Figure 1.28, lane 3. A gene-specific primer P107 together with 5'-AOX1P primer
(Figure 1.28, lane 4) was also used to confirm the presence of CYB5. Mut" integrants
with only the parent vector pPIC9K produced a 492 and 2100 bp PCR products as seen
in Figure 1.28, lane 5.
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The same PCR analysis was carried out on KM71 integrants. Two bands were produced.
One corresponded to the CYB5 (921 bp) and the other to the AOXI gene (4500 bp) as
shown in Figure 1.29, lane 3.
.550 bp
492 bp
Figure 1.28 Direct PCR screening of GSI15/pIC9K-CYB5 clones. Lane 1: Amplification of the wild-
type AOXI gene (2100 bp) using AOXIP primers. Lanes 2 and 6: DNA molecular weight marker VI.
Lanes 3 and 4: Contains a clone carrying both the AOXI gene (2100 bp) and CYB5 insert cloned into the
pPIC9K plasmid resulting in a 921 bp PCR product. In lane 3'AOXIP primers were used and in lane 4
insert-specific primer PI07 and the 3'AOXIP primer were used resulting in a 550 bp PCR product. Lane
5: Contains a clone with the AOXI gene (2100 bp) carrying the pPIC9K vector without insert (492 bp).
AOXIP primers were used. Lane 7: Positive PCR control containing CYPB fragment (550 bp) amplified
from pPIC9K-CYB5 plasmid using AOXIP primers. Lane 8: Negative control, PCR amplification
without DNA template. 20 III reaction mixtures were loaded.
921 bp •
~ 550 bo
492 bp
4500 bP.
Figure 1.29 Direct PCR screening of KM711pIC9K-CYB5 clones. The reaction product (20 Ill) were
analysed by 1% agarose gel electrophoresis. Lane 1: Amplification of the wild-type AOXI gene (4500 bp)
using AOXIP primers. Lanes 2 and 6: DNA molecular weight marker VI. Lanes 3 and 4: Contains a
clone carrying both the AOXI gene (4500 bp) and the CYB5 (921 bp). In lane 3 AOXIP primers were
used and in lane 4 a gene specific primer PlO7 and the 3'AOXIP primer were used resulting in a 550 bp
fragment. Lane 5: Contains a clone carrying the parent pPIC9K vector without insert (492 bp). AOXIP
primers were used. Lane 7: Positive PCR control containing CYB5 fragment (550 bp) amplified from
pPIC9K-CYB5 plasmid using AOXIP primers. Lane 8: Negative control, PCR amplification without
DNA template. 20 III reaction mixtures were loaded.
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1.4 Cloning and construction of full-length human CYP19 into the
pPIC9K expression vector
1.4.1 Materials and Methods
1.4.1.1 Subeloning of the CVP19 eDNA
All DNA manipulations were carried out using standard procedures (55). The full-length
human CYP19, located in the pCMV-CYPI9 vector, was used as the DNA template to
amplify a CYP19 cDNA as depicted in Figure 1.30. The first amplification used the
upstream primer P19Al (5'-GGTCAAGGAACACAAGATGG-3') and the downstream
primer P19A2 (5'-ATGGTGATGGTGATGGTGTTCCAGACACCTTCTGA-3'). The
latter introduced a nucleotide sequence encoding six histidine residues (bold). The PCR
I product was the template for the second amplification using the forward primer P19BI
(5'-TCCCCGCGGAGATGGTTTTGGAAATGCTGAA-3') and reverse primer PI9B2
(5' -TCCCCGCGGIT AATGGTGATGGTGATGGTGTT -3 '). Both primers introduced
SadI sites (underlined) and the latter primer inserts a stop codon (italics) after the six
histidine tag coding region (bold).
Each PCR amplification mixture (100 Ill) contained pCMV-CYPI9 plasmid DNA (750
ng) and the reaction was carried out as described in section 1.1.1.2. The PCR 1 product
was electrophoresed on an 0.8% low melting agarose, extracted and purifIed as
described in section 1.1.1.2. The same reaction procedure was followed for a second
amplification using the purified PCR 1 product (400 ng) as a template. The PCR 2
product was electrophoresed, extracted and purified as described in section 1.1.1.2.
The CYPI9 PCR 2 product was digested with SadI and cloned into the pGEM-T®Easy
(pGEM- T) vector (promega) linearised with SacII as depicted in Figure 1.31. Two
separate restriction digestions, one containing amplified CYP19 (2 ug) and the other
containing pGEM-T DNA (2 ug) were carried out at 37°C for 120 min, each in a final
2 A kind gift from Prof Ian Mason, Clinical Biochemistry Section University of Edinburgh School of
Clinical Sciences & Community Health, Edinburgh, Scotland, UK.
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Figure 1.30 Schematic representation of the cloning strategy for the CYP19 amplified from the
pCMV-CYPI9 expression vector. The first peR amplification using the upstream primer P19Al and the'
downstream primer Pl9A2 introduced a nucleotide sequence encoding the six histidine tag at the 3'-
terminal of the cDNA. Primers Pl9BI and Pl9B2 were used in the second amplification, Both primers
introduced Sac/l sites and the latter primer additionally introduced nucleotide bases encoding a stop codon
after the residues encoding the six histidine tag.
volume of30 ul containing 5.0 !-lIof 10 x restriction buffer D (supplied), acetylated BSA
(5.0 ug) and Sad! (lO U). The digested CYP19 fragment and linearised vector were
electrophoresed on an 0.8% low-melting agarose gel in TAE buffer (40 mM), extracted
and purified as described in section 1.1.1.2.1.
A dephosphorylation reaction containing linearised pGEM- T vector (4.0 ug) was carried
out at 37°C for 15 min in a final volume of 50 ul containing dephosphorylation buffer
(50 mM Tris-HCI, pH 8.5, 5 mM MgCh) and shrimp alkaline phosphatase/SAP (4.0
U)(Roche). The reaction was terminated at 65°C for 15 min and the DNA was purified
with the Wizard™ DNA Clean-up® kit. The purified digested CYP19 fragment (100 ng)
and pGEM- T DNA (200 ng) were subsequently ligated as described in section 1.1.1.2.4.
Competent JM 109 cells were transformed with the ligated vectors. In addition to
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ampicillin selection, the vector contained the lacZ gene, which allowed for blue/white
colony selection.
pGEM.T'E •• y
3015 bp
!
pGEM·T·CYP19
4532 bp
Figure 1.31 Schematic representation of the subcloning of the CVP19 into pGEM-T.
Positive colonies were subsequently incubated overnight in LB medium (5 ml) at 37°C
and the plasmid DNA was isolated using the Wizard™ Plus Minipreps DNA Purification
System as described in section 1.1.1.2.5. The purified recombinant plasmid DNA was
digested with Sac! and analysed by agarose gel electrophoresis. Plasmids containing the
correct insert were subsequently prepared by a modified alkaline/SDS lysis method
using a Nucleobond'" AXtOO plasmid isolation kit as described in section 1.1.1.2.5. The
purified isolated plasmid DNA was analysed by Sac! restriction digestion and DNA
sequencing and subsequently used in construction of the pPIC9K-CYPI9 expression
vector.
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1.4.1.2 Construction of the pPIC9K-CYP19 expression vector
The pGEM-T-CYP19 construct (4532 bp) was digested by Not! and the CYPI9 was
ligated into pPIC9K vector, previously linearised with NotI as depicted in Figure 1.32.
-CHlelorTAA(:ICQCQ<00M1rTCG<; ClQCCOC·3'
Figure 1.32 Schematic representation of the cloning strategy for the construction of the pGEM-T-
C¥P19 expression vector. The cloned CVPl9 in the pGEM-T vector was inserted into the pPIC9K
expression vector with compatibleNotl sites.
Two separate restriction digestions, one containing pGEM-T-CYPI9 DNA (1 ug) and
the other containing pPIC9K DNA (1 ug) were carried out at 37°C for 90 min each in a
fmal volume of 25 III containing 2.5 III SuRE/Cut buffer H (supplied) and Not! (2 U)
restriction enzyme. The digested pPIC9K DNA was purified with the Wizard™DNA
Clean-up® kit according to the manufacturer's instructions. The digested CYPI9
fragment was electrophoresed on an 0.8% low-melting agarose gel, extracted and
purified using the QIAquick Gel Extraction kit (Qiagen), according to the
manufacturer's instructions.
The linearised pPIC9K DNA (6 ug) was dephosphorylated with CIAP (1.96 U) and
purified as described in section 1.1.1.2.3. The purified digested CYPI9 (32.2 ng) and
dephosphorylated linear pPIC9K DNA (200 ng) were used in aIO III ligation reaction
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containing T4 ligase (1 U) (Roche), ligase buffer (66 mM Tris-HeI, pH 7.5, 5 mM
MgCh, 1 mM DIT and 1 mM ATP) and AT-P-(l mM). The reaction was incubated at
l6°C for 22 hours and stored at -20°C. Competent JM109 cells were transformed with
the ligated vectors and transformants were selected on LB-agar plates with ampicillin.
Positive colonies were subsequently incubated overnight in LB medium (8 ml) at 37°C
and the plasmid DNA was isolated using the Wizard™ SVPlus Minipreps DNA
Purification System (Promega), according to the manufacturer's instructions. The
purified recombinant plasmids were digested with Sac! and analysed by agarose gel
electrophoresis. Plasmids containing the correct insert were subsequently prepared by a
modified alkaline/SDS lysis method using a Nucleobond" AXlOO plasmid isolation kit
as described in section 1.1.1.2.5.
The purified recombinant pPIC9K-CYP19 construct was analysed by DNA sequencing
as described in section 1.1.1.4.3. The full-length CYP19 with its insertion sites was
sequenced with seven primers as illustrated in Figure 1.33. The upstream primers were
5'AOXlP, AromB1 (5'-GTCACAGTCTGTGCTGAATC-3') and AromCl (5'-
GGTGACCTGACAAGAGAGAA-3') and the downstream primers were 3'AOXlP,
AromA2 (5'-CTCCAACCTGTCCAGATGTG-3'), AromB2 (5'-GCACTGGTTCA
CATTCTCTC-3') and AromC2 (5'-CACCTGT CTGAGTTTCTTGG-3').
..9. S'AOXI • Tl ~'
"AOX',. .ArtmA2
Argm". .Areml2
Aremel. .brproea
Figure 1.33 Schematic representation of the DNA sequencing strategy for the full-length human
CYP19 in the pPIC9K-CYP19 expression vector.
1.4.1.3 Screening of GS115/pPIC9K-CVP19 and KM71/pPIC9K-CVP19
transformants for integration
The cloned expression vectors, pPIC9K-CYPl9 (10 ug) and the parent vector pPIC9K
(10 ug), were linearised with Sail and transformed into competent P. pastoris strains,
GS115 Mut" (Methanol ytilisation plus) and KM7l MutS (Methanol ytilisation ~low)
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using the spheroplast method as described section 1.1.1.5. The presence of CYP19
cDNA integrated into the yeast chromosomes was subsequently confirmed by PCR
amplification analyses as described in section 1.1.1.5.
1.4.2 Results
1.4.2.1 Subeloning of the CYP19 eDNA
The full-length CYPI9, located in the pCMV-CYP19 expression vector was used as the
template to amplify a full-length CYP19 cDNA, yielding a PCR 1 product (1540 bp).
This amplified product was used as a DNA template for the second amplification, which
yielded the expected PCR 2 product (1547 bp)(results not shown). The amplified CYP19
was subeloned into an intermediate vector, pGEM- T, before cloning it into the pPIC9K
expression vector.
The integrity of the newly constructed pGEM- T-CYP19 vector was confirmed by
restriction digest analyses using Sac! and 1% agarose gel electrophoresis. The plasmid
(4532 bp) carrying the insert yielded the expected two bands corresponding to 3378 and
1154 bp for the Sac! digestion as shown in Figure 1.34, lanes 1,3, 7, 8 and 16.
1 2 3 " 5 8 7 8 910 1112 13 1" 15 18171819
Figure 1.34 Restriction digest analysis of pGEM-T plasm ids containing the CVPI9. Lanes 1,3,7,8
and 16: Sad digest of plasmid DNA (0.5 !lg) containing the CYP19 in the 5'-3' orientation yielding 3378
bp and 1154bp fragments. Lanes 2, 6, 10, 11, 13, 14, 15, 17 and 18: Sad digest of plasmid DNA (0.5 ug)
containing the CVP19 in the 3'-5' orientation. Lanes 4 and 19: DNA marker ADNNEcoRIlHindlII.
Lanes 5 and 9: Religated pGEM-T vector (0.5 ug) without an insert. Lane 12: DNA molecular weight
marker VI.
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1.4.2.2 Construction of the pPIC9K-CYP19 expression vector
The Not I digested pGEM-T-CYPI9 and pPIC9K plasmid DNA were electrophoresed
on an 0.8% low melting agarose gel and the CYP19 and linearised plasmid DNA were
excised and purified. Prior to ligation the cohesive compatible ends of the Not I
linearised pGEM-T-CYPI9 DNA were dephosphorylated and the CYP19 successfully
ligated.
Eighteen positively transformed bacterial colonies were grown in small-scale cultures.
Plasmid DNA isolated from each culture was digested with Sad and analysed by 1%
agarose gel electrophoresis. The cloned pGEM-T-CYPI9 vector (10827 bp) yielded the
correct 9371 and 1456 bp fragments as seen in Figure 1.35, lanes 12 and 14.
DNA sequencing analyses, Appendix A.4, of these clones confirmed that the CYP19 had
been inserted in reading frame for eukaryotic translation initiation and secretion.
1 2 3 4 5 6 7 8 9 10 11 1213141516171819 20
9371 bO.
Figure 1.35 Restriction digest analysis of pPIC9K plasm ids containing CYPI9. Lane 1: Positive
control containing Sad digested pPIC9K plasmid DNA (0.5 ug). Lanes 2-4, 7,15 and 17-20: Sad digest
of plasmid DNA (0.5 ug) containing the CYP19 in the 5'-3' orientation yielding 9371 and 1456 bp
fragments. Lanes 5, 6, 8,10-14,16 and 17: Sad digest of plasmid DNA (0.5 ug) containing the insert in
the 3'-5' orientation. Lane 9: DNAmarker ADNAIEcoRIlHindIII.
1.4.2.3 Screening of GS115/pPIC9K-CYP19 and KM711pPIC9K-CYP19
transformants for integration
peR followed by 1% agarose gel electrophoretic analyses of lysed His+ transformants
could not determine if the CYP19 was integrated correctly, since the expected 2 bands,
have similar sizes and could not be separated. One corresponded to the CYP19 (2044
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bp) and the other to the AOXI gene (2100 bp) as shown in Figure 1.36, lane 3. A gene-
specific primer AromB1 together with 5'AOX1P primer was used to confirm the
presence of CYP19 (1171 bp) as shown in Figure 1.36, lane 4. Mut+ integrants with only
the parent vector pPIC9K produced 492 bp and 2100 bp PCR products seen in Figure
1.36, lane 5.
II 492 bp
Figure 1.36 Direct PCR screening of GS115/pPIC9K-CYP19 clones. Lane 1: Amplification of the
wild-type AOXI gene (2100 bp) using AOXIP primers. Lanes 2 and 6: DNA molecular weight marker
VI. Lanes 3 and 4: Contains a clone carrying both the AOXI gene and CYPI9. In lane 3, AOXIP primers
were used resulting in the 2100 bp product containing the AOXI gene (2100 bp) and the 2044 bp product
containing the CYP19 (1552 bp) together with 492 bp of flanking AOXI sequence from pPIC9K-CYPI9.
In lane 4, insert-specific primer AromB 1 and the 3' AOX 1P primer were used resulting in a 1171 bp PCR
product. Lane 5: Contains a clone with the AOXI gene (2100 bp) carrying the pPIC9K vector without
insert (492 bp). AOXIP primers were used. Lane 7: Positive PCR control containing CYP19 fragment
(1171 bp) amplified from pPIC9K-CYI9 plasmid using AOXIP primers. Lane 8: Negative control, PCR
amplification without DNA template. 20 III reaction mixtures were loaded.
The successful integration of the CYP19 into the yeast genomic DNA was shown by
Sad restriction digestion of the amplified PCR products. The integrated CYP19 with
one Sad restriction site, produced three fragments. Two corresponded to the CVP 19
(1233 and 811 bp) and the remaining to the AOXI gene (2100 bp) as shown in Figure
1.37, lane 4. The same clone was also digested withXbaI. The integrated CYP19 has no
SacI restriction site, but the AOXI gene has one site, which resulted in three bands. Two
corresponded to the AOXI (1233 and 811 bp) and the remaining to the CYP19 (2044 bp)
as shown in Figure 1.37, lane 6.
The same PCR analysis was carried out on KM71 integrants. The results were similar,
except that the wild-type AOXI gene in KM71 cells was approximately 4500 bp instead
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of 2100 bp, because the ARG4 gene was inserted into the AOXI gene. Two bands were
produced. One corresponded to the CYP 19 (2044 bp) and the remaining to the AOXI
gene (4500 bp) as shown in Figure 1.38, lane 3.
•9371 bg
Figure 1.37 Restrietion digest analysis of the peR products from GS115/pPIC9K-CYP19 clones. The
reaction products (0.5 ug) were analysed by 1% agarose gel electrophoresis. Lanes 1 and 2: undigested
and Sad digested PCR products of the wild type AOXI gene), respectively. Lane 3: DNA molecular
weight marker VI. Lane 4: Sad digested PCR products of the clone carrying both the AOXI gene and the
CYPI9. The CYP19 produced two bands (1233 and 811 bp) and the AOXI gene produced the remaining
band (2100 bp). Lanes 5 and 6: undigested and XbaI digested PCR product. The CYP19 produced an
undigested band (2044 bp) and the AOXI gene produced the remaining two bands (1456 and 644 bp).
Lane 7: XbaI digested PCR product of the AOXI gene resulted in two bands (1456 and 644 bp). Lane 8:
Positive control containing Sad digested pPIC9K-CYPI9 plasmid yielding bands 9371 and 1456 bp.
II 492 bp
Figure 1.38 Direct PCR screening of KM71/pPIC9K-CYP19 clones. The reaction products (20 Ill)
were analysed by 1% agarose gel electrophoresis. Lane 1: Amplification of the wild-type AOXI gene with
ARG4 insert (4500 bp) using AOXIP primers. Lanes 2 and 6: DNA molecular weight marker VI. Lanes
3 and 4: Contains a clone carrying both the AOXI gene (4500 bp) and CYPI9. In lane 3, AOXIP primers
were used resulting in two PCR products. One corresponded to the CVP 19 (2044 bp) and the other to the
AOXI gene (4500 bp). In lane 4 insert-specific primer AromBI and the 3'AOXIP primer were used
resulting in an 1171 bp PCR product. Lane 5: Contains a clone carrying the parent pPIC9K vector without
insert (492 bp). AOXIP primers were used. Lane 7: Positive PCR control containing CYP19 fragment
(1171 bp) amplified from pPIC9K-CY19 plasmid using AOXIP primers. Lane 8: Negative control, PCR
amplification without DNA template.
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CHAPTER 2: CULTURE OF P. PASTORIS EXPRESSING
DIFFERENT PROTEINS
2.1 Growth and expression of P45017a, aromatase and b5 in P.
pastoris
2.1.1 Materials and Methods
2.1.1.1 Growth
Clones that had been verified by direct PCR were tested for the expression of the desired
protein. Single colonies of P. pastoris strains (GS115 and KM71) transformed with
pPIC9K-CYP17, pPIC9K-truncCYP17, pPIC9K-CYB5 and pPIC9K-CYP19 expression
vectors were grown for in BMGY (25 ml) to an optical density of 600 nm (OD600)
between 2 and 6 at 275 rpm for 20 hours at 30°C in an Innova 4000 shaking incubator
(New Brunswick). Yeast cells were harvested by centrifugation at 2500 x g for 5 min at
room temperature and resuspended to approximately OD600= 1 in BMMY induction
media (200 ml). Methanol-induced cultures were grown at 30°C with shaking at 275
rpm. Methanol was added to 0.5% (v/v) final concentration after every 24 h and the
induction was carried out up to 96 hours. To determine the optimal time for expression,
aliquots (30 ml) of the culture media were removed at selected time intervals i.e. 0, 24,
48, 72 and 96 hours. The expression culture was centrifuged and the cells were separated
from the induction media. The supernatant and pellet, resuspended in buffer BB (50 mM
sodium phosphate, pH 7.6, 1 mM EDTA, 5% glycerol and 1 mM PMSF), were stored at
-80°C. Both fractions were analysed for the presence of extracellularly expressed and
intracellular heterologous P450 proteins by SDS-PAGE (Coomassie staining) and
immunoblot analyses.
2.1.1.2 Screening of yeasts for secretory expression of proteins
Culture media aliquots (30 ml) were removed at specific time intervals and stored at
-80°C. The frozen samples were defrosted on ice and concentrated to a predetermined
volume as described by Swart et al. (57). The dialysis tube used was Spectapor NO.1
(20.4 mm inflated diameter, 6000-8000 MCO) from Spectrapor, LA and the
Stellenbo ch University http:// cholar.sun.ac.za
Part III Growth and expression of cytochromes P450 in P. pastoris 178
concentration was run in polyethylene glycol 35.000 (Fluka) (20% w/v) overnight at
4DC. The concentrated suspension (4 ml) was centrifuged at 12000 x g. at 4DC for 10
min and the clear media was further concentrated with an Ultrafree-15 Centrifugal filter
device (Millipore), according to the manufacturer's instructions. The concentrated
medium was recovered from the device and stored at -20DC for SDS-PAGE and
immunoblot analyses.
2.1.1.3 Screening for intracellular expression of the proteins
A rapid procedure was used to obtain a crude membrane fraction from cells grown by
batch cultivation, to monitor specific P450 protein expression. Cell pellets, stored at
-80DC, were thawed on ice and resuspended in breaking buffer (BB) (1 ml)(50 mM
NalhP04, pH 7.4, 1mM PMSF, 1 mM EDTA and 5% glycerol). All further steps were
carried out at 4DC.The suspension was transferred to a 2 ml microcentrifuge tube and
centrifuged at 3000 x gat 4DCfor 7 min. The washed cells were resuspended in BB (0.5
ml, OD600 of 100-125) and an equal amount of acid washed glass beads (Sigma G-9268,
425-600 urn) was added. The mixture was vortexed vigorously 10 times for 30 s each,
with 30 s intervals on ice. The supernatant was centrifuged at 12000 x g for 10 min to
remove the glass beads and cell debris. The clear lysate (200-250 Ill) was pipetted off
carefully and stored at -20DC.
2.1.1.4 SDS-PAGE and Western blot analyses
SDS-PAGE was carried out according to the method of Laemmli (58) using an
acrylamide concentration of 10% (v/v), except for the b, expression experiments, which
used 12% SDS-PAGE. Low Range molecular weight markers (Biorad) and Rainbow
coloured protein molecular weight markers (Amersham Pharmacia) consisting of myosin
(220 kDa), phosphorylase b (97.4 kDa), bovine serum albumin (66.2 kDa), ovalbumin
(45 kDa), carbonic anhydrase (30 kDa), trypsin inhibitor (21 kDa) and lysozyme (14.4
kDa) were used. Wide range ColorBurst® Electrophoresis Markers (Sigma) were used
alternatively to the Rainbow Markers, which have a 60 kDa protein marker instead of 66
kDa. Proteins were stained with Coomassie brilliant blue.
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Electroblotting was carried out in a wet blotting system. Proteins were transferred onto a
nitrocellulose membrane (Schleicher&Schuel) and the antigen-probe complex, which is
a nickel (Ni2l activated horseradish-peroxidase (INDIA™ HisProbe-HRP, Pierce,
Rockford, USA) was visualised by chemiluminescence (SuperSignal West HisProbe Kit,
Pierce, Rockford. IL). The probe was diluted 1:2000 in TBST buffer. A six histidine
tagged ureate oxidase (pierce, Rockford, IL) was used as a positive control.
2.1.2 Results
2.1.2.1 Growth
GSl15 transformants (Mutl were grown in BMGY media for 18 hours in the log-phase.
They were harvested and resuspended in expression media (BMMY) at - OD600 of 1 and
grown for four days supplementing with methanol every 24 hours. The cell density of
cultures during the induction phase increased linearly up to 48 hours after which it
decreased into stationary phase as shown in Figure 2.1. The growth of the transformants
was similar to the growth of the control strain GS 115/J3-Gal (Mut). The wild-type strain
GS 115 had a similar initial growth rate as the cloned transformants, but after 24 hours
the rate was maintained to 48 hours doubling the cell density before decreasing and
changing into stationary phase. This high growth rate was also observed with the
GSl15/pPIC9K-CYB5 clone.
KM71 transformants (MutS) were grown and induced the same way as the GS 115
strains. The cultures grew in a linear fashion up to 48 hours, but then abruptly reached
stationary phase as shown in Figure 2.2.
All the GSl15 and KM71 strains, transformed with pPIC9K-CYP17, pPIC9K-
truncCYP17, pPIC9K-CYB5 and pPIC9K-CYP19 constructs, were characterised by
Western blot analyses. The supernatant (induction media) was concentrated and
analysed for extracellular expression. Low levels or no external detection of the
expressed hemo-proteins were found and the cells were subsequently analysed for
intracellular localisation of expressed proteins.
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Figure 2.1 Growth curve of GSllS transform ants during induction phase. Growth of the strains was
monitored by optical density at 600 nm after the addition of methanol (0.5%, v/v fmal concentration). The
medium was supplemented with methanol at 24 hours intervals. GSI15/I3-Gal is a Mut" control strain and
WT is the wild-type GS lIS strain.
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Figure 2.2 Growth curve of KM7l transformants during induction phase. Growth of strains was
monitored at OD600 after the addition of methanol (0.5%, v/v final concentration). The medium was
supplemented with methanol at 24 hours intervals. Control/Albumin is a Muf control strain.
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2.1.2.2 Expression of full-length and truncated P45017a by GS115 cells
Secretory expression of the full-length P45017a in the induction media (30 times
concentrated), analysed by SDS-PAGE and Western blot analyses, was slightly
detectable at 96 hours as seen in Figure 2.3B, lane 8. GS 115 transformed with the parent
vector pPIC9K without an insert was used as the negative control and a background
protein band of 58 kDa was observed, Figure 2.3, lanes 1-2.
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Figure 2.3 SDS-PAGE (A) and Western blot (B) analyses of proteins from the induction media and
SDS-PAGE (C) and Western blot (D) analyses of proteins in the intracellular fraction of GSl15 cells
transformed with pPIC9K-CYPI7 expression vector. Lanes 1 and 2: Negative control containing total
proteins of GSl15/pPIC9K cell cultures at 72 and 96 h, respectively. Lanes 3 and 9: Low-molecular
weight Marker. Lanes 4-8: Total proteins of GSl15/pPIC9K-CYP17 cell cultures at 0,24,48, 72 and 96
hours. Lane 10: Positive control containing histidine tagged ureate oxidase. Total protein concentration
(10 ug) per well was loaded for the intracellular fractions. The arrow indicates a 62 kDa and 55 kDa
histidine tagged P45017a protein. Detection was carried out using an INDIA HisProbe-HRP at 1:2000.
Immunoblot analysis of induction media of GS115, transformed with pPIC9K-
truncCYP17 expression vector showed similar results. Secretory expression of histidine
tagged truncated P45017a was detectable at 96 hours (Figure 2.4B, lanes 4-7). However,
four faint bands were observed, as seen in Figure 2.4B, lane 8. GSl15 strain transformed
with the parent vector pPIC9K without an insert was used as the negative control (Figure
2.4, lanes 1-2).
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Figure 2.4 SOS-PAGE (A) and Western blot (B) analyses of proteins from the induction media and
SDS-PAGE (C) and Western blot (D) analyses of proteins in the intracellular fraction of GS115 cells
transformed with pPIC9K-truncCYPI7 expression vector. Lanes 1 and 2: Negative control
containing total proteins of GSI15/pPIC9K cell cultures at 72 and 96 h, respectively. Lanes 3 and 9:
Low-molecular weight Marker. Lanes 4-8: Total proteins of GS115/pPIC9K-truncCYPI7 cell cultures at
0, 24, 48, 72 and 96 hours. Lane 10: Positive control containing histidine tagged ureate oxidase. Total
protein concentration (10 ug) per well was loaded for the intracellular fractions. The arrow indicates a 62
kDa and 55 kDa histidine tagged P45017a protein. Detection was carried out using an INDIA HisProbe-
HRP at 1:2000.
The GSI15/pPIC9K-CYPI7 and GSlI5/pPIC9K-truncCYPI7 transformants at different
time course were lysed and the intracellular fractions analysed by SDS-PAGE and
Western blot analyses. The lysed GS 115 cells contained a histidine tagged P450 17a
protein of an estimated molecular weight of 62 kDa (Figure 2.3D, lanes 5-8. The total
protein concentration of the samples loaded per well was kept equal and the histidine
signal, hence P45017a concentration was the highest at 24 hours and decreased with
time. Western blot analysis of the intracellular fraction of the control strain
GS115/pPIC9K as shown in Figure 2.3D, lanes 1-2, has two background proteins, size
58 and 66 kDa. Similar results were observed from lysed GS115/pPIC9K-truncCYPI7
cells expressing the truncated P45017a (62 kDa) as seen in Figure 2.4 D, lanes 5-8.
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2.1.2.3 Expression of full-length P45017a. by P. pastoris KM71
Secretory expression of the full-length P45017a. in the induction media (30 times
concentrated), analysed by SDS-PAGE and Western blot analyses, was not detectable
Figure 2.5B.
Figure 2.5 SDS-PAGE (A) and Western blot (B) analyses of proteins from the induction media of
KM71 cells transformed with pPIC9K-CYPI7 expression vector. Lanes 1 and 2: Negative control
containing total extracellular proteins ofKM71/pPIC9K cell cultures at 72 and 96 h, respectively. Lanes 3
and 9: Low-molecular weight Marker. Lanes 4-8: Total extracellular proteins (10 ug) of KM71/pPIC9K-
CYPt7 cell cultures at 0, 24, 48, 72 and 96 hours. Lane 10: Positive control containing histidine tagged
ureate oxidase. Detection was carried out using an INDIA HisProbe-HRP at 1:2000.
2.1.2.4 Expression of bs by P. pastoris GS115
Secretory expression of the full-length b, in the induction media (100 times
concentrated), analysed by SDS-PAGE and Western blot analyses, was detectable at 48
and 72 hours as seen in Figure 2.6B, lanes 6 and 7. However bs has a molecular weight
of 16 kDa and the estimated 64 kDa protein band might be an aggregated tetramer (59).
GS115 transformed with the parent vector pPIC9K without an insert was used as the
negative control (Figure 2.6B, lanes 1-2).
The GS115/pPIC9K-CYB5 transformants at different time course were lysed and the
intracellular fractions analysed by Western blot analyses. The lysed GS 115 cells
contained no detectable histidine tagged b, protein (Figure 2.6D, lanes 4-8).
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Figure 2.6 SDS-PAGE (A) and Western blot (B) analyses of proteins from the induction media and
SDS-PAGE (C) and Western blot (D) analyses of proteins in the intracellular fraction of GSllS cells
transformed with pPIC9K-CYBS expression vector. Lanes 1 and 2: Negative control containing total
proteins of GSI15/pPIC9K cell cultures at 72 and 96 h, respectively. Lanes 3 and 9: Low-molecular
weight Marker. Lanes 4-8: Total proteins ofGSl15/pPIC9K-CYB5 cell cultures at 0, 24, 48,72 and 96
hours. Lane 10: Positive control containing histidine tagged ureate oxidase. Total protein concentration
(lO ug) per well was loaded for the intracellular fractions (lane 1 and 4-6). Detection was carried out using
an INDIA HisProbe-HRP at 1:2000.
2.1.2.5 Expression of b, by P. pastoris KM71
Secretory expression of the full-length b, in the induction media (100 times
concentrated), analysed by SDS-PAGE and Western blot analyses, was undetectable
using polyclonal mouse anti-sheep b, antibodies (see Figure 2.7B, lanes 4-8) or using
INDIA HisProbe-HRP (Figure 2.7C, lanes 4-8) at 48 and 72 hours as seen in Figure
2.6B, lanes 6 and 7. However bs has a molecular weight of 16 kDa and the estimated 64
kDa protein band might be an aggregated tetramer (59). GS115 transformed with the
parent vector pPIC9K without an insert was used as the negative control (Figure 2.6B,
lanes 1-2). A faint band at approximately 58 kDa was also detected in the negative
control.
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Figure 2.7 SDS-PAGE (A) and Western blot (B and C) analyses of proteins from the induction
media of KM71 cells transformed with pPIC9K-CYB5 expression vector. Lanes 1 and 2: Negative
control containing total induction media proteins of KM711pPIC9K cell cultures at 72 and 96 h,
respectively. Lanes 3 and 9: Low-molecular weight Markers. Lanes 4-8: Total extracellular proteins (lO
ug) ofKM71/pPIC9K-CYB5 cell cultures at 0, 24, 48, 72 and 96 hours. Lane 10: Western blot B contains
b, in a crude microsomal extract as a positive control. Detection was carried out using polyclonal mouse
anti-sheep b, antibodies at 1:2000. Western blot C contains histidine tagged ureate oxidase as a positive
control. Detection was carried out using an INDIA HisProbe-HRP at 1:2000.
2.1.2.6 Expression of aromatase by P. pastoris GS115
Secretory expression of the full-length aromatase in the induction media (80 times
concentrated), analysed by SDS-PAOE and Western blot analyses, was detectable at 48,
72 and 96 hours as seen in Figure 2.8B, lanes 6, 7 and 8. Two protein bands
corresponding to molecular masses of 55 and 68 kDa are visible, however, the lower
molecular mass protein is also present in the control strain. Therefore the higher
molecular mass protein might be histidine tagged aromatase. OS115 strain transformed
with the parent vector pPIC9K without an insert was used as the negative control (Figure
2.8, lanes 1-2).
The OS115/pPIC9K-CYP19 transformants at different time course were lysed and the
intracellular fractions analysed by Western blot analyses. The lysed OS115 cells
contained a histidine tagged aromatase protein of an estimated molecular weight of 62
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kDa as shown in Figure 2.8D, lanes 5-8. The total protein concentration of the samples
loaded per well were kept equal and the histidine signal corresponding to a molecular
mass of approximately 64 kDa appeared at 72 and 96 hours as indicated by an arrow in
Figure 2.8D, lanes 7 and 8.
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Figure 2.8 SDS-PAGE (A) and Western blot (B) analyses of proteins from the induction media and
SDS-PAGE (C) and Western blot (D) analyses of proteins in the intracellular fraction of GS115 cells
transformed with pPIC9K-CYP19 expression vector. Lanes 1 and 2: Negative control containing total
proteins of GSI15/pPIC9K cell cultures at 72 and 96 h, respectively. Lanes 3 and 9: Low-molecular
weight Marker. Lanes 4-8: Total proteins (10 ug) ofGSl15/pPIC9K-CYP19 cell cultures at 0, 24, 48, 72
and 96 hours. Lane 10: Positive control containing histidine tagged ureate oxidase. The arrow indicates a
68 kDa and 64 kDa histidine tagged aromatase protein in the medium and intracellularly, respectively.
Detection was carried out using an INDIA RisProbe-HRP at 1:2000.
2.1.2.7 Expression of aromatase by P. pastoris KM71
Secretory expression of the full-length aromatase in the induction media ,(30 times
concentrated), analysed by SDS-PAGE and Western blot analyses, was not detectable
(Figure 2.9B, lanes 4-8).
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Figure 2.9 SDS-PAGE (A) and Western blot (B) analyses of proteins from the induction media of
KM71 cells transformed with pPIC9K-CYP19 expression vector. Lanes 1 and 2: Negative control
containing total extracellular proteins ofKM71/pPIC9K cell cultures at 72 and 96 h, respectively. Lanes 3
and 9: Low-molecular weight Marker. Lanes 4-8: Total extracellular proteins (lO ug) of KM7l/pPIC9K-
CYP19 cell cultures at 0,24,48, 72 and 96 hours. Lane 10: Positive control containing histidine tagged
ureate oxidase. Detection was carried out using an INDIA HisProbe-HRP at 1:2000.
2.1.2.8 Control strains
The OS 115/His + MutSAlbumin strain was a control for expression and secretion and the
molecular mass of the protein was 67 kDa as shown in Figure 2.10.
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Figure 2.10 SDS-PAGE (A) and Western blot (B) analyses of albumin proteins from the induction
media of P. pastorls GSllSlHis+ Mut" albumin cell culture. Lanes 1 and 2: Negative controls of P.
pas/oris with only the pPIC9K plasmid. Lanes 3 and 9: Rainbow Markers. Lanes 4-8: Expressed albumin
at 6, 24, 48, 72 and 96 hours, respectively. Total extracellular proteins (lO ug) of GS1151His+Mut'
albumin cell culture at 0, 24, 48, 72 and 96 hours. Lane 10: Positive control containing histidine tagged
ureate oxidase.
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CHAPTER 3: DISCUSSION
In cytochrome P450 research, the use of heterologous expression systems for the
expression of cDNA encoding specific cytochromes P450 has given researchers a tool to
obtain and study various, less abundant cytochromes P450. Especially human
cytochromes P450, which are extremely labile and occur in low concentrations in
tissues, can only be studied when heterologously expressed. Many benefits arise from
using heterologous expression systems which include - (i) determination of
cytochrome P450 enzymatic activities in an environment which has a low cytochrome
P450 background; (ii) determination of structure/function relationships associated with
cytochromes P450 by site-directed mutagenesis and (iii) evaluation of xenobiotics on the
effect of expressed cytochromes. The most important aspect of heterologous expression
for this project was, however, the preparation of sufficient pure P450 proteins for
polyclonal and monoclonal antibody production and ultimately possible crystallisation.
Several different heterologous expression systems have been used to express P450
enzymes, including E. coli (60, 61, 62, 63, 64), S. cerevisiae (65), baculoviral cells (66),
vaccinia virus (67), COS cells (68, 69, 70, 71), mammalian cells (72) and recently non-
conventional yeast such as P. pastoris (73, 74, 75). Although most of these systems
yielded sufficient P450 enzymes, in microsomal fractions for investigative purposes,
only a few were successful in producing P450 enzymes on a relatively large-scale.
To date, all heterologously expressed P450 proteins were cytoplasmically expressed.
Intracellular expression systems have the following disadvantages. Firstly, in order to
achieve high-level cytochrome P450 expression, strong promoters (i.e. T7) need to be
used which result in either no expression or the appearance of P450 protein in E. coli
inclusion bodies. Secondly, it was found that the amino terminal of several cytochrome
P450 enzymes needed to be modified to prevent the possibility of secondary structure
formation, thereby inhibiting the initiation of translation. Thirdly, to gain access to the
intracellular expressed cytochrome P450, it is necessary to disrupt the cell wall either
mechanically or enzymatically, which is a tedious and timeconsuming method. Often
strong denaturants are used and the yield of microsomal proteins is not very good. The
expressed P450 proteins located in the mierosomes need to be solubilised using strong
surfactants, which could remove the heme from the protein.
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In this study we used an extracellular expression system, to secrete human P45017a, b,
and aromatase into the media, where it would be readily available for purification and
characterisation. The cDNA of these microsomal enzymes were cloned in frame with the
secretion signal open reading frame, which is a a-factor prepro peptide from S.
cerevisiae. A nickel chelated probe was used for all the Western blot analyses, which not
exclusively detects histidine tagged proteins but can also identify histidine rich proteins
and metalloenzymes. Therefore the Western blot results were regarded as preliminary
results and further characterisation of expressed proteins need to be investigated. Protein
fractions from yeast cells transformed with the parent vector (indicating any background
proteins) however, did not produce the same target proteins as seen from the
recombinant P450 expressing cells.
SDS-PAGE and Western blot analyses of the concentrated cell culture medium of
GS115 cells expressing the full-length P45017a enzyme only showed a faint band
corresponding to a molecular mass of 68 kDa at 96 hours. However, the yeast cells did
produce a histidine tagged P45017a protein, which was detected in the cytoplasmic
fraction of the cells. Two distinct protein bands of 55 and 62 kDa were detected and the
concentration, according to the intensity of the chemiluminescent signal, gradually
decreased from 24 to 96 hours. It is most likely that the higher molecular mass protein is
the uncleaved P45017a protein, which is linked to the a-factor secretion signal and the
smaller molecular mass protein is the correctly processed and folded P45017a protein in
the secretory pathway. The reason for the low extracellular expression of P45017a may
be because the correctly translated protein is retained in the ER of the yeast cell. All
microsomal cytochromes P450, including P45017a, are membrane bound proteins,
which means they have a hydrophobic domain, i.e. the signal anchor sequence (SAS). It
is believed that, by deleting the SAS from the amino terminal of microsomal
cytochromes P450, a soluble form of P450 enzyme might be produced which could be
secreted into the media unhindered by any membranes. We therefore truncated the
human P450 17a by deleting the first 18 hydrophobic amino acids and inserting the gene
in reading frame to the secretory signal sequence MFa-factor. Removal of the putative
SAS from the P45017a did, to a certain degree, prevent the integration of the modified
protein into the P. pastoris membranes, as a stronger signal (68 kDa) in the concentrated
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medium of the 96 hour fraction was observed. However the 55 kDa protein observed
was not the P45017a protein since the same sized background protein was seen in the
medium of the control strain.
The extracellular expression has therefore not proven to be very successful. Although
the SAS of P45017a has been deleted, it is likely that other hydrophobic domains could
still ensure binding to the yeasts membranes. Indeed, this had been seen with other
truncated cytochromes P450 (76, 77). Pernecky and Coon have shown with P450 2El
that there must be an additional membrane targeting domain beyond the first two
hydrophobic regions, called SI and S2, since the expressed protein was still found in the
membrane fraction although the residues 3-48 were deleted (46). Clark and Waterman et
al. have used the COS 1 heterologous expression system to model the targeting and
insertion of bovine P45017a into the ER membrane in vivo and shown that deletion of
the signal anchor domain did not abolish membrane association of the truncated
P45017a, but resulted in a 5 fold reduction in insertion into the membrane (78).
Expression levels of cytochrome P45017a in KM71 (Mue) strains was not observed.
Muf phenotype affects both the growth rate during induction and the accumulation of
large amounts of endogenous alcohol oxidase. MutS strains may yield a higher
proportion of correctly folded product in situations where folding is rate-limiting (79).
The secretion of human b, by P. pastoris was not observed. Neither in the medium nor
in the cytoplasmic fraction of the yeast did we detect any histidine tagged bs, which
should have shown a protein band around 16 kDa. It has been observed that b, can
aggregate into a dimer (32 kDa) or tetramere (64 kDa) (59), but no protein of identical
molecular mass were detected. It could be possible that the histidine tag has either been
digested by proteases or the access of the nickel-chelated probe to the histidine residues
were obstructed by the folding of the protein. Polyclonal mouse anti-sheep b, antibodies
were subsequently used but these antibodies also failed to detect any expressed bs.
Western blot analysis of the cell culture medium of P. pastoris cells, expressing
aromatase, indicated a protein with a molecular mass corresponding to 68 kDa after 72
and 96 hour induction phases. In the cytoplasmic fraction of these cells the aromatase
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protein was seen in the 72 and 96 hour fractions, however, the molecular mass of the
protein was 64 kDa. Although the expected molecular mass of aromatase would be
around 58 kDa, the protein might be glycosylated or the a-factor secretion peptide was
not successfully cleaved by proteolytic enzymes, which would explain the presence of a
slightly larger molecular mass protein. The possibility that aromatase was glycosylated
exist as aromatase has two potential glycosylation sites (Asn-12 and Asn-180) and
Shimozawa et al. showed that the Asn-12 in the amino-terminal portion of aromatase is
the site of glycosylation (54). Gartner et al. found a glycosylated aromatase expressed in
baculoviral cells and has determined that the molecular weight of glycosylated
aromatase was about 59 kDa compared to the 57.7 kDa unglycosylated aromatase (80).
Interestingly, the first 20 amino acids of the aromatase sequence has been identified as
an N-linked glycosylation consensus sequence with asparagine at position 12 of the
glycosylation site while aromatase of human placenta has been shown to have attached
sugar residues (81, 54, 82, 83). It is believed that the first 20 amino acid sequence with
the sugar residues is protruding into the luminal space of the endoplasmic reticulum
membrane with the hydrophobic region (residue 20 to 40) acting as the membrane
spanning domain (80).
Several antibodies directed against aromatase have been prepared from purified human
placental aromatase (20, 84). Polyclonal and monoclonal antibodies raised against a
synthesised peptide, which is highly conserved within the sequence of aromatase, was
also shown (85,86).
From the data presented here it seems that it would be very interesting to show activity
ofP45017a and aromatase in living cells. We have only screened the different clones for
expressed proteins outside and inside the cells and have shown for P45017a and
aromatase that they are produced and located intracellularly. By showing exactly where
the proteins are located along the secretory pathway, i.e. ER, Golgi, secretory vesicle,
periplasm or cell wall, we would be able to make better assumptions on the lack of
cytochrome P450 export into the media. Tagging the expressed proteins with green
fluorescent protein (GFP) could assist with the detection, although the additional size of
the GFP protein could hamper the secretory process.
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Based on this research, we can conclude that the full-length proteins, with their
hydrophobic membrane domains intact, will not be readily secreted into the media. By
deleting certain regions of the original cDNA, the protein can become more soluble and
might then be secreted into the media. The process of optimising the extracellular
secretion of P450-dependent enzymes will be extremely time consuming and it was
decided to investigate the intracellular expression of the unmodified cytochromes P450
in P. pastoris instead.
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INTRODUCTION
In the previous section, extracellular expression of a full-length human P45017a in P.
pastoris produced insufficient amounts ofP45017a proteins. Many factors, which could
have contributed to the failure of secreting expressed proteins were previously discussed.
There was, however, a possibility that P45017a would be expressed intracellulary in P.
pastoris. Therefore, in this section we cloned and expressed the full-length human
CYP17 cDNA into an intracellular, pPIC3.5K, expression vector.
We overexpressed of functional human P45017a in P. pastoris. The recombinant yeast
strains were capable of converting progesterone to 17a-hydroxyprogesterone and 16a-
hydroxyprogesterone. Different detergents and cell lysis methods were used to isolate
the yeast mierosomes and the P450 content in detergent-solubilised clear lysate and
yeast mierosomes was determined by reduced-carbon monoxide and substrate induced
spectra. The intact hemeprotein with six histidine residues incorporated to the carboxyl
terminus was purified by a two-step purification procedure to electrophoretic
homogeneity.
This is the first expression of a human P450-dependent enzyme in P. pastoris. In
addition, it is the first report of the overexpression of any P45017a with an unmodified
amino terminal.
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CHAPTER 1: CONSTRUCTION OF THE FULL-LENGTH
HUMAN CYP17 INTO pPIC3.5K EXPRESSION
VECTOR AND INTEGRATION IN P. PASTORIS
1.1 Materials and Methods
1.1.1 Subeloning of the CYP17 eDNA
All DNA manipulations were carried out using standard procedures (1). The full-length
human CYPI7, located in the pPIC9K-CYPI7 vector, was used as the DNA template to
amplify a CYP17 as depicted in Figure 1.1. The upstream primer P105 (5'-
ATGCGAATTCATGTGGGAGCTCGTG-3') and the downstream primer P106 (5'-
GTACGCGGCCGCGAATTCITAGTGATGGTGAT-3') were used. The PI05 and
PI06 primers each introduced an EcoRI site (underlined). PI05 introduced a stop codon
(italics) after the nucleotide bases encoding six histidine residues.
PeR pnIducI (1879 bpI ....,
I
Figure 1.1 Schematic representation of the cloning strategy for the human CVPl7 from the
pPIC9K-CYPI7 recombinant vector. The downstream primer PI06 was homologous to the last four
histidine sequences and the stop codon. Both primers had an EcoRI site for subeloning into the pUC18
vector.
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Each PCR amplification mixture (100 JlI) contained pPIC9K-CYP17 vector DNA (750
ng) and the reaction was carried out as described in Part III section 1.1.1.2. The
amplified DNA fragment was electrophoresed on an 0.8% low melting agarose gel,
extracted and purified as described in Part III section 1.1.1.2.
The CYP17 PCR product was digested with EcoRi and cloned into the pUC18 vector
linearised with EcoRI, depicted in Figure 1.2. Two separate digestions, one containing
amplified CYP17 DNA (2 Jlg) and the other containing pUC18 DNA (2 ug) were carried
out as described in Part III section 1.1.1.2.2. The digested CYP 17 fragment and
linearised vector were electrophoresed on an 0.8% low-melting agarose gel in TAE
buffer (40 mM) and purified as described in Part III section 1.1.1.2.2.
pUC18
2686 bp
!
pUC1S-CVP17
4243bp
Figure 1.2 Scbematic representation of tbe subcloning of the CVP17 into pUC18 vector.
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The linearised pUC18 vector (3.66 ug) was dephosphorylated with CIAP(0.042 U) as
described in Part III section 1.1.1.2.3. The purified digested CYP17 fragment (112 ng)
and pUC18 (200 ng) DNA were subsequently ligated as described in Part III section
1.1.1.2.4. Competent JMl09 cells were transformed with the ligated vectors. In addition
to ampicillin selection, the vector contained the lacZ gene which allowed for blue/white
colony selection.
Positive colonies were subsequently incubated overnight in LB medium (5 ml) at 37°C
and the plasmid DNA was isolated using the Wizard™ Plus Minipreps DNA Purification
System as described in Part III section 1.1.1.2.5. The purified recombinant plasmid DNA
was digested with XbaI and analysed by agarose gel electrophoresis. Plasmids
containing the correct insert were subsequently prepared by a modified alkaline/SDS
lysis method using a Nucleobond" AXlOO plasmid isolation kit as described in Part III
section 1.1.1.2.5. The purified isolated plasmids were analysed by DNA sequencing and
subsequently used in the construction of the pPIC3.5K-CYP17 expression vector.
1.1.2 Construction of the pPIC3.5K-CYP17 expression vector
The pUC18-CYP17 construct (4243 bp), was digested with EcoRI and the CYP17 was
ligated into pPIC3.5K vector, linearised with EcoRI as depicted in Figure 1.3.
Restriction digestions ofpUC18-CYP17 (2 ug) and pPIC3.5K vector DNA (2 ug) were
carried at 37°C for 2 hours each in a final volume of 30 ul containing 5 ul restriction
buffer B (supplied), acetylated BSA (5 ug) and EcoRI (10 U). The digested CYP17
fragment and linearised vector were electrophoresed on an 0.8% low-melting agarose
gel, extracted and purified from the agarose as described in Part III section 1.1.1.2.2.
The linearised pPIC3.5K DNA (3.66 J.tg)was dephosphorylated with ClAP (0.012 U)
and purified as described in Part III section 1.1.1.2.3. The purified digested CYP17 (35
ng) and pPIC9K DNA (200 ng) were subsequently ligated as described in Part III section
1.1.1.2.4. Competent JMl09 cells were transformed with the ligated vectors and
transformants were selected on LB-agar plates with ampicillin as described in Part III
section 1.1.1.4.1. Positive colonies were subsequently incubated overnight in LB
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EcoRI
5'..0 AAnc
EcoRI
o AATTC-3'
pPIC3.5K
9004bp
Figure 1.3 Schematic representation of the cloning strategy for the construction of the pPIC3.5K-
CYP17 expression vector. The cloned CVP 17 in the pUC 18 vector was digested with EcoRJ and inserted
into the pPIC3.5K expression vector at the EcoRI site. The CYP17 was cloned in reading frame of the (1-
factor secretion signal and contains a nucleotide sequence encoding the six histidine tag,
medium (5 ml) at 37°C and the plasmid DNA was isolated as described in Part III
section 1.1.1.2.5. The purified recombinant plasmid DNA was digested with XbaI and
analysed by agarose gel electrophoresis. Plasmids containing the correct insert were
subsequently prepared by a modified alkaline/SDS lysis method using a Nucleobond"
AXlOO plasmid isolation kit as described in Part III section 1.1.1.2.5.
The purified recombinant pPIC3.5K-CYP17 vector was confirmed by restriction digest
analyses and DNA sequence analyses as described in Part III section 1.1.1.4.3. Primers
5'AOXIP and 3'AOXIP were used as illustrated in Figure 1.4.
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Figure 1.4 Schematic representation of the DNA sequencing strategy for the full-length human
CYP17 in the pPIC3.5K-CYP17 expression vector.
1.1.3 Screening of GS115/pPIC9K-CYP17 and KM71/pPIC9K-CYP17
transformants for integration
The cloned expression vectors, pPIC3.5K-CYPI7 (10 ug) and the parent vector
pPIC3.5K (10 )lg), were linearised with Sail and transformed into competent P. pastoris
strains, OS115 Mut (Methanol ytilisation plus) and KM71 Mue (Methanol ytilisation
~low) using the spheroplast method as described in Part III section 1.1.1.5. The presence
of CYP17 cDNA integrated into the yeast chromosomes was subsequently confirmed by
PCR amplification analyses as described in Part III section 1.1.1.5.
1.2 Results
1.2.1 Subeloning of the CYP17 cDNA
The full-length human CYPI7, located in the pPIC9K-CYP17 expression vector was
used as the template to amplify a CYPI7, yielding a PCR product (1557 bp). This was
confirmed by 1.0% agarose gel electrophoresis (Figure l.S. This amplified product was
subsequently subeloned into an intermediate vector, pUC18, before cloning it into the
pPIC3.5K expression vector.
The integrity of the newly constructed pUC18-CYP17 vector was confirmed by
restriction digest analyses with XbaI followed by 1% agarose gel electrophoresis. The
pUC18-CYP17 plasmid (4243 bp) containing the insert yielded the expected two bands
corresponding to 2970 and 1273 bp as shown in Figure 1.6, lanes 5 and 6.
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Figure 1.5 PCR amplification analysis of the amplified CYPI7. The reaction products (lO ~I) were
analysed by 1% agarose gel electrophoresis. Lane 1: Negative control, PCR amplification without DNA
template. Lane 2: Amplified CYP17 (pCR product, 1557bp, using primers PI05 and PI06. Lane 3:DNA
marker, ADNAIEcoRIlHindIII.
2345878
Figure 1.6 Restriction digest analysis of pUC18 plasmids containing the CVPI7. Lanes 1,4 and 7:
DNA marker, ADNAIEcoRIlHindIll. Lanes 2 and 3: undigested plasmid DNA (0.5 ug), Lanes 5 and 6:
Xbal digest of plasmid DNA (0.5 ug) containing the CYP17 yielding 2970 and 1273 bp fragments. Lane
8: Positive control containingXbal digest ofpPIC9K-CYPI7 plasmid DNA (0.5 ug).
1.2.2 Construction of the pPIC3.5K-CYP17 expression vector
The EcoRI digested pUCI8-CYPI7 and pPIC3.5K plasmid DNA were electrophoresed
on an 0.8% low melting agarose gel and the CYP17 and linearised plasmid DNA were
excised and purified. Prior to ligation the cohesive compatible ends of the linearised
pPIC3.5K plasmid were dephosphorylated and the CYP17 successfully ligated.
Transformed bacterial colonies were grown in small-scale cultures. Plasmid DNA
isolated from each culture was digested with EcoRI and analysed by 1% agarose gel
electrophoresis. The cloned pPIC3 .5K-CYP 17 vector (10561 bp) yielded the correct
fragments of8508 and 2053 bp as shown in Figure 1.7, lanes 13 and 15.
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Figure 1.7 Restriction digest analysis of pPIC3.5K plasmids containing tbe CYPI7. Lanes 1 and 11:
DNA molecular weight marker VI (Roche). Lanes 6 and 16: DNA marker, A.DNAlHindIIl. Lanes 2 and
3: Xbal digest of plasmid DNA (0.5 ug) containing the CYP17 in the 3'-5' orientation. Lanes 4-5, 7-10,
12 and 14: Xbal digest of plasmid DNA (0.5 ug) without an insert. Lanes 13 and 15: Xbal digest of
plasmid DNA (O.Sug) containing the CYPl7 in the 5'-3' orientation yielding fragments 8508 and 2053 bp.
Lane 17: Positive control containing Sad digested pPIC9K plasmid DNA (0.5 ug),
DNA sequencing analyses, Appendix A.5, confirmed that the CYPI7 had been inserted
in reading frame for eukaryotic translation initiation and secretion.
1.2.3 Screening of GSl15/pPIC3.5K-CYP17 and KM711pPIC3.5K-CYP17
transformants for integration
PCR followed by 1% agarose gel electrophoretic analyses of lysed His+ transformants
showed that the CYP17 was integrated correctly, since two bands were produced. One
corresponded to the CYPI7 (1777 bp) and the other to AOX1 gene (2100 bp) as shown
in Figure 1.8, lane 3. A gene-specific primer STEl together with 5'-AOXIP primer
(Figure 1.8, lane 4) was also used to confirm the presence of CYPI7. Mut" integrants
with only the parent vector pPIC3.5K produced a 220 and 2100 bp PCR products as seen
in Figure 1.8, lane 5.
The same PCR analyses were carried out on KM7l integrants. Two bands were
produced. One corresponded to the CYP17 (1777 bp) and the other to the AOX1 gene
(4500 bp) as shown in Figure 1.9, lane 3.
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Figure 1.8 Direct PCR screening of GS1l5/pIC3.5K-CYP17 clones. Lane 1: Amplification of the wild-
type AOXI gene (2100 bp) using AOXIP primers. Lanes 2 and 6: DNA molecular weight marker Vl.
Lanes 3 and 4: Contains a clone carrying both the AOX1 gene (2100 bp) and CVP 17 insert cloned into the
pPIC3.5K plasmid resulting in a 1777 bp PCR product. In lane 3 AOXI P primers were used and in lane 4
insert-specific primer STEl and the 3'AOXIP primer were used resulting in a 1674 bp PCR product.
Lane 5: Contains a clone with the AOXI gene (2100 bp) carrying the pPlC3.5K vector without insert (220
bp). AOXIP primers were used. Lane 7: Positive PCR control containing CYPl7 fragment (1674 bp)
amplified from pPIC9K-CYPI7 plasmid using AOXIP primers. Lane 8: Negative control, PCR
amplification without DNA template. Each lane contained 20 J.l1reaction mixture.
Figure 1.9 Direct PCR screening of KM711pIC3.SK-C¥P17 clones. The reaction products (20 ul) were
analysed by 1% agarose gel electrophoresis. Lane 1: Amplification of the wild-type AOXI gene (4500 bp)
using AOXIP primers. Lane 2: DNA marker, A.DNAlEcoRl/HindlII. Lanes 3 and 4: Contains a clone
carrying both the AOXI gene (4500 bp) and the CYP15 (1777 bp). In lane 3 AOXIP primers were used
and in lane 4 a gene specific primer STEl and the 3'AOXIP primer were used resulting in a 1674 bp
fragment. Lane 5: Contains a clone carrying the parent pPIC3.5K vector without insert (220 bp). AOXIP
primers were used. Lane 6: DNA molecular weight marker VI. Lane 7: Positive PCR control containing
CYPl7 fragment (1674 bp) amplified from pPIC9K-CYPI7 plasmid using AOXIP primers. Lane 8:
Negative control, PCR amplification without DNA template.
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CHAPTER 2: CULTURE OF P. PASTORIS EXPRESSING
P45017a AND SUCCESSFUL EXPRESSION OF THE
PROTEIN
2.1 Materials and Methods
2.1.1 Expression ofP45017a in P. pastoris by batch cultivation
Clones that had been verified by direct PCR were tested for the expression of the desired
protein. Single colonies of P. pastoris strains (GSl15 and KM71) transformed with
pPIC3.5K-CYP17 expression vectors were grown in BMGY (25 ml) to an optical
density of 600 nm (ODi;oo) between 2 and 6 at 275 rpm for 20 hours at 30°C in an Innova
4000 shaking incubator (New Brunswick). Yeast cells were harvested by centrifugation
at 2500 x g for 5 min at room temperature and resuspended to approximately OD600= 1
in BMMY induction media (200 ml). Methanol-induced cultures were grown at 30°C
with shaking at 275 rpm. Methanol (0.5% v/v final concentration) was added every 24 h
and the induction was carried out up to 96 hours. To determine the optimal time for
expression, aliquots (30 ml) of the culture media were removed at various time intervals
i.e. 0, 24, 48, 72 and 96 hours. The expression culture was centrifuged at 2000 x g for 15
min at room temperature, the cell pellet was snap frozen in liquid nitrogen and stored at
-80°C. These cells were tested for the presence of intracellu1arly expressed proteins by
SDS-PAGE (Coomassie staining) and immunoblot analyses.
2.1.2 Expression ofP45017a in P. pastoris by large-scale batch cultivation
GS115 cells from a freezer stock were inoculated in BMGY (25 ml), grown for 6 hours
and added to BMGY media (200 ml), which was further incubated for 18 hours at 30°C
at 250 rpm. Yeast cultures were centrifuged at 2000 x g for 5 min at room temperature
and resuspended to an OD600 of between 0.6 and 1 in 4 times BMMY (250 ml).
Methanol-induced cultures were grown at 30°C in a shaking incubator at 250 rpm.
Methanol (0.5% (v/v) final concentration) was added to after every 24 h and the
induction was carried out for up to 72 hours. The cells were harvested by centrifugation
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at 2000 x g for 15 min at room temperature, weighed and resuspended in breaking buffer
(BB). The cells were stored at -80°C until used for the preparation of micro somes.
2.1.3 P45017a activity assay in yeast cells
The metabolism of radio labeled steroids was investigated in 48 h induced living yeast
cells (OD600 =10, which is 5 x 107 cells/ml) in a shaking incubator at 30°C in a total
volume of 2 ml. For each reaction, the cell suspension (4 ml) was harvested by
centrifugation at 2000 x g for 5 min at room temperature, washed with phosphate
buffered saline and resuspended in fresh BMMY induction media (1 ml). After a 15 min
pre-incubation period at 30°C in an Erlenmeyer flask (25 ml), the reaction was initiated
by adding an equal volume of BMMY medium supplemented with the appropriate
tritium-labelled progesterone (600.000 cpm). The steroids present in the reaction media
were extracted with methylene chloride (100:1 solvent to incubation mixture). The water
phase was aspirated off and the methylene chloride was evaporated under a stream of
nitrogen gas. The dried steroids were redissolved in methanol and analysed by HPLC
(Waters, Milford,MA) equipped with in-line UV and radioactive (Radiomatic.Tampa,
CA) detectors. Steroid metabolism was quantified by radioactivity.
2.1.4 Monitoring intracellular expression of P450 17a
A rapid procedure was used to obtain a crude membrane fraction from cells grown by
batch cultivation as described in section 2.1.1), to monitor specific P450 enzyme
expression. Cell pellets, stored at -80°C, were thawed on ice and resuspended in BB (1
ml). All further steps were carried out at 4°C. The suspension was transferred to a 2 ml
micro centrifuge tube and centrifuged at 3000 x g for 7 min at 4°C. The washed cells
were resuspended in BB (0.5 ml) (OD600 of 100-125) and an equal amount of acid
washed glass beads (Sigma G-9268, 425-600 urn) were added. The mixture was
vortexed vigorously 10times for 30 s each, with 30 s on ice between each vortexing.
The supernatant was spun at 12000 x g for 10 min at 4°C to remove the glass beads and
cell debris. The clear lysate (200-250 JlI) was pipetted off carefully and stored at -20°C
until analysed with SDS-PAGE and Western blot analyses.
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2.1.5 SDS-PAGE and Western blot analyses
SDS-PAGE was carried out according to the method of Laemmli (2) usmg an
acrylamide concentration of 10% (v/v). Low Range molecular weight markers (Biorad)
and Rainbow coloured protein molecular weight markers (Amersham Pharmacia)
consisting of myosin (220 kDa), phosphorylase b (97.4 kDa), bovine serum albumin
(66.2 kDa), ovalbumin (45 kDa), carbonic anhydrase (30 kDa), trypsin inhibitor (21
kDa) and lysozyme (14.4 kDa). Wide range ColorBurst® Electrophoresis Markers
(Sigma) were used alternatively to the Rainbow Markers, which have a 60 kDa protein
marker instead of 66 kDa. Proteins were stained with Coomassie brilliant blue.
Electroblotting was carried out in a wet blotting system. Proteins were transferred onto a
nitrocellulose membrane (Schleicher&Schuel) and the antigen-probe complex, which is
a nickel (Ni2+) activated horseradish-peroxidase (INDIA TM HisProbe-HRP, Pierce,
Rockford, USA) was visualised by chemiluminescence (SuperSignal West HisProbe Kit,
Pierce, Rockford. IL). The probe was diluted 1:5000 in TBST buffer. A six histidine
tagged ureate oxidase (Pierce, Rockford, IL) was used as a positive control.
2.1.6 Other Methods
Protein concentrations were determined by the bicinchoninic acid method, BCA (Pierce
Chemicals Co.) with bovine serum albumin as standard. Samples that contained f3-
mercaptoethanol interfered with the assay and had to be dialysed against MQ water to
remove f3-ME, before using the BCA assay.
Fractions collected after Ni2+-NTA chromatography were concentrated and desalted with
Ultrafree-15 Centrifugal filter devices (Millipore), according to the manufacturer's
instructions. Samples with low concentrations of protein were concentrated with
Ultrafree-CL centrifugal filter devices (Millipore) for optimal protein recovery.
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2.2 Results
2.2.1 Growth of P. pastoris strains
aS115 transformants (Mut) were grown in BMay media for 18 hours. They were
harvested and resuspended in expression media (BMMY) at - OD600 of 1 and grown for
four days supplementing with methanol every 24 hours. The cell density of cultures
during the induction phase seems to increase linearly up to 48 hours after which it
decreased into stationary phase as shown in Figure 2.1. The growth of the transformants
was similar to the growth of the control strain as 115/~-aal (Mut+). The Control strain
as lIS/Albumin (Mut") had a lower initial growth rate, as expected, but after 48 hours
the rate did not decrease as much as the wild-type methanol utilising strains (Mutl
therefore reaching similar cell densities as the fast growing strains.
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Figure 2.1 Growtb curve of GS1l5 transformants during induction phase. Growth of the strains was
monitored by optical density at 600 nm after the addition of methanol (0.5%, v/v fmal concentration). The
medium was supplemented with methanol at 24 hour intervals. GS 115/j3-Gal is a Mut" control strain and
WT is the wild-type GSl15 strain.
KM71 transformants (MutS) were grown and induced the same way as the as 115
strains. The cultures grew in a linear fashion up to 48 hours, but then abruptly reached
stationary phase as shown Figure 2.2.
expression experiments.
It was therefore decided that the as 115 transformants would be used for further
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Figure 2.2 Growth curve of KM71 transformants during the induction phase. Growth of strains was
monitored by OD600 after the addition of methanol (0.5%, v/v final concentration). The medium was
supplemented with methanol at 24 hour intervals. GS 115/Albumin is a Muf control strain.
2.2.2 Substrate conversion ofP45017a expressing cells
P45017a was functionally expressed in P. pastoris as evidenced by the ability of
recombinant yeast cells to convert progesterone to 17a-hydroxyprogesterone and 16a-
hydroxyprogesterone as seen in Figure 2.3. At 4 min ~ 55% of the progesterone had
been metabolised, yielding ~ 35% 17a-hydroxyprogesterone and ~ 20% 16a-
hydroxyprogesterone.
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Figure 2.3 In vivo progesterone metabolism by yeast GS115 expressing human P45017a. Yeast cells,
GS115, were transformed with pPIC3.5K expression plasmid containing the human CYP17 cDNA
(pPIC3.5K-CYPI7) or no cDNA insert (pPIC3.5K). 10 11Mof 3H-Iabeled progesterone was added to the
cultures (1 x 109 cells/ ml). Aliquots of the culture were removed at certain time intervals, steroids
extracted from the media and analysed by HPLC. e, progesterone; ., l7a-hydroxyprogesterone; D, 16a-
hydroxyprogesterone. x, progesterone metabolised by GS115 cells transformed with pPIC3.5K expression
plasmid containing no cDNA insert.
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From 4 to 6 min the metabolism of progesterone gradually decreased and reached a
stationary level of ::::::65% progesterone metabolised. After 6 min the hydroxylated
steroids also reached a maximum yield of' e 45% for 17a-hydroxyprogesterone and ::::::
20% for 16a-hydroxyprogesterone. The metabolites were measured for up to 2 hours
and remained at the same levels. The assay was repeated several times resulting in
similar substrate conversion rates. No conversion of progesterone was detectable using
P. pastoris cells transformed with the pPIC3.5K vector containing no insert.
2.2.3 Expression ofP45017a by P. pastoris GSl15
The effect of duration of methanol induction (1-4 days) on the expression of the human
P45017a is illustrated in Figure 2.4. Western blot analysis of the rapid membrane
preparation of GS 115 transformants, grown by batch cultivation (described in section
2.1.1), indicate the expression of P450 17a from 24 to 96 h. Each lane contained the
lysate of an equal number of cells (OD600 =1= 5 x 107) indicating a slight increase in
P45017a expression per day was observed, although a protein band at a molecular mass
corresponding to 40 kDa appears at 72 h and increases over time. This might be the
result of the degradation ofP45017a.
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Figure 2.4 SDS-PAGE (A) and Western blot (B) analyses of total intracellular yeast proteins of
GS115 cells induced to express P45017a for four days. Lanes 1 and 2: GS115 cells transformed with
pPIC3.5K vector at 0 and 96 h, respectively. Lanes 3 and 9: Low-molecular weight Marker. Lanes 4-8:
08115 cells transformed with pPIC3.5-CYPI7 vector at 0,24,48,72 and 96 hours. Each lane contained
20 ug total proteins. P45017a (58 kDa) is indicated by the arrow. Detection was carried out using an
INDIAHisProbe-HRP at 1:5000.
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CHAPTER3: DEVELOPMENT AND EVALUATION OF
METHODS FOR THE PREPARATION OF
MICRO SOMES FROM P. PASTORIS
EXPRESSING HUMAN P45017a
3.1 Materials and Methods
Two different methods (section 3.1.1 and section 3.1.2) were used to isolate P45017a
from P. pastoris. The first method was to prepare mierosomes (with or without Emulgen
913) from P. pastoris and to extract P45017a from the prepared micro somes with or
without sonication in the presence of different detergents. The second method was to
omit the preparation of the microsomes, but to directly extract the P45017a from the
crude intracellular extract.
3.1.1 Isolation ofP45017a from mierosomes
3.1.1.1 Preparation of yeast mierosomes and isolation of P45017a with sonication
in Emulgen 913
All steps were carried out at 4°C. A 72 h cell pellet (5 ml, 2 g wet weight), stored at
-20°C, was thawed on ice and resuspended in buffer A (2 ml)(50 mM KPi, pH 7.6, 20%
glycerol and 1 mM PMSF). An equal volume of acid washed glass beads (Sigma G-
9268, 425-600 um) was added. The cells were broken by vortexing (12 x 30 s) at 4°C
with intermediate cooling on ice. The lysate was centrifuged at 12.000 x g for 10 min at
4°C to remove the cell debris and glass beads and the resulting supernatant (crude cell
extract) was centrifuged at 165.000 x g for 1 h at 4°C to recover a microsomal pellet.
The soluble fraction (crude lysate), was separated from the pellet and kept for SDS-
PAGE analysis. The insoluble microsomal pellet was resuspended in buffer A (2 ml)
with Emulgen 913 (1% v/v) and homogenised with a teflon rod. The lysate was
sonicated (8 x 30 s on with 30s intervals) on ice and centrifuged at 200.000 x g for 1 hat
4°C to sediment the microsomes. The solubilised microsomal proteins and insoluble
microsomal membranes, which were resuspended in buffer A with Emulgen 913 (1%
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v/v), were stored at -80oe and used for SDS-PAGE and Western blot analyses. The
same protocol was used for the preparation of micro somes from the wild type and
control strains.
3.1.1.2 Preparation of mierosomes in detergent and subsequent isolation of
P45017a. with Emulgen 913 or Triton X-I00
All steps were carried out at 4°e. A 72 h cell pellet (5 ml, 2 g wet weight), stored at
-20oe was thawed on ice and resuspended in buffer A (5 ml). The washed cells were
harvested at 3000 x g for 10 min and resuspended in cell lysis buffer (50 mM sodium
phosphate, pH 7.6, 20% glycerol, 1% v/v Emulgen 913 and 1 mM PMSF). An equal
volume of acid washed glass beads (Sigma G-9268, 425-600 um) was added. The cells
were broken by vortexing (8 x 1 min with 1 min intervals) and sonication (8 x 30 s with
30 s intervals). The lysate was centrifuged at 12000 x g for 15 min at 4°e to remove the
cell debris and glass beads and the resulting supernatant (crude cell extract) was
centrifuged at 165.000 x g for 1 h at 4°e to recover a microsomal pellet. The soluble
fraction (crude lysate), was separated from the pellet and kept for SDS-PAGE analysis.
The insoluble microsomal pellet was resuspended in buffer A, homogenised in a Teflon
homogeniser and divided into two equal volumes. Emulgen 913 (1% v/v) was added to
one microsomal aliquot and Triton-XlOO (1% v/v) was added to the other. The two
suspensions were stirred at 4oe for 2 hours and then centrifuged at 165000 x g for 1
hour at 4°e. The solubilised microsomal proteins were stored at -80oe and used for
SDS-PAGE and Western blot analyses.
3.1.2 Direct solubilisation ofP45017a from P. pastoris
3.1.2.1 Lysis of P. pastoris and solubilisation of P45017a. by in Emulgen 913
All steps were carried out at 4°e. A 72 h cell pellet (20 ml, 0.5 g wet weight/ml), stored
at -80oe was thawed on ice and resuspended in buffer A (10 ml). The cells were
harvested by centrifugation at 2500 x g for 10 min at 4°e and resuspended in cell lysis
buffer (8 ml). An equal volume of acid washed glass beads (Sigma G-9268, 425-600
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urn) was added. The cells were broken by vortexing (8 x 1 min with 3 min intervals).
The mixture was stirred for 20 min to ensure proper breakage of cells. The lysate was
centrifuged at 12.000 x g for 15 min at 4°C to remove the cell debris and glass beads and
the resulting supernatant (crude cell extract) was centrifuged at 165000 x g for 1 h at
4°C to separate solubilised proteins and insoluble microsomal membranes. These
preparations were stored at -80°C and used for SDS-PAGE and Western blot analyses.
3.1.2.2 Lysis of P. pastorls in ~-mercaptoethanol (~-ME) and solubilisation of
P45017a. by Emulgen 913
All steps were carried out at 4°C. A 72 h cell pellet (10 ml, 0.5 g wet weight/ml),
previously stored at -80°C, was thawed on ice and resuspended in buffer A (1 ml per 0.5
g cells wet weight). The washed cells were harvested by centrifugation at 2000 x g for
10 min at 4°C and resuspended in cell lysis buffer (1 ml per 0.5 g cells wet weight)
containing 1 mM EDTA and 10 mM ~-ME. An equal volume of acid washed glass
beads (Sigma G-9268, 425-600 um) was added. The cells were broken by vortexing
eight times for 1 min, with chilling on ice for 1 min between vortexing. The cell debris,
nuclei, mitochondria and glass beads were removed by centrifugation at 14000 x g for
30 min at 4°C. Emulgen 913 (1% v/v) was added to the crude cell extract and the
mixture was stirred for 4 hours at 4°C to ensure proper solubilisation of P45017a. The
crude cell extract was centrifuged at 165000 x g for 1 h at 4°C to separate the solubilised
P45017a from the insoluble microsomal pellet. These preparations were stored at -80°C
and used for SDS-PAGE, Western blot and carbon monoxide (CO) difference spectra
analyses.
3.1.3 Reduced versus oxidised carbon monoxide induced difference spectra
The cytochrome P450 concentration in the solubilised lysate and insoluble microsomal
pellet was determined spectrophotometrically as described by Omura and Sato (3). The
sample (1 ml) was diluted in phosphate buffer (1 ml)(O.I M, pH 7.0) and the mixture
was saturated with carbon monoxide by bubbling for 30 s on ice. The homogenate was
divided into two equal volumes in two optically matched cuvettes. After an incubation
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period of 3 min at 25°C a baseline was recorded between 500 and 400 nm in a dual-
beam Cary 100 spectrophotometer (Varian, USA). Sodium dithionite was added to the
sample cuvette and the contents mixed until the reduction of the cytochrome P450 was
complete. A difference spectrum was recorded between 500 and 400 nm and after
baseline correction the concentration of cytochrome P450 in the sample calculated using
the extinction coefficient of 91 mM-lcm-I for the difference in absorbance between 490
and 450 nm (3).
3.1.4 Substrate-induced difference spectra
Solubilised microsomal lysate (1 ml, 4.54 mg/ml), with a P450 enzyme concentration of
0.95 )lM, was diluted in phosphate buffer (1 ml) (0.1 M, pH 7.0). The suspension was
incubated for 5 min at 25°C, equally divided into two optically matched cuvettes and a
baseline was recorded between 450 and 350 nm. Progesterone or pregnenolone,
dissolved in ethanol, was added to the sample cuvette and an equal volume of ethanol to
the reference cuvette. The final concentration of both steroids was 10 )lM and the total
volume of the additions did not exceed 0.2% of the volume in the cuvette. The contents
of both cuvettes were mixed and a spectrum was recorded between 500 and 350 nm
3.2 Results
3.2.1 Preparation and solubilisation ofP45017a from yeast mierosomes
The fust attempt to isolate P45017CJ.from the yeast cells was to use mechanical breakage
of cells with glass beads (see Materials and Methods 3.1.1.1). The cell lysate was
subjected to differential centrifugation to separate the crude extract, containing soluble
proteins (supernatant) from the insoluble mierosomes (pellet). A small amount P45017CJ.
was solubilised in this step (Figure 3.1, lane 10), but the majority ofP45017CJ. was in the
microsomal fraction, indicating microsomal localisation of P450 17CJ.(Figure 3.1, lane 8).
Recombinant P45017CJ. was isolated from P. pastoris mierosomes by initial
solubilisation in Emulgen 913 (1% v/v) followed by sonication and ultracentrifugation to
recover solubilised P450 17CJ.(Figure 3.1, lane 7) from the insoluble microsomal
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membrane (Figure 3.1, lane 8). No P45017a could be solubilised from the microsomal
membrane in this manner. The yield of mierosomes was 2-3 mg per 1 g of wet weight
cells, which was too low for microsomal extractions from P. pastoris .
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Figure 3.1 SDS-PAGE (A) and Western blot (B) analyses of proteins isolated from P. pastoris
GS115/pPIC3.5K-CYP17 microsomes with Emulgen 913 and sonication. Lanes 1 and 2: solubilised
microsomal proteins and insoluble microsomal membranes from GSI15/3.5K cells, respectively. Lanes 3
and 9: Rainbow Marker. Lane 4: crude lysate (20 ug) from GSI15/3.5K cells. Lanes 5 and 6: solubilised
microsomal proteins and insoluble microsomal membranes from wild-type GS1l5 cells, respectively.
Lanes 7 and 8: solubilised microsomal proteins (8 ug) and insoluble microsomal membranes (8 !lg) from
GS1l5/3.5K-CYPI7 cells, respectively. Lane 10: crude lysate (20 ug) from GSI15/3.5K-CYPI7 cells.
P450 170. (58 kDa) is indicated by the arrow. Detection was carried out using an INDIA HisProbe-HRP at
1:5000.
The yeast cells were subsequently lysed by vortexing with glass beads in the presence of
Emulgen 913 (1% v/v) (see Materials and Methods 3.1.1.2) followed by sonication. The
idea was that vortexing would mechanically disrupt the cell wall of the yeast and the
detergent would stabilise P45017a in the crude lysate and prevent the hydrophobic
protein to interact with the microsomal membrane. Recombinant P45017a was isolated
subsequently from P. pastoris mierosomes by initial solubilisation in Emulgen 913 (1%
v/v) and ultracentrifugation to recover solubilised P45017a (Figure 3.2, lane 6) from the
insoluble microsomal membrane (Figure 3.2,lane 7). Soluble and insoluble microsomal
fractions were also isolated from slow growing yeast KM7113.5K-CYP17 (Figure 3.2
lanes 4 and 5) and the GSl15/9K-CYP17 (Figure 3.2 lanes 9 and 10), which is an
extracellular expression construct. Equal amounts of cells (wet weight) were used for the
isolations. About 10-20% of P45017a (58 kDa) could be solubilised, but most of the
protein stayed in the microsomal membrane. The slow growing yeast strain KM71 had
no solubilised P45017a (Figure 3.2, lane 4 A and B). Comparing the GSl15 to the
KM71 strain, more protein was expressed by the fast methanol utilising strain.
Interestingly, the extracellular expression clone GS115/9K-CYP17 contained the
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expected protein band (P450l7a) at a molecular mass corresponding to 58 kDa (lane 10,
A and B), but an additional protein at a molecular mass corresponding to 60 kDa in the
microsomal membrane (Figure 3.2, lane lOA and B) was present. This could be a
glycosylated form of P45017a, since the protein is translated under the secretory
promoter (MFa-I).
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Figure 3.2 SDS-PAGE (A and C) and Western blot (B and D) analyses of proteins isolated from P.
pastoris GS115/pPIC3.5K-CVPI7 and KM711pPIC3.5K-CYPI7 microsomes with Emulgen 913 and
sonication. (A) represents the first round of isolation of P45017a and (C) represents the re-isolation
of P45017a from previously isolated insoluble microsomes: Lanes 1 and 2: solubilised microsomal
proteins and insoluble microsomal membranes from GSI15/3.5K cells, respectively. Lanes 3 and 8:
Molecular Weight Marker. Lanes 4 and 5: solubilised microsomal proteins and insoluble microsomal
membranes from KM7113.5K-CYP17cells, respectively. Lanes 6 and 7: solubilised microsomal proteins
and insoluble microsomal membranes from GSl15/3.5K-CYP17 cells, respectively. Lanes 9 and 10:
solubilised microsomal proteins and insoluble microsomal membranes from GSl15/9K-CYP17 cells,
respectively. Each lane contained 20 and 5 ug of total protein in the left and right SDS-PAGE,
respectively. P45017a (58 kDa) and potentially glycosylated P45017a are indicated by the solid and
dotted arrows, respectively. Detection was carried out using an INDIA HisProbe-HRP at 1:5000.
The solubilisation method to yield P450l7a from the yeasts mierosomes was very poor,
therefore an optimisation of the method was investigated (see Materials and Methods
3.1.1.2). Triton X-lOO was used as an alternative to Emulgen 913. The comparison
showed that neither detergents increased the yield of soluble P450l7a from mierosomes
significantly (see Figure 3.3).
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3.2.2 Direct solubilisation ofP45017a from P. pastoris
As sonication might produce insoluble miscellular vesicles, impossible to solubilise, it
was decided to add the detergent to the lysis buffer together with glass beads (see
Materials and Methods 3.1.2) and instead of sonication a gentle stirring of the crude
extract was attempted. Results show that approximately 60% of P45017a was in the
solubilised supernatant (Figure 3.4; lane 6). 176 mg of total soluble protein (8.82 mg/ml)
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Figure 3.3 SDS-PAGE (A) and Western blot (B) analyses of P45017a solubilied from P. pastons
microsomes with different detergents. Lanes 1 and 2: Emulgen 913 solubilised microsomal proteins
and insoluble microsomal membranes from GSI15/3.5K-CYPI7 cells, respectively. Lanes 3 and 4:
Triton X-too solubilised microsomal proteins and insoluble microsomal membranes from GSI15/3.5K-
CYP17 cells, respectively. Each lane contained 10 IJ.gtotal protein .. Lane 5: Molecular Weight Marker.
P45017a (58 kDa) is indicated by the arrow. Detection was carried out using an INDIA HisProbe-HRP at
1:5000.
and 16.92 mg of total insoluble microsome (8.46 mg/ml) was isolated, which produced
2.85 mg of soluble proteins per 1 g cells wet weight.
The final change in protocol, to optimise the isolation and solubilisation of P45017a
from yeast cells, was to add ~-ME to the cell lysis buffer (see Materials and Methods
3.1.2.2). Emulgen 913 (1% v/v) was added to crude extract and the lysate stirred for 4
hours. This gentle agitation (instead of sonication) was found to recover 70% of the
P45017a as solubilised protein (Figure 3.5, lane 5), but a significant amount ofP45017a
was still in the insoluble microsomal membrane (Figure 3.5, lane 6). The yield of total
soluble protein (4.54 mg/ml) was 227 mg while 33.5 mg of total insoluble mierosomes
(6.70 mg/ml) was isolated. The yield of micro somes was 2-3 mg per 1 g of wet wt cells.
Stellenbosch University http://scholar.sun.ac.za
Part IV Microsome preparation 224
A
-
B
Figure 3.4 SDS-PAGE (A) and Western blot (B) analyses of proteins solubilised by Emulgen 913
from P. pastoris cells. Lanes 1 and 8: Molecular weight markers. Lane 2: crude cell extract from
GSI15/3.5K cells. Lanes 3 and 4: solubilised proteins and insoluble microsomal membranes from
GS115/3.5K cells, respectively. Lane 5: crude cell extract from GSl15/3.5K-CYP17 cells. Lanes 6 and
7: solubilised proteins and insolublemicrosomal membranes from GSl15/3.5K-CYP17 cells, respectively.
Lane 9: Positive control containing a histidine tagged ureate oxidase (10 ug). Each lane contained 20 ug
total protein. P45017a (58 kDa) is indicated by the arrow. Detection was carried out using an INDIA
HisProbe-HRP at 1:5000.
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Figure 3.5 SDS-PAGE (A) and Western blot (B) analyses of proteins solubilised by [3-
mercaptoethanol and Emulgen 913 from P. pastorts cells. Lanes 1 and 7: Low molecular weight
markers. Lanes 2 and 3: solubilised proteins and insoluble microsomal membranes from GS115/3.5K
cells, respectively. Lanes 5 and 6: solubilised proteins and insoluble microsomal membranes from
GSl15/3.5K-CYP17 cells, respectively. Lane 8: Positive control containing a histidine tagged ureate
oxidase (10 ug). Each lane contained 20 ug total protein. P45017a (58 kDa) is indicated by the arrow.
Detectionwas carried out using an INDIA HisProbe-HRP at 1:5000.
3.2.3 Spectral properties of P45017a 10 solubilised and insoluble
mierosomes
A typical cytochrome P450 CO-induced difference spectrum with an absorption
maximum of 448 nm was recorded for the soluble and insoluble preparation of
mierosomes from P45017a expressing GS115 cells as shown in Figure 3.6. No P450
enzyme was detected in any of the fractions from control cells (pPIC3.5K vector without
cDNA). Figure 3.6A shows the reduced CO-induced difference spectra of detergent-
solubilised proteins with p-ME. Only one peak at 448 nm, indicating the presence of a
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hemeprotein P45017a, was recorded with a small shoulder at 427 nm. The heme group
was not lost in the presence of p-mercaptoethanol (10mM), which can occur
occasionaly (4, 5). The yield of P450 enzyme in the solubilised cell lysate was
approximately 50 nmol/L of cell culture at a P450 enzyme concentration of 0.95 )lM.
Figure 3.6B shows the reduced CO-induced induced difference spectra of solubilised
proteins without Emulgen 913 and p-ME. An additional peak at 427 nm, indicating
cytochrome oxidase, was recorded. The P450 enzyme was in a stable form since no
absorption maximum around 420 nm was observed although it might be slightly
obscured by the native mitochondrial cytochrome oxidase (425-427 nm).
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Figure 3.6 Reduced CO difference spectra of solubilised proteins (A and B) and microsomal fraction
(C) of P. pastoris transformed with either the parent pPIC3.5K plasmid (....... ) or recombinant
pPIC3.5K-CYP17 vector (--). (A) Soluble protein fraction isolated in buffer A (100 mM sodium
phosphate, pH 7A, 20% v/v glycerol, 1 mM EDTA,1 mM PM SF, 10 mM f3-mercaptoethanol and 1% v/v
Emulgen 913). (B) Soluble protein fraction isolated in buffer BB (50 mM NaH2P04, pH 7A, 5% v/v
glycerol, 1 mM EDTA 1 mM PMSF and 1% v/v Emulgen 913). (C) Insoluble microsomal fraction
isolated in buffer BB (50 mM NaH2P04, pH 7A, 5% v/v glycerol, I mM EDTA, 1 mM PMSF and 1% v/v
Emulgen 913)_ The samples were diluted 1:1 in 100 mM sodium phosphate buffer, pH 7.0, which was
saturated with carbon monoxide. 2 mg/ml of solubilised protein was used.
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This interference had previously been reported (29,6). To minimise the interference of
mitochondrial cytochrome oxidase (peak at 427 nm), Emulgen 913 with p-ME is added
to the lysis buffer. This addition will lower the 427 nm peak, as seen in Figure 3.6A,
therefore exposing any P420 if present. Figure 3.6C shows the reduced CO-induced
difference spectra of microsomal fraction resuspended in buffer BB and the P450
enzyme concentration was calculated to be 0.70 f..lM.The degradation of detergent-
solubilised P450l7a after 2 months is shown in Figure 3.7.
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Figure 3.7 Reduced CO-induced induced difference spectra showing the stability of detergent
solubilised proteins from P. pastoris. (.......) spectra of freshly prepared soluble fraction as seen in Figure
3.6 A and (--) spectra of the same fraction after 2 months stored at -20oe.
The detergent-solubilised P450l7a was unstable as indicated by the maximum
absorbancy shift from 448 nm to 422 nm in a reduced CO-induced difference spectrum.
The detergent-solubilised human P450l7a with p-ME produced a type I substrate
induced difference spectrum in the presence of 10 f..lMprogesterone (Figure 3.8A) as
well as 10 f..lMpregnenolone (Figure 3.8 B). The spin state change from low spin to high
spin is characteristic of human P450l7a.
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Figure 3.8 Substrate induced difference spectra of recombinant P45017a in a detergent-solubilised
fraction (0.473 JlM) in the presence of 10 JlM progesterone (A) and 10 JlM pregnenolone (B).
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CHAPTER4: THE DEVELOPMENT AND EVALUATION OF A
PROTOCOL FOR THE PURIFICATION OF
P45017a FROM MICROSOMES
4.1 Materials and Methods
4.1.1 Purification of Emulgen 913 solubilised P45017a
4.1.1.1 Ni+ -NTA column chromatography
Ni-CAM'"HC affinity resin (5 ml suspension) (Sigma, St. Louis, USA) was washed with
MQ and pre-equilibrated with equilibration/wash buffer (50 mM sodium phosphate, pH
8.0, 0.3 M NaCl, 20% v/v glycerol, 0.2% v/v Emulgen 913, 10 mM imidazole).
Solubilised proteins (80 mg), isolated as described in section 3.1.2, was added at a
concentration of 8.82 mg/ml to the equilibrated resin and gently agitated on a shaker
(STR9, Stuart Scientific) for 19 hours at 4°C. A 5 x 0.9 cm perspex column was packed
with the overnight incubated lysate-Nr" -NTA resin mixture resulting in a 2 ml bed
volume (BV). During the packing of the column the flow-through was collected. The
column was washed with wash buffer at a flow rate of 0.2 ml/min and the total volume
was 20 ml. The histidine tagged P450l7a was eluted from the column with elution
buffer (50 mM sodium phosphate, pH 8.0, 0.3 M NaCI, 20% v/v glycerol, 0.2% v/v
Emulgen 913, 250 mM imidazole) at a flow rate of 0.2 ml/min. After eluting ten
fractions (2 ml each), the column was cleaned and regenerated according to the
manufacturer's instructions. The collected fractions were stored at -20°C until analysed
by SDS-PAGE and Western blot analyses.
4.1.1.2 Size exclusion chromatography
Eluate (300 J.lI)from the Ni2+-NTA column, containing the histidine tagged P450l7a
protein was loaded on the Sephadex G-75 column (20 ml bed volume, flow rate 0.18
ml/min), which had been pre-equilibrated with loading buffer (100 mM sodium
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phosphate, pH 7.6, 10% v/v glycerol). The fractions having an absorbance at 280 nm
were collected and analysed by SDS-PAGE and Western blot analyses.
4.1.2 Purification of Emulgen 913 solubilised P45017a and direct column
loading
Solubilised microsomal proteins (45 ml, 2.38 mg/ml), isolated as described in section
3.1.2, were loaded onto a Ni_CAM™HC affinity resin (Sigma, St. Louis, USA) column
(2 ml BV), which had been pre-equilibrated with equilibration buffer, at a flow rate of
0.2 ml/min. The column was washed with wash buffer (20 ml) containing imidazole (20
mM) and with wash buffer (25 ml) containing imidazole (50 mM) at a flow rate of 0.5
ml/min. Histidine tagged P45017a. was eluted with elution buffer (12.5 ml) at a flow rate
of 0.2 ml/min. The fractions with an absorbtion larger than 0.2 at 412 nm were pooled.
An aliquot of the pooled fractions was analysed by SDS-PAGE while the rest was
concentrated with an Amicon Ultracell-4 (Millipore). These preparations were also
analysed with SDS-PAGE and Western blot analyses.
4.1.3 Purification of Emulgen 913/P-ME solubilised P45017a
Ni-CAM™HC affinity resin (4 ml suspension) was washed with MQ and equilibrated
with equilibration buffer containing Emulgen 913 (1% v/v). Solubilised microsomal
proteins (90.8 mg), isolated as described in section 3.1.2.2, was added at a concentration
of 4.54 mg/ml to the equilibrated resin and gently agitated on a shaker for 19 hours at
4°C. A 5 x 0.9 cm perspex column was packed with the overnight incubated lysate-Ni'"«
NTA resin mixture resulting in a 3 ml BV. During the column packing, the flow-through
(37.5 ml) was collected. The column was washed with wash buffer (11 ml) containing
Emulgen 913 (1% v/v) and imidazole (15 mM) and wash buffer (24 ml) containing
Emulgen 913 (1% v/v) and imidazole (20 mM) at a flow rate of 0.15 ml/min. The
histidine tagged P450l7a. was eluted from the column with elution buffer (4 ml)
containing Emulgen 913 (1% v/v) at a flow rate of 0.15 ml/min. The column was
cleaned and regenerated according to the manufacturer's instructions. The collected
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fractions were pooled and stored at -20°C until analysed by SDS-PAGE and Western
blot analyses.
4.1.4 Adsorption chromatography
Before removing the detergent from the Ni2+-NTA purified P45017a fraction, a trial
batch experiment was conducted to show that the hydrophobic polymeric Amberlite
XAD-1600 (Rohm & Haas) resin was able to adsorb Emulgen 913.
An Emulgen 913 (1% v/v) solution was prepared and a spectrum was recorded between
500 and 200 nm with a Cary spectrophotometer (USA). The detergent solution (4 ml)
was added to Amberlite XAD-1600 (Rohm & Haas) adsorption resin (4 ml BV) in a 10
ml Falcon tube. As a control deionised water (4 ml) was added to a second Falcon tube
containing the same amount of resin. Both tubes were gently agitated on a shaker for 20
min at 4°C. The resins were left to settle and the top aqueous layers were analysed
spectrophotometrically.
4.1.5 Two-step Purification of Emulgen 913/P-ME solubilised P45017a
Two methods for the preparation of pure human P45017a were evaluated. In the first
method the detergent was first removed by adsorption chromatography followed by
Ni2+-NTA chromatography while in the second method the Ni2+-NTA chromatography
was carried out before detergent removal.
4.1.5.1 Detergent removal with Amberlite XAD resin followed by Ni2+-NTA
column chromatography
Two chromatography columns were packed. One, 12 x 0.9 cm, with Amberlite XAD-4
and one, 14 x 0.9 cm, with and XAD-1600. Both columns received identical treatment.
After equilibrating the columns with buffer C (50 mM sodium phosphate, pH 7.4, 20%
v/v glycerol and 20 mM NaCl) each was loaded with solubilised microsomal proteins
(45 mg, 4.54 mg/ml, isolated as described in section 3.1.2.2). To ensure maximum
adsorption of the detergent a flow rate of 0.15 ml/min was maintained. The fractions that
had an absorbance greater than 0.2 at 412 nm were pooled. The XAD-4 column yielded
10 ml and the XAD-1600 column yielded 15 ml detergent free protein preparations.
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TM
Each Emulgen 913 free protein fraction was immediately added to a Ni-CAM HC
affinity resin, previously equilibrated with equilibration buffer containing no Emulgen
913, and gently agitated on a shaker for 19 hours at 4°C. Two 5 x 0.9 cm perspex
column were packed with the overnight incubated lysate-Ne+-NTA resin mixtures
resulting in two 1 ml BV. During the packing the flow-throughs of both columns were
collected (7 ml each). The columns were subsequently washed with wash buffer
containing (15 mM imidazole), without Emulgen 913, at a flow rate of 0.1 ml/min and
the total volume was 10 ml for each column. The histidine tagged P450l7a was eluted
from the columns with elution buffer without Emulgen 913 at a flow rate ofO.1 ml/min.
After eluting five 2 ml fractions (10 ml total), the column was cleaned and regenerated
according to the manufacturer's instructions. The collected fractions were concentrated
10 times with an Amicon Ultrafee-4 (Millipore) to a final protein concentration of 1.37
mg/ml and stored at -20°C until analysed by SDS-PAGE and Western blot analyses.
4.1.5.2 Ni2+-NTA column chromatography followed by detergent removal with
Amberlite XAD resin
Ni-CAM™HC affinity resin slurry (Sigma, St. Louis, USA) (5 ml) was washed with MQ
and equilibrated with equilibration buffer containing Emulgen 913 (0.1% v/v).
Solubilised microsomal protein (136 mg), isolated as described in section 3.1.2.2, was
added at a concentration of 4.33 mg/ml to the equilibrated resin and gently agitated on a
shaker for 12 hours at 4°C. The lysate-Ni-NTA mixture was packed into a 5 x 0.9 cm
perspex column (1.9 ml BV) and the flow-through was collected (50 ml). The column
was washed with wash buffer (13.5 ml) containing Emulgen 913 (0.1% v/v) and
imidazole (15 mM) at a flow rate of 0.15 ml/min. The histidine tagged P45017a was
eluted from the column with elution buffer containing Emulgen 913 (0.1% v/v) and
imidazole (100 mM) and elution buffer containing Emulgen 913 (0.1% v/v) and
imidazole (250 mM) at a flow rate of 0.15 ml/min, The column was cleaned and
regenerated according to the manufacturer's instructions.
The Ni2+-NTA purified P45017a was added to equilibrated Amberlite XAD-1600 (5 ml
BV) and gently agitated on a shaker for 20 min at 4°C. The Emulgen 913 was adsorbed
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and the human P45017u was eluted in buffer C (20 ml). The eluted sample was
concentrated 26 times in an Amicon Ultracell-t and analysed by SDS-PAGE and
Western blot analyses.
4.2 Results
4.2.1 Purification ofP45017a with Emulgen 913 and incubation overnight
The first attempt to purify histidine-tagged P45017u from a detergent-solubilised yeast
fraction (see Materials and Methods 4.1.1) with a Ni2+-NTA column yielded a fairly pure
P450 17u protein at around 54 kDa (Figure 4.1, lanes 5-7). The majority of P450 17u was
in fraction 2, however two dominant proteins (81 and 42 kDa) co-eluted.
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Figure 4.1 SDS:'PAGE (A) and Western blot (B) analyses of Ni2+-NTA purified proteins from the
detergent-solubilised fraction. Lane 1: crude cell lysate (20 ug) loaded on column. Lanes 2 and 9:
Low-molecular weight Marker. Lane 3: First fraction of flow through while packing the column. Lane 4:
Last fraction of flow through while packing the column. Lanes 5-9: Fractions of eluting Ni-purified
P45017a. Lane 10: Positive control containing a histidine-tagged ureate oxidase (10 ug), P45017a (58
kDa) is indicated by the arrow. Detection was carried out using an INDIA HisProbe-HRP at 1:5000.
An attempt to separate P45017u from these proteins by gel SIze exclusion
chromatography with Sephadex G-75 was unsuccessful (Figure 4.2 and Figure 4.3 lane
4).
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Figure 4.2 Chromatogram of the purification of P45017a. with size exclusion chromatography. The
eluting proteins detected at 280 nm were separated and pooled into four fractions.
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Figure 4.3 SDS-PAGE (A) and Western blot (B) analyses of gel filtration separated proteins. Lane I:
Ne+-NTA purified P45017a.loaded on the G75 column. Lanes 2 and 7: Low-molecular weight Marker.
Lanes 3-6: The 4 pooled fractions of the eluted proteins. Lane 8: Positive control containing a histidine-
tagged ureate oxidase (10 ug). P45017a. (58 kDa) is indicated by the arrow. Detection was carried out
using an INDIA HisProbe-HRP at 1:5000.
To optimise the Ni2+-NfA purification P45017a a direct purification procedure was
carried out.
4.2.2 Purification of P45017a with Emulgen 913 and direct column
loading
Direct loading of detergent-solubilised proteins, increased Nael concentration (from 0.3
to 0.5 M) and step wise washing steps with increased imidazole concentration (20 to 50
mM imidazole) in the wash buffer (see more detail in Materials and Methods 4.1.2), did
prevent non specific binding of contaminating proteins, but most of P450 17a was eluted
(Figure 4.4, lanes 3 and 4). The elution of P45017a at an imidazole concentration of 50
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mM, indicates that the binding of P45017a. to the resin is not high and the column must
not be washed with imidazole concentrations higher than 15 mM. It was necessary to
incubate the lysate with the resin overnight.
The concentrated fractions from the washing and elution steps show a prominent protein
band at a molecular mass corresponding to 40 kDa in the SDS-PAGE shown in Figure
4.4C, lanes 3-8. This protein was not detected with the HisProbe in the Western blot
analysis (Figure 4.4D, lanes 3-8) and was therefore not a histidine tagged or histidine
rich protein. This unidentified protein can remain bound to the resin at very high
imidazole concentrations (up to 250 mM). Another contaminating protein (45 kDa) co-
eluted with the P45017a. protein was also detected in the Western blot analysis (Figure
4.4D, lanes 3-5). This could be either a partially proteolytic degraded P45017a., a
histidine rich protein or a metalloenzyme.
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Figure 4.4 SOS-PAGE (A and C) and Western blot (B and 0) analyses of Ne+-NTA purified proteins
from the detergent-solubilised fraction. The protein fractions seen in SOS-PAGE A were
concentrated with Amicon and run again on SOS-PAGE C. A and B: Lanes land 2: flow-through
while packing the column. Lane 3: wash I step. Lane 4: wash II step. Lanes 5-8: elution of P45017a.
Lane 9: Low-molecular weight Marker. Lane 10: crude soluble extract incubated with resin. C and 0:
Lanes 1 and 2: flow-through while packing the column. Lane 3: wash I step. Lane 4: wash II step. Lanes
5-8: elution of P45017a. Lane 9: Low-molecular weight Marker. Lane 10: Positive control containing a
histidine-tagged ureate oxidase (lO ug). P45017a (58 kDa) is indicated by the arrow. Detection was
carried out using an INDIA HisProbe-HRP at 1:5000.
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It appeared that the 40 and 45 kDa proteins were always co-eluting with P45017a, hence
a disulphide bond between the expressed P45017a and the contaminating proteins might
have formed. The complex will be purified during the Ne+-NTA step and as soon as the
samples were denatured by ((3-mercaptoethanol) in the SDS loading buffer, the
disulphide bonds were broken, thus two protein bands and P45017a appeared on the
SDS-PAGE (Figure 4.4C, lanes 3-5).
The fraction shown in Figure 4.5 lane 3, was analysed by electro spray mass
spectrometry (ESMS) to determine the molecular masses of the size proteins present in
the preparation. ESMS results (Figure 4.5) revealed only a characteristic ion pattern of a
polymer or detergent. This chromatogram is of Emulgen 913 in the sample which was
not successfully removed during the desalting and concentration steps. Emulgen 913 has
a very low CMC (critical miscellar concentration) therefore it is neither possible to
separate nor dialyse the Emulgen 913 away from the protein sample.
4.2.3 Purification of Emulgen 913/(3-ME solubilised P45017a
Two additional modifications to the purification protocol were made (see Materials and
Methods 4.1.3) Firstly, (3-ME was added to the solubilised cell lysate to prevent any
disulfide bonds forming between P45017a and the contaminating proteins. A second
purification step, to remove the Emulgen 913 from the P45017a sample, was also
implemented. Hydroxyapatite was used successfully to remove the detergent (18, 7),
however Amberlite XAD-1600 (Rohm & Haas) has not been shown previously to
remove detergent from protein containing solution.
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Figure 4.5 ESMS analyses of proteins in the wash buffer Figure 4.4 lane 3. Characteristic ion pattern
of Emulgen 913.
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The detergent solubilised lysate from P. pastoris, incubated overnight with the Ni2+_
NTA resin, was packed into a column. Washing was done in the presence of detergent
by applying a step-wise gradient of imidazole and elution was achieved at high
imidazole concentration. The elution of different proteins was monitored at 412 nm and
recorded as seen in Figure 4.6. The chromatogram shows 2 distinct peaks, one during the
flow-through step and one during the elution step. SDS-PAGE and Western blot
analyses of these peaks show that the contaminating proteins (peak 1), which previously
co-eluted with P45017a, were washed away Figure 4.7, lane 3, and a pure P45017a
protein (peak 2) was eluted in Figure 4.7, lane 6.
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Figure 4.6 Elution profile of human P45017a. purified on a Ne+-NTA column. Absorption at 412 nm
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Figure 4.7 SDS-PAGE (A) and Western blot (B) analyses of proteins from the IMAC purification
step: Lane 1: microsomal crude cell lysate (23 ug) loaded on Ne+ column. Lanes 2 and 7: High-
molecular weight Marker. Lane 3: flow-through (76 ug) during packing the column. Lane 4: wash I step
(0.4 ug) (15 mM imidazole). Lane 5: wash II step (0.32 ug) (20 mM imidazole). Lane 6: elution (1.38
ug) ofP45017a. (250 mM imidazole). P45017a. (58 kDa) is indicated by the arrow. Detection was carried
out using an INDIA HisProbe-HRP at 1:5000.
Results further show that an electrophoretic more homogeneous P450I7a fraction eluted
in the washing steps (Figure 4.7 lanes 4 and 5). From these results it followed that the
optimum elution for P450I7a would probably be between 15-100 mM imidazole.
Owaki A. et al. have shown that, during the purification with Ni2+-NTA of the guinea
pig P450I7a, the protein was also eluted between 0-40 mM of imidazole (20). Therefore
it can be concluded that the histidine tail incorporated into P450 enzymes has a relative
weak binding affinity for the Ni2+-NTA.
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4.2.4 Adsorption chromatography
Purifying protein samples from Emulgen 913 containing solutions with XAD-4 and
XAD-2 have previously been demonstrated (8). We carried out an experiment with
XAD-1600 determine the efficiency of Emulgen 913 removal. Emulgen 913 has an
aromatic ring structure which absorbs and therefore allows monitoring at 280 nm.
Results show that Emulgen 913 was adsorbed by Amberlite XAD-1600, as seen in
Figure 4.8.
2.0
-1IoIuIIon (00) XAD-11OO
··..··1IoIuIIon (+) l!A1).11OO
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Figure 4.8 Wavelength scan of the adsorption of Emulgen 913 (1% v/v) solution by Amberlite XAD-
1600.
4.2.5 Two-step Purification of Emulgen 913/f3-ME soluhilised P45017a
Two experiments (see Materials and Methods 4.1.5) were conducted to see which
purification sequence will produce a pure P45017a.. Either removing the detergent via
adsorption chromatography first followed by Ni2+ -NTA chromatography or vice versa.
4.2.5.1 Detergent removal followed by Ni2+-NTA chromatography
Two different adsorption resins (Amberlite XAD-4 and XAD-1600) were used to
compare the efficiency of removing the Emulgen 913 from the crude solubilised
microsomal lysate. Results show that P45017a. was separated from Emulgen 913,
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because the eluted protein fraction contained P45017a (Figure 4.9, lanes 3 and 4) but
lacked the typical Emulgen 913 spectrum, indicating detergent removal by the resins.
The XAD-1600 resin adsorbed proteins up to 40 kDa compared to XAD-4, which only
adsorbed up to 20 kDa as seen in Figure 4.9, lanes 3 and 4. This was expected since the
former has a bigger pore size. Although both type of resins offer the same high surface
area and controlled pore size, XAD-1600 is a better resin to use due to the closely
controlled particle size which results in better separation.
A B
1 2 3 4
~---+-
Figure 4.9 SDS-PAGE (A) and Western blot (B) analyses of purified P45017a. with Adsorption
resins. Lane I: microsomal crude cell lysate loaded on XAD columns. Lane 2: Low molecular weight
Marker. Lane 3: XAD-I600 purified proteins. Lane 4: XAD-4 purified proteins. P45017a. (58 kDa) is
indicated by the arrow. Detection was carried out using an INDIA HisProbe-HRP at 1:5000.
The detergent-free P45017a was subsequently purified with Ne+-NTA and results show
that the P45017a could not be purified to electrophoretic homogeneity (see Figure 4.10,
lanes 5 and 7). The co-elution of a 40 kDa protein was again present as was seen in
Figure 4.10, lanes 3-8.
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Figure 4.10 SDS-PAGE (A) and Western blot (B) analyses of the 2-step purification of P45017a.:
Lane I: microsomal crude cell lysate loaded on XAD columns. Lanes 2 and 9: Low molecular weight
Marker. Lanes 3-5: Proteins that were first purified by XAD-4 and subse~uently loaded onto Ne+-NTA
column, lanes 3-5 is the flow-through, wash and elution step from the Ni +-NTA column, respectively.
Lanes 6-8: Proteins that were first purified by XAD-1600 and subsequently loaded onto Ni2+-NTA
column, lanes 6-8 is the flow-through, wash and elution steps from the Ne+-NTA column, respectively.
Lane lO: Positive control containing a histidine-tagged ureate oxidase (10 ug), P45017a. (58 kDa) is
indicated by the arrow. Detection was carried out using an INDIA HisProbe-HRP at 1:5000.
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4.2.5.2 Ne+-NTA chromatography followed by detergent removal
The detergent solubilised lysate from P. pastoris, incubated overnight with the Ni2+_
NTA resin, was packed into a column. Washing was carried out in the presence of
detergent by applying a step-wise gradient of imidazole and elution was achieved at high
imidazole concentration (see Material and Methods 4.1.5.2). The elution of different
proteins was monitored at 412 nm and the recorded chromatogram is shown in Figure
4.11. Two distinct peaks were detected. Peak 1 indicated elution of material during the
flow-through step and Peak 2 indicated elution of material during elution. SDS-PAGE
and Western blot analyses of these peaks show that the contaminating proteins (peak 1),
which previously co-eluted with P45017a (Figure 4.12, lane 5), were effectively
separated from P45017a which eluted with 100 mM imidazole buffer (Figure 4.12, lane
7) There was no detectable of P45017a in the flow-through fraction of the Ni2+-NTA
column (Figure 4.12, lane 5), which indicated complete binding ofP45017a without any
overloading of the resin. The optimal concentration of imidazole in the elution buffer
was 100 mM which was empirically determined from previous purification experiments.
No detectable P45017a was present in the 250 mM imidazole-eluting fraction (Figure
4.12, lane 8), indicating that 100 mM imizazole was sufficient to remove all the
P450 17a from the column. The XAD-1600 adsorption resin produced a detergent free
P45017a which migrated as a single band on SDS-PAGE with an estimated molecular
mass of 58000 Da (Figure 4.12, lane 10). ES-MS analyses showed that the detergent was
removed successfully by XAD-1600 resin but the protein concentration was too low for
a protein mass spectrum and the volume obtained in this preparation was too small to
record a reduced CO-induced P450 difference spectrum (results not shown).
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Figure 4.11 Elution profile of human P45017a purified on a Nil+-NTA column. Absorption at 412 nm
( ); imidazole concentration ( ").
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Figure 4.12 SDS-PAGE (A) and Western blot (B) analyses of the 2-step purification of P45017a:
Lane 1. detergent-solubilised proteins from GSI15/3.5K cells. Lanes 2 and 3: insoluble microsomal
membranes and detergent-solubilised proteins from GSI15/3.5K-CYPI7 cells, respectively. The latter was
loaded on the Ni2+-NTA column. Lanes 4 and 9: Low molecular weight Marker. Lane 5: The flow-
through and wash I step from the Ni2+-NTA column. Lane 6: wash II step. Lane 7: elution ofP45017a
with imidazole (100 mM). Lane 8:elution of proteins with imidazole (250 mM). Lane 10: Purified
P45017a obtained by Ne+-NTA chromatography followed by detergent removal with XAD-1600 resin.
P45017a (58 kDa) is indicated by the arrow. Detection was carried out using an INDIA HisProbe-HRP at
1:5000.
A cytochrome P450 CO-induced difference spectrum Figure 4.13 with an absorption
maximum of 422 nm was recorded from the Ni2+-NTA purified P45017a Figure 4.12,
lane 7, which had been kept for 2 months at -80°C. Results show that the protein had
denatured to P420 nm, indicating an expected denaturation since the sample was
dissolved in the elution buffer in the presence of 250 mM imidazole. The imidazole acts
as the fifth ligand to the active site ofP45017a forming a charge transfer complex.
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Figure 4.13 Reduced CO-induced induced difference spectra of Nil+-NTA purified P45017a;
( ), Detergent-solubilised protein fraction from GSl15/pPIC3.5K-CYP17 cells loaded onto the Ni2+_
NTA column; (--) Ni2+-NTA purified P45017a. The latter sample suspended in (50 mM sodium
phosphate, pH 8.0, 0.3 M NaCI, 20% v/v glycerol, 0.1% v/v Emulgen 913, 250 mM imidazole) was
diluted 1:1 in 100 mM sodium phosphate buffer, pH 7.0 which was previously saturated with carbon
monoxide.
The isolation and purification of P45017a expressed by P. pastoris is summarised in
Table 4.1.
Table 4.1 Purification of P45017a from a one liter P. pastorls cell culture.
Purification Protein Total Total P.so Total Specific
steps cone. Volume protein cone. P.so content. Yield
(mglml (ml) (mg) (!1M or (nmol/l (nmol/mg (%)
) nmOI/ml)a culture) protein
MIcrosomes 6.70 5 33.5 0.703 3.5 0.104
Clear solubilised 4.54 50 227 0.946 47.3 0.208 100b
lysate
NI2+·NTAeluate 0.52 30 15.6 0.928 27.8 1.780 58.7
XAD-1600 eluate nl nd
a The total amount ofP450 was determined by the reduced CO· induced difference spectra (3).
b The detergent solubilised cell lysate from P. pastoris was used for the purification.
C Not determined
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CHAPTER 5: DISCUSSION
The awareness of the importance of steroidogenic human cytochrome P450 enzymes has
increased significantly in recent years. The cDNA sequences for more than thirty
different CVP 17' s have been deposited in databases (e.g. GenBank) 1• In this context
human cytochrome P45017a can be singled out as one of the steroidogenic cytochromes
P450 which attracted the attention of many researchers for a number of reasons
including its role in human disease and its unique dual hydroxylase and lyase activities.
The enzyme is also currently being examined for its ability to catalyse the formation of
16-ene steroids, via 16-ene-synthase activity (9) and has also lately been indicated as an
important factor involved in polycystic ovarian syndrome (PCaS) (10, 11) and
pheromone biosynthesis. The interest shown in this microsomal P450 enzyme in these
current studies requires the demand for sufficient quantities of pure human P45017a
protein. The availability of reasonable amounts of human P45017a will facilitate studies
of this fascinating steroidogenic hemoprotein and will go a long way in facilitating our
search for the functional characteristics of this enzyme. In addition, sufficient amounts
of a pure P45017a can also be used to raise antibodies against P45017a, which are
currently not readily available. Moral issues, aggregation in the absence of detergents,
relative low concentrations and instability have severely complicated or hamperd efforts
to isolate and purify P45017a from human tissue.
Heterologous expression systems have been used to produce relatively high
concentrations of cytochrome P45017a proteins from various vertebrates, such as
bovine (12), rat (13), pig (14), hamster (15), trout (16) and shark (17), but the human
P45017a enzyme has only been overexpressed for purification and characterisation in E.
coli (18). However, modifications of the amino terminal sequence of human P450 17a,
precisely described for bovine P45017a by Barnes et al. (12) resulted in high-level
expression in E. coli. This modification also increased expression levels of the shark
P45017a (19, 20). For expression in prokaryotes alterations within seven codons of the
cDNA, as described by Barnes (21), created an mRNA that is efficiently translated and
minimises secondary structure formation (22).
1 ProfR W. Estabrook, personal communication.
Stellenbosch University http://scholar.sun.ac.za
Part IV Discussion 244
During this investigation the human cytochrome P45017a was successfully cloned and
overexpressed P45017a in the methylotrophic yeast, P. pastoris (23, 24), without
modifying the 5' terminal of CYP17 cDNA. P. pastoris has become a very attractive
system for heterologous expression of heme-containing proteins (25, 26, 27, 28) and
three P450-specific enzymes from spiny dogfish shark(29), the spiny lobster (30) and
Cassava plant (31) (CYPI7, CYP2Ll and CYP71Dl, respectively) have functionally
been expressed in this organism which suggests that P. pastoris has the potential
capability of producing active heme-containing proteins. In our hands the expression
level of human P45017a in the P. pastoris system was 50 nmol of P45017a/L of
culture, as measured by P45017a recovered in the solubilised lysate. This figure was
slightly lower than results obtained for bovine P45017a previously expressed in
baculovirus (32). The total cytochrome P450 content was 300 pmol/mg microsomal
protein, which is significantly higher when compared to the P. pastoris expressed shark
P45017a (15-30 pmol/mg microsomal protein), lobster CYP2Ll (20 pmol/mg
microsomal protein) and plant CYP79Dl (125 pmol/mg microsomal protein). The low
expression of shark P45017a in P. pastoris prevented Trant to determine the cytochrome
P450 content of whole cells, lysed cells or microsomal fraction from P. pastoris (29).
The high expression levels of human P45017a may either be due to the optimised
context of the translational initiation consensus sequence or of a gene dosage effect.
Multi-copy integration of the CYP17 into the yeast genome may have occurred, since
the clones have been selected on 0.5 mg/ml 0418 antibiotics. The copy number was,
however, not determined by Southern blot analysis.
Growth of OS115 (Mut) cell cultures, during growth and induction phases, was normal
and after 72 hours the cells reached cell densities with an OD6oo= 12. The KM71 (Mue)
cell cultures ceased growing abruptly after 48 h of induction. The two most likely
explanations for this phenomenon could be: (i) there could have been a problem with the
media and the cultures nutrients were limited; (ii) the cultures could have been
contaminated at the 48 hours time point, because at that time the supplementation of
methanol for induction was administered. The risks of contamination at these induction
times was high, since the flasks had to be removed from the shaking incubators and the
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cheese cloth removed to pipette the appropriate amount of methanol into the flasks. The
control strain GS 115/Albumin (Mut") also stopped growing after 48 hours, an indication
that the medium was most likely contaminated since in the GS 115 growth experiment
their growth was normal. Therefore it was decided to continue with the GS 115 strains in
the subsequent expression and purification experiments.
P450l7a was functionally expressed in P. pastoris as evidenced by the ability of
recombinant yeast cells to convert progesterone to 17a-hydroxyprogesterone and l6a-
hydroxyprogesterone. The conversion of progesterone in intact P. pastoris cells
demonstrated that the endogenous yeasts reductase system was able to sustain electron
transport to the human P45017a. At a total concentration of 10 ~M, only 65% of the
progesterone was converted within the first 6 min. The incomplete conversion of
progesterone to its intermediates was probably caused either by the high initial
concentration of progesterone, because activity studies in whole cells are usually
executed with 1 ~M of substrate (29, 32) or the cell density was too high (1 x 109
cells/ml) (33). The initial conversion rate was so high that the demand for reducing
equivalents could not be supplied by the cells and were exhausted, leading to a decrease
in conversion rate. The initial rate of the l7a-hydroxylation of progesterone (10 ~M) in
a 48 hr yeast culture expressing heterologous human P45017a, was 1.37 nmol/min/l O''
cells. This rate was 90 times faster than the shark P45017a expressed in P. pastoris (29).
Another explanation for the rapid ceasure of the reaction after 5 min could be due to the
limitation of oxygen required for the hydroxylation reaction. The assay was performed
in small unbaffled Erlenmeyer flasks and shaken slowly, most probably resulting in an
inefficient oxygen supply. The linear growth of the yeast cells, opposed to the
logarithmic growth, substantiates the explanation of a lack of oxygen. This hypothesis is
currently under investigation, however, to ensure a constant supply of oxygen during the
assay is technically difficult and remains to be elucidated.
The solubilisation of P45017a from yeast mierosomes with different detergents
(Emulgen 913, Triton X-IOO), with or without sonication, was not very successful.
Sonication was probably creating strong miscellar superstructures, which were holding
P45017a so tightly bound that the detergents were not able to solubilise the protein from
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these miscells. We were able to solubilise the majority of P45017a. from the membrane
fraction with drop-wise addition of a Emulgen 913 (1% v/v) to stirring cell lysate for 4
hours. The recombinant P45017a. in the solubilised lysate and insoluble microsomal
fraction produces a reduced cytochrome P450 CO-induced difference spectrum and type
I substrate-induced difference spectra in the presence of progesterone and pregnenolone,
indicating that the P. pastoris expression system produced a correctly folded
hemeprotein. The spectrally detectable P45017a. showed a peak at 448 nm and no peak
was detected for the control strain (empty vector). This confirmed that, although the
yeast has its own cytochrome P450 and OR responsible for ergosterol biosynthesis, the
endogenous concentrations of these enzymes were low and had no effect on the
expression or detection of human P45017a. (34, 35).
The reduced CO-induced different spectra of the solubilised cellular protein fraction,
isolated with two different buffers (buffer A and buffer BB), showed that in the presence
of (3-ME (10 mM), one dominant 448 nm peak with a shoulder at 427 nm occurred,
compared to two peaks at 448 and 427 nm in the absence of (3-ME. The 427 nm peak
originates from mitochondrial cytochrome oxidase (absorption maximum around 430
nm) (36, 37) and is not native b, or cytochrome bl, since it cannot be reduced with
NADPH (38). The presence of (3-ME most probably reduced the mitochondrial
cytochrome oxidase resulting in a low 427 nm peak.
The isolation of the membrane fraction of P. pastoris was omitted and only the
solubilised cell lysate was used in the purification procedures. To purify recombinant
human P45017a. from P. pastoris, we have employed a quick 2-step purification
procedure consisting of metal chelate affinity chromatography (Ni2+-NTA) followed by
adsorption chromatography. The decision was made to incorporate a six histidine tag at
the carboxyl terminus, because previous reports have shown that the presence of the
affinity tag at the carboxyl terminus did not significantly influence the activity of the
purified cytochromes P450 (18, 39, 40)
An overnight incubation was required between the detergent-solubilised yeast fraction
and the Ni2+-NTA resin to ensure proper binding of the histidine-tagged P45017a. to the
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resin. With direct loading of the P45017a onto the Ni2+-NTA column the protein eluted
with the washing buffer. During Ni2+-NTA purification it is crucial that the crude
microsomal extract has J3-mercaptoethanol present, since J3-ME prevents disulphide
bridges between cysteine residues of P450 17a and other contaminant proteins (81 and
42 kDa), thereby preventing co-aggregation. The unwanted proteins can then be readily
eluted in the wash step. This binding of native contaminants to recombinant expressed
protein via disulfide bonds has been regularly observed in E. coli expression systems
(41). Dithiotreitol (DTT) is normally added to all the buffers when working with P450
enzymes. DIT, however, reduces the nickel ions of the Ni2+-NTA resin and therefore
DTT was replaced with of J3-ME(10 mM) in the solubilisation buffer.
Other contaminants interfering during lMAC purification are endogenous histidine-rich
or metal-binding proteins from P. pastor is which interfere with the histidine tag of
P45017a by co-purifying or outcompeting recombinant histidine-tagged P45017a when
using a Ni2+-NTA column. A 100 kDa protein co-eluted with P45017a in the elution
buffer containing imidazole (250 mM) and a signal was observed in the Western blot
analysis. However, when using 100 mM of imidazole, only P45017a (i.e. weaker
binding for nickel) was eluted, but the bigger size protein was not (i.e. stronger affinity
for nickel). Therefore the optimum elution range of P45017a was between 15-100 mM
imidazole. Interestingly, research has shown that generally low imidazole concentrations
were used for eluting histidine-tagged cytochromes P450 during !MAC purification. (42,
20). Schalk et al. found that his CYP73Al with four histidine residues at carboxyl
terminal eluted with 50 mM imidazole (39) while Kempf et al. used 80 mM imidazole to
elute the CYP2D6 with a six histidine tag at the amino terminal (40).
Emulgen 913 in Ne+-NTA purified P45017a fraction was removed successfully with a
polymeric adsorbant Amberlite XAD-1600. Although XAD-2 and XAD-4 resins have
been shown to remove detergents from P450 enzyme fractions (43), XAD-2 has been
discontinued by the Rohm and Haas Company. The newly developed XAD-1600 resin
yielded a finer separation than XAD-4 by combining narrow particle distribution, good
mesoporosity and high surface area.
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The investigation of the sequence between the two purification steps, i. e. first using Ni-
NTA chromatography and subsequently using the adsorption chromatography or vica
versa, has been considered. Results show that removing Emulgen 913 and f3-ME with
adsorption chromatography, prior to Ni2+-NTA purification, creates a nonreduced
environment allowing for the aggregation of the 40 kDa protein with P45017a., which
co-elutes in the Ni2+-NTA elution step.
The CO induced difference spectrum of reduced electrophoretic ally pure P45017a.
protein, obtained from the Ni-NTA chromatography, showed an absorbance at 420 nm.
To prevent this degradation of the P450 enzyme, the addition of a ligand, including an
inhibitory ligand, to the binding site of the specific P450 protein is necessary as shown
in literature (44, 45). Adding a ligand like progesterone to the buffers not only stabilises
the protein, but it specifically protects the membrane protein from proteolytic digestion
(46), and purification with little conversion to P420 was observed (47, 48). The CO
different spectrum of the reduced purified bovine P45017a. under detergent-solubilised
conditions was not detectable in the absence of progesterone, indicating the extreme
instability of the enzyme in the substrate free form (34). Kominami et al. has shown that
the stability of purified bovine P450 17a. without progesterone can only be maintained in
liposome membranes and similar stabilisations of membrane proteins in liposome
membranes have been shown (49).
The P. pastoris expression system for steroidogenic cytochromes P450 opens
possibilities for future projects. The conversion of pregnenolone in intact yeast cells and
activity assays of progesterone and pregnenolone in microsomal fraction warrant further
investigation. In addition to the presently developed expression systems studying
mammalian cytochrome P450 (50, 51), this genetically modified Pichia expression
system can assist to study the activities of expressed cytochrome P450 in the presence of
inhibitors and reducing equivalents in living cells or in the microsomal milieu. To fully
understand the cellular environment of the unexplored P. pastoris, the P450 content,
endogenous b-, OR and cytochrome oxidase should be investigated as all these
accessory proteins might impact on the heterologously expressed steroidogenic
cytochromes P450. The P. pastoris expression system for steroidogenic cytochromes
P450 can also be scaled up from shake-flasks to fermentors to further increase the yield
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of P450 proteins. Proper enzyme kinetic studies can be conducted in bioreactors as cells
can be grown under well controlled conditions. Further increase in yield can be
accomplished by producing multi-copy strains with the pPIC3.5K-CYP17 vector.
The production of polyclonal and monoclonal antibodies against the purified human
P45017a obtained in this study is currently under investigation. These antibodies will be
used in studies of the developmental and regulatory features of human P45017a. The
production of therapeutic inhibitors linked to these antibodies will also be investigated.
P45017a is a target in pharmacological interest for prostatic androgen dependent
diseases, such as begnin hypertrophy and carcinoma.
In conclusion, this human P45017a construct, overexpressed in P. pastoris, yielded
sufficient amounts of functional P45017a. The two simple purification steps yielded
sufficient amount of pure human P45017a for further studies on the enzyme which
would include enzymology, control of catalysis, crystallisation and antibody production.
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CONCLUSION
Insertion of a foreign gene into an expression vector does not guarantee a high level of
expression of the foreign protein. Heterologous expression is a complex multi-step
process and problems can arise at numerous stages, from transcription through to protein
stability. Results dealing with failures and even low yields of heterologously expressed
P450 enzymes are often not reported and has hindered biotechnologists to readily
produce a sought after protein. Wrong options with regards to hosts, promoters and
coding sequences are frequently chosen and novel ideas or strategies to improve
expression levels are difficult to formulate. However, with this study, there is now a
considerable accumulated experience on P450 gene expression, especially in yeasts. This
overview can be informative and helpful in the identification of a particular problem
during expression and may contribute to quicker solutions. We have investigated all the
different expression systems that were used and focused on those systems which are the
most suitable for the large-scale production of expressed cytochromes P450.
Not only was the main objective, that of producing a pure unmodified P450 enzyme
achieved, but P. pas/oris was shown to be an excellent host, as was demonstrated with
the human P45017a expression. The success of overexpressing and producing
unmodified human P450 enzymes in P. pas/oris offers several potential applications in
P450 research. This study was merely a stepping stone for future projects such as -
development of activity assays in intact cells, large-scale P450 production with
alternative reducing sources, multi-copy expressions and industrial fermentations.
Undoubtedly, P. pas/oris will be the next generation of heterologous expression system
used as a tool to elucidate and solve many debated issues regarding the role and
functions of cytochromes P450.
"May the Pichia be with you"
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APPENDIX A
DNA sequencing analyses of the human cytochrome P450 cDNAs cloned into the
extracellular (PPIC9K) and intracellular (pPIC3.5K) expression vectors. Plasmid specific and
gene specific primers (listed in Appendix B) were used for the different recombinant
expression vectors. The transcription of the open reading frame is in bold.
Appendix A.I
DNA sequencing alignments of the pPIC9K-CYP17
expression vector harbouring the full-length CYP17
gene.
PPICtlt-CYP17
PriTn@c S-alpha
Primer STEl
Primer 3989
Primer 4011
Primer 8982
Primer 1496
Primer P104
Primer 3_AOX 1
pPlct!t-CYP17
Primer 5-alpha
Primer STEl
Primer 3989
Primer; 4011
Primer 8982
Primer 1496
Primer P104
Primer 3_AOX 1
pPlctJ:-CYP17
Primer 5-alphOl
Primer STEl
Primer 3989
Primer 4011
Primer 8982
Primer 1496
Primer P104
Primer 3_AOX 1
pPlct!t-CYP17
Primer 5-alpha
Primer STEl
Primer 3989
Primer 4011
E'rlmer 8982
Primer 1496
Primer Pl04
Primer 3_AOX 1
pPIC ...... crP17
Primer 5-alpha
Primer STEl
Primer 3989
Primer 4011
Primer 8982
Primer 1496
Primer PI04
Primer 3_AOX 1
pPIC.lt-CYP17
Primer 5-alpha
Primer STEl
Primer 3989
Primer 4011
Primer 8992
Primer 1496
Primer PI04
Primer 3_AOX 1
PPICllt-CYP17
Primer 5-alpha
Primer STEl
Primer 3989
Primer 4011
Primer 9982
Primer 1496
Primer PI04
Primer 3_AOX 1
pPICllt-CTP17
Primer 5-alpha
Primer STEl
Primer 3989
Primer 4011
Primer 8982
Primer 1496
Primer PI04
Primer 3_AOX I
pPICta.-cn17
Primer 5-alpha
Primer STEl
Primer 3989
Primer 4011
Primer 8982
Primer 1496
Primer PI04
Primer 3_AOX 1
pPIc.a-cD17
Pri..m@r S-alpha
Primer STEl
Primer 3989
Pdmer 4011
Primer 8982
Primer 1496
Primer PI04
Primer 3_AOX 1
5'AOX1 primer slte
TTGCGACTGGTTCCAATTGACAAGCTTTTGATTTTAACGACTTTTAACGA 900
-------------------------------------------------- 1
-------------------------------------------------- 1
TTTATKAYKATATAGYTKCTTCAAATTGSNCNGGTCCAATTGCAAGTTTT 128
-------------------------------------------------- 1
------- -- --- -- -- -- ---- -- ----- ------------ -- .....--- --- 1
-------------------------------------------------- 1
------- -- --------------- -- --- -- ------------------- 1
-------------------------------------------------- 1
Start a.~tactor signal ..
CAACTTGAGAAGATCAAAAAACAACTAATTATTCGAAGGATCCAAA.cGAT 950
-------------------------------------------------- 1
-------------------------------------------------- 1
NATTTTACGCTTTNACGCCACTTARAAGATCAAAANCCACTTATTNTNGA 178
------------------------------ ....------------------- 1
----------------------------------- ..-------------- 1
-------------------------------------------------- 1
-------------------------------------------------- 1
--------- ------------------- ---------- ---- ---- ---- 1
BAOA'l"l'TCC'l"'l'CAAT'l"rl."l'AcmcAG'l"l"r''l''rCGCAaCATCC'l'CCGCAT 1 000
-------------- -- ------------------------- --------- 1
-------------------------------------------------- 1
AGNTCCAACGATGRATTCCNTCAATTTTKCGSAGTTTATTGSARSATCCN 228
---------------------- ....--------------------------- 1
-------------------------------------------------- 1
-------------------------------------------------- 1
-------------------------------------------------- I
-------- --------------------- ---------- -------- --- 1
DGCTGC'l'C~'l'QMACCJOCACAAA'l"rCCG 1050
--- -- ----- -- ------ --- --- -- -- ---------------------- 1
-------------------------------------------------- 1
CCGSATAAGGGTCCNGMNACCNTCCACKAAAATTAAKCGGCCNAAN'M'CC 278
-------------------------------------------------- 1
-------------------------------------------------- 1
-------------------------------------------------- 1
-------------------------------------------------- 1
-------------------------------------------------- I
GC'1'GAAGC1'G'1'l'C~'1'"rl'ACIAAGGGGA.'l"1"l'CQA.'l'G'l"'1'GC 1100
-- -------------- ---- ---- - -- --- ------------ -------- 1
--- ....---------------------------------------------- 1
GGTYMAAGCTGTKAYGGTTACTCAGATTNANAAGGGGATTTCGATGTTGC 328
------ ...------------------------------------------- 1
-------------------------------------------------- 1
-------------------------------------------------- I
-------------------------------------------------- 1
--------------- ------- ---- -------------------- ---- 1
'1"G'l"f"1'TCA'f"l"rl'CO"'CAOCACJI&&TWGOCJ'T'fA'1"l'G"l"'l'ATw.n 1150
-------------------------------------------------- 1
-------------------------------------------------- 1
TGT'l'TTGCCATTTTCCAACAGCACAAATAACGGGTTATTGTTTATAAATA 378
-------------------------------------------------- 1
-------------------------------------------------- 1
-------------------------------------------------- 1
-------------------------------------------------- I
-------------------------------------------------- 1
s'e-reecr primer site
C'l'AC".rA'1'TGCCAGCA~'l'CTC'l'CCJAQAAA 1200
-------------------------ARNNANANGGGTATCTCTCGRNAAA 25
-------------------------------------------------- 1
C'I'ACTATTGCCAGCATTGCTGCTAAAGAAGAAGGGGTATCTCTCGAGAAA 428
-------------------------------------------------- 1
- -- - ...----------- -- --------- -- ------ --- ....- -- ----- --- 1
-------------------------------------------------- 1
---------- -------- -- ---- -- - --- ...------- -- -- -------- 1
-------------------------------------------------- 1
Ec:oRl. -e- start '" CYP17
~~I250
RGARRRGCI'GAAGCTTJ\Cr:rAGAA'l'TCATGTGGGJ\.GCTCr:rGGCTC'I'CTT 75
-----------------------------------------J\HANNNAAC 9
AG.J\GAGGCTGAAGC"l"TACGTAGAATl'CATGTGGGAGCTCGTGGCTCTC'I'T 418
-------------------------------------------------- 1
-------------------------------------------------- I
-------------------------------------------------- 1
-------------------------------------------------- 1
-------------------------------------------------- 1
~~~OX~~~~~~~CU~~~9a~~1300
GCTGCTTACCCTAGC'l'TMT.l'GTTl'TGGCCCAAGAGAA,G(;fGCCCTGG'l'G 125
ATGF\ATTMGCATAGCTTATTTGTTTTGGCCCAAGAGAAGGTGCCCTGGTG 59
GCTGCTTACCCTAGCT'I'ATTTGTT'l'TGGCCCAA.G1\GAAGGrGCCCTGGl'G 528
-------------------------------------------------- I
-------------------------------------------------- 1
------- ...---------- ...------------------------------- 1
pPIC9K-CY.l1
Primer 5-alpha
Primer STEl
Primer 3989
Primer 4011
Primer 8982
Primer 1496
Primer PI04
Primer 3_AOX 1
p.IC9lt-CYP17
Primer 5-alpha
Primer STEl
Primer 3989
Primer 4011
Primer 8982
Primer 1496
Primer PI04
Primer 3_AOX 1
pPIC9lt-CYP17
Primer S-alpha
Primer STEl
Primer 3989
Primer 4011
Primer 8982
Primer 1496
Primer PI04
Primer 3_AOX 1
pPIC91t-CYP17
Primer 5-alpha
Primer STEl
Primer 3989
Primer 4011
Primer 8982
Primer 1496
Primer Pl04
Primer 3_AOX 1
pPICllt-CYP17
Primer S-alpha
Primer STEl
Primer 3989
Primer 4011
Primer 8982
Primer 1496
Primer PI04
Primer 3_AOX 1
pPICIIt-CYP17
Primer 5-alpha
Primer STEl
Primer 3989
Primer 4011
Primer 8982
Primer 1496
Primer PI04
Primer 3_AOX 1
pPICllt-CYP17
Primer 5-alpha
Primer STEl
Primer 3989
Primer 4011
Primer 8982
Primer 1496
Primer PI04
Primer 3_AOX 1
pPJ:C9I-cr.17
Primer S-alpha
Primer STEl
Primer 3989
Primer 4011
Primer 8982
Primer 1496
Primer Pl04
Primer 3_ADX 1
pPtc9a-cD17
Primer 5-alpha
Primer STEl
Primer 3969
Primer 4011
Primer 8962
Primer 1496
Primer PI04
Primer 3_AOX 1
CCAAG'!ACCCCAA.IaOCC'l'CC'l'Q'I'CCC'1'GCCC~ 1350
CCAAGTACCCCAAGAGCCTCCTGTCCC'I'GCCCCTGGTGGGCAGCCTGCCA 175
CCAAGTACCCCAAGAGCCTCCTGTCCCTGCCCCTGGTGGGCAGCCTGCCA 109
CCAAGTACCCCAAGAGCCTCCTGTCCCTGCCCCTGGTGGGCAGCCTGCCA 578__________________________________________________1
-------------------------------------------------- 1
- -_ --- ----- ---------------- -- -- -- -- --------------- 1
-------------------------------------------------- 1----- - ------ ------- - 1
T"l'CC'l'CCCCNJIt.CA'l'GGCCA.'1'ATGCAT~'rGCAtJAA 1400
TTCCTCCCCAGACATGGCCATATGCATAACAACTTCTTCAAGCTGCAGAA 225
TTCCTCCCCAGACATGGCCATATGCATAACAACTTCTTCAAGCTGCAGAA 159
TTCCTCCCCAGACATGGCCATATGCATAACAACTTCTTCAAGCTGCAGAA 628
---- --- -- ...- ------------------------ -- -- -- -- ---- --- 1
--------------------------------------------- ...---- 1
---- ------- -------------------- -- -- -- ------ -- ---- - 1
---------------------- ....--------------------------- 1__________________________________________________
AAAATA'1'OGCCC~G'fA'l.'OOGCAC~ 1450
AAAATATGGCCCCATCTATTCTGTTCGTATGGGCACCAAGACTACAGTGA 275
AAAATATGGCCCCATCTATTCTG'l'TCGTATGGGCACCAAGACTACAGTGA 209
AAAATATGGCCCCATCTATTCTGTTCGTATGGGCACCAAGACTACAGTGA 678__________________________________________________1
---- -- --- -- ------- -- -- ------- ----------- ...------- -- 1
-- ----- - ...------------------ -- -- -- ---- ------------- 1
-------------------------------------------------- 1--
'1"1'G'1'C(J(JCCACCACCAOCTOGC~'l'TAAQAa.(J(J(J(?'" 1500
TTGTCGGCCACCACCAGCTGGCCAAGGAGGTGCTTATTAAGAAGGGCAAG 325
TTGTCGGCCACCACCAGCTGGCCAAGGAGGTGCTTATTMGAAGGGCAAG 259
TTGTCGGCCACCACCAGCTGGCCAAGGAGGTGCTTATTAAGAAGGGCAAG 728
-------------------------------------------------- 1
----- ----------- --- --------- --------- ---- -- -- -- -- - 1
-------------------------------------------------- 1
-------------------------------------------------- 1
-------------------------------------------------- 1
~GOCC".t'CAAA~GCQTCCAACAA 1550
GACTTCTCTGGGCGGCCTCAAATGGCAACTCTAGACATCGCGTCCAACAJ\ 375
GACTTCTCTGGGCGGCCTCAAATGGCAACTCTAGACATCGCGTCCAACAA 309
GACTTCTCTGGGCGGCCTCAAATGGC.AA.CTCTAGACATCGCGTCCAACAA 778
-------------------------------------------------- 1
----- ----- ------- ------------- ---- ------------ -- -- 1
-------------------------------------------------- 1
-------------------------------------------------- 1
----------------- -------------------- ---- -- -- ----- 1
CCGTAAGOG'l'ATCQCC'l"l'CGCroACTCTGGCOCACACTGGCAOCTGCA'fC 1600
CCGTAAGGGTATCGCCTTCGCTGACTCTGGCGCACACTGGCAGCTGCATC 425
CCGTAAGGGTATCGCCTTCGCTGACTCTGGCGCACACTGGCAGCTGCATC 359
CCGTAAGGGTATCGCCTTCGC'I'GACTCTGGCGCA 812
-------------------------------------------------- 1
-------- ----------- ------- -- ------ -- --- ---- -- - - --- 1
-------------------------------------------------- 1
--- ----- -- ------------------------ -- ------- -----..:- 1
-------------------------------------------------- 1
OAACJCJCTGGCcaM'GCJCCACCT'1"1"CJCCCTCI'l"'l'CAAITGCJCQAT'CAI1AAB 1650
GAAGGCTGGCGATGGCCACCTTTGCCCTGTTCAAGGATGGCGATCAGAAG 475
GAAGGCTGGCGATGGCCACCTTTGCCCTGTTCAAGGATGGCGATCAGAAG 409
B12
--------GCGATGGCCACCTTTGCCCTGTTCAAGGATGGCGATCAGRAG 42
---- -------------------- -------- --------------- --- 1
-------------------------------------------------- 1
-------------------------------------------------- 1
------ ------- ------------------- --------- ------ --- 1
~TCA~'l'CAG'l'ACA'l"l'GT<J'l'GA.TATGC'1'GGC 1700
CTGGAGAAGATCATTTGTCAGGAAATCAGTACATTGTGTGATATGCTGGC 525
CTGGAGAAGATCATTTGTCAGGAAATCAGTACATTGTGTGATATGCTGGC 459
B12
CTGGAGAAGATCATTTGTCAGGAAATCAGTACATTGTGTGATATGCTGGC 92
---------- ---- --- ---- - ------- ----- --- - -- --ATATGTNG 8
-------------------------------------------------- 1
------ ----------- ---- -- ---- ----- --- -- --- --- -- --- -- 1
--------------------------- ....---------------------- 1
~~~~~~~~~~~~~~~~n9~1750
CACCCACAJ\CGGJ\CAGTCCATJ\GACATCTCC'M"TCCTr:rCTTCGTGGCGG 515
CACCCACAACGG1\CAGTCCATA 481
B12
CACCCP.CAA.CGGACAGTCCJtlAGACATCTCCT"I-rCCTGTCTl'CGTGGCGG 142
CCACCCACAACGGAC'AGCCATAGACATCTCCTTTCCTGTCTTCGTGGCGG 58
-------------------------------------------------- 1
-------------------------------------------------- 1
-------------------------------------------------- 1
~CO~~~~~~~~~~~~~~~~lBOO
TAACCAATGTCAl'CTCCTTGATCTGCTTCAAl"ACCTCCTACAANAATGGG 625
4Bl
B12
TAACCAATr:rCATCTCC'I'TGATCTGCTTCAATACcrCCTACAAGAATGGG 192
TAACCAATGTCATCTCCTTGATCTGC'I"l'CMTACCTCCTACAAGAATGGG 1 08
-------------------------------------------------- 1
-------------------------------------------------- 1
-------------------------------------------------- 1
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pIIC'It-CTP17
Primer S-alpha
Primer STEl
Pd.mer 3989
Primer 4011
Primer 8982
Primer 1496
Primer P104
Primer 3_AOX 1
pPIC'It-CYP17
Primer 5-alpha
Primer STEl
Primer 3989
Primer 4011
Primer 8982
Primer 1496
Primer P104
Primer 3_AOX 1
PPIC'lt-cr'17
Primer 5-alpha
Primer STEl
Primer 3989
Primer 4011
Primer 8982
Primer 1496
Primer P104
Primer 3_AOX 1
pPle'It.-CY'1?
Primer 5-alpha
Primer STEl
Primer 3989
Primer 4011
Primer 8982
Primer 1496
Primer P104
Pz:imer 3_AOX 1
pPIC'It-CTP17
Primer 5-alpha
Primer STEl
Primer 3989
Primer 4011
Primer 8982
Primer 1496
Primer P104
Primer 3_AOX 1
pPIC'It-CYP17
Primer 5-alpha
Primer STEl
Primer 3989
Primer 4011
Primer 8982
Primer 1496
Primer P104
Primer 3_AOX 1
p'IC'It-CYP17
Primer 5-alpha
Primer STEl
Primer 3989
Primer 4011
Primer 8982
Primer 1496
Primer P104
Primer 3_AOX 1
p.ICilt-a.17
Primer 5-alpha
Primer STEl
Primer 3989
Primer 4011
Primer 8982
Primer 1496
Primer Pl04
Primer 3_AOX 1
pUC9X-CYP17
Primer 5-alpha
Primer STEl
Primer 3989
Primer 4011
Primer 8982
Primer 1496
Primer Pl04
Primer 3_AOX 1
pPIC91t-CYP17
Primer 5-alpha
Primer STEl
Primer 3989
Primer 4011
Primer 8982
s r.Ime r 1496
Primer PI04
Primer 3_AOX 1
CM.CC~'1"OAMOCA'1'CA'lABACAA 1850
GACCCTGAG'l'TGAATGTCATACAGAATTACAA.TGAAGGCATCATAGA.~ 615
812
GACCCTGAGTI'GAATGTCATACAGAATTACAATGAAGGCATCATAGACAA 242
GACCCTGAGTTGAATGTCATACAGAATTACAA.TGAAGGCATCATAGACAA 158
-------------------------------------------------- 1
------------------------ --- ------------ -------- --- 1
-------------------------------------------------- 1
CC'l'GA(JO"QACAGCCTGlJ'l'GQkCC'fAQTCCCCTGCl"l"'l'QA'l"l"l"l'CC 1900
CCTGANCAAAACNGCCTGGNGGACCTAGTCCCCTGGNTGAAAATTTNCCC 125
.81
812
CCTGAGCAAAGACAGCCTGGTGGACCTAGTCCCCTGGTTGAAGATTI'TCC 292
CCTGAGCAAAGACAGCCTGGTGGACCTAGTCCCC'I'GGTTGAAGAT'M'TCC 208
------- -------- ------------------ ---------------- - 1
-------------------------------------------------- 1
----------------YYTTN'I'TCNNNCCAANGGGNCNGTTTMNCAAA.TA 34
CCAACAAAACCC'l"OCIAAAAA'l"l'&&ACaQCCA'1"CJ'1'TAAAATACGAAA'1'GAT 1950
CACAAACCCTGGAAAANNAAAGRCCNTGTTAMNNCNAA.TGATCTGGTGA. 115
812
CCAACAAMCCCTGGAAAAATTAAAGAGCCATGTTAAAATACGAAA.TGAT 342
CCAACAAAACCCTGGAAAAATTMAGAGCCATGTTAAAATACGAAATGAT 258
-------------------------------------------------- 1
-------------------------------------------------- 1
AANGGCTAACCCCMNNAAACNGGGGGNCTHCCCNGNAA.NTTTCCCNNACC 84
C'f'GC'l'GAATAW.'UC'l"1'CMAAA'l"rAQ\QGAQI.a~rrcCQGAtJ'l'GAC'l'C 2000
AAAAANCTTGAAATNCANGGNAATTNCGGGNKNCTTTTTNCCNATGGTGG 825
.81
812
CTGCTGAATAAAATACTTGAAAATTACAA.GGAGAAATTCCGGAGTGACTC 392
CTGCTGAATAAAATACTTGAAAATTACAAGGAGAAA.TTCCGGAGTGACTC 308
- -------------- -------- ---------- ---------- ------- 1
-------------------------------------------------- 1
CCNGAAAATAAANCCNMTAAAASAAAMMTTGTMAAAAAANTTAAANTACA 134
TA'1'CACCAACA~'l'CJCAIJICCAAG'l'GAAC'l'C:AGITA 2050
NAMCTGGGCAGCCANWKAACTNAAWWNGGNWKGTGGCCAAAAAANYAARS 815
.81
812
TATCACCAACATGCTGGACACACTGATGC.AAGCCAAGATGAACTCAGATA 442
TATCACC1\A.CATGCTGGACACACTGATGCAAGCCAAGATGAACTCAGATA 358
-------------------------------------------------- 1
------- ------------ --- ---------------------- ------ 1
GNAAANTCNGGGNNTTTTTNCCCNKATTGMGNCCCTTTl\MCAAGCNAGAT 184
A'1"OGCAA'1'GCCCABA'I'CAIJa~TAACCAC 2100
KNTTTSANACMNTTNNCCCWNGGGMNTTNGGG'X'GGGGGNNMCCCCNTNGG 925
.81
812
ATGGCAATGCTGGCCAGATCAAGACT-CAGAGCTGCTTTCAGATA 486
ATGGCAATGCTGGCCCAGATCAAGACTCAGAGCTGCTTTCAGATAACCAC 408
-------------------------------------------------- 1
----- ------------ -- ----------- -------- ------------ 1
AANTCANANNWMGCAATGGNGCCCNRATCAAAAY'fNAAASNMNTTNKAAN 234
A'l"l'CTCACCACCA'l'AGQOOACATC'l"l"rGGQQCC7l'GCIMACCACCAC 2150
AAAGNCCKCCTCNCNCNCCYCGGNAAKA.CTYCGGATRCCANGGGYN 971
'81
812
.86
ATTCTCACCACCATAGGGGACATCTTTGGGGCTGGCGTGGAGACCACCAC 458
-------------------------------------------------- 1
--- -------------- --------- -- ---------------------- 1
AACCCCATTNTCNCCNCNWWNGGGACATCTTGGGGCTGGCGTGNRRCCCC 284
~'l'GGACCCTOOCC'l".l'CC'1'GC1'GCACAA~ 2200
971
.81
812
.86
CTCTGTGGTTAAATGGACCCTGGCCTTCCTGCTGCACAATCCTCAGG 505
-------------------------------------------------- 1
-------------------------------------------------- 1
CCCCCTCTGTGGTAAATGGACCCTGNCTTCCTGNTGCACAATCCTCAGGT 334
~'l""rGACCI.GM~ 2250
971
.81
812
.86
505
------------------------------ATGTGGGTTTCAGCCGCACA 20
-------------------------------------------------- 1
~GCTCTACGAGGAGA.TGACCAGAATGTGGGTT'TCAGCCGCACA 384
CCAACTATCAGTQACCG'l'MCCQTCTCCTC~CACCATCCG 2300
971
'81
812
'86
505
CCAACTATCAGTGACCGTAACCGTCTCCTCCTGCTGGAGGCCACCATCCG 10
-------------------------------------AGGCCACCATCCG 13
CCAA.CTATCAGTGACGGTAACNGTCTCCTCCTGCTGNAGGCCACCATCCG 434
pPIC91t-cYP17 ~CTCAQOCCCCJ'l'G(JCCCC'!A'fGC'TCATCCCCCACAABG 2350
Pr:1mer 5-a1pha 971
Primer STEl 481
Primer 3989 812
Primer 4011 486
Primer 8982 505
Primer 1496
Primer Pl04
Primer 3_AOX 1
pPIC9B.-CYP17
Primer 5-a1pha
Primer STEl
Primer 3989
Primer 4011
Primer 8982
Primer 1496
Primer Pl04
PrimeI 3_AOX 1
AGAGGTGCTTCGCCTCAGGCCCGTGGCCCCTATGCTCATCCCCCACAAGG 120
AGAGGTGCTTCGCCTCAGGCCCGTGGCCCCTATGCTCATCCCCCACAAGG 63
AGAGGTGCTTCGCNTCAGGCCCGTGGCCCCTATGCTCATCCCCCACAAGG 484
~~~~~~~~Kn~nT~~~~~~~~~ 2.00
971
.81
812
.86
505
CCAACGTTGACTCCAGCATCGGTGAGTTTGCTGTGGACA.A.GGGCACAGM. 110
CCAACGTTGACTCCAGCATCGGTGAGTTTGCTGTGGACAAGGGCACAGAA 113
CCAACGTTGA.CTCCAGCATCGGTGAGTTTGCTGTGGACAAGGGCACAGAA 534
.81
pPIC91{-CYP17
Primer 5-a1pha
Primer STEl
Primer 3989
Primer 4011
Primer 8982
Primer 1496
Primer Pl04
Primer 3_AOX 1
pPIC9K.-CYPl '1
Primer 5-alpha
Primer STEl
Primer 3989
Primer 4011
Primer 8982
Primer 1496
Primer Pl04
Primer 3_AOX 1
.81
ppICJIt-CTPl '1
Primer 5-alpha
Primer STEl
Primer 3989
Primer 4011
Primer 8982
Pdmer 1496
Primer P104
Primer 3_AOX 1
pPICJIt-CYP17
Primer 5-alpha
Primer STEl
Primer 3989
s r.tmer 4011
Primer 8982
Primer 1496
Primer PI04
Primer 3_AOX 1
pPICJIt-CYP17
Primer 5-alpha
Primer STEl
Primer 3989
Primer 4011
Primer 8982
Primer 1496
Primer P104
Primer 3_AOX 1
pPIC91t-CYP17
Primer 5-alpha
Primer STEl
Primer 3989
Primer 4011
PIimer 8982
Primer 1496
Primer PI04
Primer 3_AOX 1
pPlC9K.-CYPl '1
Primer 5-alpha
Primer STEl
Primer 3989
Primer 4011
Primer 8982
Primer 1496
Primer Pl04
Primer 3_AOX 1
pPIC91t-CYP17
Primer 5-alpha
Primer STEl
Primer 3989
Primer 4011
Primer 8982
Primer 1496
Primer PI04
Primer 3_AOX 1
p.IC91t-CYP17
Primer 5-a1pha
Primer STEl
Primer 3989
Primer 1011
Primer 8982
Primer 1496
Primer Pl04
Primer 3_ AOX 1
pPIC9lt-CYP17
Primer 5-alpha
Primer STEl
Primer 3989
Primer 4011
Primer 8982
Primer 1496
Primer Pl04
Priml!r 3_AOX 1
pPICJIt-CYP17
IJ'l"l'ATCA'l'TCTCJ'l'GOOCOC'f'QCA'1'C.AC~CA 2450
971
.81
812
.86
505
GTTATCATCAATCTGTGGGCGCTGCATCACAATGAGAAGGAGTGGCACCA 220
GTTATCATCAATCTGTGGGCGCTGCATCACAATGAGAAGGAGTGGCACCA 163
GTTATCATCAATCTGTGGGCGC'I'GCATCACAATGAGAAGGAGTGGCACCA 584
QCCQ(M.'1'CAGT'1'CA'fGCC"l'QAQC(JT'l''I'C'l'''l'aM'1'CCAQCQQGQACCCArlC 2500
971
.81
812
.86
505
GCCGGATCAGTTCATGCCTGAGCGTTTCTTGAATCCAGCGGGGACCCAGC 210
GCCGGATCAGTTCATGCCTGAGCGTTTCTTGAA.TCCAGCGGGGACCCAGC 213
GCCGGATCAGTTCATGCCTGAGCGTTTCTTGAATCCAGCGGGGACCCAGC 634
'l'CM'C"l'CACC~'1"1"'fQCCCftC~C'l"COC'l'CC 2550
971
.81
812
.86
505
TCATCTCACCGTCAGTAAGCTATTTGCCCTTCGGAGCAGGACCTCGCTCC 320
TCATCTCACCGTCAGTAAGCTATTTGCCCTTCGGAGCAGGACCTCGCTCC 263
TCATCTCACCGTCAGTAAGCTATTTGCCCTTCGGAGCAGGACCTCGCTCC 684
'l'OTA'l'AOG'l'QAQA.'l'CC'l'GGCccocCAlJQAQCTC'l"lCTCA'l'CA'l'GGCC'M 2 6 00
971
.81
812
.86
505
TGTATAGGTGAGATCCTGGCCCGCCAGGAGCTCTTCC1'CATCATGGCCTG 310
TGTATAGGTGAGATCCTGGCCCGCCAGGAGCTCTTCCTCATCATGGCCTG 313
TGTATAGGTGAGATCCTGGCCCGCCAGGA.GCTCTTCCTCATCATGGCCTG 134
~CAQA'1'GA.'l'GGGCAOC'l'GCC'I' 2650
971
.81
812
.86
505
GCTGCTGCAGAGGTTCGACCTGGAGGTGCCAGATGATGGGCAGCTGCCCT 420
GCTGCTGCAGAGGTTCGACCTGGAGGTGCCAGATGATGGGCAGCTGCCCT 363
GCTGCTGCAGAGGTTCGACCTGGAGGTGCCAGATGATGGGCAGCTGCCCT 784
CCC'l'GGAAQCJCATCC~TC~ 2100
971
.81
812
.86
505
CCCTGGAAGGCATCCCCA.A.GGTGGTCTTTCTG1\TCGACTCTTTCAAAGTG 410
CCCTGGAAGGCATCCCCAAGGTGGTCTTTCTGATCGACTCTTTCAAAGTG 413
CCCTGGAAGGCATCCCCAAGGTGGTCTTTCTGATCGA.CTCT'I'TCAAAGTG 834
AAGA.'l'CAAGG'l'GCGCCAGCJCC'l'GGAQQGU.QCCCAQGC'l'<IPJJ(J(J'l'A.<JCAC 215 0
971
.81
812
'86
505
AAGATCAAGGTGCGCCAGGCCTGGAGGGAAACCCAAGC'l'GAGGGT 515
AAGATCAAGGTGCGCCAGGCCTMGAGGGAAGCCCAGGCTGAGGGT 458
AAGATCAAGGTGCGCCAGGCCTGGAGGGAAGCCCAGGCTGAGGGTAGCAC 884
6 ;0: histidine tag
CCA'l'CACCA'f'CACCATCACTAAGAATTCCCTAGGGCGGCCGCGAATTAAT 2800
971
.81
812
.86
505
515
.58
CCATCACCATCACCATCACTAAGAATTCCCTAGGGCGGCCGCGAATTAAT 934
TCGCCTTAGACATGACTGTTCCTCAGTTCAAGTTGGGCA.CTTACGAGAAG 2850
971
.81
812
'86
505
515
.58
TCGCCTTAGACATGACTGTTCC'I'CAGTTCAAGTTGGGCACTTACGAGAAG 984
3'AOXf primer sit.
ACCGGTCTTGCTAGATTCTAATGAAGAGGATGTC.AGAATGCCATTTGCCT 2900
971
.81
812
.86
505
515
.58
999ACCGMNCTTGNTAGA
GAGAGATGCAGGCT ..~.".~ 10821
Stellenbosch University http://scholar.sun.ac.za
Appendix A.2: pPIC9K-truncCYP17 256
AppendixA.2
DNA sequencing alignments of the pPIC9K-
truncCYP17 expression vector harbouring the
truncated (~1-18) CYPI7.
pPIC9lt-t. CYII17
Primer 5-alpha
Primer 3989
Primer 4011
Primer 8982
Primer 1496
5' AOX1 primer site
TTGCGACTGGTTCC.AA.TTGACAAGCTTTTGATTTTMCGACTTTTAACGA 900
- ------ ...-- --- -- --------- ------ -------- ---- ...---- --- 1------------------------------------------------GA 2
-- --------- --- ...------ -------- ------- ------------- 1
-- -- ------- ------- ------------ ------------------- 1
-------------------------------------------------- 1
Primer PlOt -------------------------------------------------- 1
Primer 3-AQXl -------------------------------------------------- 1
Start «-fador signal ..
PPIC9K-t. aPl7 CAA..CTTGAGAA.GATCAAAAM.CAACTAATTA'ITCGAAGGATCCAMCG&Y950
Primer 5-alpba -------------------------------------------------- 1
Primer 3969 CAACTTGAbAAGATCAAAAAACAA..CTAATTATTCGAAGGATCCAAACGAT 52
Primer 4011 -------------------------------------------------- 1
Primer 6982 -------------------------------------------------- 1
Primer 1496 -------------------------------------------------- 1
Primer PI04 -------------------------------------------------- 1
Primer 3-AOXl -------------------------------------------------- 1
pPIC91t-t.CYP17 caaa.'1"l"1'CCT'l'CAA'l"l"l"1"l'~GCAGCATCC'l'CCtJCAT 1000
Primer 5-alpha -------------------------------------------------- 1
Primer 3989 GAGATTTCCTTCAATTTTTACTGCAGTTTTATTCGCAGCATCCTCCGCAT 102
Primer 4011 -------------------------------------------------- 1
Primer B962 -------------------------------------------------- 1
Primer 14 96 --------------------------------------------------
Pri.m.er PI 04 ------------- ----- ------ ----------------------- ---
Primer 3-AOX1 ---------------- --- ------------------ -------- -----
pPIC91t-t.CYPl1
Primer 5-alpha
Primer 3989
Primer 4011
Primer 8982
Primer 1496
Primer P104
Primer 3-AOX1
PPIC9lt-t.CYPl7
Primer 5-alpha
Primer 3969
Primer 4011
Primer B982
Primer 1496
Primer P104
Primer 3-AOX1
pPIC91t-t. CYPl1
Primer 5-alpha
Primer 39B9
Primer 4011
Primer 8982
Primer 1496
Primer P104
Primer 3-AOXl
TAOC"l'GCTC~'f'QAAACIJGCACAAM'TCCIJ 1050
---------------------------------------- ..--------- 1
TAGCTGCTCCAGTCAA.CACTACAACAGAA.GATGAAACGGCACAAATTCCG 152
-------------------------------------------------- 1
-------------------------------------------------- 1
-------------------------------------------------- 1
------------------------------------- -- -- ------- -- 1
-------------------------------------------------- 1
acT<lAAOC'1"GTl3O"1"1'AC'l'CABA~~ 1100
-------------------------------------------------- 1
GCTGAAGCTGTCATCGGTTACTCAGATTTAGAAGGGGATTTCGATGTTGC 202
-------------------------------------------------- 1
-------------------------------------------------- 1
---------- ------- -- ---------------- -- -- ----------- 1
------- -- -- --- ----- --- --------------------- ------- 1
-------------------------------------------------- 1
'l'OT'l"1"'J.CAT'l"'rI'CCAI\CMJCAoaa.TAACCJGCJ't"l'ATT<JT'1'TATAAATA 1150
-------------------------------------------------- 1
TGTTTTGCCATTTTCCAA.CAGCACAAATAACGGGTTATTGTTTATAAATA 252
-------------------------------------------------- 1
------------------ ------------- ----- -------- ------ 1
-------------------------------------------------- 1
-------------------------------------------------- 1
-------------------------------------------------- 1
5' a.-factor pOner sle
PPIC9K.-t.CYP17 C'l'AC'!M"'l'O~ 1200
Primer 5-alpha -----------------------ARNHANHANGGGTATHNTNTCGRHAAA 27
Primer 3989 CTA.CTATTGCCAGCATTGCTGCTAAAGAAGAAGGGGTATCTC'l'CGAGAAA. 302
Primer 4011 -------------------------------------------------- 1
Primer 8982 ------------------------------------ _
Primer 1496 ---------------------- _
Primer P104 ---------- ----------------------------------------
Primer 3-AOXI -------------------------------------------------- 1
pPIC9lt-t. CYP17
Primer 5-alpha
Primer 3989
Primer 4011
Primer B982
Primer 1496
Primer Pla"
Primer 3-AOX1
pPIC9lt-t.CTP11
Primer 5-alpha
Primer 3989
Primer 4011
Primer 8982
Primer 14.96
Primer Pl04
Primer 3-AOXl
pPIC9lt-t. CYPl7
Primer 5-alpha
Primer 3989
Primer 4011
Primer 8982
Primer 1496
Primer Pl04
EooRlY -+ start of CYP17
~ACCJ'l'AtJAA.~CCTGCJ'fGCCAA. 1250
RGANRRGCTGAAGCTTACGTAGAATTCAAGACiAAGGTGCCCTGGTGCCAA 77
AGAGAGGCTGAAGCTTACGTAGAATTCAAGAGAAGGTGCCCTGGTGCCAA 352
-------------------------------------------------- 1
-------------------------------------------------- 1
-- -- ---------------------- ------------- ----------- 1
-------------------------------------------------- 1
-------------------------------------------------- 1
CJD.CCCCAAGlJiCC'l'CCTQlfCCC'l'QCC~ 1300
GTACCCCAAGAGCCTCCTGTCCCTGCCCCTGGTGGGCAGCCTGCCATTCC 127
GTACCCCAAGAGCCTCCTGTCCCTGCCCCTGGTGGGCAGCCTGCCATTCC 4 02
-------------------------------------------------- 1
-------------------------------------------------- 1
------------- ----- ------ ---------- -- -- --- --------- 1
-------------------------------------------------- 1
-------------------------------------------------- 1
TCCCCAGACM'GGCCATATGCA.~ 1350
TCCCCAGACATGGCCATATGCATAACAACTTCTTCAAGCTGCAGAAAAAA 177
TCCCCAGACATGGCCATATGCATAACAA.CTTCTTCAA.GCTGCAGMAAAA 452
--- ------ -------- -------- -- ---------- -- --- - ------- 1
-------------------------------------------------- 1
-------------------------------------------------- 1
------------------------ -- ------------------ ---- -- 1
Primer 3-AOX1 ------------------------------ 1
Primer 4011
Primer 8992
Primer 1496
pPIC9K-t.CYP17 TA'MQCCCCA'f'C'rA!TC'fQTICC'I!A'l"GCJOCA.C~'I"fG"r 1400
Primer 5-alpha TATGGCCCCATCTATTCTGTTCGTATGGGCACCAAGACTACAGTGATTGT 227
Primer 3989 TATGGCCCCATCTATTCTGTTCGTATGGGCACCAA.GACTACAGTGATTGT 502
-------------------------------------------------- 1
---------- ---- ------------ ----- ----- -- ------ ------ 1
Prime r P104 ----------------------------- _
Primer 3-AOX1 ----------------- _
pPlcttt-t. CTPl7
Primer 5-alpha
Primer 39B9
Primer 4011
Primer B9B2
Primer 1496
Primer P104
Primer 3-AOX1
pPICtlt-t. CYP17
Primer 5-alpha
Primer 3989
Primer 4011
Primer 8982
Primer 1496
Primer P104
Primer 3-AOX1
CGGCCACCACCAGCTGGCCAA.GGA.GGTGCTTATTAAGAAGGGCAAGGACT 277
CGGCCACCACCAGCTGGCCAAGGAGGTGCTTATT.AAGAAGGGCAAGGACT 552
------------------- ----- ----------------- ---- -- -- - 1
-------------------------------------------------- 1
-------------------------------------------------- 1
------ ----- ------------ -- ----- --- ---- -- -- -- ------- 1
-------------------------------------------------- 1
TC'l'C'fQIJGCCJCJCC'l'CAAA~~Cft 1500
TCTCTGGGCGGCCTCAAATGGCAACTCTAGACATCGCGTCCAACAACCGT 327
TCTCTGGGCGGCCTCAAATGGCAA.CTCTAGACATCGCGTCCAA.CAACCGT 602
--- ----- ------------------ ---------- ------ -------- 1
---------------------------------------------ACCGT 5
---------- ---- ------ -- ---------------------- ---- -- 1
-------------------------------------------------- 1
------------------------__________________________ 1
pPIC91t-t.CTP11 AA.IJCJCI'fM'CQC~ 1550
Primer 5-alpha AAGGGTATCGCCTI'CGCTGACTCTGGCGCACAC'I'GGCAGCTGCA.TCGAAG 377
Primer 3989 AAGGGTA'fCGCCl"TCGCTGA 622
Primer 4011 -------------------------------------------------- 1
Primer 8982 AAGGGTATCGCCTTCGTTGACTCTGGCGCACAC'I'GGCAGC'I'GCATCGAAG 55
Primer 1496 -------------------------------------------------- 1
Primer PI04 -------------------------------------------------- 1
Primer 3-AOX1 -------------------------------------------------- 1
pPIC!j!t-t.CTPl1 tJC'I'OCICca'l'OOC'~~ 1600
Primer 5-alpha GCTGGCGATGGCCACCTTTGCCCTGTTeAAGGATGGCGATCAGAAGCTGG 427
Primer 3989 622
Primer 4011 -----CGATGGCCACCTTTGCCCTGTTCAAGGATGGCGATCAG.AAGCTGG 45
Primer 8982 GCTGGCGATGGCCACCTTTGCCCTGTTCAAGGATGGCGATCAGAA.GCTGG 105
Primer 1~96 -------------------------------------------------- 1
Primer P104. -------------------------------------------------- 1
Primer 3-AOX1 -------------------------------------------------- 1
Primer 5-alpha
Primer 3989
Primer 4011
Primer 8982
Primer 1496
Primer P104
Primer 3-AOX1
pPIC'lt-t. CTPl7
Primer 5-alpha
Primer 3989
Primer 4011
Primer 8982
Primer 1496
Primer PI04
Primer 3-AOX1
pPIC9lt-t.CYP17
Primer 5-alpha
Primer 3989
Primer 4011
Primer 8992
Primer 1496
Primer P104
Primer 3-AOX1
pPIC'It-t. CYPl7
Primer 5-alpha
Primer 3989
Primer 4011
Primer 8982
Primer 1496
Primer P104
Primer 3-ADXl
AGAAGATCATTTGTCAGGAAATCAGTACATTGTGTGATATGCTGGCCACC 477
622
AGMGATCATTTGTCAGGAAATCAGTACATTGTGTGATATGCTGGCCACC 95
AGMGATCATTTGTCAGGAAATCAGTACATTGTGTGATATGCTGGCCACC 155
---------------- ...--------------------------_ ..----- I
-------------------------------------------------- 1
-------------------------------------------------- 1
~'!AGACATCTCC'l"l"l'CC'1'I3!'C:'tTetJIfG(JCCIG"l'AAC 1700
CACAA.CGGACAGNNYGTCCNNMSCTCCCGMKNNNNNNNNNNNNNNNNNNN 527
622
CACAACGGACAGTCCATAGACATCTCCTTTCCTGTCTTCGTGGCGGTAAC 145
CACAACGGACAGTCCATAGACATCTCCTTTCCTGTCTTCGTGGCGGTAAC 205
---- ...--------------------------------------------- 1
-------------------------------------------------- 1
-------------------------------------------------- I
CAA'1'O'l'CATC'l'CCT'l'GA'f'Cl'OCT!l'CAATACCTC~TGCJGCIACC 1750
NNNNNNNNNNNNNNN 542
622
CAATGTCATCTCCTTGATCTGCTTCAATACCTCCTACAAGAATGGGGACC 195
CAATGTCATCTCCTTGATCTGCTTCAATACCTCCTACAA.GAATGGGGACC 255
-------------------------------------------------- 1
-------- -- ---------- ----------------------------- - 1
-------------------- ..----------------------------- 1
C'MAG'l'TQAA~T'1'ACAA'f'GAAGGCA'!CA1'AaA.CAACCTG 18 0 0
542
622
CTGAGTTGAATGTCATACAGAA.TTACAATGAAGGCATCXJ:AGACAACC'l'G 245
CTGAGTTGAA.TG'l'CATJ\CAGAATTACAATGAAGGCATCATAGACAACCTG 305
-------------------------------------------------- I
-------------------------------------------------- 1
-------------------------------------------------- I
pPIC9k-t.CYP11 JliOC'A·~c<MGTGGACCTAG"l'CCC~'l"r'l"l"CCCCAA. 1650
Primer 5-a1pha 542
Primer 3989 622
Primer 4011 AGCAAAGACAGCCTGGTGGACCTAGTCCCCTGGTTGAAGATTTTCCCCAA 295
Primer 8982 AGCAAAGACAGCCTGGTGGACCTAGTCCCCTGGTTGAAGATTTTCCCCAA 355
Primer 1496 -------------------------------------------------- 1
Primer PI04 -------------------------------------------------- 1
Primer 3-AOXI -------------------------------------------------- 1
pPIC91t-t.CYP17 CAAAACCC'l'OQAAAAA'I"fAAAQAlJCCA~OAAA'l'<IATC:'l'OC 1900
Primer 5-alpha 542
Primer 3989 622
Primer 4011 CAAAACCCTGGAAAAATTAAAGAGCCATGTTAAAATACGAAATGATCTGC 345
Primer 9962 CAAAACCCTGGN\MATTAAAGAGCCATGTTAMATACGAAATGATCTGC 405
Primer 1496 - .. ---- ...---------------- ...--- ...---------------------- 1
Primer PI04 ------------------------------------------------ ...- 1
Primer 3-A.QX1 ----------------------------------GGTMYSGGHTTNTTTN 16
pPIC91C-t.CYP17
Primer 5-alpha
Primer 3989
Primer 4011
Primer B982
Primer 1496
Primer PI04
Primer 3-AOX1
TGAA'l!AAAATAC'1"'1'QAAAA'!"l'ACA·QCUIIA·A.~'l'C 1950
542
622
TGAATAAAATACTTGAAAATTACAAGGAGAAATTCCGGAGTGACTCTATC 395
TGAATAAAATACTTGAAAATTACAAGGAGAAATTCCGGAGTGACTCTATC 455
-------------------------------------------------- 1
---------------- --- ----------- ----- -- ----- ---- ---- 1
CCCCCACCCCGG.AAAAAA.AANCCNMTNAAANAAAATTTNNNNAAAAAANT 66
Primer 4011
Primer 9992
pPIC!jIt-t. CYP17 ACCAACA'lGC'l'IJGACACA'MCAAIJeCA.AllA.'1"GAAC'1'CAQA'l'AA'l'GG 2000
Primer 5-alpha 542
Primer 3989 622
ACCAACATGCTGGACACACTGATGC.M.GCCAAGATGAACTCAGATAATGG 445
ACCAACATGCTGGACACACTGATGC.AAGCCAAGATGAACTCAGATMTGG 505
Primer 1496 -------------------------------------------------- 1
Primer P104 -------------------------------------------------- 1
Primer 3-AOXl TAAAAAAA.RANAAATTNGGGGTTTTTTNCCCCNANGMGGNCCNTTTNNNN 116
Stell nbosch University h tp://scholar.sun.ac.za
Appendix A.2: pPIC9K-truncCYP17 257
pPICilt-t.crp17
Primer 5-alpha
Prime.r 3989
Primer 4011
Primer 8982
Primer 1496
Primer PI04
Primer 3-AOXl
pPIC9X.-t.CYP17
p r Lmer 5-alpha
Primer 3989
Primer 4011
Primer 8982
Primer 1496
Primer PI04
Primer 3-AOxl
pPIC9lt-t. CYP1'
Primer 5-alpha
Primer 3989
Primer 4011
Primer 8982
Primer 1496
Primer PI04
Primer 3-AOXl
pPIC9lt-t,CYP17
Primer 5-alpha
Primer 3989
Primer 4011
Primer 8982
Primer 1496
Primer PI04
Primer 3-AOXl
pPIC9X-t.CYP17
Primer 5-alpha
Primer 3989
Primer 4011
Primer 8982
Primer 1496
Primer PI04
Primer 3-AOXl
pPIC91t-t. crPl 7
Primer 5-alpha
Primer 3989
CAATGCTGGCCCAGATCAAGACTCAGAGCTGCTTT
CAATGCTGGCCCAGA.TCMGACTCAGAGCTGCTTTCAGATAACCACATTC 555
-------------------------------------------------- 1
-AATGCTGGCCCAGATCMGACTCAGAGCTGCTTTCAGATAACCACATTC 49
NCNAAMNNNNYNAAAWNGGNAANGGGNCCAAA.YAAAA.YAA.AJ1INGNTTTTA 166
~TC'1"1"'l'GOG~CTCT 2100
542
622
480
TCACCACCATAGGGGACATCTTTGGGGCTGGCGTGGAGACCACCACCTCT 605
-------- ----- ---------- -- ----------------- -------- 1
TCACCACCATAGGGGACATCTTTGGGGCTGGCGTGGAGACCACCACCTCT 99
AAAA.CCCANTTTCCCCCCNNAGGGGAKTTTTNGGGGGGGGMGNANCCCCC 216
GTGGT'l'AAA'l'GGACCCTGGCC'l'TCCTGCTGCACAATC~ 2150
542
622
480
GTGGTTAAATGGACCCTGGCCTTCCTGCTGCACAATCCTCAGGT------ 649
-------------------------------------------------- 1
GTGGTTAAATGGACCCTGGCC'I'TCCTGCTGCACAATCCTCAGGTGAAGAA 149
CCCNTTGGGTTAAAGNNNCNGGCCTNCNTTTMNCNAATCCNAGGNNAAAA 266
~'l"l'CMC~CGCACACCAA 2200
542
622
480
-------------------------------------------------- 649
--------------------------ATKTGGGTTTCAGCCGCACACCAA. 24
GAAGCTCTACGAGGAGATTGACCAGAATGTGGGTTTCAGCCGCACACCM 199
AAAASYTTNCNAGNANNTNNCCCAAANTTGGGTTTCANCCGCNCCCCAAC 316
Cl'ATCAaTClACCtn"AACCcm:'l'CC'l'CC'1'GCT'GQA(JGCCACCATCCGA.aAa 2250
542
622
480
-------------- ------------- ----- ------------------ 649
CTATCAGTGACCGTAACCGTCTCCTCCTGCTGGA.GGCCACCATCCGAGAG 74
CTATCAGTGACCGTAACCGTCTCCTCCTGCTGGAGGCCACCATCCGAGAG 249
NWTCANMGNCNGNANCCGTTTCNTCNTGTTGGAGGCCACCATCCNAAAGG 366
G'MC'rl'CCJCCTCAGQCCCIJ'MCJCCCCTATGCTCATCCCCCA.CAAGQCCAA 2300
542
622
Primer 4011 480
Primer 8982 -------------------------------------------------- 649
Primer 1496 GTGCTTCGCCTCAGGCCCGTGGCCCCTATGCTCATCCCCCACAA.GGCCAA 124.
Primer Pl04 GTGCTTCGCCTCAGGCCCGTGGCCCCTA.TGCTCATCCCCCACAA.GGCCAA 299
Primer 3-A.OXl TGTTTNGCCTCAGGNCCNGNGNCCCCTATGCTCATCCCCCACAAGGCCAA 416
pPIC9k-t,CYP11 CGT'l'GACTCCACJCATCGG'l'GAaT'rl'GC1'G'l'GGACAAOGGCAGAAG'1"1'A 2350
Primer 1496
Primer PI04
Primer 3-AQXl
Primer 5-alpha
Primer 3989
Primer 4011
Primer 8982 ----------------------
CGTTGACTCCAGCATCGGTGAGTTTGCTGTGGACMGGGCACAGAAGTTA 174
CGTTGACTCCAGCATCGGTGAGTTTGCTGTGGACAAGGGCACAGAAGTTA 349
CGTTGACTCCAGCATCGGTGAGTTTGCTGTGGACAAGGGCACAGAAGTTA .( 66
pPICSlk-t.CYPI7
Primer 5-alpha
Primer 3989
Primer 4.011
Primer 8982
Primer 1496
Primer PI04
Primer 3-AQXl
pPIC9lt-t, CYP17
Primer 5-alpha
Primer 3989
Primer 4011
Primer 8982
Primer 1496
Primer PI04
Primer 3-AOXl
pPICSllt-t, CYPI7
Primer 5-alpha
Primer 3989
Primer 4011
Primer 8982
Primer 1496
Primer PI04
Primer 3-A.OXl
pPICSIk -t. CYPI1
Primer 5-alpha
Primer 3989
Primer 4011
Primer 8982
Primer 1496
Primer PI04
Primer 3-AQXl
pPICSllt-t,CYP17
Primer 5-alpha
Primer 3989
Primer 4011
Primer 8982
Primer 1496
Primer PI04
Primer 3-AOXl
pPIC91t-t,CYPI7
Primer 5-alpha
Primer 3989
Primer 4011
Primer 8982
Primer 14.96
Primer PI04.
Primer 3-AOXl
TCA~~CAGCCG 2400
542
622
480
649
TCATCAATCTGTGGGCGCTGCATCACAATGAGAAGGAGTGGCACCAGCCG 224
TCATCAATCTGTGGGCGCTGCATCACAATGAGAAGGAGTGGCACCAGCCG 399
TCATCAATCTGTGGGCGCTGCATCACAATGAGAAGGAGTGGCACCAGCCG 516
C1A'l'CAIl'rl'CA'MCC'l'GACICa'l"'l'TC'l"l'l'CCAaCCJGGCIACCCACJC'l'CAT 2 4.5 0
542
622
480
649
GATCAGTTCATGCCTGAGCGTTTCTTGAATCCAGCGGGGACCCAGCTCAT 274
GATCAGTTCATGCCTGAGCGTTTCTTGAATCCAGCGGGGACCCAGCTCAT 4 -4 9
GATCAGTTCATGCCTGAGCGTTTCTTGAATCCAGCGGGGACCCA.GCTCAT 566
CTCACC~'1"l"1'GCCC'1"1'CCJcatJC.AGGACC'tCGCreC!'G"l 2 500
542
622
480
649
CTCACCGTCAGTAAGCTA'I'TTGCCCTTCGGAGCAGGACCTCGCTCCTGTA 324
CTCACCGTCAGTAAGCTATTTGCCCTTCGGAGCAGGACCTCGCTCCTGTA 499
CTCACCGTCAGTAAGCTA.TTTGCCCTTCGGAGCAGGACCTCGCTCCTGTA 616
TACJCJTGAGA'1'CC'1'GCJCCCCJCCAtJCIAGCTC'rl'CCTCA'l'CATGGCC'1'GCJC'l"G 2 550
542
622
480
649
TAGGTGAGATCCTGGCCCGCCAGGAGCTCTTCCTCATCATGGCCTGGCTG 374
TAGGTGAGATCCTGGCCCGCCAGGAGCTCTTCCTCATCATGGCCTGGCTG 549
TAGGTGAGATCCTGGCCCGCCAGGAGCTCTTCCTCATCATGGCCTGGCTG 666
CTGCAtJAOO'l"'rGACC'1'G<aOCJ'l'GCGA.TM'l'GGGCABC'l'OCCCTCCa 2600
542
622
480
649
CTGCAGAGGTTCGACCTGGAGGTGCCAGATGATGGGCAGCTGCCCTCCCT 424
CTGCAGAGGTTCGACCTGGAGGTGCCAGATGATGGGCAGCTGCCCTCCCT 599
CTGCA.GAGGTTCGACCTGGAGGTGCCAGATGATGGGCAGCTGCCCTCCCT 716
GCaAl'JGCATCCCCAAOO'l'G<J'l'CTC~ 2650
542
622
480
649
GGAAGGCATCCCCAAGGTGGTCTTTCTGATCGACTCTTTCAAAGTGAAGA 474
GGAAGGCATCCCCAAGGTGGTCTTTCTGATCGACTCTTTCAAAGTGAAGA 64. 9
GGAAGGCATCCCCAAGGTGGTCT'I'TCTGATCGACTCTTTCAAAGTGAAGA 766
622
480
pPICSlk .. t, CYP17
Primer 5-alpha
Primer 3989
Primer 4011
Primer 8982
Primer 1496
Primer PI04.
Primer 3-AOXI
PPICSlk-t, crPl1
Primer 5-alpha
Primer 3989
Primer 4011
Primer 8982
Primer 1496
Primer PI04
Primer 3-A.OX1
pPICSlK-t. CYP17
Primer 5-alpha
Primer 3989
Primer 4011
Primer 8982
Primer 1496
Primer Pl04
Primer 3-AOXI
pPICSlK-t.CYP11
Primer 5-alpha
Primer 3989
Primer 4011
Primer 8982
Primer 1496
Primer PI04
Primer 3-A.OX1
pPICH.-t, CYPl7
Primer 5-alpha
Primer 3989
Primer 4011
Primer 8982
Primer 1496
Primer PI04
Primer 3-AOXl
pPICtlt-t, CYP17
542
622
480
649
'l'CAAOO'l'GCQCCAOOC~~T 2700
- 542
622
480
649
TCAAGGTGCGCCAGGCCTGGAGGGAAACCCAGGCTGAGGGTAGCACCCAT 524
TCAAGGTGCGCCAGGCC--------------------------------- 666
TCAAGGTGCGCCAGGCCTGGAGGGAAGCCCAGGCTGAGGGTAGCACCCAT 816
ISx hlstidine tag
CACCATCACCATCAC'fAAGAATTCCCTAGGGCGGCCGCGAATTAATTCGC 2750
542
622
480
649
CACCATCACCATCACTAAGAATTCCCTAGGGCGGCCGCGAATTAATTCGC 514__________________________________________________ 666
CACCATCACCATCACTAAGAATTCCCTAGGGCGGCCGCGAATTAATTCGC 866
CTTAGACATGACTGTTCCTCAGTTCAAGTTGGGCACTTACGAGAAGACCG 2800
542
622
480
649
CTTAGACATGACTGTTCCTCAGTTCAAGTTGGGCACTTACGAGAAGACCG 624
______________________________ ---- - --------------- 666
CTTAGACATGACTGTTCCTCAGTTCAAGTTGGGCACTTACGAGAAGACCG 916
3'AOXI primer sit.
GTCTTGCTAGATTCTAATCAAGAGGATGTCAGAATGCCATTTGCCTGAGA 2850
542
622
480
649
GTCTTGCTAGATTCTAATCAA 645__________________________________________________ 66
MMNCTGNTASAWNNTATNGNNCA.--------------------------- 939
GATGCAGGCTTCATTTTTGATACTTTTTTATTTGTAACCTATATAGTATA 2900
542
622
480
649
645
666__________________________________________________ 939
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Appendix A. 3
DNA sequencing alignments of the pPIC9K-CYB5
expression vector harbouring the full-length CYB5.
pPIC9K-CYBS
Primer 5 xoxr
Primer 3::::"OXI
pPIC9K-CYB5
Primer 5 AOX!
Primer 3=AOX1
pPIC9K-CYB5
PrilTll!r 5 AOXI
Primer 3::::>'OXI
pPIC9K-CYB5
Primer 5_AOX1
Primer 3_AOX1
pPIC9K-CYBS
Primer 5 AOXI
Primer 3:AOXl
pPIC9K-CYB5
Pri.mer 5 AOX!
Primer 3::::AOXl
pPIC9K-CY85
Primer 5 AOXI
Primer 3::::AOXl
pPIC9K-CYB5
Primer 5 AaXl
Prlmer 3::::"OXI
pPIC9K-CYB5
Primer 5 AOXI
Primer 3::::"OXl
pPIC9K-CYB5
Primer 5_AOX1
Primer 3_AOXl
pPIC9K-CYBS
Primer 5 AaX!
Primer 3::::"OXI
pPIC9K-CYBS
Primer 5 AOXI
Primer 3::::AOXl
pPIC9K-CfB5
Primer 5 AOXI
Primer 3::::AOXl
pPIC9K-CYB5
Primer 5 1\OXI
Primer 3::::"OXI
pPIC9K-CYB5
Primer 5_AOXl
Primer 3_ AOXI
pPIC9K-CYB5
Primer 5 AOXI
Primer 3::::AOXI
pPIC9K-CYB5
Primer 5 AOXI
Primer 3::::AOXl
pPIC9K-CYB5
Primer 5 AOXl
Primer 3)~,OXl
pPIC9K-CYB5
Primer 5 AOXI
Primer 3::::AOK1
pPIC9K-CYB5
Primer 5 AaXl
Primer 3::::AOXl
pPIC9K-CYB5
Primer 5_AOX1
Primer 3_AOX1
pPIC9K-CYB5
CCCTGTCTTAAACCTTTTTTTTTATCATCATTATTAGCTTACTTTCATAA 850
------ ------------- -- ----- -------- --- ------------- 1
-------------------------------------------------- 1
5'A.OX1prtnerah
TTGCGACTGGTTCCAATTGACAAGCT1'TTGATTTTAACGACTTTTAACGA 900
-----------------------------GWNTTTMACGACTTTTAACGA 21
------------------------ --------- -------------- --- 1
Starta-f8Ctoralgnal ....
CAACTTGA~TCAAAAAA.CMCTAATTATTCGAAGGATCCAAACGAT 950
CARSTTGAGAAGATMAAAAAACAACTAATTATTCGMGGATCCA.AACGAT 71
----------------- --- ---------------- ------- ------- 1
QAQA'1"l"l'CCTTCAA~'l"f'CGCA(JCA1'CCTCCGCAT 1000
GAGATTTCCTTCAATTTTTACTGCAGTTTTATTCGCAGCATCCTCCGCAT 121
-----------------NNNNNNNNNGAGGGGNN1\RGNGGNNGGGGNNGG 33
~~TGAAAc:QCJC:ACAAA'l"'l'CCQ 1050
TAGCTGCTCCAGTCAACAC1'ACAACAGAAGATGAAACGGCACAAATTCCG 171
NGGNGGGGGGGFl.ANTNAACANTACAACAGAA.GATAAACGGCACAAATTCC 83
~'l'CCJCJ'l"1'.ACTC~'l"!"rCGATO'l"l'GC 1100
GCTGMGCTGTCATCGGTTACTCAGATTTAGAAGGGGATTTCGATGTTGC 221
GGCTGAAGCTGTCATCGGTTACTCAGATTAGAAGGGGATTTCGATGNTGC 133
'l"O'1'T'l"MC'l"l"'1"'1'CCA~OCACAa~'rAACGCJOf1"TA'1"1'G'1'T'l'A'1'AAATA 1150
TG'M'T'TGCCATTTTCCAACAGCACAAATAACGGGTTA'I'TGTTTATAMTA 271
TGTTTTGCCAT'I"I'TCCAACAGCACAAATAACGGGTTATTGTTTATAAATA 183
~~1200
CTACTA'I'TGCCAGCATTGCTGMI'TAAGAAGAAGGGGTATCTCTCGAGAAA 321
CTACTATTGCCAGCATTGCTGCTAAAGAAGAAGGGGTATCTCTCGAGAAA 233
EcoRI • .... .. rt ol evas
~~~QQACGAGQC 1250
AGAGAGGCTGAAGCTTACGTAGAATTcATGGCAGAGCAGTCGGA.CGAGGC 371
AGAGAGGCTGAAGCTTACGTAGAATTCATGGCAGAGCAGTCGGACGAGGC 283
CCJ'l'GAACJ'fAC"CACCC1'A<JAaCIACJA.~CJCAAQA 1300
CGTGAAGTACTACACCCTAGAGGAGATTCAGAAGCACMCCACAGCAAGA 421
CGTGAAGTACTACACCCTAGAGGAGATTCAGAAGCACAACCACAGCAAGA 333
OCACC'l'GOC'l'CM!lCC'l'GCAC~'1"l"fGAC~ 1350
GCACCTGGCTGATCCTGCACCACAA..GGTGTACGATTTGACCAAATTTCTG 471
GCACCTGGCTGATCCTGCACCACAAGGTGTACGATTTGACCAAATTTCTG 383
~~1400
GAAGAGCA.TCCTGGTGGGGAA.GMGTTTTAAGGGAACAAGCTGGAGGTGA 521
GAAGAGCATCC'l'GGTGGGGAAGAAGTTTTAAGGGAACAAGCTGGAGG1'GA 433
CGC1'AC'l'<WJA.C'l"'l"1'GAOGA'r<ft'CG(J(JCAC'l'C'rACAQA'l"QCCAQGQAAA 1450
CGCTACTGAGAACTTTGAGGATGTCGGGCACTCTACAGATGCCAGGGAAA 571
CGCTACTGAGAACTTTGAGGATGTCGGGCACTCTACAGATGCCAGGGAAA 483
~CABA.~ 1500
TGTCCAAAACATTCATCATTGGGGAGCTCCATCCAGA.TGACAGACCAAAG 621
TGTCCAAAACA'M'CATCATTGGGGAGCTCCATCCAGATGACAGACCAAAG 533
'l"l'AAACAAGCCTCCOGAAAC'l'CT'l'A'l'CACDC'rM."'l'GA."r'l'CTAQ'l'TCCAO 1550
TTAAACAAGCCTCCGGAAACTCTTATCACTACTATTGATTCTAGTTCCAG 671
TTAAACAAGCCTCCGGAAACTCTTATCACTACTATTGATTCTAGTTCCAG 583
~CCAACT<JCJQTGATCCC'1'CJCCA'fCT'C'l'GCAt'JCQTCQCC"1" 1600
TTGGGGGGACCAACTGGGTGATCCCTGCCATCTCTGCAGTGGCCGTCGCC 721
TTGGTGGACCAACTGGGTGATCCCTGCCATCTCTGCAGTGGCCGTCGCCT 633
e , hilltldlntt.g
f'M'1'G'fA'1'CtJCCTA'l'ACA~CATCACCA'fCACCA'l'CAC'rGA 1650
TTGATGTATCGCCTATCATGGGAGAGGACCWTCACCTTCCCATNACTGAG 771
TGATGTATCGCCTATACATGGCAGAGGACCATCACCATCACCATCACTGA 683
GAATTCCCTAGGGCGGCCGCGAATTAATTCGCCTTAGACATGACTGTTCC 1700
ANTNCCTAGGGCGGCCGGAANTAATTCGCCTTAAMMTGACTGNTCCTNAN 821
GAATTCCCTAGGGCGGCCGCGAATTAATTCGCCTTAGACATGACTGTTCC 733
TCAGTTCAAGTTGGGCA.CTTACGAGAAGACCGGTCTTGCTAGATTCTAAT 1750
TNNAGNNGGGCMNTNMNAAAAANCNGTCTTGNTNATTNTATNAANAGATG 871
TCAGTTCAAGTTGGGCACTTACGAGAAGACCGMMNCTTGNTAGATTNCTA 783
3'A.OX1primenile
CAAGAGGATGTCAGAATGCCA'M'TGCCTGAGAGATGCAGGCTTCATTTTT 1800
TMMAATGCCTTTGCCTGNAAANGCAGGCTNATTTGGANCTTTTNNTTGNA 921
WNC 786
GATACTTTTTTATTTGTAACCTATATAGTATAGGATTTTTTTTGTCATTT 1850
CCCWAWNGANANGATTTTTTGGMATTTGNTTNTTCGNCCNNCTGCTCC 969
786
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Appendix A.4
DNA sequencing alignments of the pPIC9K-CYP19
expression vector harbouring the full-length CYP19.
pPlctK.-CYPU
Primer 5 AOX!
Primer AromA2
Primer AromB!
Pri.n1er AromB2
Primer Momael
Primer AromaC2
P:rimer 3_AOX
pPIC9lt-CTP19
P.rimer 5 AOX!
Primer ALomA2
Primer A.romS!
Primer AromB2
Primer AromaCl
Primer AromaC2
Primer 3_AOX
pPlcSnt-CYPu
Primer 5 AOX!
Primer AÏomA2
Primer AromS!
Primer AramB2
Primer A.ramaC!
Primer Aromae2
Primer 3_AOX
pplctlt-cYPU
Primer 5 ADX!
Primer ALornA2
Primer AromS!
Primer AromB2
Primer ArOInaCl
Primer AromaC2
Primer 3_AOX
pPIC9K-CYP19
Primer 5 AOX!
Primer ~omA.2
Prime r AromSl
Primer AtomB2
Primer ArmMCl
Primer AromaC2
Primer 3_AOX
pPlctlt-CTPU
Primer 5 AOXI
Primer AÏomA2
Primer ArarnS!
Primer Arom82
Primer AromaCl
Primer AromaC2
Primer 3_ AOX
pPlctlt-CfP19
Primer 5 AOX!
Primer AromA2
Primer AromSl
Primer AromB2
Primer AromaCl
Primer AromaC2
Primer 3_AOX
pPIC91t-crP19
Primer 5 AOXI
Primer AComA2
Primer AromBl
Primer AromB2
Primer AromaCl
Primer AromaC2
Primer 3_AOX
pPIC9lt-CYP19
Primer 5_AOXI
Primer AromA2
Primer AromSl
Primer AromB2
Primer AromaCl
Primer 1u:omaC2
Primer 3_AOX
pPIC9X-CY.19
Primer 5 AOXI
Primer AromA2
Primer ArornB1
Primer AromB2
Primer AromaCl
Primer AromaC2
Primer 3_AOX
PPIC9X-ctP19
Primer 5 AOXI
Primer AÏomA2
Primer AromB1
Primer ArornB2
Primer AromaCl
Primer AromaC2
Primer 3_AOX
CCCTGTCTT.AAA.CCTTTTTTTTTATCATCATTATTAGCTTACTTTCATAA 850
-------------------------------------------------- 1
--------- --- ------ --- -- --- ------ --- -- ----------- -- 1
------------------------ ....------------------------- 1
-------------------------------------------------- 1
-------------------------------------------------- 1
-------------------------------------------------- 1
--- - - --------------- ------------------ ----- ------- 1
5'AOX1prtmer ••
TTGCGACTGGTTCCAATTGACAAGCTTTTGAT'I'TTAACGACTTTTMCGA 900
---------------------------------------CGACTTTTACG Il
-------------------------------------------------- 1
-------------------------------------------------- 1
Starta·factoraignal ....
CAACTTGAGAA.GATCAAAMACAACTMTTATTCGAAGGATCCAAACGAT 950
ACACTTGAGAAGATCAAAMACAACTAATTATTCGAAGGA.TCCAAACGAT 61
-------------------------------------------------- 1
---- -------- ------------------ ----- --------------- 1
----------------------------------- .._------------- 1
--------------------------------- ...---------------- 1
--------- -------------------- ----- ---- ------------ 1
-------------------------------------------------- 1
~~'l"l'COCACJCA'fCC'fCCGCAT 1000
GAGATTTCCTTCAAT'ITT'fACTGCAG'lTI'TATTCGCAGCA.TCCTCCGCAT 111
-------------------------------------------------- 1
-------------------------------------------------- 1
-------------------------------------------------- 1
TAGCTGCTC~CIAAI1ATGAAAC:OGCACAAAT'l'CCG 1050
TAGCTGCTCCAGTCAACACTACAACAGAA.GATGAAACGGCACAAATTCCG 161
-------------------------------------------------- 1
-------------------------------------------------- 1
-------------------------------------------------- 1
-------------------------------- -- ----- -- -------- - 1
-------------------------------------------------- 1
-------------------------------------------------- 1
~'l'CGG'l"'lAC'J.'CA'1"'1"1'AI1AA'1"l"1'CGA.'l 1100
GCTGAA.GCTGTCATCGGTTACTCAGATTTAGAA.GGGGATTTCGATGTTGC 211
-----------------------------------------CGATGTTGC 9
-------------------------------------------------- 1
-------------------------------------------------- 1
- ---------- ------------- ------ ------------- ------- 1
-------------------------------------------------- 1
--- ---------- -- -- --- --------- ------ --------------- 1
'l'G'l""l"1'CA'1"'1"1"1'COaCAGCACAaa'rAACCJC»'1"1'A'1'TCJ'J."1"r'l'AAATA 1150
TGTTTTGCCATTTTCCAACAGCACAAATAACGGGTTATTGTTTATAAATA 261
TGTTTTGCCATTTTCCAACAGCACAAATAACGGGTTATTGTTTATAAATA 59
-------------------------------------------------- 1
-------------------------------------------------- 1
-------------------------------------------------- 1
-------------------------------------------------- 1
-------------------------------------------------- 1
~~'1'C'1'C'1'CQABAAA 1200
CTACTATTGCCAGCATTGCTGCTAAAGAAGAA.GGGGTATCTCTCGAGAAA. 311
CTACTATTGCCAGCATTGCTGCTAAAGAAGMGGGGTATCTCTCGAGAAA 109
-------------------------------------------------- 1
-------------------------------------------------- 1
-------------------------------------------------- 1
NotI • .urtofCYP17.
~crrAGAA'l"'f'CCCDGGQCCGCQGAt'IM'QCJ'l' 1250
AGAGAGGCTGAAGCTTACGTAGAATTCCCTAGGGCGGCCGCGGAGFGGT 361
AGAGAGGCTGAAGCTTACG'I'AGAA'M'CCCTAGGGCGGCCGCGGAGATGGT 159
-------------------------------------------------- 1
-- ------ --- -------- ----- -- ----------------- ------- 1
-------------------------------------------------- 1
--- ...---------------------------------------------- 1
-- -- -- ----------------------- -- -- -- --------------- 1
~'l'GC'TCaACCCCJATACA'1'TATAACATCAC~TCIJTCJCC'l'G 1300
TTTGGAAATGCTGAACCCGATACATTATAACATCACCAGCATCGTGCCTG 411
TTTGGAAA.TGCTGAACCCGATACATTATAACATCACCAGCATCGTGCCTG 209
-------------------------------------------------- 1
TTTGGAAATGCTGAACCCGATACATTATAACATCACCAGCATCGTGCCTG 50
------------------- ...---------------- ...------------- 1
-------------------------------------------------- 1
--------- ----------- --------- --------------- ------ 1
ANICCA'J'GCC1'OC'1'GCCACCA~C"1"l"'1"1"' 1350
AAGCCATGCCTGCTGCCACCATGCCAGTCCTGCTCCTCACTGGCCTTTTT 461
AAGCCATGCCTGCTGCCACCATGCCAGTCCTGCTCCTCACTGGCCTTTTT 259
-------------------------------------------------- 1
AAGCCATGCCTGCTGCCACCATGCCAGTCCTGCTCCTCACTGGCCTTTTT 100
--- ------ ----------- ------ ------------------------ 1
--- ----------- -- ---- ------ --- -------------- ------- 1
-------------------------------------------------- 1
pPIC'lt-CY'19
Primer 5 AOXI
Primer ALomA2
Primer Arom.Bl
Primer AromB2
Primer AromaCI
Primer AromaC2
Primer 3_AOX
p'IC'X-ct'18
Primer 5 AOXI
Primer Ar0mA2
Primer AromSl
Primer AromB2
Primer AromaCI
Primer AromaC2
Primer 3_AOX
p'IC'X-CY'19
Primer 5 AOXI
Primer AromA2
Primer AromBl
Primer AromB2
Primer AromaCl
Primer AromaC2
Primer 3_AOX
p'IC91t-CY'U
Primer 5 AOXI
Primer AromA2
Primer AromBl
Primer AromB2
Primer AromaCI
Primer AromaC2
Primer 3_AOX
p.IC8X-Cl'19
Primer 5 AOXI
Primer AÏomA2
Primer AromSl
Primer AromB2
Primer AromaC1
Primer ArornaC2
Primer 3_AOX
p.IC9X-cYPU
Primer 5 AOXI
Primer AromA2
Primer AromBI
Primer AromB2
Primer AromaCI
Prltn@r AromaC2
Primer 3_AOX
pPIC91t-CY'U
Primer 5 AOXI
Primer AÏomA2
Primer AromBl
Primer AromB2
Primer AromaCI
Primer A.romaC2
Primer 3_AOX
pPIC'X-CYPU
Primer 5_AOXI
Primer AromA2
Primer AromBl
Primer AromB2
Primer A.romaCI
Primer AromaC2
Primer 3_AOX
PPIC9X-CY'U
Primer 5 AOXI
Primer AComA2
Primer AromBl
Primer AromB2
Primer AromaCI
Primer AromaC2
Primer 3_AOX
p'IC9lt-CY'1'
Primer 5 AOXI
Primer AComA2
Primer AromBl
Primer AromB2
Primer AromaCl
Primer AromaC2
Primer 3_AOX
p'IC'lt-CYPl9
Primer 5 AOXI
Primer AromA2
Primer AromBl
Primer AromB2
Primer A.romaCl
Primer AromaC2
Primer 3_AOX
pPIC'X-CY'U
Primer 5 AOXI
Primer AIomA2
Primer AromBl
Primer AromB2
Primer AromaCI
Primer AromaC2
Primer 3_AOX
CTC'I"l'OGTO'l~TCC'l'CAA'fACC1QQ'1'C~ 1400
CTCTTGGTGTGGAA'I'TATGAGGGCACATCCTCAATACCAGGTCCTGGCTA 511
CTCTTGGTGTGGAATTATGAGGGCACATCCTCAATACCAGGTCCTGGCTA 309__________________________________________________ 1
CTCTTGGTGTGGAATTATGAGGGCACATCCTCAATACCAGGTCCTGGCTA 150__________________________________________________
__________________________________________________ 1
__________________________________---- ---------- -- 1
C'fGCA'fGCJGAA'l"'MGACCCC'fCA'l'C'TCCCACOCJCAM'l"'l'CCTOTOC1AfOG 1450
CTGCATGGGAATTGGACCCCTCATCTCCCACGGCAGATTCCTGTGGA.TGG 561
CTGCATGGGAATTGGACCCCTCATCTCCCACGGCAGATTCCTGTGGATGG 359__________________________________________________ 1
CTGCATGGGAATTGGACCCCTCATCTCCCACGGCAGATTCCTGTGGATGG 200
____________________ --------------- -- ------------- 1
__________________________________________________1
_________________________________ ------------- ---- 1
CJQA.~CCIGCJ'1'O'tATGCJAQAA'r'l'CA'fG 1500
GGATCGGCAGTGCCTGCAACTACTACAACCGGGTGTATGGAGAATTCATG 611
GGATCGGCAGTGCCTGCAACTACTACAACCGGGTGTATGGAGAATTCATG 409
_______________________________ ------- -- -- -- - - ---- 1
GGATCGGCAGTGCCTGCAACTACTACAACCGGGTGTATGGAGAATTCATG 250
___________________ ------- ----- - ..- -- -------- ---- -- 1
__________________________________________________1
_____________________-_--------- -- --- --- ..---- ----- 1
~~'1'TA'1'CIJICAACJ'l'CTCAAIJ 1550
CGAGTCTGGATCTCTGGAGAGGAAACACTCATTATCAGCAA.GTCCTCAAG 661
CGAGTCTGGATCTCTGGAGAGGAAACACTCATTATCAGCAAGTCCTCAAG 459__________________________________________________ 1
CGAGTCTGGATCTCTGGAGAGGAAACACTCATTATCAGCMGTCCTCAA.G 300__________________________________________________1
__________________________________________________1
__________________________________________________1
TATO'l"'J.'CCACATAATaAlJICACAA'l'CA'l'TACAOCTC'l'CaA.'r'l'COGCAOCA 1600
TATGTCNNWNWNTDGGKRGMMRYANBTTNGNRVKKBKGNNNATNAHTAAA 711
TATG'I'TCCACATAATGAAGCACAATCATTACAGCTCTCGATTCGGCAGCA 509
__________________________---- ---- -- -- -- ----- ----- 1
TATGTTCCACATAATGAAGCACAATCATTACAGCTCTCGATTCGGCAGCA 350_______________________________________-- --------- 1
__________________________________________________1
_________________________ ---- ------ -- ----------- -- 1
~TCGC'I'l'A'l'GCA'l'GACIAUJJQCA'l'CATA'l"rrAAC 1650
TACDBANNABNYCDTDWTCNTNANNTANNSNNNNAGNNNNNNNNNNN 758
AACTTGGGCTGCAGTGCATCGGTATGCATGAGAAAGGCATCATATTTAAC 559________________________________.._----- -- -- ----- -- 1
MCTTGGGCTGCAGTGCATCGGTATGCATGAGAAAGGCATCATATTTAAC 400__________________________________________________1
__________________________________________________1
__________________________________________________1
AACAATC~GACCC'1'TC'l"r'l'ATGAAAGCTC'l' 1700
758
AACAATCCAGAGCTCTGGAAAACAACTCGACCCTTCTTTATGAAAGCTCT 609__________________________________________________1
AACAATCCAGAGCTCTGGAAAACAACTCGACCCTTCTTTATGAAAGCTCT 450-_________________________________________________ 1
_____________________________________________-- --- 1
__________________________________________________1
~Cc:JCICC'l"'1'MGD.~'lCCC'f'CA 1750
758
GTCAGGCCCCGGCCTTGTTCGTATGGTCACAGTCTMGCGWCC 651__________________________________________________1
GTCAGGCCCCGGCCTTGTTCGTATGGTCACAGTCTGTGCTGAATCCCTCA 500
-------------------------------------------------- 1
---_ ---- ----------- ------------- ------- ----------- 1
------------- -- ---------- ---- ---- ---------- 1
J.AACACA~CAATOAATCQCJGC'l'A'lGTG 1800
758
651
-----ACATCTGGMCGGTTGGAGGAGGTGACCAATGAATCGGGCTATGTG 45
AAACACATCTGGACAGGTTGGAGGAGGTGACCAATGAATCGGGCTATGTG 550------____________________________________________1
-------------------------------------------------- 1
-------------------------------------------------- 1
~CC!"f'C"I'GCG'I'C<JTGTCA~OC"1' 1850
758
651
GACGTGTTGACCCTTCTGCGTCGTGTCATGCTGGACACCTCTAACACGCT 95
GACGTGTTGACCCTTCTGCGTCGTGTCATGCTGGACACCTCTAACACGCT 600
----------- ------- --------- ---- -- -- --- -- --- ------- 1--
__________________- -- ------- -- --- - 1
~TCCC"1"1"'J!'(JMtJrAAA1n'QCTATC~TCCAAa 1900
758
651
CTTCTTGAGGATCCCTTTGGACGAAAGTGCTATCGTGGTTAAAATCCAAG 145
CTTCTTGA.GGATCCCTTTGGACGAAAGTGCTATCGTGGTTAAAATCCAAG 650
__________------ -- -- ------ -- ----- ---- -------- - ---- 1
-------------------------------------------------- 1
-------------------------------------------------- 1
651
GTTATTTTGATGCATGGCAAGCTCTCCTCATCAAACCAGACATCTTCTTT 195
GTTATTTTGATGCATGGCAAGCTCTCCTCATCAAACCAGACATCTTCTTT 700
-------------------------------------------------- 1
-------------------------------------------------- 1
-------------------------------------------------- 1
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pPIC'.-CYP1'
Primer 5 AaX!
Primer AIomA2
Primer Al::omBl
Primer AromB2
PriJner AromaCl
Primer AromaC2
Primer 3_AOX
pPIC9Jt-CYPU
Primer 5 AQXI
Primer AëomA2
Primer AromBl
Prime r Ar0m82
Primer Mamael
Primer Momae2
Primer 3_AOX
pPIC'l[-CYPU
Primer 5 AOX!
Primer AromA2
Primer A.romBl
Primer AromB2
Primer Momael
Primer AromaC2
Primer 3_AOX
PPIC'J,-CYPU
Primer 5 AOX!
Primer AromA2
Primer AromS!
Primer AramB2
Primer Arornael
Primer AromaC2
Primer 3_AOX
pPIC'lt-CYPU
Primer 5_AOXI
Primer AromA2
Primer AromSl
Primer AromB2
Primer AromaCl
Primer AromaC2
Primer 3_AOX
pPIC'lt-CYPU
Primer 5 AOX!
Primer ALom1\2
Primer AromSl
Primer ArornB2
Primer Momael
Primer AromaC2
Primer 3_AOX
PPIC91t-CYPU
Primer S_AOXI
Pr irue r AromA2
Primer MOInB!
Primer AromB2
Primer ArornaCl
Printer AromaC2
Primer 3_AOX
pPIC9lt-CYPU
Primer 5_AOXI
Primer AromA2
Primer AromSl
Pz:imer AromB2
Primer ArornaCI
Primer AromaC2
Primer 3_AOX
pPIC9lt-CTPU
Primer 5_AOXI
Primer AromA2
Primer A.r:omBl
Primer AromB2
Primer AromaCI
Primer ArornaC2
Primer 3_AOX
pRIC9lt-CYP19
Primer 5 AOXI
Primer ALomA2
pri.rner ArornBl
Primer AromB2
Primer AromaCI
Primer Al:omaC2
Primer 3_ADX
pPIC9lt-CYPU
Primer 5 AOXI
Primer AÏomA.2
Primer A.r:omBl
Primer A.r:omB2
Primer AromaCl
Primer AromaC2
Primer 3_AOX
pPIC9lt-CYP19
Primer 5_ AOXI
Primer AromA2
Primer ArornBl
Primer AromB2
Primer ArOlnaCl
Primer AromaC2
Primer 3_AOX
PPIC91C.-CYPU
Primer 5 AOXI
Primer Ar0mA2
Primer AromBl
Primer ArornB2
Primer ArOlnaCl
Primer AromaC2
Primer 3 _AOX
~~2000
758
651
AAGAT'l'TCTTGGCTATACAAAAAGTATGAGAAGTCTGTCAA.GGAT'l'TGAA 245
AAGA.TTTC'rTGGCTATACAAAAAt:;TATGAGAAGTCTGTCAAGGAT'l'TGAA 750
-------------------------------------------------- 1
..-- ------------ ----- ----------- --- -- --- ------- -- -- 1
-------------------------------------------------- I
ACJA'1'GCCA~TAGCAaa····~TGCAQQA.T'l"l'CCACAG 2050
758
651
AGATGCCATAGAAGTTCTGATAGCAGAAAAAAGACGCAGGATTTCCACAG 295
AGATGCCATAGAAGTTCTGATAGCAGAAAAAAGACGCAGGATTTCCACAG BOO
-------------------------------------------------- 1
--------------------- ------- ------- ------------- -- 1
-------------------------------------------------- 1
~!'CJ'rA~~2l00
758
651
AAGAGAAAC1'GGAAGAATGTATGGACTTTGCCACTGAGTTGATTTTAGCA 345
AAGAGAAACTGGAAGAATGTATGGACTTTGCCACTGAGTTGATTTAGCAG 950
-------------------------------------------------- 1
--------- -------- ---- -------- ..- ..--- ---------- ----- 1
----------------- ...-------------------------------- 1
GAGAAACGTGGTGACCTGACAAGAGAGAATGTGAACCAGTGCATATTGGA 395
AGAAACGGAC
-----------------------------------------CATATTGGA 9
-------- ..--------------------------------------- ...- 1
-------------------------------------------------- 1
~'l'CCJCAOC'I'CCTGACA.CCA'f<J'lC'M'1'CTC'I'Il'G%'l'C'r'1'CAmc 2200
758
651
AATGCTGATCGCAGCTCCTGACACCATGTCTGTCTCTTTGTTCTTCATGC 445
AATGCTGAYCGCAGCTCCTGN4ACCATGTC1'GTCTCTTTGTTCTTCATGC 59
- ------------- --------- -- ---------------------- --- 1
-------------NWTTGNAAMSMRTNSAGNTCTGCCCCAAGTTGTTTTT 37
TATTTCTCATTGCAAAGCACCCTAATGTTGAAGAGGCAATAATAAA.GGA.A 495
860
TATTTCTCATTGCAAAGCACCCTAATG'M'GAAGAGGCAATMTAAAGGAA 109
--------- ------- ----- ------------- ------------ -- ..- 1
GTTTTCANGNATTTNCATGCAAANCCCCTANTNNNNANRGGCAATATAAN 97
A'l'CCAGACTG'l"l'A'l"l'OG'l'aAGACA'IAAAaA'l"l'GAT<lATATACAAAA 23 00
758
651
ATCCAGACTGTTATTGGTGAGAGAGACATAAAGATTGATGATATACAAAA 545
860
ATCCAGACTGTTATTGGTGAGAGAGACATAAAGATTGATGATATACAAAA 159
-------------------------------------------------- 1
GNMTCCAGNCTGTTTTGGTGAGGGNGCKWAAAGNTTGATGATWTCNAAA 137
A~~NABAGCA'l'CJCGCJ!!ACCAC'fQ 2350
758
651
ATTAAAAGTGA.TGGAAAACTTCATTTATGAGAGCATGCGGTACCAGCCTG 595
ATTAAAAGTGATGGAAAACTTCATTTATGAGAGCATGCGGTACCAGCCTG 209
------------NCNNNGSGTTHGCTATGAGAGCATGCGGTACCAGCCTG 39
ATTAAAAGTGATGGAAAACTTCATTTATGAGAGCATGCGGTACCAGCCTG 197
TCG'l'GQA.C"l"l'QG'l'CATGCIJCAAAGCCT'l'AaAAQATGA'IO'l'AA'l'CGATGOC 2 4 00
758
651
TCGTGGACTTGGTCATGCGCAAAGCCTTAGMGATGATGTAATCGATGGC 645
860
TCGTGGACTTGGTCATGCGCAAAGCCTTAGAAGA.TGATGTAATCGATGGC 259
TCGTGGACTTGGTCATGCGCAAAGCCTTAGAAGATGATGTAATCGATGGC B8
TCGTGGACTTGGTCATGCGCAAAGCCTTAGAAGATGATGTAATCGATGGC 237
'l'ACCCAaTGA· •• ~.ACA'1"tA'l'CC1'GAA.~'lGCA 2450
758
651
TACCCAGTGNAAMGGGGACAAACATTATCCTGAATATTGGAAGGATGCA 695
TACCCAGTGAAAAAGGGGACAAACATTATCCTGAATATTGGAAGGATGCA 309
TACCCAGTGAAAAAGGGGACAAACATTATCCTGAATATTGGAAGGATGCA 139
TACCCAGTGAAAAAGGGGACAAACATTATCCTGAATATTGGAAGGATGCA 297
CAGACTC<aCJT'1"l"1"'CCCAAACCCAATCaA~'l"rrTG 2500
758
651
CAGACTCGAGTTTTTCCCCAACCCAATGAN'I'TACTCTTGAAANTTTGCAA 745
860
CAGACTCGAGTTTTTCCCCAMCCCAATGAATTTACTCTTGAAAATTTTG 359
CAGACTCGAGTTTTTCCCCAAACCCAATGAATTTACTCTTGAAAATTTTG 188
CAGACTCGAG'I'TTTTCCCCAAACCCAATGAATTTACTCTTGAAAATTTTG 337
CAAAaAAT<J'rl'CC'l"l'ATAGCJ'1'AC'l"l"TCABCCAT'r1'GGC'l"'1'CCG'l' 2 550
758
AAAAGTGCYCNTANGNGNACTTNMCCCATTTGGNTTNGGNCCCGTGGCTG 795
860
CAAAGAATGTTCCTTATAGGTACTTTCAGCCATTTGGCTNKGGNGNGNN 409
CAAA.GMTGTTCCTTATAGGTACTTTCAGCCATTTGGCTTTGGGCCCCGT 239
CAAAGAATGTTCCTTATAGGTACTTTCAGCCATTTGGCTTTGGGCCCCGT 397
TGCANGAAA(;J'CATCGCCATGGTGATGATGAAGCATCCTCGTNMMCTTCT 945
860
GGCTGTGCAGGAAAGTACATCGCCATGGTGATGATGAAAGCCATCCTCGT 298
GGCTGTGCAGGAAAGTACATCGCCATGGTGATGATGAAAGCCATCCTCGT 437
pPIC9I-cYPU
Primer 5 AOX!
Primer AIomA2
P.rimer ALomSI
P.rimer AromB2
Primer ALomaCl
Primer AromaC2
Primer 3_AOX
pPIC9lt-CYPlt
Primer 5 AOXI
Pdmer ALomA2
Primer AromSl
Primer AromB2
Primer ALomaCl
Prime.r AromaC2
Primer 3_AOX
pPIC91C.-CfP19
Primer 5 ADXI
Primer ALomA2
Primer AromSl
Primer AromB2
Primer AromaCl
Primer Al:omaC2
Primer 3_AOX
651
pPIC9I-CYP19
Primer 5 AOXI
Primer AL'omA2
Primer 1\romBl
Primer AromB2
Primer AromaCl
Primer AromaC2
Primer 3_AOX
860
860
pPIC9X-CYP19
Primer 5 AOX!
Primer AÏomA2
Primer MomSl
Primer ALomB2
Primer ArornaCI
Pr-Ime r AromaC2
Primer 3_ AOX
651
pPIC9lt-CYP19
Primer 5 ADXI
Primer AromA2
Primer AromBl
Primer AromB2
Prime.r ALomaCl
Primer AromaC2
Primer 3_AOX
pPIC9X-CYP19
860
860
651
651
408
651
GAAACGATCCACGTGAAACNTTGCANGACRGGTGTTGANNSAWACAAAAA 895
860
408
TACACTTCTGAGACGATTCCACGTGAAGACATTGCAAGGACAGTGTGTTG 338
TACACTTCTGAGACGATTCCACGTGAAGACATTGCAAGGACAGTGTGTTG 497
ABA.GCA~'lACACcacT"fG'1'CC'J."'l'QCACCCAClA.~ 2700
758
651
NACCGACTNNNCTTGCCCNAATGAACTAAMCATGYTGNAATRYCTTNCC 945
860
408
AGAGCATACAGAAGATACACGACTTGTCCTTGCACCCAGATGAGACTAAA 388
AGAGCATACAGA.AGATACACGACTTGTCCTTGCACCCAGATGAGACTAAA 537
651
CCANJ\AITCNANGGGGTYGGANCCCTCCCCCCCNTTACCGGGGAATCCNG 995
860
408
AACATGCTGAAA 400
AACATGCTGGAMTGA.TCTTTACCCCAAGAAACTCAGACAGGTGTCTGGA 597
e .. hillklinetag
M:N:CA'l'CAC~ftAACCGCGGGAATTCGCGGCCGCGAATTAAT 2900
758
651
CCGNAATANTCCCTNAAATGAYKKTNNCANTNAGTGGGMYNCANAAANGG 1045
860
'08
400
ACACCATCACCATCACCATTAACCGCGGGAATTCGCGGCCGCGAA.TTAAT 637
TCGCCTTAGACATGACTGTTCCTCAGTTCAAGTTGGGCACTTACGAGAAG 2950
758
651
NNTSYAATYTAACAAGRGKCAAAGCCTTNCCGAAGGMGGTYYNTTTNACT 1095
860
408
400
TCGCC'M'AGACATGACTGTTCCTCAGTTCAAGTTGGGCACTTACGAGAAG 697
3'AOX1 primer.
ACCGGTCTTGCTAGATTCTAATCAAGAGGATGTCAGAATGCCATTTGCCT 2900
758
651
1106
860
408
400
ACCGMCTTGCTAG------------------------------------- 700
TTTTNRANNAN
ACACTGAAAAATAACAGTTATTATTCG .................. ~.~.H.~....~... 10827
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Appendix A.5
DNA sequencing alignments of the pPIC3 .5K-CVP 17
expression vector harbouring the full-length CVPI7.
pPIC3.5K-CYP17
5 AOXI
4011
3989
8962
3 AOXI
1496
pPIC3.5K-CYP17
5 AOXI
4011
3989
8982
3 AOXI
1496
S'AOX1 prVnefaite
TTGCGACTGGTTCCAATTGACAAGCTTTTGATTTTAACGACTTTTAACGA 900
-- ---- --- .....---- ..-- -- ------- ------ -- -- -- ---- --- ---.. 1
-------------------------------------------------- 1
TTGCGA.CTGGTTCCAA'l'TGACAAGCTTT"I'GATTTTAACGA.CTTTTAACGA 334
-------------------------------------------------- 1
-------------------------------------------------- 1
------------------ --- --- -- ------------------------ 1
EcoRl •
CAACTTGAGAAGATCAAAAAA.CAACTAATTATTCGAA.GGATCCTACGTAG 950
----------------AAAAACAACTMTTATTCGAAGGATCCTACGTAG 34
-------------------------------------------------- 1
CAACTTGAGAAGATCAAAAAACAACTAATTAT'I'CGAAGGATCCTACGTAG 384
------------------------ -- ------------ -------- ---- 1
-------------------------------------------------- 1
-------------------------------------------------- 1
_. startofCYP11
pPIC3.5K-CYP17 AATTC"..,..,.""'''''''l'CC .... OC'l=''"''''''''''...",'''''c:u'''''_'1"'I'TG 1000
5 AOXI
4'011
3989
8982
3 AOXI
1496
pPIC3.5K-CYP17
5 AOXI
4011
3989
8982
3 AOXI
1496
pPIC3.5K-CYP17
5 AOXI
4011
3989
8982
3 AOX1
1496
pPIC3.5K-CYP17
5 AOXI
4011
3989
8982
3 AQXl
1496
pPIC3.5K-CYP17
5 AOX1
4011
3989
8982
3 AOXI
1496
pPIC3.5K-CYP17
5 AOX1
4011
3969
8962
3 AOX1
1496
pPIC3.5K-CYP17
5 AOX1
4011
3989
8982
3 AOX1
1496
pPIC3.5K-CYP17
5_AOX1
4011
3989
8982
3 AOXI
1496
pPIC3. 5K-CYP1 7
5 AOX1
4011
3909
8982
3 AOXI
1496
pPIC3.5K-CYP17
5 AOX1
4011
3989
8982
3 AOXI
1496
pPIC3.5K-CYP17
5_AOXI
4011
3989
8982
3 AOXI
1496
pPIC3.5K-CYP17
5 AOXI
4011
MTTCATGTGGGAGCTCGTGGCTCTCTTGCTGCTTACCCTAGCTTATTTG 84
-------------------------------------------------- 1
AATTCATGTGGGAGCTCGTGGCTCTCTTGCTGCTTACCCTAGCTTATTTG 434
----------------- ---- ------------ ------- ---------- 1
-------------------------------------------------- 1
-------------------------------------------------- 1
'1"'l"'1"1'O~CC'l'OO'MCCAAO'l'ACCCCAAClACJCC"J.'C(:tl 1050
T'I'TTGGCCCAAGAGAAGGTGCCCTGGTGCCAAGTACCCCAAGAGCCTCCT 134
-------------------------------------------------- 1
TTTTGGCCCAAGAGAAGGTGCCCTGGTGCCAAt;TACCCCAAGAGCCTCCT 484
-------------------------------------------------- 1
-------------------------------------------------- 1
-------------------------------------------------- 1
G'l'CCC'1'QCCCC'l'GG'J."GGGCCA'l"l'CC'rCCCCAattCA'fGGCCA'rA 1100
GTCCCTGCCCCTGGTGGGCAGCCTGCCATTCCTCCCCAGACATGGCCATA 184
-------------------------------------------------- 1
GTCCCTGCCCCTGGTGGGCAGCCTGCCATTCCTCCCCAGACATGGCCATA 534
-------------------------------------------------- 1
------ ------ ------------ -- -- ----- ---- ---- -- -- ...---- 1
---------------------------------------------- ...--- 1
~~'rA'I'GGCCCCA'l'C'rA'I"l'C'l' 1150
TGCATAACAACTTCTTCAAGCTGCAGAAAAAATATGGCCCCATCTATTCT 234
-------------------------------------------------- 1
TGCA.TAACAACTTCTTCAA.GCTGCAGAAAAAATATGGCCCCATCTATTCT 584
-------------------------------------------------- 1
------------------------------------ ...------------- 1
-------------------------------------------------- 1
CJftC~'l"'l'G'l'CQGCCACCACCAOC'MGC 1200
GTTCGTATGGGCACCAAGACTACAGTGATTGTCGGCCACCACCAGCTGGC 284
-------------------------------------------------- 1
GTTCGTATGGGCACCAAGACTACAGTGATTGTCGGCCACCACCAGCTGGC 634
-------------------------------------------------- 1
-- ---------------------- ------------- -- -- --------- 1
----------------------------------------------- ....-- 1
~~C1'CAAA. 1250
CAAGGAGGTGCTTATTAAGAA.GGGCAA.GGACTTCTCTGGGCGGCCTCAAA 334
-------------------------------------------------- 1
CAAGGAGGTGCTTA.TTAAGAAGGGCAAGGACTTCTCTGGGCGGCCTCAAA 684
------------GGTGCTTATTAAGAAGGGCAAGGACTTCTCTGGGCGGC 38
-------------------------------------------------- 1
--------------------- --- ----------- -- -- ---- ------- 1
~'fCGCG'l'C~'I'CGCC'l'TCGC' 1300
TGGCAACTCTA.GACATCGCGTCCAACAA.CCGTAAGGGTATCGCCTTCGCT 384
-------------------------------------------------- 1
TGGCN\ 690
CTCAAATGGCAACTCTAGACATCGCGTCCAACAACCGTAAGGGTATCGCC 88
-------------------------------------------------- 1
-------------------------------------------------- 1
~~CJA.'f'OCJCCACCft 1350
GACTCTGGCGCACACTGGCAGCTGCATCGAAGGCTGGCGATGGCCACCTT 434
-------------------------------------------------- 1
690
TTCGCTGACTCTGGCGCACACTGGCAGCTGCATCGAAGGCTGGCGATGGC 138
-------------------------------------------------- 1
-------------------------------------------------- 1
'l'GCCCTGTTCAAIJGA'MGCGA'l'CAQAAGC'l'GGAGAAQATCA'lTl'GTCABG 1400
TGCCCTGTTCAARGATGGCGATCAGAAGCTGGAGAAGATCATTTGTCAGG 484
---------------------------------------CATTTGTCAGG 11
690
CACCTTTGCCCTGTTCAAGGATGGCGATCAGAAGCTGGAGAAGATCATTT 188
-------------------------------------------------- 1
-- ......-------- -------- ----- ----------- -- -- ---- ------ 1
AAA'l'CAB'17.CA~~ 1450
AAATCAGTACATTGTGTGATATGCTGGCCACCCACAACGGACAGTCCATA 534
AAATCAGTACATTGTGTGATATGCTGGCCACCCACAACGGA.CAGTCCATA 61
690
GTCAGGAAATCAGTACATTGTGTGATATGCTGGCCACCCACAACGGACAG 238
-------------------------------------------------- 1
-------------------------------------------------- 1
CJA.CA'lC'l'CCTTTCCNTC'TCG'l'OQC~TC'f'CC'l"f'QA'l' 1500
GACATCTCCTTTCCTGTCT'I'CGTGGCGGTAACCAATGTCATCTCCTTGAT 584
GACATCTCCTTTCCTGTCTTCGTGGCGGTAACCAATGTCATCTCCTTGAT III
690
TCCATAGACATCTCCTTTCCTGTCTTCGTGGCGGTAACCAATGTCATCTC 288
---------------------------------------------- ....--- 1
-- ------------------------ - ....-- - ....----------------- 1
C'1'GC"1"1'CAM"CCTCCT.ACAAaAA.TGCJGCIACC~~ 1550
CTGCTTCANTACCTCCTACAAGAATGGGGACCCTGAGTTGAATGTCATAC 634
CTGCTTCAATACCTCCTACAAGAATGGGGACCCTGAGTTGAATGTCATAC 161
3989
8982
3 AOXI
1496
pPIC3.5K-CYP17
5_AOX1
4011
3989
8982
3 AOK1
1496
pPIC3.5K-CYP17
5 AOX1
4011
3989
8982
3 AOXI
1496
pPIC3. 5K-CYPl '1
5 AOX1
4011
3989
8982
3 AOX1
1496
pPIC3.5K-CYP17
5 AaKI
4011
3989
8982
3 AOKl
1496
pPIC3.5K-CYP17
5 AOX1
40ll
3989
8982
3 AOX1
1496
pPIC3.5K-CYP17
5 AOX1
4011
3989
8982
3 AOXI
1496
pPIC3. 5K-CYPI 7
5 AOXI
4'011
3989
8982
3 AOXI
1496
pPIC3.5K-CYP17
5 AOX1
4011
3989
8982
3 AOXI
1496
pPIC3.5K-CYPI7
5 AOK1
4011
3989
8982
3 AOXI
1496
pPIC3.5K-C'rp17
5 AOX1
4'011
3989
8982
3 AOKI
1496
pPIC3.5K-CYPI7
5 AOX1
4011
3989
8982
3 AOKI
1496
pPIC3.5K-CYP17
5 AOX1
4011
3989
8982
3 xoxi
1496
pPIC3.5K-CYP17
5 AOK1
4'011
3989
6982
3 AOXI
1496
pPIC3.5K-CYPI7
5 AQXl
4'011
3989
8982
3 AOK1
1496
690
CTTGATCTGCTTCAA.TACCTCCTACAA.GAATGGGGACCCTGAGTTGAATG 338____________________________________----- ---- ----- 1
__________________________________-- ------- ------- 1
AaAA'l"nCAA'fQAAQGCA'fCA'l'ACM.CAA.C~ 1600
AGAATTACANTGAAGGCATCATAGACAACCTGAGCAAAGACAGCCTGGTG 684
AGAA.TTACAATGAAGGCATCATAGACAA.CCTGAGCl\AA.GACAGCCTGGTG 211
690
TCATACAGAATTACAATGAAGGCATCATAGACAACCTGAGCAAAGACAGC 388
________________________ --- -- -------------- 1
__________________________________________________1
~~~~1650
GACCTAGTCCCCTGGTTGAAGATTTTCCC 713
GACCTAGTCCCCTGGTTGAAGATTTTCCCCAACAAAACCCTGGAAAAATT 261
690
CTGGTGGACCTAGTCCCCTGGTTGAA.GATTT'I'CCCCAACAAAACCCTGGA 438__________________________________________________ 1
____________.......... ----- ------ 1
~CATO'1"'1'AAAA'l'ACcaaA'l'GA'lC'l<IC'l'GJ.A'l'AAAA'l'AC'l"'l'GAAA 1700
713
AAAGAGCCATGTTAAAATACGAM.TGATCTGCTGAATAAAATACTTGAAA 311
690
.AAAATTAAAGAGCCATGTTAAAATACGAAATGATCTGCTGAATAAAATAC 488____________________________________ --- --- -- ---- -- 1
__________________________________________________ 1
A'1'"!AC.A~aa.'1"1'CC~'l'CACCAACA'l'GC'l'GQACACA 1750
713
A'M'ACAAGGAGAAATTCCGGAGTGACTCTATCACCAACATGCTGGACACA 361
690
TTGAAAATTACAAGGAGAAATTCCGGAGTGACTCTATCACCAACATGCTG 538__________________________________________________ 1
__________________________________________________ 1
~~~1800
713
CTGATGCAAGCCAAGATGAACTCAGATAATGGCAATGCTGGCCCAGATCA 411
690
GACACACTGATGCAAGCCAAGATGAACTCAGATAATGGCAATGCTGGCCC 588__________________________________________________1
__________________________________________________1
AtIA.~'l'AACCACA'l"'rCT'CACCACc:AfttIGQCIJ,.CA 1850
713
AGACTCAGAGCTGCTTTCAGATAACCACATTCTCACCACCATAGGGGACA 461
690
AGATCAAGACTCAGA.GCTGCTTTCAGATAACCACATTCTCACCACCATAG 638__________________________________________________1
________________________________--- -- -- -- --------- 1
~~~1900
713
TCTTTGGGGCTGGCGTGGAGACCACCACCTCTGTGGTTAAATGGA.CCCTG 511
690
GGGACATCTTTGGGGCTGGCGTGGAGACCACCAC 672
---------------------------CCTCTGTGGTTAAATGGACCCTG 23__________________________________________________1
QCC"r1'CC"MCTt'JCA.CAA~QAQCMGA'l' 1950
713
GCCTTCCTGCTGCACAATCCTCAGGTGAAGAANAAGCTCTACGAGGAGAT 561
690
672
GCCTTCCTGCTGCACAATCCTCAGGTGAAGAAGAAGCTCTACGAGGA.GAT 73
____________________________-- -- ----------- ------- 1
orc:acc:AtMA'1'G'l'GOO"l"ClCACACCAAC'l'A'l'CAtJ'fCD.CCQ'fAACC 2000
713
TGACCAGAATGTGGGTTTCAGCCGCACACCAACTATCAGTGACCGTAACC 611
690
672
TGACCAGAATGTGGGTTTCAGCCGCACACCAACTA'l'CAGTGACCGTMCC 123
---------AGTGGGTTTCAGCCGCACACCAACTATCAGTGACCGTAACC 41
615
690
672
GTCTCCTCCTGCTGGA.GGCCACCATCCGAGAGGTGCTTCGCCTCAGGCCC 173
GTCTCCTCCTGCTGGAGGCCACCATCCGAGAGGTGCTTCGCCTCAGGCCC 91
GTCT
G'l'GOCCCC'fATGC'f'CA'l'CCCCCACAAGQCCAACCJ'1'Il'QA.C'l''l'COQ 2100
713
615
690
672
GTGGCCCCTATGCTCATCCCCCACAAGGCCAACGTTGACTCCAGCATCGG 223
GTGGCCCCTATGCTCATCCCCCACAAGGCCAACGTTGACTCCAGCATCGG 141
~A'fCA~QC 2150
713
615
690
672
TGAGTTTGCTGTGGACAAGGGCACAGAAGTTATCATCAATCTGTGGGCGC 273
TGAGTTTGCTGTGGACAAGGGCACAGAAGTTATCATeAATCTGTGGGCGC 191
'1'OCM'CACAA~CAQCCQt1J,.'1'CAQ'l'TCATGCC1'QAO 2200
713
615
690
672
TGCA.TCACAATG.AGAAGGAGTGGCACCAGCCGGATCAGTTCATGCCTGAG 323
TGCATCACAATGAGAAGGAGTGGCACCAGCCGG.ATCAGTTCATGCCTGAG 241
CtI'l"l"l'C'l'CABCCJGCJCIACCCAOCI'CA'l'Cf'CAC'C~ 2250
713
615
690
672
CGTTTCTTGAATCCAGCGGGGACCCAGCTAATCTCACCGTCAGTAAGCTA 373
CGTTTCTTGAATCCAGCGGGGACCCAGCTAATCTCACCGTCAGTAAGCTA 291
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pP res. SK-C'tP 11
5 AOXI
4011
3999
8982
3 AnKl
1496
pPIC3.5K-CYPl1
5 AOK1
4011
3989
8982
3 AOKl
1496
pPIC3. SK-CYPl7
5 AnK!
4011
3989
8982
3 xox;
1496
pPlC3.5K-CYPll
5 AOXl
4'011
3989
8982
3 AOXI
1496
pPIC3. SK-CYPl?
5 AOX!
4'011
3989
8982
3 AOKl
1496
pP!C3. SK-CYPl?
5 AOXI
4011
3989
8982
3 AOKl
1496
pPIC3. SK-CYPl 7
5 AOX!
40ll
3989
8982
3 xoxi
1496
pPIC3. SK-CYPl7
5 AOX!
4011
3989
8982
3 AOXl
1496
~'l'CC"fGQCCC 2300
713
615
690
612
TTTGCCCTTCGGAGCAGGACCTCGCTCCTGTATAGGTGAGATCCTGGCCC 423
TTTGCCC'I'TCGGAGCAGGA.CCTCGCTCCTGTATAGGTGAGATCCTGGCCC 341
~CTCATCATQGC~CJACC'rG 2350
713
615
690
672
GCCAGGAGCTCTTCCTCA.TCATGGCCTGGCTGCTGCAGAGGTTCGACCTG 473
GCCAGGAGCI'CTTCCTCATCATGGCCTGGCTGCTGCAGAGGTTCGACCTG 391
c:aacrroc~C'fCC~CCCAAlJl71' 2400
713
615
690
612
GAGGTGCCAGATGATGGGCAGCTGCCCTCCCTGGAAGGCATCCCCAAGGT 523
GAGGTGCCAG1\TGATGGGCAGCTGCCCTCCCTGGAA.GGCATCCCCAAGGT 441
<J<J"l'CT'l"l~'1'CAAQ(J"f'OCCAQOCC'r 2450
713
615
690
672
GGTCTTTCTGATCGACTCTTTCAAAGTGAAGATCAAGGTGCGCCAGGCCT 573
GGTCTTTCTGATCGACTCTTTCAAAGTGAAGATCAAGGTGCGCCAGGCCT 491
l!I"hiIIldlnetag
~CCAGGC~CCA.TCACCA'l'CACCA.TCACTAA 2500
713
615
690
672
GGA.GGGAAGCCCAGGCTGAGGGTAGCACCCATCA.CCATCACCATCACTAA 623
GGAGGGAAGCCCAGGCTGAGGGTAGCACCCATCACCATCACCATCACTAA 541
GAATTCCCTAGGGCGGCCGCGAATTAATTCGCCTTAGACATGACTGTTCC 2550
713
61S
690
672
GAATTCCCTAGGGCGGCCGCGAATTAATTCGCCTTAGACATGACTGTTCC 673
GAATTCCCTAGGGCGGCCGCGAATTAATTCGCCTTAGACATGAC'l'GTTCC 591
TCAGTTCAAGTTGGGCACTTACGAGAAGACCGGTCTTGCTAGATTCTAAT 2600
713
61S
690
672
TCAGTTCAAGTTGGGCAC'l'TACGAGAAGACCGGT 707
TCAGTTCAAGTTGGGCACTTACGAGAAGACCGGTCTTGCTAGATTCTATT 641
CAAGAGGA.TGTCAGAATGCCATTTGCCTGAGAGP.TGCAGGCTTCATTTTT 2650
713
615
690
672
707
64.CAAGAGG
pPIC3.SK-CYP17 GATACTTTTTTATTTGTAACCTATATAGTATAGGA.TTTTT'I'TTGTCATTT 2700
5 AOXI 713
4011 615"~ -8982 672
3 AOXI 707
1496 648
pPIC3. 5K-CYP1 7 ATTCGACCGCC 10561
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APPENDIXB
Primers used in this study.
Primer Genespecificity
STEl
4011
1496
S74 CYPl7
3989
8982
STE2
VaN-U
YaC-21
pFLAG-I
PI04 CYPl7
a-factorP MFa-1
3'-AOXI3'AOXIP
PI03 TruncCYPl7
PI07
PI08
PI09
P110
CYB5
Primer sequence
Type
of
Primer
5' -ATGCGAA TTCATGTGGGAGCTCGTGGCTCTC-3' Sense
5'-TGGCAGCTCATCGAAGGCT-3' Sense
5' -GAAGC TCT ACGAGGAGA TTGACCAG-3' Sense
5' -TAGAAGCTT ATGGTGATGGTGATGGGTGCT ACCCTCAGCCTG-3' Antisense
5' -AGCCTTCGATGCAGCTGCCAG-3' Antisense
5' -CTGGTCAA TCTCCTCGT AGAGCT TC-3' Antisense
5' -AGCT AAGCTTTT AGGTGCT ACCCTCAGCCTG-3' Antisense
5' -AGCACAAA TAACGGGTT ATTG-3'
5-TACAGACGCGTGTACGCATGT-3'
5' -CCGGAATTCTTATGATGGTGATGGTGATGGGTGCT-3'
5' -TACT ATTGCCAGCA TTGCTGC-3'
5' -GCAAA TGGCATTCTGACATCC-3'
5' -ATGCGAATTCAAGAGAAGGTGCCCTGGTGC-3'
5' -AGGCGAA TTCATGGCAGAGCAGTCGGAC-3'
5' -GTGATGGTGATGGTGATGGTCCTCTGCCATGT ATAGG-3'
5'-AGGCGAATTCATGGCAGA-3 '
5' -CCGGAATTCTCAGTGATGGTGATGGTGATGGT-3'
Sense
Antisense
Antisense
Sense
Antisense
Sense
Sense
Antisense
Sense
Antisense
Pl9AI 5'-GGTCAAGGAACACAAGATGG-3 ' Sense
P19A2 5' -ATGGTGATGGTGATGGTGTTCCAGACACCTTCTGA-3' Antisense
Pl9BI 5' -TCCCCGCGGAGATGGTTTTGGAAATGCTGAA-3' Sense
Pl9B2 5' -TCCCCGCGGTT AATGGTGATGGTGATGGTGTT-3' Antisense
AromBI CYPl9 5' -GTCACAGTCTGTGCTGAATC-3' Sense
AromCI 5' -GGTGACCTGACAAGAGAGAA-3' Sense
AromA2 5' -CTCCAACCTGTCCAGATGTG-3' Antisense
AromB2 5' -GCACTGGTTCACA TTCTCTC-3' Antisense
AromC2 5' -CACCTGTCTGAGTTTCTTGG-3' Antisense
PIOS
PI06
S'AOXIP
CYPl7
5'-AOXI
5' -ATGCGAATTCATGTGGGAGCTCGTG-3'
5' -GTACGCGGCCGCGAA TTCTT AGTGATGGTGAT-3'
5' -GACTGGTTCCAA TTGACAAGC-3'
Sense
Antisense
Sense
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